accession,name,description,Parent study,Study Disease/Focus,Study Design,Study Markerset,Study Molecular Data Type,Study Content,Ancestry (computed),NIH Institute,Study Consent,Release Date,Embargo Release Date,Related Terms,Collections
"phs003348.v1.p1","A genotype-phenotype study of tumors from patients with inherited    mutations in DNA repair genes","This study investigated the genomic landscape of tumors from patients with inherited mutations in DNA repair genes. The aim of this study was to determine the relationship between locus-specific loss  of heterozygosity (LOH) and genomic signatures of homologous recombination-based DNA repair (HR) deficiency in tumors associated with pathogenic","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 25 variables, 39 samples sequenced, 39 subjects, 39 samples","","NCI","GRU --- General Research Use","2024-08-28","2024-08-28","BRCA1- and BRCA2-associated hereditary breast and ovarian cancer; BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC); Breast and ovarian cancer; Familial Breast and Ovarian Cancer Syndrome; Familial Breast/Ovarian Cancer (BRCA1, BRCA2); HBOC Syndrome",""
"phs003640.v1.p1","The Somatic Mutational Landscape of Thyroid Cancer in Patients with    Germline PTEN Mutations","PTEN hamartoma tumor syndrome (PHTS) is associated with a high rate of thyroid cancer and benign thyroid disease, yet nothing is known of the genomic landscape of PHTS-associated thyroid tumors.  In this study, exome sequencing was performed on 58 thyroid tumors (28 cancers, 30 benign nodules) from 19 patients with PHTS, sequenced in","Not Applicable","Hamartoma Syndrome, Multiple","Tumor vs. Matched-Normal","WES_markerset_grc37","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 68 samples sequenced, 16 subjects, 68 samples","","NCI","DS-CWDN-COL-NPU --- Disease-Specific (Cowden Syndrome or another condition within the PTEN Hamartoma Tumor Syndrome, COL, NPU), DS-CWDN --- Disease-Specific (Cowden Syndrome or another condition within the PTEN Hamartoma Tumor Syndrome)","2024-08-26","2024-08-26","BANNAYAN-RILEY-RUVALCABA SYNDROME; BANNAYAN-ZONANA SYNDROME; BBRS; BZS; CD; CS",""
"phs003717.v1.p1","Molecular Analysis of Alliance A031201 Study","This is the first study examining the relationship between clonal hematopoiesis and clinical outcomes in prostate cancer patients. We used a targeted gene sequencing panel to identify patients in the  A031201 clinical trial with and without clonal hematopoiesis. We found that clonal hematopoiesis did not affect overall or progression free survival","Not Applicable","Prostatic Neoplasms","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 13 variables, 957 samples sequenced, 957 subjects, 957 samples","","NCI","DS-PC --- Disease-Specific (Prostate Cancer)","2024-08-23","2024-08-23","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003704.v1.p1","Botensilimab, an Fc-enhanced Anti-CTLA-4 Antibody, is Effective Against    Tumors Poorly Responsive to Conventional Immunotherapy","This study explores the genomic landscape associated with a novel Fc-engineered anti-CTLA-4 antibody (botensilimab) in advanced solid tumors. We seek to understand if enhancing the Fc-region affinity of anti-CTLA-4 antibodies  can improve anti-tumor efficacy and expand clinical benefit to tumors poorly responsive to conventional immunotherapy. As part of an ongoing","Not Applicable","Immunotherapy","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 12 variables, 95 samples sequenced, 70 subjects, 95 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2024-08-23","2024-08-23","Sarcoma; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine",""
"phs003683.v1.p1","Somatic Mutations in Individual Skin Cells","Ultraviolet (UV) radiation is the primary cause of melanoma through the acquisition of driver mutations in melanocytes. It also plays a significant role in oncogenesis in other skin cells, such  as keratinocytes. However, the mutational profiles vary widely among different skin cancers, and the early mutational processes in different cell","Not Applicable","Carcinoma, Squamous Cell","Cross-Sectional","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 347 samples sequenced, 16 subjects, 347 samples","","NCI","GRU --- General Research Use","2024-08-22","2024-08-22","Skin Neoplasms; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular",""
"phs003676.v1.p1","Chromothripsis in Small Cell Lung Carcinoma Associated with Carcinoid    Transformation","Small cell lung carcinoma (SCLC) is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. We performed detailed clinicopathologic, genomic, and transcriptomic profiling of an atypical subset  of SCLC in never/light smokers that lacked RB1 and TP53 co-inactivation and found that most cases were associated with chromothripsis &#x02013;","Not Applicable","Carcinoma, Small Cell","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 13 variables, 29 samples sequenced, 12 subjects, 29 samples","","NCI","GRU --- General Research Use","2024-08-22","2024-08-22","Carcinoid Tumor; Chromothripsis; Carcinoid; Carcinoid tumor (disease); Carcinoid tumors; Carcinoid tumour","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002922.v2.p1","Genomic and Transcriptomic Sequencing of CAR-T-Treated Patients","Chimeric Antigen Receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B-cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however,  failure mechanisms are identified in only a fraction of cases. Here we use next-generation sequencing technologies to characterize the genomic and","Not Applicable","Lymphoma, B-Cell","Prospective Longitudinal Cohort","Not Provided","OTHER","4 phenotype datasets, 16 variables, 95 samples sequenced, 58 subjects, 155 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-08-22","2022-10-06","",""
"phs003697.v1.p1","Evolving Cell States and Oncogenic Drivers during the Progression of    IDH-Mutant Gliomas","The study aims to understand the changes in cell states during the progression of IDH mutant gliomas. We generated scATAC-seq data from tumor samples of patients with IDH mutant gliomas,  ranging from grade 2 to grade 4, including both IDH mutant oligodendroglioma and IDH mutant astrocytoma samples. Additionally, we have generated","Not Applicable","Glioma","Methods","Not Provided","ATAC-seq, RNA-Seq","3 phenotype datasets, 12 variables, 15 samples sequenced, 11 subjects, 15 samples","","NCI","GRU --- General Research Use","2024-08-15","2024-08-15","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs002366.v2.p2","Lung Cancer Genetic Study Among Asian Never Smokers","The Lung Cancer Genetic Study Among Asian Never Smokers includes data from four population-based studies conducted among Asian women: the Shanghai Women's Health Study (SWHS), the Hwasun Cancer Epidemiology Study  (HCES1 and HCES2), the Female Lung Cancer Consortium in Asia (FLCCA, including sFLCA), and the Guangzhou Lung Cancer Study (GLCS). Shanghai Women's","Not Applicable","Lung Neoplasms","Case-Control","WES_markerset_grc37, MEGA_Consortium_Array","SNP Genotypes (Array), SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 17 variables, 2 molecular datasets, 1195 samples sequenced, 8310 subjects, 8369 samples","","NCI","HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-LC --- Disease-Specific (Lung Cancer), GRU-NPU --- General Research Use (NPU)","2024-08-13","2024-08-13","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs001524.v3.p2","The Genetic Basis of Aggressive Prostate Cancer, The Role of Rare    Variation","In this study, we will apply a multi-staged approach to reveal genes harboring rare variants that are associated with aggressive PCa. Whole-exome sequencing (Aim 1a) of 2,774 aggressive cases and  2,776 non-aggressive cases of European ancestry will be conducted followed by rare variant analysis of single sites and gene burden testing to","Not Applicable","Prostatic Neoplasms","Case Set","WES_markerset_grc37","SNP/CNV Genotypes (NGS), Targeted-Capture, WXS","4 phenotype datasets, 29 variables, 3 molecular datasets, 21898 samples sequenced, 21745 subjects, 21898 samples","","NCI","GRU --- General Research Use, DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), CADM --- Cancer in all age groups, other diseases in adults only, and methods, DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-PC --- Disease-Specific (Prostate Cancer), MHNSI-MDS --- Men's Health and Nutrition in Serious Illnesses (MDS), DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), DS-PC-NPU-MDS --- Disease-Specific (Prostate Cancer, NPU, MDS)","2024-08-12","2024-08-12","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003488.v1.p1","APOLLO-OV: Applied Proteogenomics of High Grade Serous Ovarian Carcinoma","APOLLO is a proteogenomic study seeking to describe the major genome, transcriptome, proteome and phosphoproteome alterations, subtypes, and molecular predictors of patient outcomes. This study includes 70 high grade serous  ovarian carcinoma tissues from the Gynecologic Cancer Center of Excellence","Not Applicable","Ovarian Neoplasms","Tumor vs. Matched-Normal","Not Provided","Not Provided","3 phenotype datasets, 13 variables, 70 subjects, 70 samples","","NCI","GRU --- General Research Use","2024-08-09","2024-08-09","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs003282.v2.p1","Genetic Analysis of Skin Cells","Cutaneous squamous cell carcinoma (cSCC) is a form of skin cancer originating from keratinocytes in the skin. They have high mutation burdens, primarily driven by UV-radiation-induced DNA damage. The order  in which mutations undergo selection during the evolution of cSCC is not known. A subset of cSCCs grow out of benign neoplasms called actinic","Not Applicable","DNA Copy Number Variations","Methods","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 13 variables, 54 samples sequenced, 16 subjects, 54 samples","","NCI","GRU --- General Research Use","2024-08-09","2023-08-18","Not Provided",""
"phs003563.v1.p1","Transfer Learning Associates CAFs with EMT and Inflammation in Tumor    Cells in Human Tumors and Organoid Co-Culture in Pancreatic Ductal    Adenocarcinoma","This study examined the transcriptional changes induced by cancer associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma patient-derived tumor organoids. We hypothesized that cancer associated fibroblasts impacted tumor cell transcription to  promote tumorigenic behavior. Using patient-matched cells from 3 patients, we compared the transcriptional profiles of patient-derived organoids in","Not Applicable","Pancreatic Neoplasms","Collection","Not Provided","RNA-Seq","3 phenotype datasets, 16 variables, 12 samples sequenced, 3 subjects, 12 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","2024-08-08","2024-08-08","Inflammation; Inflammatory Response, Innate; Innate Inflammatory Response; Innate Inflammatory Responses; Cancer of the pancreas; Neoplasia of the pancreas",""
"phs003579.v1.p1","Phase II Study of Cryoablation and Post-Progression Immune Checkpoint    Inhibition in Metastatic Melanoma","Percutaneous cryoablation guided by imaging is a well-established, minimally invasive treatment for oncological conditions. We posited that cryoablation could alter the immune microenvironment by directly influencing the tumor, potentially eliciting  an anti-tumor response in cases resistant to immune checkpoint inhibition (ICI). In this non-randomized phase II single-center study (NCT03290677),","Not Applicable","Melanoma","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 20 samples sequenced, 15 subjects, 20 samples","","NCI","DS-MSC-MDS --- Disease-Specific (Melanoma and Skin Cancer Research, MDS)","2024-08-05","2024-08-05","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs003286.v2.p1","Multi-Omic Profiling of Glioma Patient Tumors and Patient-Derived Model    Systems","We have created a resource of transcriptomic (RNAseq), genomic (whole-exome seq), and lipidomic (untargeted shotgun) profiling data from over 175 molecularly diverse glioma tumors and derivative models in orthotopic mouse  xenografts and gliomasphere cultures from over 110 unique patient tumor lines. Provided in this dataset are matched bulk RNA and whole-exome","Not Applicable","Glioblastoma","Collection","RNAseq_gene_transcripts, RNAseq_gene_transcripts, WES_markerset_grc38","RNA-Seq, CNV Segments (NGS), RNA Seq (NGS), WXS","5 phenotype datasets, 23 variables, 1 molecular datasets, 461 samples sequenced, 119 subjects, 461 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2024-08-05","2024-08-05","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs003682.v1.p1","EWS-WT1 Fusion Isoforms Establish Oncogenic Programs and Therapeutic    Vulnerabilities in Desmoplastic Small Round Cell Tumors","Desmoplastic Small Round Cell Tumor (DSRCT) is an aggressive mesenchymal tumor driven by fusions between the disordered domain of the Ewing sarcoma RNA binding protein 1 (EWSR1) and the developmental  transcription factor Wilms tumor 1 (WT1). We used genome-wide chromatin profiling to identify EWSR1-WT1-dependent gene regulatory networks and target","Not Applicable","Sarcoma","Case Set","Not Provided","ChIP-Seq","3 phenotype datasets, 10 variables, 12 samples sequenced, 2 subjects, 12 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-07-31","2024-07-31","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003480.v1.p1","Single-Cell RNA-Sequencing of Human Prostatectomy Tissue","The tissue microenvironment in prostate cancer is profoundly altered. How prostate cancer cells and their precursors mediate those changes is unclear, in part due to the inability to longitudinally study  the disease evolution in human tissues. To overcome this limitation, we performed extensive single-cell RNA-sequencing (scRNA-seq) to assess the","Not Applicable","Prostatic Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq","4 phenotype datasets, 17 variables, 12 samples sequenced, 7 subjects, 12 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","2024-07-30","2024-07-30","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001287.v19.p6","CPTAC Proteogenomic Study","Recently, significant progress has been made in characterizing and sequencing the genomic alterations in statistically robust numbers of samples from several types of cancer. For example, The Cancer Genome Atlas  (TCGA), International Cancer Genome Consortium (ICGC) and other similar efforts are identifying genomic alterations associated with specific cancers","Not Applicable","Neoplasms","Case Set","Not Provided","Not Provided","3 phenotype datasets, 11 variables, 7117 subjects, 7117 samples","","NCI","GRU --- General Research Use","2024-07-26","2023-06-29","Lung Neoplasms; Sarcoma; Uterine Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003712.v1.p1","Early Detection of Malignant and Pre-Malignant Peripheral Nerve Tumors    Using Cell-Free DNA Fragmentomics","Early detection of neurofibromatosis type 1 (NF1) associated peripheral nerve sheath tumors (PNST) informs clinical decision-making, potentially averting deadly outcomes. Here, we describe a cell-free DNA (cfDNA) fragmentomic approach which  distinguishes non-malignant, pre-malignant and malignant forms of NF1 PNST. Using plasma samples from a novel cohort of 101 NF1 patients and 21","Not Applicable","Neurofibromatosis 1","Case-Control","Not Provided","WGS","3 phenotype datasets, 12 variables, 166 samples sequenced, 122 subjects, 166 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2024-07-25","2024-07-25","Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I; NEUROFIBROMATOSIS, TYPE I, SOMATIC",""
"phs003519.v1.p1","Childhood Cancer Data Initiative (CCDI): Single-Cell Atlas of NF1 Nerve    Sheath Tumors","The worst outcome of NF1 is the development of the aggressive and highly metastatic malignant peripheral nerve sheath tumors (MPNST), which transform from benign plexiform neurofibroma (PN) and lack effective  treatment. In this study, we performed single-cell RNA sequencing of 63 clinically annotated NF1-associated peripheral nerve sheath tumors, including","Not Applicable","Rare Diseases","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 29 subjects, 55 samples","","NCI","GRU --- General Research Use","2024-07-22","2024-07-22","Neurofibromatosis 1; Rare Disease; Blastoma; CA; CA - Cancer; Cancer",""
"phs002517.v3.p2","Childhood Cancer Data Initiative (CCDI): Molecular Characterization    across Pediatric Brain Tumors and Other Solid and Hematologic    Malignancies for Research, Diagnostic, and Precision Medicine","This study contains tumor and germline WGS, RNA-Seq, Clinical Panel Sequencing, and other omics and molecular data for patients with pediatric brain tumors and other solid and hematologic malignancies. This  data has been collected from multiple organizations including the multi-institute Children's Brain Tumor Network (CBTN), the Pacific Pediatric","Not Applicable","Brain Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, Targeted-Capture, WGS, WXS, miRNA-Seq","2 phenotype datasets, 5 variables, 3187 samples sequenced, 3937 subjects, 8972 samples","","NCI","GRU --- General Research Use","2024-07-22","2023-05-12","Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain",""
"phs003008.v1.p1","Comprehensive Genomic Characterization of Translocation Renal Cell    Carcinoma","Xp11 translocation renal cell carcinoma (tRCC) is a rare, female-predominant cancer driven by a fusion between the TFE3 gene on chromosome Xp11.2 and a partner gene on either chrX or  an autosome. It remains unknown what types of rearrangements underlie TFE3 fusions, whether fusions can arise from both the active (chrXa) and","Not Applicable","Kidney","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 15 variables, 61 samples sequenced, 16 subjects, 61 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-07-19","2024-07-19","Not Provided",""
"phs001988.v2.p1","Molecular Characterization of Prostate Cancer Specimens by Bulk and    Single Cell Analysis","Version 1: We performed single-cell RNA-sequencing (scRNA-seq) of fresh biopsies from metastatic castration resistant prostate cancer. Additionally, where available, we performed matched bulk whole exome sequencing (WXS; tumor and normal  paired) and whole transcriptome sequencing for the same individuals. We also performed bulk whole exome (WXS) and RNA-sequencing (RNA-Seq) from FFPE","Not Applicable","Prostatic Neoplasms","Clinical Trial","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 26 variables, 201 samples sequenced, 58 subjects, 201 samples","","NCI","GRU --- General Research Use, DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS)","2024-07-19","2021-04-27","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003569.v1.p1","Aberrant Activation of Wound Healing Programs within the Metastatic Niche    Facilitates Lung Colonization by Osteosarcoma Cells","Lung metastasis is responsible for nearly all deaths caused by osteosarcoma, the most common pediatric bone tumor. How malignant bone cells coerce the lung microenvironment to support metastatic growth is  unclear. This study delineates how osteosarcoma cells educate the lung microenvironment during metastatic progression. Using single-cell","Not Applicable","Osteosarcoma","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 19 variables, 7 samples sequenced, 5 subjects, 7 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2024-07-18","2024-07-18","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma",""
"phs003613.v1.p1","Chromatin Landscape of BET Inhibitor-Treated CD8+ T-cells from Chronic    Lymphocytic Leukemia Patients","The pan-BET (bromodomain and extra-terminal) inhibitor, OPN-51107 (OPN5) was found to alleviate features of T-cell exhaustion in models of chronic lymphocytic leukemia (CLL). To evaluate if OPN5 treatment could relieve  fixed chromatin states associated with terminal T-cell dysfunction, ATAC-sequencing was performed on CLL patient T-cells. Peripheral blood","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","Not Provided","ATAC-seq, SRA Metadata","3 phenotype datasets, 15 variables, 1 molecular datasets, 8 samples sequenced, 5 subjects, 10 samples","","NCI","GRU --- General Research Use","2024-07-10","2024-07-10","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs002790.v7.p1","Childhood Cancer Data Initiative (CCDI): Molecular Characterization    Initiative","The National Cancer Institute's (NCI) Childhood Cancer Data Initiative (CCDI) focuses on the critical need to collect, analyze, and share data to address the burden of cancer in children, adolescents,  and young adults (AYAs). The Molecular Characterization Initiative (MCI) will further the CCDI's goals by providing access to better diagnostic tests","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","OTHER, WXS","2 phenotype datasets, 5 variables, 6375 samples sequenced, 3014 subjects, 8485 samples","","NCI","GRU --- General Research Use","2024-07-10","2022-11-03","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003503.v1.p1","ILyAD (Indolent Lymphoma And vitamin D)","Indolent non-Hodgkin lymphomas are incurable diseases, and require intermittent and often morbid and expensive therapy during their prolonged natural history. Lower intensity and better-tolerated, cost-effective treatment strategies are needed for  these patients. Low vitamin D levels at diagnosis of indolent lymphomas are strongly associated with inferior outcomes to treatment. Standard therapy","Not Applicable","Lymphoma, Non-Hodgkin","Clinical Trial","WES_markerset_grc38","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 185 samples sequenced, 185 subjects, 185 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2024-07-08","2024-07-08","Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma",""
"phs003462.v1.p1","Tumor detection by analysis of both symmetric- and hemi-methylation of    plasma cell-free DNA","Aberrant DNA methylation plays a critical role in tumorigenesis. While DNA methylation has been used for cancer detection and classification, DNA hemi-methylation, a novel epigenetic mark has not been analyzed  extensively in cancer epigenomes. Here we report a strand-specific (ss) sequencing method (MeDIP-Seq) for plasma cell free (cf) DNA (sscf-MeDIP-Seq),","Not Applicable","Early Detection of Cancer","Case-Control","Not Provided","MeDIP-Seq","3 phenotype datasets, 13 variables, 271 samples sequenced, 271 subjects, 271 samples","","NCI","DS-HCC --- Disease-Specific (Hepatocellular Carcinoma), DS-BT --- Disease-Specific (Brain Tumors)","2024-07-08","2024-07-08","Liver Neoplasms; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour",""
"phs003220.v2.p1","Identification of High-Risk PHF19 Expressing Cells in Myeloma Single-Cell    Multiomics","The aim of this study is to identify novel subsets of cells that are associated with progression and response to treatment. In this project, we study the tumor fraction from  49 myeloma patients across stages of progression. Samples were collected from 10 smoldering multiple myeloma (SMM), 22 newly diagnosed multiple","Not Applicable","Multiple Myeloma","Case Set","Not Provided","OTHER, WGS","4 phenotype datasets, 30 variables, 186 samples sequenced, 49 subjects, 186 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2024-07-08","2024-03-07","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease",""
"phs002180.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Z1B","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 384 variables, 29 subjects, 29 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-07-08","2024-07-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002177.v1.p1","Genomic Characterization CS-MATCH-0007 Arm C1","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 316 variables, 11 subjects, 11 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-07-08","2024-07-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002152.v1.p1","Genomic Characterization CS-MATCH-0007 Arm P","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 297 variables, 28 subjects, 28 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-07-08","2024-07-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002192.v3.p2","Cancer Moonshot Biobank","The National Cancer Institute initiated the Cancer Moonshot Biobank to accelerate research through the collection and distribution of biospecimens for key research efforts. The Biobank will engage with over one  thousand cancer patients, being treated with standard-of-care therapies, for longitudinal biospecimen and data collection. Cancer patients will be","Not Applicable","Neoplasms","Case Set","custom_markerset","SNP/CNV Genotypes (NGS)","31 phenotype datasets, 367 variables, 2 documents, 2 molecular datasets, 248 subjects, 1140 samples","","NCI","GRU --- General Research Use","2024-07-03","2024-07-03","Lung Neoplasms; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine",""
"phs003455.v1.p1","Correlative Studies for Protocol #14-C-0059: T Cells Expressing an    Anti-GD2 Chimeric Antigen Receptor in Patients with GD2+ Solid Tumors,    a Collaboration with CIMAC-CIDC","This study is a retrospective correlative analysis of immune cell phenotypes in samples from a Phase I clinical trial (NCT02107963) of GD2 CAR-T cells (GD2-CAR.OX40.28.z.iC9) in children and young adults  with osteosarcoma and neuroblastoma. The study was a 3+3 dose-escalation study with four dose levels (1 x 10(5) transduced T cells/kg; 1 x 106","Not Applicable","Osteosarcoma","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 12 variables, 15 subjects, 103 samples","","NCI","GRU-PUB-COL --- General Research Use (PUB, COL)","2024-06-28","2024-06-28","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002681.v2.p1","Natural Killer Cell Therapies for Hematologic Malignancies","The ""Natural Killer Cell Therapies for Hematologic Malignancies"" study is an umbrella repository for data pertaining to multiple related clinical trials that aim to assess NK cell therapies as part  of treatment strategies for a range of hematologic malignancies. Here, data from two trials, NCT03068819 and NCT02782546, are presented. Cytokine","Not Applicable","Leukemia","Clinical Trial","Not Provided","OTHER","5 phenotype datasets, 19 variables, 81 samples sequenced, 25 subjects, 81 samples","","NCI","DS-HM --- Disease-Specific (Hematological Malignancies)","2024-06-28","2022-08-10","Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias",""
"phs003623.v1.p1","BIRC5 Upregulation Enhances DNMT3A-Mutant T-ALL Cell Survival and    Pathogenesis","The goal of this study was to determine how patients with T-ALL who have DNA methyltransferase 3 alpha (DNMT3A) mutations develop resistance to therapy. Since DNMT3A is a methyltransferase, we  examined the effect of those mutations on epigenetic regulation using whole genome bisulfite sequencing (WGBS). We also assessed any changes in gene","Not Applicable","Leukemia-Lymphoma, Adult T-Cell","Case Set","Not Provided","Bisulfite-Seq, RNA-Seq","4 phenotype datasets, 12 variables, 10 samples sequenced, 10 subjects, 10 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2024-06-13","2024-06-13","ATLL; Adult T Cell Lymphoma/Leukemia; Adult T-Cell Leukemia; Adult T-Cell Leukemia-Lymphoma; Adult T-Cell Leukemia-Lymphomas; Adult T-Cell Leukemias",""
"phs002343.v1.p1","Structure of the Mucosal and Stool Microbiome in Lynch Syndrome","The gut microbiota has been associated with colorectal cancer (CRC), but causal alterations preceding CRC have not been elucidated. To prospectively assess microbiome changes prior to colorectal neoplasia, we investigated  samples from 100 Lynch syndrome patients using 16S rRNA gene sequencing of colon biopsies, coupled with metagenomic and metatranscriptomic sequencing","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 27 variables, 361 samples sequenced, 100 subjects, 361 samples","","NCI","GRU --- General Research Use","2024-06-13","2024-06-13","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001486.v4.p4","NCI Cancer Model Development for the Human Cancer Model Initiative (HCMI)","The Cancer Model Development Center (CMDC) project is part of the Human Cancer Model Initiative (HCMI) and is managed by the Office of Cancer Genomics within the Center for Cancer  Genomics at the National Cancer Institute (NCI). The goal of the HCMI is to generate approximately 1000 novel human ""next generation"" tumor-derived","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 1117 subjects, 1117 samples","","NCI","GRU --- General Research Use","2024-06-13","2019-02-07","Esophageal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms, Germ Cell and Embryonal; Sarcoma, Ewing; Breast Cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003432.v1.p1","Childhood Cancer Data Initiative (CCDI): Identification and Targeting of    Treatment Resistant Progenitor Populations in T-cell Acute    Lymphoblastic Leukemia","Our goal with this study was to identify the mechanisms of treatment resistance in T-cell acute lymphoblastic leukemia (ALL) using single-cell genomics. We profiled 40 T-ALL cases from the Children's  Oncology Group AALL0434 clinical trial using CITE-seq/snATAC-seq, capturing a breadth of immunophenotypes, including early T-cell precursor (ETP) and","Not Applicable","Pediatrics","Case Set","Not Provided","ATAC-seq, RNA-Seq","2 phenotype datasets, 5 variables, 43 samples sequenced, 43 subjects, 43 samples","","NCI","GRU --- General Research Use","2024-06-12","2024-06-12","Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs003379.v1.p1","Germline Mutations and Developmental Mosaicism Underlying EGFR-Mutant    Lung Cancer","We designed this study to examine the etiology of multiple lung tumors in EGFR-mutant non-small cell lung cancer patients who undergo surgical resection. Participants were 52-85 years old never or  former smokers, who had at least 2 surgical lung tumor pathology specimens available in the Massachusetts General Hospital biobank, at least one of","Not Applicable","Carcinoma, Non-Small-Cell Lung","Case Set","Not Provided","WXS","4 phenotype datasets, 17 variables, 68 samples sequenced, 12 subjects, 68 samples","","NCI","GRU --- General Research Use","2024-06-12","2024-06-12","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs003219.v1.p1","Single-Cell Sequencing Reveals Distinct Microenvironment Cell Types    Associated with Response to High Dose Melphalan and Autologous Stem    Cell Transplant in Multiple Myeloma","The aim of this study is to understand the transcriptome of microenvironment cells in pre- and post- autologous stem cell transplantation (ASCT) samples between patients with complete response and partial  response to transplant. Here, we studied immune cells from 40 multiple myeloma patients who have undergone ASCT. Samples were collected from 40","Not Applicable","Multiple Myeloma","Cross-Sectional","Not Provided","OTHER","4 phenotype datasets, 17 variables, 136 samples sequenced, 40 subjects, 136 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2024-06-06","2024-06-06","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease",""
"phs003590.v1.p1","FIGHT-207: Anonymized Genomic Alterations and Clinical Responses","Background: FIGHT-207 was a phase 2 study of the FGFR1-FGFR3 inhibitor pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor  (FGFR) gene alterations. Population information: 107 patients were divided into 3 cohorts: A. FGFR1&#x02013;FGFR3 fusions/rearrangements; n 49 B.","Not Applicable","Antineoplastic Agents","Clinical Trial","custom_markerset","SNP/CNV Genotypes (NGS)","4 phenotype datasets, 22 variables, 1 molecular datasets, 101 subjects, 262 samples","","NCI","HMB-COL --- Health/Medical/Biomedical (COL)","2024-06-05","2024-06-05","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001087.v4.p1","Common Deleterious Germline Variants Shape the Urothelial Cancer Genome","Our study used whole-exome, whole-genome, and RNA sequencing to analyze samples from primary tumors, locally recurrent or metastatic urothelial tumors collected over time, and matched normal urothelium. We described the  molecular landscape of mutational signatures and structural variants in chemotherapy-resistant urothelial cancer. Inclusion Criteria: Patients with","Not Applicable","Carcinoma, Transitional Cell","Case Set","target_markerset_grc37","AMPLICON, RNA-Seq, CNV Segments (NGS), SNV (.MAF), WGS, WXS","4 phenotype datasets, 20 variables, 1 molecular datasets, 504 samples sequenced, 174 subjects, 554 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2024-06-05","2018-04-09","Neoplasm Metastasis; Urinary Bladder Neoplasms; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs003413.v1.p1","Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor","Immune checkpoint inhibitors (ICIs) are widely used in anti-cancer therapies, but they can cause morbid and potentially fatal immune-related adverse events (irAEs), such as ICI-related myocarditis (irMyocarditis). The pathogenesis of  irMyocarditis and its relationship to anti-tumor immunity remain poorly understood. We sought to define immune responses in heart, tumor, and blood","Not Applicable","Cardiovascular Diseases","Case-Control","Not Provided","RNA-Seq","5 phenotype datasets, 26 variables, 147 samples sequenced, 69 subjects, 147 samples","","NCI","GRU --- General Research Use","2024-06-03","2024-06-03","Adverse Cardiac Event; Adverse Cardiac Events; Cardiac Event; Cardiac Event, Adverse; Cardiac Events; Cardiac Events, Adverse",""
"phs003452.v1.p1","Phase 2 Study of Pembrolizumab in Combination with Gemcitabine and    Cisplatin as Neoadjuvant Therapy","The purpose of the clinical trial (NCT02690558) is to evaluate whether adding pembrolizumab (Keytruda) to the combination of gemcitabine and cisplatin will improve shrinkage of the tumor before having a  cystectomy, for people with muscle-invasive bladder cancer (MIBC). Patients from Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and","Not Applicable","Urinary Bladder Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 16 variables, 193 samples sequenced, 37 subjects, 193 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2024-05-30","2024-05-30","Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder",""
"phs002371.v6.p1","Human Tumor Atlas Network (HTAN)","An NCI-funded Cancer Moonshot initiative to construct 3-dimensional atlases of the dynamic cellular, morphological, and molecular features of human cancers as they evolve from precancerous lesions to advanced disease. Note  for data in CDS: The raw sequencing files for this study are hosted in the NCI's Cancer Data Service (CDS), a data repository under the Cancer","Not Applicable","Neoplasms","Collection","Not Provided","Not Provided","2 phenotype datasets, 6 variables, 1547 subjects, 4615 samples","","NCI","GRU --- General Research Use","2024-05-22","2022-05-27","Adenomatous Polyposis Coli; Lung Neoplasms; Skin Neoplasms; ADENOMATOUS POLYPOSIS OF THE COLON; APC; APC - Adenomatous Polyposis Coli","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003164.v1.p1","Childhood Cancer Data Initiative (CCDI): CCDI Pediatric In Vivo Testing    Program - Leukemia","The goal of this study is to molecularly characterize a large panel of pediatric acute lymphoblastic leukemia (ALL) patient-derived xenografts (PDXs) previously established in immune-deficient mice. These PDXs are utilized  as part of the NCI-funded Pediatric Preclinical In vivo Testing (PIVOT) program to identify novel agents and combinations. Biospecimen data include","Not Applicable","Pediatrics","Xenograft","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 40 subjects, 126 samples","","NCI","GRU --- General Research Use","2024-05-21","2024-05-21","Leukemia, Biphenotypic, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; ALL with myeloid markers; AML with lymphoid markers; Acute Biphenotypic Leukemia; Acute Biphenotypic Leukemias",""
"phs003538.v1.p1","Light at Night and Prostate Cancer in the Health Professionals Follow-Up    Study","The Health Professionals Follow-Up Study (HPFS) is a prospective cohort study of men designed to evaluate hypotheses about men's health related to diet and lifestyle to the incidence of serious  illnesses, such as cancer, heart disease, and other vascular diseases. It consisted of 51,529 U.S. male health professionals who were 40-75 years old","Not Applicable","Light Pollution","Prospective Longitudinal Cohort","Not Provided","Not Provided","3 phenotype datasets, 142 variables, 49148 subjects","","NCI","HMB --- Health/Medical/Biomedical","2024-05-20","2024-05-20","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs002317.v2.p1","Genetic Underpinnings of Ethnic Disparities in Bone Toxicities Between    Hispanic and Non-Hispanic Children Treated for Acute Lymphoblastic    Leukemia","Acute lymphoblastic leukemia (ALL) is the most common malignancy among children and young adolescents. More than 90% of children are cured with a combination of multiple chemotherapeutic drugs. Some may  suffer from debilitating toxicities due to the cytotoxic drugs, necessitating pharmacogenetic research to search for genetic markers predictive of","Not Applicable","Fractures, Bone","Clinical Trial","HumanOmniExpress-24","SNP Genotypes (Array)","5 phenotype datasets, 33 variables, 2 molecular datasets, 516 subjects, 516 samples","European (395), African (4), East Asian (3), African American (22), Hispanic1 (39), Hispanic2 (29), Other Asian or Pacific Islander (5), South Asian (9), Other (10)","NCI","GRU-PUB --- General Research Use (PUB), DS-LEUKLYM --- Disease-Specific (Leukemia and Lymphoblastic Lymphoma)","2024-05-20","2024-05-20","Osteonecrosis; Bone Fracture; Bone Fractures; Bone, Broken; Bones, Broken; Broken Bone",""
"phs001052.v3.p1","Modelling Multi-Dimensional ClinOmics for Precision Therapy of Children    and Adolescent Young Adults with Relapsed and Refractory Cancer: A    Report from the Center for Cancer Research","The Center for Cancer Research (CCR), of the intramural NCI undertook a multidimensional clinical genomics study of children and adolescent young adults with relapsed and refractory cancers who were enrolled  on other therapeutic trials to determine the feasibility of a genome guided precision therapy protocol in these patients. Note: NCIPM001blood - This","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 15 variables, 179 samples sequenced, 83 subjects, 180 samples","","NCI","GRU --- General Research Use","2024-05-17","2019-10-07","Carcinoma, Transitional Cell; Desmoplastic Small Round Cell Tumor; Neuroendocrine Tumors; Rhabdoid Tumor; Sarcoma; Sarcoma, Ewing","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003501.v1.p1","Systems Analysis of Single-Cell Heterogeneity Underlying Glioma Drug    Resistance","This study characterizes the transcriptional regulatory mechanisms that drive responses of two patient-derived glioblastoma multiforme (GBM) stem-like cells (PD-GSCs) that have distinct phenotypes - one sensitive and another resistant to  the drug pitavastatin. This study investigates the differing mechanisms driving drug response in the two PD-GSCs at the single-cell level, and","Not Applicable","Glioma","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 22 variables, 29 samples sequenced, 2 subjects, 29 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2024-05-14","2024-05-14","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs003586.v1.p1","Luminal Androgen Receptor-Enriched Triple Negative Breast Cancer","This is a study to determine the efficacy of androgen receptor (AR) inhibitors in LAR (luminal androgen receptor)-enriched triple-negative breast cancer (TNBC) in the neoadjuvant setting. Twenty-four patients were treated  with neoadjuvant AR inhibitor enzalutamide and paclitaxel for 12 weeks. Whole exome sequencing and RNA-sequencing was performed prior to treatment.","Not Applicable","Breast Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 4 samples sequenced, 2 subjects, 4 samples","","NCI","GRU --- General Research Use","2024-05-13","2024-05-13","Triple Negative Breast Neoplasms; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors",""
"phs003570.v1.p1","Detecting and Subtyping Lung Cancer Through Analysis of Circulating Tumor    DNA","Small cell lung cancer (SCLC) is among the most aggressive tumors with poor clinical outcomes. Tumors are rarely resected, which is a major barrier to molecular profiling of tumor tissue;  therefore, non-invasive approaches using circulating tumor DNA (ctDNA) from liquid biopsies are needed to help advance research and clinical care for","Not Applicable","Lung Neoplasms","Case-Control","Not Provided","Targeted-Capture, WGS","4 phenotype datasets, 15 variables, 348 samples sequenced, 143 subjects, 348 samples","","NCI","GRU --- General Research Use","2024-05-10","2024-05-10","Carcinoma, Neuroendocrine; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002288.v1.p1","Analysis of Epigenomes and Genome Topology in Colorectal Cancer","When diagnosing cancer, pathologists use nuclear morphology as a hallmark of tumor cells, but the topological changes linked to alterations in the shape of the nucleus were poorly understood. To  uncover the molecular changes that occur in the 3D structure of cancer genomes, we integrated topological maps for colon tumors and normal colon","Not Applicable","Computational Biology","Case Set","Not Provided","Bisulfite-Seq, ChIP-Seq, Hi-C, OTHER, RNA-Seq, WGS","5 phenotype datasets, 21 variables, 99 samples sequenced, 28 subjects, 99 samples","","NCI","DS-GRR-MDS --- Disease-Specific (Gastroenterology related research, MDS)","2024-05-10","2024-05-10","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs003369.v2.p1","The Melbourne Urological Research Alliance (MURAL) Collection of    Patient-Derived Models of Prostate Cancer","1. Low-Dose Carboplatin Modifies the Tumor Microenvironment to Augment CAR T Cell Efficacy in Human Prostate Cancer Models Single-cell RNA sequencing (scRNA-seq) was performed to analyze the transcriptional modifications in  the tumor microenvironment of prostate cancer patient-derived xenografts (PDX). The analyzed PDX tumor was PDX-287R from the MURAL collection of PDXs","Not Applicable","Prostatic Neoplasms","Xenograft","Not Provided","RNA-Seq","4 phenotype datasets, 21 variables, 89 samples sequenced, 10 subjects, 89 samples","","NCI","GRU --- General Research Use","2024-05-09","2023-10-18","Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma",""
"phs003178.v1.p1","Combined PDCD1, BRAF and MAP2K7 Inhibition in BRAFV600E Colorectal    Cancer: A Phase 2 Trial","In this study, we evaluated the clinical efficacy of combined PDCD1, BRAF, and MAP2K7 inhibition in metastatic BRAFV600E Colorectal Cancer (CRC) patients (NCT03668431). We performed bulk whole exome sequencing (WXS)  and bulk RNA sequencing (RNA-Seq) in 35 pre-treatment tumor biopsies and matching germline for tumor mutational burden (TMB), BM1/BM2 transcriptional","Not Applicable","Colorectal Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 28 variables, 159 samples sequenced, 34 subjects, 159 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2024-05-09","2024-05-09","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs000933.v4.p1","Genomic Profiling of Melanoma","This study reports on genomic profiling [whole-exome sequencing (WXS), bulk RNA sequencing (RNA-seq), and/or single-cell RNA sequencing (scRNA-seq)] of patient-derived melanoma samples and matched normal samples. The goal is to  elucidate the genetic and cellular basis of sun-exposed and sun-shielded melanomas and to relate these findings to survival and regional metastasis.","Not Applicable","Melanoma","Case Set","other","RNA-Seq, SNV (.MAF), SNV Aggregate (.MAF), WXS","4 phenotype datasets, 14 variables, 3 molecular datasets, 999 samples sequenced, 403 subjects, 999 samples","","NCI","DS-M-MDS-GSO --- Disease-Specific (Melanoma, MDS, GSO)","2024-05-06","2022-01-27","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001657.v3.p1","Functional Genomic Landscape of Acute Myeloid Leukemia","The implementation of targeted therapies for acute myeloid leukemia has been challenged by complex mutational patterns within and across patients as well as a dearth of pharmacologic agents for most  mutational events. The initial findings from the Beat AML program were from a cohort of 672 tumor specimens collected from 562 patients. Additional","Not Applicable","Leukemia, Myeloid, Acute","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","3 phenotype datasets, 9 variables, 72 samples sequenced, 829 subjects, 2161 samples","","NCI","DS-LEU --- Disease-Specific (Leukemia)","2024-05-02","2019-08-26","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs002431.v1.p1","Childhood Cancer Data Initiative (CCDI): Enhancement of Data Sharing in    Pediatric, Adolescent and Young Adult Cancers","NCI's Childhood Cancer Data Initiative (CCDI) is building a community centered around childhood cancer care and research data. Through enhanced data sharing, we can improve our understanding of cancer biology  to improve preventive measures, treatment, quality of life, and survivorship, as well as ensure that researchers learn from every child with cancer.","Not Applicable","Neoplasms","Clinical Genetic Testing","Not Provided","Not Provided","2 phenotype datasets, 7 variables, 611 subjects, 1448 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-04-23","2024-04-23","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003275.v1.p1","Prediction of Resistance and Sensitivity to HER2 Targeted Therapy in the    Neoadjuvant Setting","Women with breast cancers that overexpress HER2 are at greater risk for disease progression and death than women whose tumors do not overexpress HER2. Trastuzumab, a recombinant humanized monoclonal antibody  against the extracellular domain of the HER2 protein blocks downstream signaling of HER2 and substantially improves the efficacy of chemotherapy in","Not Applicable","Breast Neoplasms","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 26 variables, 245 samples sequenced, 245 subjects, 245 samples","","NCI","HMB-NPU --- Health/Medical/Biomedical (NPU)","2024-04-17","2024-04-17","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002677.v1.p1","Childhood Cancer Data Initiative (CCDI): Integrating Longitudinal    Clinical, Sociodemographic and Genomic Data into the NCCR","The goal of this study is to contribute clinical and genomic data from a large institutional cohort of pediatric cancer patients who had tumor genomic profiling between 2013 and 2019  at Dana-Farber/Boston Children's Hospital Cancer and Blood Disorders Center. Clinical data include demographics, diagnosis (classified according to","Not Applicable","Pediatrics","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 835 subjects, 835 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-04-16","2024-04-16","Rare Diseases; Sarcoma, Ewing; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm",""
"phs003522.v1.p1","Epigenetic Damage in Women Living in LA Food-Desert Zip Codes","This study investigated the impact of insulin resistance on chromatin acetylation and inflammation. Blood samples were obtained from women consented to City of Hope Institutional Review Board (IRB)-approved COH Protocol#/Ref#:18306/158149.  Women provided demographic information and completed a survey assessing diet, housing and medical history. BMI was obtained from medical records.","Not Applicable","Insulin Resistance","Case Set","Not Provided","ChIP-Seq","4 phenotype datasets, 13 variables, 30 samples sequenced, 30 subjects, 30 samples","","NCI","GRU --- General Research Use","2024-04-15","2024-04-15","",""
"phs001587.v3.p1","Characterization of Prostate Cancer Organoids","Using models from the LuCaP series as well as those generated at the National Cancer Institute, we have established organoids for in vitro mechanistic testing, including drug screening and genetic  manipulation. The major findings from these continuing studies is the durability of organoids for maintaining complex subpopulation and intratumoral","Not Applicable","Prostatic Neoplasms","Case Set","HumanOmniExpress-24","ATAC-seq, SNP Genotypes (Array), ChIP-Seq, RNA-Seq, WGS, WXS","5 phenotype datasets, 17 variables, 1 molecular datasets, 153 samples sequenced, 34 subjects, 165 samples","","NCI","GRU --- General Research Use","2024-04-09","2018-06-25","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003102.v1.p1","Multivalent State Transitions Shape the Intratumoral Composition of Small    Cell Lung Carcinoma","Small cell lung carcinoma (SCLC) is an aggressive, tobacco-associated tumor characterized by rapid growth, early metastases, and initial response followed by almost invariable resistance to chemotherapy. Studies to date have  not resolved the extent that diverse transcriptional programs drive SCLC and contribute to its lethality. We combined patient-derived xenograft (PDX)","Not Applicable","Small Cell Lung Carcinoma","Xenograft","Not Provided","RNA-Seq","5 phenotype datasets, 20 variables, 70 samples sequenced, 64 subjects, 70 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2024-04-03","2024-04-03","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL",""
"phs003561.v1.p1","Spatial Transcriptomics Reveals Discrete Tumor Microenvironments and    Autocrine Loops Within Ovarian Cancer Subclones","Ovarian masses from patients with high grade serous ovarian carcinoma undergoing debulking surgery were subjected to spatial transcriptomics profiling using the 10x Genomics Visium (fresh frozen) platform. Copy number inference  using inferCNV predicted the presence of subclones with mutually exclusive copy number alterations (CNAs) in 5 of the 8 patient samples studied. In","Not Applicable","Carcinoma, Ovarian Epithelial","Tumor vs. Matched-Normal","Not Provided","WGS","4 phenotype datasets, 16 variables, 12 samples sequenced, 2 subjects, 13 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2024-03-25","2024-03-25","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian",""
"phs003535.v1.p1","Integrating Genomic and Transcriptomic Data to Identify Breast Cancer    Susceptibility Genes","Genetic factors play an important role in the etiology of both sporadic and familial breast cancer. Since 2007, common genetic variants in 200 loci have been identified in genome-wide association  studies (GWAS) in relation to breast cancer risk. However, it is often difficult to translate GWAS findings to disease prevention and treatment since","Not Applicable","Breast Neoplasms","Collection","custom_markerset","SNP Genotypes (Array), RNA-Seq","4 phenotype datasets, 14 variables, 1 molecular datasets, 150 samples sequenced, 150 subjects, 150 samples","","NCI","DS-BRCA-PUB-NPU-MDS --- Disease-Specific (Breast Cancer, PUB, NPU, MDS)","2024-03-22","2024-03-22","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002857.v2.p1","MSK SPECTRUM - SPatiotemporal Evolution of Cancer Traced Using    Multimodalities","MSK SPECTRUM is a multi-modal, interdisciplinary prospective study of spatiotemporal determinants of high-grade serous ovarian cancer (HGSOC) evolution, treatment and response. Accounting for 80% of ovarian cancers, HGSOC is the  most lethal gynecological malignancy and is a cancer of major unmet clinical need. Challenges in disease management relate to several unresolved","Not Applicable","Ovarian Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","5 phenotype datasets, 16 variables, 51 subjects, 167 samples","","NCI","GRU --- General Research Use","2024-03-22","2023-01-20","Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic",""
"phs002171.v1.p1","Serrated Colorectal Cancer: An Emerging Disease Subtype","This dataset represents two combined study populations. Serrated Colorectal Cancer: An Emerging Disease Subtype (called the Advanced Colorectal Cancer of Serrated Subtype Study or ACCESS Study) was a grant awarded  to investigate a newly-recognized, biologically-distinct subtype of colorectal cancer (CRC) called &#x0201c;serrated CRC.&#x0201d; The objective of","Not Applicable","Colorectal Neoplasms","Case Set","imputation_panel, custom_PCR_marker_set","SNP Genotypes (imputed), Short Tandem Repeats (PCR)","7 phenotype datasets, 371 variables, 2 molecular datasets, 1364 subjects, 1466 samples","European (1126), African (1), East Asian (27), African American (17), Hispanic1 (5), Hispanic2 (36), Other Asian or Pacific Islander (24), South Asian (5), Other (3)","NCI","GRU --- General Research Use, DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS)","2024-03-22","2024-03-22","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs003099.v1.p1","Integration of Clinical and Molecular Biomarkers for Melanoma Survival    (Berwick)","The long-term goal of the InterMEL Program Project: Integration of Clinical and Molecular Biomarkers for Melanoma Survival is to identify molecular and clinical factors that predict survival of melanoma patients.  Our overarching hypothesis is that we can identify factors in the primary melanoma tumor that will lead to more aggressive disease. Melanoma patients","Not Applicable","Biomarkers, Tumor","Case-Control","MethylationEPIC, custom_probe_set","Methylation (CpG), miRNA Expression (Array), Targeted-Capture","4 phenotype datasets, 33 variables, 2 molecular datasets, 569 samples sequenced, 697 subjects, 697 samples","","NCI","GRU --- General Research Use","2024-03-21","2024-03-21","Not Provided",""
"phs000206.v6.p3","Whole Genome Scan for Pancreatic Cancer Risk in the Pancreatic Cancer    Cohort Consortium and Pancreatic Cancer Case-Control Consortium    (PanScan)","Within the framework of the NCI-sponsored Cohort Consortium, investigators from 12 prospective epidemiologic cohorts formed the Pancreatic Cancer Cohort Consortium in 2006. This study, also known as ""PanScan"", is funded  by the National Cancer Institute (NCI) and involves conducting a genome-wide association study (GWAS) of common genetic variants to identify markers","Not Applicable","Pancreatic Neoplasms","Case-Control","Human610-Quad, HumanHap550, Human610-Quad, HumanHap550, HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 15 variables, 1 documents, 3 analyses, 2 molecular datasets, 9437 subjects, 9702 samples","European (8770), African (5), East Asian (320), African American (161), Hispanic1 (33), Hispanic2 (92), Other Asian or Pacific Islander (31), South Asian (14), Other (11)","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods, DS-PACA-GSO --- Disease-Specific (Pancreatic Cancer, GSO), DS-PACA-IRB-COL-GSO --- Disease-Specific (Pancreatic Cancer, IRB, COL, GSO), GRU --- General Research Use, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO)","2024-03-18","2015-09-25","Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001437.v2.p1","Pediatric Preclinical Testing Consortium (PPTC)","The Pediatric Preclinical Testing Consortium (PPTC) is addressing the unmet need of streamlining the development of new therapies for childhood cancers. The PPTC seeks to develop robust biomarkers of anticancer  drug activity, and the majority of these are predicted to be genetic mutations that can be detected in tumor DNA and/or RNA. In order to design the","Not Applicable","Leukemia, Lymphoid","Xenograft","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 33 variables, 300 samples sequenced, 267 subjects, 301 samples","","NCI","GRU --- General Research Use","2024-03-14","2019-09-25","Neoplasms, Germ Cell and Embryonal; Sarcoma, Ewing; ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002834.v1.p1","Clinical and Molecular Features of Acquired Resistance to Immunotherapy    in Non-Small Cell Lung Cancer","PD-(L)1 blockade has been shown to promote durable responses in non-small cell lung cancer (NSCLC) patients and has been rapidly incorporated into the treatment regimens for many with advanced disease.  Despite this, mechanisms of acquired resistance (AR) to PD-(L)1 have not been well understood. To address the clinical and molecular landscape of AR","Not Applicable","Immune Checkpoint Inhibitors","Case Set","Not Provided","WXS","5 phenotype datasets, 27 variables, 57 samples sequenced, 29 subjects, 57 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-03-13","2024-03-13","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell",""
"phs002185.v2.p1","Genome-Wide Association Study of Genetic Susceptibility for Graft-vs-Host    Disease Cohort 1","Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is the only curative therapy for many advanced hematologic malignancies. Allo-HSCT is associated with significant morbidities and mortality, mainly because of the graft-versus-host disease  (GVHD) caused by donor T cells recognizing antigens present in recipient tissues, and initiating an alloimmune response resulting in damage to many","Not Applicable","Graft vs Host Disease","Prospective Longitudinal Cohort","Global_Diversity_Array-8, imputation_panel","SNP/CNV (Array), SNP/CNV Genotypes (imputed)","4 molecular datasets, 9352 subjects, 9518 samples","European (5030), African (15), East Asian (108), African American (207), Hispanic1 (70), Hispanic2 (313), Other Asian or Pacific Islander (37), South Asian (41), Other (45)","NCI","DS-HCTCT-GSO --- Disease-Specific (Hematopoietic Cell Transplantation and Cell Therapy, GSO)","2024-03-13","2024-03-13","Myelodysplastic-Myeloproliferative Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Disease, Graft-Versus-Host; Disease, Graft-vs-Host; Disease, Homologous Wasting; Disease, Runt",""
"phs003404.v1.p1","Genomic Analysis of Prostate Tumor Heterogeneity in Metastasis","To investigate the molecular changes, mutations, and signaling pathways that characterize the initial steps of prostate cancer metastasis to the lymph nodes, we analyzed 19 discrete lymph node (LN) metastases,  97 primary tumor foci, 39 benign lymph nodes, and 10 normal adjacent prostate tissue samples from 43 patients enrolled in a clinical trial","Not Applicable","Prostatic Neoplasms","Tumor vs. Matched-Normal","WES_markerset_grc38, WES_markerset_grc38, WES_markerset_grc38","RNA-Seq, SNP/CNV Genotypes (NGS), SNV (.MAF), WXS","4 phenotype datasets, 30 variables, 1 molecular datasets, 302 samples sequenced, 43 subjects, 302 samples","","NCI","GRU --- General Research Use","2024-03-12","2024-03-12","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003517.v1.p1","A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor    Musculoskeletal Symptoms (AIMSS)","Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) are common and frequently lead to Aromatase Inhibitor (AI) discontinuation. Single nucleotide polymorphisms (SNPs) in candidate genes have been associated with AIMSS and AI discontinuation.  E1Z11 is a prospective cohort study designed to validate associations between 10 SNPs and AI discontinuation due to AIMSS. We enrolled postmenopausal","Not Applicable","Musculoskeletal System","Prospective Longitudinal Cohort","custom_markerset","SNP Genotypes (Array)","4 phenotype datasets, 13 variables, 1 molecular datasets, 970 subjects, 970 samples","","NCI","GRU --- General Research Use","2024-03-07","2024-03-07","Not Provided",""
"phs003474.v1.p1","A Missense SNP in the Tumor Suppressor SETD2 Reduces H3K36me3 and Mitotic    Spindle Integrity in Drosophila","While examining DNA from renal cell carcinoma (RCC) patients we observed a single nucleotide polymorphism (SNP; rs58906143,chr3:47163422 C&#x02192;G (hg19); E902Q ) within SETD2 that was overrepresented in kidney cancer patients  compared to control patients. This original study utilized directed sequencing of 14 genes. In an expanded study using a Taqman assay to study the","Not Applicable","Kidney Neoplasms","Case-Control","custom_PCR_marker_set","SNP Genotypes (PCR), Targeted-Capture","4 phenotype datasets, 14 variables, 1 molecular datasets, 180 samples sequenced, 758 subjects, 758 samples","","NCI","GRU --- General Research Use","2024-03-05","2024-03-05","Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney",""
"phs002486.v2.p1","Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small    Cell Lung Cancer","We performed a trial of adoptive cell therapy using tumor infiltrating lymphocytes (TIL) in metastatic non-small cell lung cancer (NSCLC). We conducted a single-arm open- label phase 1 trial (NCT03215810)  of TIL administered with nivolumab in 20 patients with advanced NSCLC. Patients had tumor metastases resected for TIL, and the sequencing data from","Not Applicable","Carcinoma, Non-Small-Cell Lung","Clinical Trial","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 26 variables, 103 samples sequenced, 20 subjects, 103 samples","","NCI","HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU)","2024-03-01","2021-09-02","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs003410.v1.p1","A Human Lymphoma Organoid Model for Evaluating and Targeting the    Follicular Lymphoma Tumor Immune Microenvironment","Heterogeneity in the tumor microenvironment (TME) of follicular lymphoma (FL) can affect clinical outcomes. We developed a new organoid culture method for cultivating patient-derived lymphoma organoids (PDLOs), which include cells  from the native FL TME. We generated organoids from 12 FL patients at diagnosis, clinical progression, or relapse. These organoids were profiled with","Not Applicable","Lymphoma, Follicular","Case Set","custom_probe_set","RNA-Seq, RNA Seq (NGS), Targeted-Capture","4 phenotype datasets, 18 variables, 1 molecular datasets, 127 samples sequenced, 12 subjects, 127 samples","","NCI","DS-HLCA-IRB-PUB-COL --- Disease-Specific (Hodgkin Lymphoma, IRB, PUB, COL)","2024-02-29","2024-02-29","Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC; Follicle Center Lymphoma",""
"phs003486.v1.p1","Acquired Cross-Resistance in Small Cell Lung Cancer Patient-Derived    Xenografts","Here we present whole genome sequencing and RNA sequencing of patient-derived xenograft (PDX) models of small cell lung cancer (SCLC). These models were derived at a variety of clinical time  points from either biopsy/resection samples, malignant effusions, or circulating tumor cells (CTCs), and grown in the subcutaneous flank of NSG","Not Applicable","Small Cell Lung Carcinoma","Xenograft","WGS_markerset_grc38, RNAseq_probe_set_grc38, WGS_markerset_grc38, RNAseq_probe_set_grc38","RNA-Seq, SNP/CNV Genotypes (NGS), RNA Seq (NGS), WGS, WXS","4 phenotype datasets, 20 variables, 1 molecular datasets, 133 samples sequenced, 42 subjects, 133 samples","","NCI","GRU --- General Research Use","2024-02-12","2024-02-12","DNA Damage; DNA Injuries; DNA Injury; DNA Lesion; DNA Lesions; Deoxyribonucleic acid damage","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003435.v1.p1","Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma","In this study, we show that the plasma representation of mutations exceeds the bulk tumor representation in most cases, making classic Hodgkin Lymphoma (cHL) particularly amenable to noninvasive profiling. Leveraging  single-cell transcriptional profiles of cHL tumors, we demonstrate hazard ratios (HRs) circulating tumor DNA (ctDNA) shedding to be shaped by","Not Applicable","Hodgkin Disease","Case-Control","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), Targeted-Capture, WXS","4 phenotype datasets, 19 variables, 1 molecular datasets, 1195 samples sequenced, 445 subjects, 1281 samples","","NCI","DS-LYM-IRB-PUB-COL --- Disease-Specific (Lymphoma, IRB, PUB, COL)","2024-02-12","2024-02-12","CHL; Classic Hodgkin disease; Disease, Hodgkin; Disease, Hodgkin's; Disease, Hodgkins; Familial Hodgkin Disease",""
"phs000673.v5.p1","University of Michigan Clinical Sequencing Exploratory Research (CSER)","Overview. The personalization of therapy for cancer will require molecular characterization of unique and shared genetic aberrations. In particular, patients who have a sarcoma or other rare cancers and are  candidates for clinical trials could potentially benefit by identifying eligibility for ""targeted"" drugs based on the ""actionable"" genes in their","Not Applicable","Neoplasms","Case Set","Not Provided","RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 21 variables, 4403 samples sequenced, 1427 subjects, 4403 samples","","NCI","GRU --- General Research Use","2024-02-12","2014-11-13","Sarcoma; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002183.v1.p1","The Multiethnic Cohort (MEC) Study","The Multiethnic Cohort (MEC) study of over 215,000 men and women in Hawaii and California is unique in that it is population-based and includes large representations of older adults (45-75  years at baseline) for five US racial/ethnic groups (Japanese Americans, African Americans, European Americans, Latinos and Native Hawaiians) at","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Global_Diversity_Array-8","SNP/CNV (Array)","9 phenotype datasets, 210 variables, 1 molecular datasets, 204142 subjects, 34213 samples","","NCI","DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2024-02-09","2024-02-09","Risk Factors; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs003447.v1.p1","MAESTRO-Pool Enables Highly Parallel and Specific Mutation-Enrichment    Sequencing for Minimal Residual Disease Detection in Cohort Studies","MAESTRO-Pool builds upon the technology MAESTRO (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) by pooling tumor-specific MAESTRO probes from multiple patients and applying these to all samples from all patients.  In this study, MAESTRO-Pool was applied to a cohort of 9 melanoma patients where 98 plasma samples were screened for 22,333 mutations. Additionally,","Not Applicable","Melanoma","Methods","target_markerset_grc37","SNV Aggregate (.MAF), Targeted-Capture, WGS","3 phenotype datasets, 18 variables, 1 molecular datasets, 234 samples sequenced, 9 subjects, 234 samples","","NCI","DS-MSC-MDS --- Disease-Specific (Melanoma and Skin Cancer Research, MDS)","2024-02-08","2024-02-08","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001451.v5.p1","A Phase I Study with a Personalized Neoantigen Cancer Vaccine in Melanoma","Effective anti-tumor immunity in humans has been associated with presence of T cells targeting neoantigens that arise from non-silent tumor-specific mutations. Here we conducted whole-exome sequencing of tumor and normal  cells from individual patients to identify mutations. We assessed the expression of mutated alleles by RNA-sequencing of tumor. We demonstrated the","Not Applicable","Melanoma","Clinical Trial","Not Provided","OTHER, RNA-Seq, WGS, WXS","4 phenotype datasets, 15 variables, 132 samples sequenced, 12 subjects, 132 samples","","NCI","GRU --- General Research Use","2024-01-26","2018-02-28","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001228.v2.p2","Gabriella Miller Kids First (GMKF) Pediatric Research Program in    Susceptibility to Ewing Sarcoma Based on Germline Risk and Familial    History of Cancer","Ewing sarcoma (EWS) is a deadly bone cancer that occurs in children and adolescents. Mounting evidence suggests that a genetic predisposition exists for this pediatric cancer, although the specific genetic  contribution has yet to be identified. EWS has never been linked to a specific cancer predisposition syndrome, although several case reports have","Not Applicable","Sarcoma, Ewing","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 1332 subjects, 1505 samples","","NCI","GRU --- General Research Use","2024-01-26","2018-06-18","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002989.v1.p1","Genomic Analysis of Follicular Lymphoma","We included tumors from newly diagnosed or untreated follicular lymphoma in this study. Samples consented to the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence (SPORE)  were included for data sharing. RNA was extracted from 1) CD19 sorted B cells from tumor cell suspension frozen in dimethyl sulfoxide (DMSO; RNA","Not Applicable","Lymphoma, Follicular","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 18 variables, 430 samples sequenced, 117 subjects, 430 samples","","NCI","GRU --- General Research Use","2024-01-24","2024-01-24","Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC; Follicle Center Lymphoma","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs001998.v2.p1","Evolutionary Analysis of Chronic Lymphocytic Leukemia Cells During    Relapse After Allogeneic Hematopoietic Stem Cell Transplant","We investigated the molecular dynamics driving relapse of chronic lymphocytic leukemia (CLL) following allogeneic hematopoietic stem cell transplant (allo-HSCT) through an integrated analysis of whole exome, bulk transcriptome, bulk methylome  and single cell transcriptional data from paired leukemic samples representing 19 patients. We found that their clinical kinetics corresponded to","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","Not Provided","Bisulfite-Seq, OTHER, RNA-Seq, WXS","3 phenotype datasets, 9 variables, 40 samples sequenced, 19 subjects, 40 samples","","NCI","GRU --- General Research Use, DS-HM-MDS --- Disease-Specific (Hematological Malignancies, MDS)","2024-01-24","2021-07-22","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003446.v1.p1","Profiling RNA Translation in Pediatric Medulloblastoma","This study provides RNA-sequencing and ribosome profiling data for patient-derived cell lines and patient tissue samples for children with medulloblastoma. Ribosome profiling is a variant protocol of RNA-sequencing that directly  sequences ribosome-bound RNA fragments only. Associated RNA-seq and Ribo-seq data obtained separately for some cancer cell lines can be found on the","Not Applicable","Medulloblastoma","Collection","Not Provided","OTHER, RNA-Seq","3 phenotype datasets, 10 variables, 57 samples sequenced, 21 subjects, 57 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-01-18","2024-01-18","Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic",""
"phs001820.v3.p1","The Institute for Genomic Medicine at Nationwide Children's Hospital    Pediatric Cancer and Blood Disorder Project","The aim of this study is to enable the unification of the clinical and research arms of comprehensive genomic profiling in the setting of cancer and hematologic disease. Increasingly, studies  of the genomic etiology of cancer and hematologic diseases are being utilized for patient management, including prognostication, informing diagnosis,","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","RNAseq_probe_set_grc38, WES_markerset_grc38, WGS_markerset_grc38, RNAseq_probe_set_grc38, WES_markerset_grc38, WGS_markerset_grc38, RNAseq_gene_transcripts, WES_markerset_grc38, RNAseq_gene_transcripts","FL-cDNA, RNA-Seq, SNP Genotypes (NGS), RNA Seq (NGS), WGA, WGS, WXS","5 phenotype datasets, 27 variables, 2 molecular datasets, 1088 samples sequenced, 259 subjects, 1088 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2024-01-18","2022-08-15","Hematologic Diseases; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour",""
"phs003269.v1.p1","GATA2 Deficiency and the MonoMAC Syndrome","The aim of this study was to identify the germline mutation(s) in an extended family with individuals having MonoMAC Syndrome/GATA2 deficiency but lacking a canonical GATA2 mutation. GATA2 deficiency patients  develop bone marrow failure, severe immunodeficiency and may progress to myeloid malignancies, including myelodysplastic syndrome (MDS), acute","Not Applicable","Bone Marrow Failure Disorders","Case Set","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGA","5 phenotype datasets, 21 variables, 1 molecular datasets, 6 samples sequenced, 6 subjects, 6 samples","","NCI","GRU --- General Research Use","2024-01-17","2024-01-17","Bone Marrow Transplantation; Congenital Bone Marrow Failure Syndromes; Bone Marrow Failure; Bone marrow hypoplasia; Failure, Bone Marrow; Hypoplastic bone marrow","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003188.v1.p1","Overcoming Clinical Resistance to EZH2 Inhibition Using Rational    Epigenetic Combination Therapy","Essential epigenetic dependencies have become evident in many cancers. Based on functional antagonism between BAF/SWI/SNF and PRC2 in SMARCB1-deficient sarcomas, we and colleagues recently completed the clinical trial of the  EZH2 inhibitor tazemetostat, leading to its FDA approval. However, the principles of tumor response to epigenetic therapy in general and tazemetostat","Not Applicable","Drug Resistance, Neoplasm","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","3 phenotype datasets, 12 variables, 17 samples sequenced, 11 subjects, 17 samples","","NCI","HMB --- Health/Medical/Biomedical","2024-01-17","2024-01-17","Not Provided",""
"phs003412.v1.p1","A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus    Nivolumab in Stage IV Squamous Cell Lung Cancer","Lung-MAP (S1400, NCT02785952) was a multicenter, open-label, phase III randomized clinical trial. The Lung-MAP-I substudy (S1400I) was conducted from December 2015 to April 2018, through the National Clinical Trials Network  and led by the SWOG Cancer Research Network. The trial compared nivolumab plus ipilimumab (nivo+ipi) with nivolumab monotherapy (nivo) in patients","Not Applicable","Carcinoma, Non-Small-Cell Lung","Interventional","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 160 subjects, 731 samples","","NCI","GRU --- General Research Use","2024-01-11","2024-01-11","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs001983.v1.p1","HTAN Pilot Project: Single-Cell Transcriptomics Toolbox for Fresh and    Frozen Human Tumors (Lung, Breast, Ovarian, Melanoma, Neuroblastoma,    Sarcoma, Glioblastoma, Glioma, and Leukemia)","Single cell transcriptomics is a powerful tool to map the complex tumor microenvironment, providing unprecedented resolution into cell types, cell states, cell interactions, and tumor heterogeneity. Depending on their tissue  site and whether processing begins from a fresh or frozen sample, different tumors require different optimizations in order to obtain high quality","Not Applicable","Carcinoma, Non-Small-Cell Lung","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 21 variables, 13 samples sequenced,  SRA, 23 subjects, 40 samples","","NCI","GRU --- General Research Use, DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB --- Health/Medical/Biomedical","2024-01-10","2024-01-10","Leukemia, Lymphoid; Sarcoma; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor",""
"phs002178.v1.p1","Genomic Characterization CS-MATCH-0007 Arm S2","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 252 variables, 3 subjects, 3 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-01-08","2024-01-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002153.v1.p1","Genomic Characterization CS-MATCH-0007 Arm S1","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 277 variables, 41 subjects, 41 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-01-08","2024-01-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002058.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Z1I","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 413 variables, 26 subjects, 26 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-01-08","2024-01-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002029.v1.p1","Genomic Characterization CS-MATCH-0007 Arm R","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 374 variables,  SRA, 28 subjects, 28 samples","","NCI","GRU-COL --- General Research Use (COL)","2024-01-08","2024-01-08","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003416.v1.p1","Transcriptomic and Epigenetic Profiling of SCLC Patient Samples","Small cell lung cancer (SCLC) is an aggressive disease with poor outcomes and limited treatment options. Recent studies have identified transcriptionally defined subsets of SCLC that may allow for the  personalization of treatment. Here we use transcriptomic sequencing and methylation profiling (RRBS) of biopsy and cfDNA to develop a highly accurate","Not Applicable","Small Cell Lung Carcinoma","Case Set","Not Provided","Bisulfite-Seq, RNA-Seq","4 phenotype datasets, 13 variables, 344 samples sequenced, 181 subjects, 344 samples","","NCI","GRU --- General Research Use","2023-12-28","2023-12-28","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002430.v1.p1","Childhood Cancer Data Initiative (CCDI): Genomic Analysis in Pediatric    Malignancies","Pediatric solid tumors are highly heterogeneous, encompassing a large number of histotypes. The genomic landscape of these diseases is characterized by few single-nucleotide variants (SNVs) compared to adult cancers. In  contrast, many exhibit a high prevalence of structural or epigenetic changes that alter gene expression, underlining the need for comprehensive","Not Applicable","Pediatrics","Collection","Not Provided","Not Provided","2 phenotype datasets, 7 variables, 239 subjects, 500 samples","","NCI","GRU --- General Research Use","2023-12-27","2023-12-27","Rare Disease; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs003141.v1.p1","Integrative Somatic and Germline Computational Biology to Redefine    Clinical Actionability in Solid Tumors","Neuroendocrine tumors (NETs) are rare cancers that arise in the gastrointestinal tract and pancreas. The fundamental mechanisms driving gastroenteropancreatic NETs (GEP-NETs) growth remain incompletely elucidated; however, the heterogeneous clinical behavior  of GEP-NETs suggests that both cellular lineage dynamics and tumor microenvironment influence tumor pathophysiology. Here, we performed single-cell","Not Applicable","Gastro-enteropancreatic neuroendocrine tumor","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 8 samples sequenced, 8 subjects, 8 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-12-21","2023-12-21","Carcinoid Tumor; Intestinal Neoplasms; Neuroendocrine Tumors; Carcinoid; Carcinoid tumor (disease); Carcinoid tumors",""
"phs001519.v2.p1","A Phase I Study With a Personalized Neoantigen Cancer Vaccine in    Glioblastoma Multiforme","Neoantigens, which are derived from tumor-specific protein-coding gene mutations, are exempt from central tolerance, can generate robust immune responses and function as bona fide antigens that facilitate tumor rejection. A  strategy of using multi-epitope and personalized neoantigen vaccination has previously been tested in patients with high-risk melanoma. We","Not Applicable","Glioblastoma","Clinical Trial","Not Provided","OTHER, RNA-Seq, WXS","4 phenotype datasets, 14 variables, 33 samples sequenced, 11 subjects, 33 samples","","NCI","GRU --- General Research Use, HMB --- Health/Medical/Biomedical","2023-12-20","2018-12-14","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs002164.v1.p1","Translating Gene-Calcium Interactions to Precision Medicine for    Colorectal Cancer","Identify functional and rare SNPs and their interactions with Ca intake levels in relation to risk of incident adenoma using whole-exome resequencing of 2468 colorectal adenoma cases and controls from  PLCO. We will genotype promising rare and functional SNPs associated with incident adenoma in 570 incident cancer cases, 1,710 healthy controls, 710","Not Applicable","Colorectal Adenoma","Case-Control","WES_markerset_grc38","SNP/CNV Genotypes (NGS)","4 phenotype datasets, 16 variables, 1 molecular datasets, 2269 subjects, 2269 samples","","NCI","GRU --- General Research Use","2023-12-19","2023-12-19","Not Provided",""
"phs001752.v2.p1","Genomics and Methylation of Neuroendocrine Prostate Cancer from cfDNA    (Cornell/Trento 2019)","A subset of castration resistant prostate cancers develop small cell neuroendocrine prostate cancer (NEPC) as a mechanism of treatment resistance. Metastatic tissue biopsies to evaluate for NEPC transformation are invasive  and challenging to perform serially. We performed whole exome and whole genome bisulfite sequencing of plasma cfDNA and matched tumor biopsy samples","Not Applicable","Adenocarcinoma","Prospective Longitudinal Cohort","Not Provided","Bisulfite-Seq, WXS","3 phenotype datasets, 10 variables, 185 samples sequenced, 65 subjects, 185 samples","","NCI","HMB-IRB --- Health/Medical/Biomedical (IRB)","2023-12-18","2020-02-21","Neuroendocrine Tumors; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma",""
"phs003466.v1.p1","Breast Cancer in Blacks: Impact of Genomics, Healthcare Use and Lifestyle    on Outcomes (BRIGHT)","Young Black females bear a disproportionate burden of breast cancer (BC) mortality compared to White females and are underrepresented in clinical studies. It remains critical to understand factors that contribute  to the high mortality from BC among young Black females in order to improve outcomes. The higher BC mortality rate among young Black females with","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","nCounter_GeneExpressionAssay, nCounter_GeneExpressionAssay, Multi-Ethnic_Global","SNP Genotypes (Array), mRNA Expression (Array)","4 phenotype datasets, 20 variables, 1 molecular datasets, 378 subjects, 481 samples","","NCI","DS-BRCA-GSO --- Disease-Specific (Breast Cancer, GSO)","2023-12-15","2023-12-15","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001818.v4.p1","Single-Cell Genomic Analysis of Gastrointestinal Cancer","Our study aimed to define the heterogeneity of gastrointestinal cancers at a single-cell resolution. We subjected single-cell suspensions derived from surgical resections of gastrointestinal cancer tissue, paired normal tissue, peripheral  blood mononuclear cells (PBMCs) or their ex vivo cultures to high-throughput microfluidics based single-cell RNA and DNA sequencing. We analyzed the","Not Applicable","Stomach Neoplasms","Case Set","Not Provided","OTHER, WGS","4 phenotype datasets, 21 variables, 136 samples sequenced, 40 subjects, 136 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-12-11","2019-10-04","Appendiceal Cancer; Metaplasia; Appendiceal Neoplasm; Appendiceal Neoplasms; Appendiceal tumor; Appendix Tumor","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002458.v2.p1","Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome (RS)","Richter's syndrome arising from chronic lymphocytic leukemia is a striking example of an aggressive malignant histology that emerges from indolent cancer. To understand this process, we reconstructed phylogenies based on  whole exome sequencing of matched normal, CLL and RS samples. We computationally deconvoluted CLL and RS clones and identified drivers of","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 16 variables, 358 samples sequenced, 133 subjects, 384 samples","","NCI","GRU --- General Research Use, HMB --- Health/Medical/Biomedical, DS-HM-MDS --- Disease-Specific (Hematological Malignancies, MDS)","2023-12-05","2021-11-23","Cell Transformation, Neoplastic; Cell Neoplastic Transformation; Cell Neoplastic Transformations; Cell Transformations, Neoplastic; Neoplastic Cell Transformations; Neoplastic Transformation, Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003428.v1.p1","CALGB/SWOG 80405: Genome-Wide Association Study of Patients with Advanced    or Metastatic Colorectal Cancer Treated with First-Line Chemotherapy    Combined with Cetuximab and/or Bevacizumab","CALGB/SWOG 80405 (NCT00265850) was a randomized phase III study of bevacizumab, cetuximab, or the combination of these two monoclonal antibodies, in addition to systemic chemotherapy for patients with untreated metastatic  adenocarcinoma of the colon or rectum. We prospectively collected germline DNA and conducted genome-wide association studies using clinical outcomes","Not Applicable","Colorectal Neoplasms","Clinical Trial","WES_markerset_grc38","SNP Genotypes (NGS)","4 phenotype datasets, 66 variables, 1 molecular datasets, 1464 subjects, 1464 samples","European (1192), African (3), East Asian (25), African American (151), Hispanic1 (12), Hispanic2 (62), Other Asian or Pacific Islander (13), South Asian (4), Other (2)","NCI","DS-CA-COL --- Disease-Specific (Cancer, COL)","2023-12-04","2023-12-04","Adenocarcinoma; Neoplasm Metastasis; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs003381.v1.p1","Cryptic Splice Mutation in the Fumarate Hydratase Gene in Patients With    Clinical Manifestations of Hereditary Leiomyomatosis and Renal Cell    Cancer (HLRCC)","Four patients with hysterectomy were evaluated for biochemical and molecular evidence of autosomal dominant Fumarate Hydratase (FH) alterations causing Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). HLRCC is an autosomal  dominant condition characterized by the development of cutaneous and uterine leiomyomas, and risk for development of an aggressive form of papillary","Not Applicable","Hereditary leiomyomatosis and renal cell cancer","Case Set","WGS_markerset_grc38","SNP/CNV Genotypes (NGS), WGS","5 phenotype datasets, 17 variables, 1 molecular datasets, 4 samples sequenced, 4 subjects, 4 samples","","NCI","GRU --- General Research Use","2023-12-04","2023-12-04","Cutaneous leiomyomata with uterine leiomyomata; FH Deficiency; Familial leiomyomatosis; Familial leiomyomatosis and renal cell cancer; Familial leiomyomatosis cutis et uteri; Familial leiomyomatosis with renal carcinoma",""
"phs003255.v1.p1","Single Duplex DNA Sequencing with CODEC Detects Mutations with High    Sensitivity","Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (single duplexes) to  discern the true mutations on both strands. Here, we present Concatenating Original Duplex for Error Correction (CODEC) which confers single duplex","Not Applicable","Neoplasms","Collection","Not Provided","Targeted-Capture, WGS","4 phenotype datasets, 16 variables, 30 samples sequenced, 7 subjects, 30 samples","","NCI","GRU --- General Research Use, HMB --- Health/Medical/Biomedical, HMB-IRB --- Health/Medical/Biomedical (IRB)","2023-12-04","2023-12-04","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003436.v1.p1","KRT17High/CXCL8+ Tumor Cells Display Both Classical and Basal Features    and Regulate Myeloid Infiltration in the Pancreatic Cancer    Microenvironment","Recent studies have uncovered the co-existence of basal and classical subtypes within pancreatic ductal adenocarcinoma (PDAC). We sought to characterize these intermediary cells using single-cell RNA sequencing of PDAC. We  performed subtyping on 18 single-cell RNA sequencing human PDAC samples to identify multiple intermediary subtypes. We compared single-cell profiling","Not Applicable","Carcinoma, Pancreatic Ductal","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 16 variables, 6 samples sequenced, 6 subjects, 6 samples","","NCI","DS-PACA --- Disease-Specific (Pancreatic Cancer)","2023-11-30","2023-11-30","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas",""
"phs003230.v1.p1","Temporal Evolution Reveals Bifurcated Lineages in Aggressive    Neuroendocrine Small Cell Prostate Cancer Trans-Differentiation","Trans-differentiation from adenocarcinoma to small cell neuroendocrine (SCN) cancer is an adverse consequence of treatment escape in various cancers, including prostate, lung, and bladder cancers (Balanis and Sheu et al.,  2019 Cancer Cell). Expression of dominant negative p53 (TP53DN), myrAkt1, RB1-shRNA, c-Myc, and Bcl2(PARCB forward transformation) using human","Not Applicable","Carcinoma, Neuroendocrine","Xenograft","RNAseq_gene_transcripts, RNAseq_gene_transcripts, RNAseq_gene_transcripts","ATAC-seq, ChIP-Seq, OTHER, RNA-Seq, RNA Seq (NGS), RNA Seq (NGS)","4 phenotype datasets, 17 variables, 1 molecular datasets, 66 samples sequenced, 11 subjects, 66 samples","","NCI","GRU --- General Research Use","2023-11-27","2023-11-27","Carcinoma, Small Cell; Carcinoma, Oat Cell; Carcinomas, Oat Cell; Carcinomas, Small Cell; Oat Cell Carcinoma; Oat Cell Carcinomas","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003418.v1.p1","Altered Interactions between Circulating and Tissue-Resident CD8 T Cells    with the Colonic Mucosa Define Checkpoint Inhibitor Colitis","Therapeutic immune checkpoint blockade has revolutionized oncology, but treatments are limited by immune-related adverse events, including checkpoint inhibitor colitis (irColitis). To define molecular drivers of irColitis, we profiled 300,000 cells  from the colonic mucosa and blood of 29 patients and controls. Patients with irColitis showed expanded mucosal Tregs (regulatory T cells), CD8","Not Applicable","Colitis","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 171 samples sequenced, 33 subjects, 171 samples","","NCI","GRU --- General Research Use","2023-11-21","2023-11-21","","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003009.v1.p1","Genomic Characterization of Duke Melanoma Brain Metastases","Previous work has shown that melanoma brain metastases (MBM) have a unique molecular profile compared to extracranial metastases (ECM). Description of the biology of MBM and associations between biological features  and clinical outcomes will facilitate the design of rational therapies for patients with MBM. To better characterize the molecular profile of MBM, we","Not Applicable","Brain Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 14 variables, 43 samples sequenced, 14 subjects, 43 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2023-11-21","2023-11-21","Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain",""
"phs002810.v1.p1","Genetic Analysis of Latin American Cervical Cancer","HPV16 is the most oncogenic type of human papillomaviruses (HPV). Integration of HPV into the human genome is an important mechanism of carcinogenesis but is absent in at least 30%  of HPV16+ tumors. We applied long-read whole-genome sequencing (WGS) to cervical cancer cell lines and tumors to characterize HPV16 carcinogenesis in","Not Applicable","Uterine Cervical Neoplasms","Case Set","Not Provided","WGS","4 phenotype datasets, 19 variables, 58 samples sequenced, 58 subjects, 58 samples","","NCI","HMB-NPU --- Health/Medical/Biomedical (NPU)","2023-11-21","2023-11-21","Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms",""
"phs003077.v1.p1","Retinoblastoma Aqueous Humor Liquid Biopsy Repository","This study involves the use of the aqueous humor (AH, the clear fluid in the front of the eye) as an organ specific liquid biopsy for retinoblastoma. This relatively new  liquid biopsy platform was started at CHLA/USC and was developed to overcome the lack of tumor tissue -- due to contraindication to biopsy -- for","Not Applicable","Retinoblastoma","Collection","Not Provided","WGS","4 phenotype datasets, 24 variables, 263 samples sequenced, 81 subjects, 264 samples","","NCI","DS-RET-DIS-IRB-PUB-COL-NPU --- Disease-Specific (Retinal Diseases, IRB, PUB, COL, NPU)","2023-11-20","2023-11-20","Retinal Neoplasms; Cancer of the Retina; Cancer, Retinal; Cancers, Retinal; Malignant Neoplasm of Retina; Malignant Neoplasm of the Retina",""
"phs003093.v1.p1","The Genomic Landscape of Interval Colorectal Cancers","Interval colorectal cancers (CRC), cancers diagnosed after a screening/surveillance exam in which no cancer is detected, and before the date of the next recommended exam, reflect an unprecedented challenge in  CRC detection and prevention. To better understand this poorly characterized CRC variant, we examined the clinical and mutational characteristics of","Not Applicable","Colorectal Neoplasms","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 14 variables, 323 samples sequenced, 168 subjects, 323 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-11-17","2023-11-17","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs003217.v1.p1","Molecular Determinants of Esophageal Cancer in Tanzania","We describe the genomic profiles of 61 esophageal squamous cell carcinoma (ESCC) cases from Tanzania and compare them to profiles from an existing cohort of ESCC cases from Malawi. We  also provide a comparison to ESCC tumors in The Cancer Genome Atlas Program (TCGA). Despite a high burden of ESCC in Eastern Africa, investigations","Not Applicable","Esophageal Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 14 variables, 178 samples sequenced, 61 subjects, 178 samples","","NCI","DS-E-C-NPU --- Disease-Specific (Esophageal Cancer, NPU)","2023-11-16","2023-11-16","Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm",""
"phs003422.v1.p1","Hereditary Gastric Cancer Syndromes: An Integrated Genomic and    Clinicopathologic Study of the Predisposition to Gastric Cancer","Gastric cancers are cancers of the stomach. Hereditary cancers are passed from parent to child. Researchers want to gather data about hereditary gastric cancers. Bulk RNA sequencing (RNA-seq) of signet  ring cells (SRCs) and adjacent non-SRC epithelium (NEP) was performed on laser-capture microdissected (LCM) regions of interest found in","Not Applicable","Stomach Neoplasms","Tumor vs. Matched-Normal","RNAseq_probe_set_grc38","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 19 variables, 1 molecular datasets, 42 samples sequenced, 20 subjects, 42 samples","","NCI","GRU --- General Research Use","2023-11-13","2023-11-13","CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs001282.v4.p1","Pathogenesis and Immunity in Endemic Burkitt Lymphoma","This genomic landscape of Burkitt lymphoma represents a multimodal sequencing of tumors and control tissues and individuals to better understand the etiology, and molecular pathogenesis of Burkitt lymphoma including the  roles of the associated Plasmodium falciparum malaria and EBV infections. Comprehensive sequencing set includes genomic, transcriptomic, and","Not Applicable","Burkitt Lymphoma","Case Set","Not Provided","RNA-Seq, miRNA-Seq, ssRNA-seq","4 phenotype datasets, 25 variables, 44 samples sequenced, 44 subjects, 44 samples","","NCI","DS-BL-PUB-NPU --- Disease-Specific (Burkitt Lymphoma, PUB, NPU)","2023-11-13","2017-02-13","Lymphoma, Non-Hodgkin; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma",""
"phs003143.v1.p1","My Pediatric and Adult Rare Tumor (MyPART) Natural History Study of Rare    Solid Tumors","The goal of this study is to comprehensively and longitudinally evaluate the natural history of patients with rare solid tumors or tumor predisposition syndromes, estimating and defining their clinical spectrum  (e.g. disease course and survival). Clinical data, patient reported outcomes (PROs), and biospecimen associated data are collected. Clinical data","Not Applicable","Rare Diseases","Prospective Longitudinal Cohort","WES_markerset_grc38","SNP/CNV Genotypes (NGS)","18 phenotype datasets, 744 variables, 10 documents, 1 molecular datasets, 497 subjects, 192 samples","","NCI","GRU --- General Research Use","2023-11-03","2023-11-03","Carcinoma, Neuroendocrine; Chordoma; ACC; Adenoid Cystic Carcinoma; Adrenal Cortex Adenocarcinoma; Adrenal Cortex Cancer","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003064.v1.p1","Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in    Patients with Metastatic Cancers","Following enrichment of neoantigen-reactive T cells using pHLA tetramers or cell-surface markers, we performed single-cell sequencing (RNA-seq and TCR-seq) of circulating CD8+ T cells from metastatic cancer patient samples (Melanoma,  Colorectal, and Breast cancer). In samples from previously studied patients, we identified cells bearing neoantigen-reactive T cell receptors and","Not Applicable","Breast Neoplasms","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 29 samples sequenced, 9 subjects, 29 samples","","NCI","GRU --- General Research Use","2023-11-01","2023-11-01","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003402.v1.p1","Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing    Chemoradiation Therapy for Bladder Cancer","Bladder preservation with trimodality therapy (TMT), consisting of transurethral tumor resection followed by chemoradiation, is an alternative to radical cystectomy for muscle-invasive bladder cancer (MIBC), but molecular determinants of response  are poorly understood. Patients with cT2-T4aN0M0 MIBC treated with definitive-intent chemoradiation as part of TMT were retrospectively identified","Not Applicable","Urinary Bladder Neoplasms","Case Set","Not Provided","WXS","76 samples sequenced, 76 subjects, 76 samples","","NCI","DS-BLADDERCA --- Disease-Specific (Bladder Cancer)","2023-10-24","2023-10-24","Urinary Bladder Neoplasm; Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder",""
"phs003249.v1.p1","Deterministic Evolution and Stringent Selection During Pre-Neoplasia","The earliest events during human tumor initiation are poorly characterized but may hold clues as to how to detect and prevent malignancy. Here we model this occult process by engineering  TP53 deficiency in primary human gastric organoids and performing experimental evolution in multiple clonally derived cultures over two years,","Not Applicable","Stomach Neoplasms","Prospective Longitudinal Cohort","WGS_markerset_grc38, WGS_markerset_grc38, WGS_markerset_grc38, WGS_markerset_grc38","AMPLICON, RNA-Seq, CNV Genotypes, WGS","3 phenotype datasets, 11 variables, 1 molecular datasets, 193 samples sequenced, 3 subjects, 193 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-10-24","2023-10-24","CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach",""
"phs002814.v1.p1","Esophageal Squamous Cell Carcinoma Precursor Study","Esophageal cancer is the sixth most common cause of cancer death in the world. High-risk areas occur across central Asia and from eastern to southern Africa, and in these populations,  nearly all of the cases are esophageal squamous cell carcinoma (ESCC). ESCC has a dismal prognosis, largely because symptoms usually appear late in","Not Applicable","Esophageal Squamous Cell Carcinoma","Case Set","Not Provided","WGS","4 phenotype datasets, 17 variables, 66 samples sequenced, 33 subjects, 66 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-10-19","2023-10-19","ESCC; Esophageal Epidermoid Carcinoma; Esophageal SCC; Esophageal Squamous Cell Carcinoma, NOS; Esophageal Squamous Cell Carcinoma, Not Otherwise Specified; Esophagus SCC",""
"phs003378.v1.p1","A Phase I Study of the Treatment of Recurrent Malignant Glioma with    CAN-3110 (AKA rQNestin34.5v.2), a Genetically Engineered HSV-1 Virus","This study is a ""first-in-human"" phase 1 trial of recurrent, IDH wild-type glioblastoma (rGBM) patients treated with CAN-3110 (aka rQNestin34.5v.2), a genetically modified oncolytic herpes simplex virus 1 (HSV-1). The  study was a 3+3 dose-escalation study starting at a single intra-tumoral injection of 106 PFU CAN-3110 going up to 1010 PFU in half-log increments","Not Applicable","Glioblastoma","Clinical Trial","custom_markerset, RNAseq_probe_set_grc38","RNA-Seq, RNA Seq (NGS), RNA Seq (NGS)","4 phenotype datasets, 49 variables, 2 molecular datasets, 28 samples sequenced, 20 subjects, 112 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-10-17","2023-10-17","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs003342.v1.p1","Meta-Analysis of Genome-Wide Association Studies of Bladder Cancer Risk","This meta-analysis consists of genome-wide genotype for 13,447 cases and 342,580 controls of European ancestry to identify novel susceptibility loci for bladder cancer. Cases were defined as histologically confirmed primary  carcinoma of the urinary bladder of all stages, including carcinoma in situ (International Classification of Diseases for Oncology, C670-C679, 188).","Not Applicable","Urinary Bladder Neoplasms","Case-Control","Not Provided","Not Provided","1 analyses","","NCI","DS-BLADDERCA --- Disease-Specific (Bladder Cancer)","2023-10-16","2023-10-16","Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder",""
"phs003190.v1.p1","Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer    Heterogeneity and is Associated with Worse Outcomes","Small-cell lung cancer (SCLC) is a very aggressive neuroendocrine lung cancer often associated with oncogenic MYC amplifications, which are known to drive SCLC heterogeneity marked by neuroendocrine (NE) and non-neuroendocrine  (non-NE) cell states. The genetic mechanisms of MYC amplification and phenotypic plasticity between cell states is not known. Using data from","Not Applicable","Small Cell Lung Carcinoma","Cross-Sectional","WGS_markerset_grc38","OTHER, RNA-Seq, SRA Metadata, WGS","4 phenotype datasets, 15 variables, 1 molecular datasets, 17 samples sequenced, 5 subjects, 23 samples","","NCI","GRU --- General Research Use","2023-10-16","2023-10-16","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003213.v1.p1","Melbourne Collaborative Cohort Study DNA Methylation Studies","This dataset contains raw Illumina 450K blood DNA methylation data from a subset of participants in the Melbourne Cohort Study (MCCS), a prospective study of 41,513 healthy adult volunteers (24,469  women) aged between 27 and 76 years when recruited between 1990 and 1994. Nested case-control studies: DNA methylation data were generated as part of","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","HumanMethylation450","SNP/CNV (Array)","4 phenotype datasets, 22 variables, 1 molecular datasets, 5951 subjects, 7898 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-10-04","2023-10-04","DNA Methylation; Life Style; Life Styles; Life pattern; Lifestyle; Blastoma",""
"phs002303.v2.p1","PEDS-PLAN - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","A multi-center clinical trial for newly diagnosed high-risk neuroblastoma patients. Molecular tumor boards selected one of six targeted agents based on tumor-normal whole exome sequencing and tumor RNA sequencing data.  Related Clinical Trails: NCT02559778 Principal Investigator: Giselle Saulnier Sholler, MD, MSc, Pediatric Oncology, Levine Children's Hospital,","Not Applicable","Neuroblastoma","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 14 variables, 147 samples sequenced, 45 subjects, 147 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-10-04","2022-05-18","Not Provided","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs003338.v1.p1","BarcUVa-Seq (Biology of Colorectal Cancer Risk Enhancers)","This study was designed to generate a cohort of normal colon mucosal biopsies from the ""average risk"" population. Its primary aims included the development of an RNA-seq dataset of normal  colon mucosal biopsies across three colon regions (ascending, transverse and descending). Further, we aimed to provide plausible prioritization to","Not Applicable","Colonic Neoplasms","Collection","imputation_panel","SNP/CNV Genotypes (imputed), RNA-Seq","4 phenotype datasets, 20 variables, 1 molecular datasets, 463 samples sequenced, 463 subjects, 463 samples","","NCI","DS-GID-IRB --- Disease-Specific (Gastrointestinal Diseases, IRB)","2023-10-03","2023-10-03","CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic",""
"phs003343.v1.p1","Targeted Linked-Read DNA-seq Analysis of Castration-Resistant Prostate    Cancers","Androgen receptor (AR) inhibition is standard of care for advanced prostate cancer (PC). However, its efficacy is limited by progression to castration-resistant PC (CRPC), usually due to AR re-activation via  mechanisms that include AR amplification and structural rearrangement. These two classes of AR alterations often co-occur in CRPC tumors, but it is","Not Applicable","Prostatic Neoplasms","Case Set","Not Provided","OTHER","3 phenotype datasets, 13 variables, 35 samples sequenced, 35 subjects, 35 samples","","NCI","DS-PC --- Disease-Specific (Prostate Cancer)","2023-09-27","2023-09-27","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003315.v1.p1","A Microwell Platform for High-Throughput Longitudinal Phenotyping and    Selective Retrieval of Organoids","In traditional bulk culture, organoids tend to overlap, hindering the analysis of individual organoid characteristics in a high-throughput manner. Additionally, variations in the local spatial properties of the bulk matrix  make it challenging to distinguish whether phenotypic differences between organoids stem from inherent cellular disparities or disparities in the","Not Applicable","Organoids","Case-Control","WES_markerset_grc38, WES_markerset_grc38, WES_markerset_grc38","ATAC-seq, RNA-Seq, CNV Segments (NGS), SNP/CNV Genotypes (NGS), WGS","3 phenotype datasets, 12 variables, 1 molecular datasets, 45 samples sequenced, 1 subjects, 45 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-09-26","2023-09-26","CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach",""
"phs002097.v1.p1","Refractory Cancer (RC) Program","The Refractory Cancer (RC) Program will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain tumor types. Comprehensive genomic characterization will be performed utilizing  the NCI CCG Genome Characterization Pipeline. Subsequent genomic data will be hosted at the NCI Genomic Data Commons (GDC)","Not Applicable","Neoplasms","Case Set","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 278 subjects, 278 samples, 3 substudies","","NCI","GRU --- General Research Use","2023-09-26","2023-09-26","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002851.v1.p1","Refractory Cancer (RC) Burkitt's Lymphoma (BL)","The Refractory Cancer (RC) Burkitt's Lymphoma (BL) study will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain Burkitt Lymphoma patients. The study will  utilize a network of sites in the US to obtain the samples and clinical data. Comprehensive genomic characterization will be performed utilizing the","Refractory Cancer (RC) Program (phs002097.v1.p1)","Burkitt Lymphoma","Case Set","Not Provided","Not Provided","20 samples","","NCI","GRU --- General Research Use","2023-09-26","2023-09-26","BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma; Burkitt's Tumor",""
"phs002247.v1.p1","Refractory Cancer - Peripheral T-Cell Lymphoma (RC-PTCL)","The Peripheral T-Cell Lymphoma (PTCL) study will investigate the underlying genomic hallmarks involved in the observed inferior response to treatment of certain PTCL patients. The study will utilize a network  of sites in the US and Asia to accrue up to 500 cases per tumor type. Comprehensive genomic characterization will be performed utilizing the NCI CCG","Refractory Cancer (RC) Program (phs002097.v1.p1)","Lymphoma, T-Cell, Peripheral","Case Set","Not Provided","Not Provided","168 samples","","NCI","GRU --- General Research Use","2023-09-26","2023-09-26","",""
"phs002098.v1.p1","Refractory Cancers (RC) HOPE-CARE","For the HOPE-CARE project, NCI will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements)  and/or gene expression signatures that would be important to the hypothesis(es) submitted by the investigators. The samples will be processed and","Refractory Cancer (RC) Program (phs002097.v1.p1)","Glioma","Case Set","Not Provided","Not Provided","90 samples","","NCI","GRU --- General Research Use","2023-09-26","2023-09-26","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs002181.v1.p1","Genomic Characterization CS-MATCH-0007 Arm I","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 439 variables, 60 subjects, 60 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-09-25","2023-09-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002179.v1.p1","Genomic Characterization CS-MATCH-0007 Arm U","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 296 variables, 23 subjects, 23 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-09-25","2023-09-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001973.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Z1A","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 465 variables,  SRA, 45 subjects, 45 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-09-25","2023-09-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001948.v1.p1","Genomic Characterization CS-MATCH-0007 Arm W","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 368 variables,  SRA, 45 subjects, 45 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-09-25","2023-09-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001888.v1.p1","Genomic Characterization CS-MATCH-0007 Arm H","The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 379 variables,  SRA, 21 subjects, 21 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-09-25","2023-09-25","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant",""
"phs002372.v1.p1","Novel Approach to High-Throughput Identification and Characterization of    Neoantigens","This study focuses on the development of novel approach for the screening, identification and characterization of neoantigen-specific T-cell receptors (TCRs). The developed method consists of collecting targeted RNA-Seq from a  T-cell specific gene panel via 3' end Illumina sequencing combined to Oxford Nanopore based full-length TCR sequencing post T-cell activation. The","Not Applicable","Receptors, Antigen, T-Cell, alpha-beta","Methods","Not Provided","AMPLICON","4 phenotype datasets, 13 variables, 3 samples sequenced, 3 subjects, 4 samples","","NCI","GRU --- General Research Use","2023-09-21","2023-09-21","Not Provided",""
"phs003330.v1.p1","Uveal Melanoma Immunogenomics Predict Immunotherapy Resistance and    Susceptibility","Immunotherapy using immune checkpoint inhibition (ICI) has shown success in treating metastatic cutaneous melanoma but has limited efficacy against metastatic uveal melanoma (UM), a rare variant arising from the immune  privileged eye. To better understand this immune resistance, we performed comprehensive immunogenomic profiling of 100 human UM metastases using","Not Applicable","Uveal melanoma","Collection","Not Provided","RNA-Seq","3 phenotype datasets, 12 variables, 100 samples sequenced, 84 subjects, 100 samples","","NCI","GRU --- General Research Use","2023-09-20","2023-09-20","Not Provided",""
"phs000218.v26.p8","National Cancer Institute (NCI) TARGET: Therapeutically Applicable    Research to Generate Effective Treatments","The Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative seeks to accelerate research in novel marker and drug development, along with understanding the molecular basis of pediatric malignancy, through  identification of genomic changes associated with the following childhood cancers: Acute Lymphoblastic Leukemia (ALL) - A fast-growing type of blood","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 7 variables, 11287 samples sequenced, 6363 subjects, 13179 samples, 9 substudies","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Acute Lymphoblastic Leukemia; Clear Cell Sarcomas; Rhabdoid Tumor; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia",""
"phs000471.v23.p8","TARGET: Kidney, Wilms Tumor (WT)","There are 130 fully characterized patient cases with high risk Wilms tumor (all tumor/normal pairs; 8 with additional samples for analysis 3 with tumor adjacent normal, 5 with relapse sample)  that will make up the TARGET WT dataset. Each case will have gene expression, tumor and paired normal copy number analyses, methylation and whole","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Wilms Tumor","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, Targeted-Capture, WGS, WXS, miRNA-Seq","2 phenotype datasets, 8 variables, 987 samples sequenced, 653 subjects, 1018 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas",""
"phs000470.v23.p8","TARGET: Kidney, Rhabdoid Tumor (RT)","To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to  treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney and","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Rhabdoid Tumor","Tumor vs. Matched-Normal","Not Provided","Bisulfite-Seq, ChIP-Seq, RNA-Seq, WGS, miRNA-Seq","2 phenotype datasets, 8 variables, 234 samples sequenced, 70 subjects, 236 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","",""
"phs000469.v23.p8","TARGET: Cancer Model Systems (MDLS): Cell Lines and Xenografts (including    PPTP)","As part of the TARGET initiative, some disease projects characterized tumor cell lines or xenografts, with or without matched normal comparators, as well as some normal non-involved tissues. MDLS includes  acute leukemia cell lines and xenografts with matched primary and/or relapsed tumor information, neuroblastoma cell line and xenografts with matched","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Xenograft Model Antitumor Assays","Tumor vs. Matched-Normal","Not Provided","Bisulfite-Seq, ChIP-Seq, RNA-Seq, Targeted-Capture, WGS, WXS, miRNA-Seq","2 phenotype datasets, 8 variables, 180 samples sequenced, 132 subjects, 183 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Not Provided",""
"phs000468.v23.p8","TARGET: Osteosarcoma (OS)","There are 93 fully characterized patient cases that make up the TARGET OS dataset, each with gene expression, tumor and paired normal copy number analyses, methylation, miRNA profiles, along with  comprehensive next-generation sequencing to include mRNA-seq and exome sequencing (whole genome sequencing where available). There are additional","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Osteosarcoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, WXS","2 phenotype datasets, 8 variables, 624 samples sequenced, 310 subjects, 744 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma",""
"phs000467.v23.p8","TARGET: Neuroblastoma (NBL)","There are 214 fully characterized patient cases with neuroblastoma (all tumor/normal pairs, 10 with relapse sample as well) that will make up the TARGET NBL dataset, along with some cell  lines and xenografts. The dataset includes 24 4S cases as well. Each fully characterized case has gene expression, tumor and paired normal copy","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Neuroblastoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, Targeted-Capture, WGS, WXS, miRNA-Seq","2 phenotype datasets, 29 variables, 1852 samples sequenced, 1204 subjects, 1977 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Not Provided",""
"phs000466.v23.p8","TARGET: Kidney, Clear Cell Sarcoma of the Kidney (CCSK)","To further explore some more aggressive subtypes in pediatric cancer already under study in OCG, CGCI is partnering with TARGET initiative to support extensive sequencing analysis of three hard to  treat childhood cancers: refractory to treatment cases of acute myeloid leukemia and two rare kidney tumors; clear cell sarcoma of the kidney (CCSK)","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Sarcoma, Clear Cell","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","2 phenotype datasets, 8 variables, 39 samples sequenced, 14 subjects, 45 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Clear Cell Sarcomas; Clear Cell Sarcoma; Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Tendons and Aponeuroses; Malignant Melanoma of Soft Parts; Malignant melanoma of soft tissue",""
"phs000465.v23.p8","TARGET: Acute Myeloid Leukemia (AML)","There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor  and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Leukemia, Myeloid, Acute","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, Targeted-Capture, WGS, WXS, miRNA-Seq","2 phenotype datasets, 8 variables, 4014 samples sequenced, 2505 subjects, 5460 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs000464.v23.p8","TARGET: Acute Lymphoblastic Leukemia (ALL) Expansion Phase 2","There are 175 fully characterized patient cases with relapsed precursor B-cell ALL (all tumor/normal pairs, 85 with relapse sample as well) that will make up Phase II of the TARGET  ALL dataset, each with gene expression, tumor and paired normal copy number analyses, and comprehensive next-generation sequencing to include whole","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, WXS, miRNA-Seq","2 phenotype datasets, 24 variables, 3309 samples sequenced, 1199 subjects, 3461 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic",""
"phs000463.v23.p8","TARGET: Acute Lymphoblastic Leukemia (ALL) Pilot Phase 1","There are 189 fully characterized patient cases that make up the pilot phase (Phase I) of the TARGET ALL dataset, each with gene expression, tumor and paired normal copy number  analyses, and at least one type of sequencing (Sanger and/or next-generation) data available. There are 230 cases with partial molecular","National Cancer Institute (NCI) TARGET: Therapeutically Applicable Research to Generate Effective Treatments (phs000218.v26.p8)","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","2 phenotype datasets, 8 variables, 48 samples sequenced, 289 subjects, 65 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2023-09-20","2012-04-10","Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic",""
"phs003233.v1.p1","Single Cell Genotypic and Phenotypic Analysis of Measurable Residual    Disease in Acute Myeloid Leukemia","Acute myeloid leukemia (AML) is a group of blood cancers with high mortality. Even though complete remission is often achieved, majority of the AML patients still relapse. Measurable residual disease  (MRD), defined as the population of cancer cells which persists following chemotherapy, is responsible for AML relapse. Understanding the biology","Not Applicable","Leukemia, Myeloid, Acute","Prospective Longitudinal Cohort","Not Provided","AMPLICON","4 phenotype datasets, 15 variables, 25 samples sequenced, 91 subjects, 25 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-09-19","2023-09-19","Neoplasm, Residual; AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult",""
"phs003318.v1.p1","Single-Cell Multi-Omic Analysis of the Vestibular Schwannoma Ecosystem    Uncovers a Nerve Injury-Like State","Vestibular schwannomas are benign tumors that can lead to significant morbidity, including hearing loss, facial nerve paralysis and obstructive hydrocephalus. The genomic landscape of vestibular schwannomas is relatively bland and  the molecular pathophysiology of vestibular schwannomas is poorly understood. Therefore, we performed single cell RNA sequencing on 15 sporadic","Not Applicable","Neuroma, Acoustic","Case Set","WES_markerset_grc38","SNP/CNV Genotypes (NGS), WXS","5 phenotype datasets, 26 variables, 1 molecular datasets, 24 samples sequenced, 12 subjects, 24 samples","","NCI","GRU --- General Research Use","2023-09-15","2023-09-15","Schwannoma, Vestibular; AN - Acoustic neuroma; Acoustic Neurilemmoma; Acoustic Neurilemmomas; Acoustic Neurilemoma; Acoustic Neurilemomas",""
"phs003284.v1.p1","Immune-Related Adverse Events after Immune Checkpoint Blockade-Based    Therapy are Associated with Improved Survival in Advanced Sarcoma","Immune activation after immune checkpoint blockade (ICB) can lead to a unique group of adverse events (AEs), which have been associated with improved outcome in many carcinomas. The association between  immune-related AEs (irAEs) and outcome in patients with sarcoma is not well studied. This study has two components: (1) a retrospective clinical","Not Applicable","Sarcoma","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 64 samples sequenced, 64 subjects, 64 samples","","NCI","DS-SARC --- Disease-Specific (Sarcoma)","2023-09-15","2023-09-15","Drug-Related Side Effects and Adverse Reactions; ADR; ADR - Adverse drug reaction; Adverse Drug Event; Adverse Drug Events; Adverse Drug Experience",""
"phs003155.v1.p1","TCGA WGS Variants Across 18 Cancer Types","Even though whole genome sequence (WGS) data has been generated and published in many studies, much of this information is not yet processed for use in down-stream analysis. This study's  aim is to provide 1342 WGS normal-tumor paired single nucleotide variations (SNP) over 18 different cancer types provided by The Cancer Genome Atlas","Not Applicable","Polymorphism, Genetic","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 1342 subjects, 2684 samples","","NCI","GRU --- General Research Use","2023-09-15","2023-09-15","Not Provided",""
"phs003000.v1.p1","ALLELE Consortium Glioblastoma Project","Glioblastoma patient samples were sequenced for this project. The purposes of this project are: (1) to establish an umbrella protocol as a mechanism for identifying patients (in the USA and  international sites) who agree to the collection, storage, and broad usage of their specimens and ongoing collection, and review of their medical","Not Applicable","Glioblastoma","Case-Control","Not Provided","WXS","4 phenotype datasets, 15 variables, 220 samples sequenced, 110 subjects, 220 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-09-06","2023-09-06","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs001707.v3.p1","University of Pennsylvania CAR T Cell Responding and Non-responding    Patients","The adoptive transfer of autologous T cells genetically modified to express a CD19-specific, 4-1BB/CD3zeta-signaling chimeric antigen receptor (CAR; CTL019) has shown remarkable activity in patients with B acute lymphoblastic leukemia.  Similar therapy can induce long-term remissions for relapsed/refractory chronic lymphocytic leukemia (CLL) patients, but in only a small subset of","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Prospective Longitudinal Cohort","Not Provided","AMPLICON, RNA-Seq","4 phenotype datasets, 13 variables, 109 samples sequenced, 37 subjects, 109 samples","","NCI","GRU-IRB-NPU --- General Research Use (IRB, NPU)","2023-09-06","2023-09-06","Sarcoma; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade",""
"phs002225.v3.p1","HTAN MCL Pre-Cancer Atlas Pilot Project - Targeted Sequencing Development    Study","The HTAN-MCL Pre-Cancer Atlas Pilot Project (PCAPP) is the result of a collaboration between the seven members of the MCL consortium. Across four organ types, PCAPP's goal is to collect  and profile pre-malignant lesions for gene expression, DNA mutations, single-cell gene expression and immune-environment. Most PML are small in size","Not Applicable","Carcinoma, Intraductal, Noninfiltrating","Case Set","Not Provided","RNA-Seq, WXS","6 phenotype datasets, 29 variables, 430 samples sequenced, 63 subjects, 430 samples","","NCI","GRU --- General Research Use","2023-09-01","2023-09-01","Breast Ductal Carcinoma In Situ, NOS; Carcinoma, Intraductal; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal; DCIS","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002439.v1.p1","Development and Validation of Organoids from Fibrolamellar Carcinoma    Human Cells","Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor affecting adolescents and young adults with no history of primary liver disease or cirrhosis. We collected fibrolamellar tumor tissue and the  adjacent non-tumor liver from patients at the time of surgery. We only used tumor tissue that was validated as fibrolamellar by the presence of the","Not Applicable","Fibrolamellar hepatocellular carcinoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 25 samples sequenced, 5 subjects, 25 samples","","NCI","DS-HCC-IRB-COL --- Disease-Specific (Hepatocellular Carcinoma, IRB, COL)","2023-08-31","2023-08-31","Hepatocellular carcinoma (fibrolamellar variant); FHCC; FL-HCC; FLC; Fibrolamellar Carcinoma of Liver Cells; Fibrolamellar Carcinoma of the Liver Cells",""
"phs003185.v1.p1","Molecular Subtyping Reveals Immune Alterations Associated with    Progression of Bronchial Premalignant Lesions","Exposure to cigarette smoke creates a field of injury throughout the entire respiratory tract inducing genomic alterations that lead to an ""at-risk"" airway where lung cancers develop. Lung squamous cell  carcinoma (SCC) arises in the epithelial layer of the bronchial airways and is often preceded by the development of premalignant lesions (PMLs).","Not Applicable","Lung Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 18 variables, 448 samples sequenced, 50 subjects, 448 samples","","NCI","GRU --- General Research Use","2023-08-23","2023-08-23","Bronchial Neoplasms; Bronchopulmonary Dysplasia; Disease Progression; Bronchial Neoplasm; Bronchial tumor; Neoplasm, Bronchial",""
"phs001783.v6.p1","Exome Recapture and Sequencing of Prospectively Characterized Clinical    Specimens From Cancer Patients","The study cohort comprises samples from patients whose tumors have been prospectively characterized as part of their care at Memorial Sloan Kettering Cancer Center. This includes a variety of distinct  tumor type and molecular subtypes. DNA samples from tumor tissue were from patients at Memorial Sloan Kettering Cancer Center. Tumor and normal","Not Applicable","Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 18 variables, 3598 samples sequenced, 1660 subjects, 3598 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2023-08-18","2019-07-10","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002189.v1.p1","Merkel Cell Carcinoma Tissue and Data Repository","Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with increasing incidence in the United States. In this study we performed the first whole genome sequencing of three  Merkel cell carcinomas with their matched normal tissues for somatic variant calling. From these data we describe the likely mechanism of Merkel cell","Not Applicable","Carcinoma, Merkel Cell","Tumor vs. Matched-Normal","WGS_markerset_grc38","RNA-Seq, SNP/CNV Genotypes (NGS), WGS","3 phenotype datasets, 10 variables, 1 molecular datasets, 12 samples sequenced, 6 subjects, 12 samples","","NCI","HMB-IRB --- Health/Medical/Biomedical (IRB)","2023-08-17","2023-08-17","Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC",""
"phs002978.v1.p1","AC-ICAM: An Atlas and Compass of Immune-CAncer-Microbiome Interactions in    Colon Cancer","Fresh frozen tumor samples and matched normal colon specimens from chemotherapy na&#x000ef;ve, consecutive patients with a histological diagnosis of colon adenocarcinoma at Leiden University Medical Center (LUMC) were subjected to  multi-omics profiling at Sidra Integrated Genomics Services, part of Sidra Medicine, Doha, Qatar. This resulted in a high-quality dataset of samples","Not Applicable","Colonic Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","5 phenotype datasets, 56 variables, 1258 samples sequenced, 348 subjects, 1258 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2023-08-16","2023-08-16","CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic",""
"phs002005.v1.p1","MP2PRT: Comprehensive Genomic Profiling to Identify Alterations    Associated with Relapse for NCI Standard Risk (SR) B-Lineage ALL and    NCI High Risk (HR) B-Lineage ALL with Favorable Genetic Features","The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of  biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program.","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Case-Control","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 1510 subjects, 1510 samples","","NCI","GRU --- General Research Use","2023-08-16","2023-08-16","Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic",""
"phs003229.v1.p1","Analysis of Donor Pancreata Defines the Transcriptomic Signature and    Microenvironment of Early Neoplastic Pancreatic Lesions","The adult healthy human pancreas has been poorly studied given lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained  pancreata from brain dead donors thus avoiding any warm ischemia time. We found that neoplastic lesions occur frequently in healthy organs, in donors","Not Applicable","Pancreas","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 17 variables, 13 samples sequenced, 7 subjects, 13 samples","","NCI","GRU --- General Research Use","2023-08-15","2023-08-15","Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic",""
"phs003054.v1.p1","Extracellular RNA Profiling of Serum, Plasma, and Urine of Healthy    Subjects","This study was conducted to generate a reference dataset of extracellular RNA (exRNA) from standard human biofluids. Small RNA-seq data was obtained from plasma, serum, and urine of healthy subjects.  Inclusion Criteria: Healthy volunteer subjects Principal Investigator: Jennifer C. Jones, MD, PhD, National Institutes of Health, Bethesda, MD, USA","Not Applicable","Healthy Volunteers","Control Set","Not Provided","RNA-Seq","3 phenotype datasets, 11 variables, 53 samples sequenced, 53 subjects, 53 samples","","NCI","GRU-IRB-PUB-COL --- General Research Use (IRB, PUB, COL)","2023-08-09","2023-08-09","Not Provided",""
"phs003170.v1.p1","Genome-Wide Analysis of Aberrant Position and Sequence of Plasma DNA    Fragment Ends in Patients With Cancer","This study investigated fragmentation characteristics in plasma cell-free DNA and evaluated the relevance of such analysis for cancer diagnostics. Specifically, we performed whole genome sequencing (WGS) of healthy individuals and  cancer patients, and evaluated genome-wide coverage and sequences surrounding fragment ends. This was a retrospective study of archived plasma","Not Applicable","Liquid Biopsy","Methods","Not Provided","WGS","4 phenotype datasets, 21 variables, 548 samples sequenced, 213 subjects, 548 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2023-08-03","2023-08-03","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003152.v1.p1","CPTAC: Proteogenomic Studies of Ovarian Tumor Responses to Agents    Targeting the DNA Damage Response","There is a critical unmet need for predictors of chemo-refractory High-grade serous ovarian cancer (HGSOC). Despite over 3 decades of research on platinum responses in cancer, no predictive biomarker has  been translated into clinical use. Predictors of refractory disease could spare these patients the unnecessary toxicity of a platinum-based regimen","Not Applicable","Carcinoma, Ovarian Epithelial","Case Set","Not Provided","RNA-Seq, WGS","156 samples sequenced, 148 subjects, 156 samples","","NCI","GRU --- General Research Use","2023-08-03","2023-08-03","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002151.v1.p1","Genomic Characterization CS-MATCH-0007 Arm N","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 327 variables, 21 subjects, 21 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-07-25","2023-07-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002028.v1.p1","Genomic Characterization CS-MATCH-0007 Arm B","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 362 variables, 33 subjects, 33 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-07-25","2023-07-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003074.v1.p1","A National Translational Science Network of Precision-Based Immunotherapy    for Primary Liver Cancer (PLC)","The primary objective of the NCI-CLARITY study is to establish a biospecimen repository for genomic, genetic and epigenetic analysis to study the biology of primary liver cancer (PLC) development and  progression. Secondary objectives include predicting overall and progression-free survival following immunotherapy. In the retrospective phase,","Not Applicable","Liver Neoplasms","Collection","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 482 samples sequenced, 93 subjects, 482 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-07-21","2023-07-21","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells",""
"phs002820.v1.p1","Cancer Risk Estimates Related to Susceptibility Genes (CARRIERS)","The CARRIERS study utilized custom amplicon-based variant screening of known cancer predisposition genes in germline DNA from breast cancer cases and age matched unaffected controls taken from predominantly cohort-based breast  cancer case-control studies to establish the risks of breast cancer associated with pathogenic variants in these genes. Inclusion Cases - affected","Not Applicable","Genetic Predisposition to Disease","Case-Control","target_markerset_grc37","SNP/CNV Genotypes (NGS)","4 phenotype datasets, 14 variables, 1 molecular datasets, 75492 subjects, 75490 samples","","NCI","HMB-COL-NPU-GSO --- Health/Medical/Biomedical (COL, NPU, GSO), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA --- Disease-Specific (Cancer), HMB-PUB --- Health/Medical/Biomedical (PUB), GRU --- General Research Use, DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB --- Health/Medical/Biomedical, DS-CA-IRB-MDS --- Disease-Specific (Cancer, IRB, MDS), DS-BROC --- Disease-Specific (Breast and Ovarian cancer), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), GRU-NPU --- General Research Use (NPU)","2023-07-20","2023-07-20","Genetic Predispositions; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors",""
"phs003316.v1.p1","A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab and Intralesional    Oncolytic Virotherapy for HER2-Negative Breast Cancer","This study was a single arm phase 1 trial that assessed the regimen safety and feasibility as well as tumor response in patients with localized HER2-negative breast cancer treated with  talimogene laherparepvec (T-VEC) in combination with nivolumab and ipilimumab. The primary objective was to evaluate the safety and adverse event","Not Applicable","Breast Neoplasms","Clinical Trial","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 18 variables, 27 samples sequenced, 6 subjects, 27 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2023-07-18","2023-07-18","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003290.v1.p1","Cell-Free, Methylated DNA in Blood Samples Reveals Tissue-Specific,    Cellular Damage from Radiation Treatment","Radiation therapy is an effective cancer treatment, although damage to surrounding healthy tissues can also occur. Cell-type specific DNA methylation patterns can be used to decode the cellular origins of  cell-free DNA fragments, allowing for minimally-invasive monitoring of tissue damage. To evaluate whether changes in cell-free DNA methylation can","Not Applicable","DNA Methylation","Prospective Longitudinal Cohort","Not Provided","Bisulfite-Seq","4 phenotype datasets, 15 variables, 59 samples sequenced, 29 subjects, 59 samples","","NCI","GRU-IRB-COL --- General Research Use (IRB, COL)","2023-07-18","2023-07-18","",""
"phs003320.v1.p1","RNA Sequencing of ECOG-E1308","This study reports the RNA sequencing of HPV positive oropharyngeal squamous cell carcinoma samples from patients with HPV-associated stage III or stage IV cancer of the oropharynx that was surgically  resectible. These patients participated in the ECOG-E1308 trial, a phase II trial that studied paclitaxel, cisplatin, and cetuximab followed by","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 14 variables, 1 molecular datasets, 71 samples sequenced, 71 subjects, 71 samples","","NCI","GRU --- General Research Use","2023-07-13","2023-07-13","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003147.v1.p1","A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole    and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+    Breast Cancer (PALTAN)","Women with early stage ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with standard of care dual HER2 blockade than patients with ER-/HER2+  BC. Additionally, the toxicity burden of standard systemic therapy is high. Thus, this single arm phase 2 clinical trial investigated a novel","Not Applicable","Breast Neoplasms","Clinical Trial","Not Provided","RNA-Seq, WXS","3 phenotype datasets, 14 variables, 55 samples sequenced, 17 subjects, 55 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2023-07-13","2023-07-13","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002515.v1.p1","Mutational Landscape of MCPyV-Positive and MCPyV-Negative Merkel Cell    Carcinomas","Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin most commonly found on the sun-exposed skin of older Caucasian adults. Roughly one-third of patients with MCCs die  of the disease; therefore, MCC is the most lethal skin cancer on a case-by-case basis. 49 cases were studied, and putative cancer driver gene","Not Applicable","Carcinoma, Merkel Cell","Case Set","Not Provided","WXS","4 phenotype datasets, 16 variables, 98 samples sequenced, 49 subjects, 98 samples","","NCI","GRU --- General Research Use","2023-07-13","2023-07-13","Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003305.v1.p1","Whole Genome Sequencing for Metastatic Mutational Burden in Extraskeletal    Myxoid Chondrosarcoma","Extraskeletal myxoid chondrosarcoma (EMC) is an ultra-rare cancer. Though it has a favorable prognosis and an indolent course, it has high rates of local recurrence and metastasis to the lungs.  EMC is most often characterized by a translocation involving the NR4A3 gene most often fusing with EWSR1, leading to constitutive expression of","Not Applicable","Sarcoma","Case Set","Not Provided","WGS","3 phenotype datasets, 12 variables, 4 samples sequenced, 1 subjects, 4 samples","","NCI","GRU --- General Research Use","2023-07-12","2023-07-12","Chondrosarcoma; Neoplasms, Connective and Soft Tissue; Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma",""
"phs003227.v1.p1","Hi-C Profiling of Solid Tumor Samples","Structural variants, such as translocations, inversions, duplications, and deletions, have long been recognized as mutations that can contribute to the initiation and progression of cancer. This can occur through a  variety of mechanisms, including changes in gene dosage and the generation of fusion genes. In recent years, it is becoming increasingly clear that","Not Applicable","Neoplasms","Case Set","target_markerset_grc38","Hi-C, Chromatin (NGS)","3 phenotype datasets, 10 variables, 1 molecular datasets, 10 samples sequenced, 10 subjects, 10 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2023-07-12","2023-07-12","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003272.v1.p1","Supraphysiologic MDM2 Expression Impacts P53-Independent Chromatin    Networks and Therapeutic Responses in Sarcoma","We collected multiple liposarcoma samples from different patients, including different subtypes (DD, WD) and normal adipose tissue as control. This study provides the biggest liposarcoma cohort to date, and examined  the molecular regulatory circuits associated with MDM2 overexpression. To this end, we obtained not only RNA-seq data, but also ChIP-seq from Jun,","Not Applicable","Liposarcoma","Collection","Not Provided","ChIP-Seq, Hi-C, RNA-Seq","3 phenotype datasets, 10 variables, 39 samples sequenced, 26 subjects, 40 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2023-07-11","2023-07-11","DDLPS; DDLS; Dedifferentiated Liposarcomas; Liposarcoma, Dedifferentiated; dedifferentiated liposarcoma",""
"phs002877.v1.p1","Mapping the Evolution of T Cell States During Response and Resistance to    Adoptive Cellular Therapy","We investigated single T cell transcriptional states that define donor lymphocyte infusion (DLI) response and resistance from cryopreserved bone marrow mononuclear cells from 15 patients with relapsed chronic myeloid leukemia  (CML) after allogeneic hematopoietic stem cell transplant. By integrating bulk ATAC-seq data from sorted T cell populations from these bone marrow","Not Applicable","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Case-Control","Not Provided","OTHER","4 phenotype datasets, 15 variables, 100 samples sequenced, 17 subjects, 106 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-07-11","2023-07-11","BCR-ABL Positive chronic myelogenous leukaemia; BCR-ABL Positive chronic myelogenous leukemia; CGL - Chronic granulocytic leukemia; CML; CML - Chronic myeloid leukemia; CML - chronic myelogenous leukaemia",""
"phs000235.v21.p6","National Cancer Institute Cancer Genome Characterization Initiative    (CGCI)","The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. CGCI","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 257 samples sequenced, 762 subjects, 884 samples, 6 substudies","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Lung Neoplasms; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lung Tumor; Lung cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000532.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Non-Hodgkin Lymphoma","The Office of Cancer Genomics (OCG) at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing  technologies in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Lymphoma, Non-Hodgkin","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, WXS","2 phenotype datasets, 33 variables, 207 samples sequenced, 118 subjects, 207 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Lymphoma, Follicular; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC",""
"phs000531.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Medulloblastoma","The Office of Cancer Genomics (OCG) at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing  technologies in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Medulloblastoma","Tumor vs. Matched-Normal","Not Provided","Not Provided","Not Provided","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic",""
"phs000530.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Lung Cancer    (HTMCP - LC)","The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Lymphoma, AIDS-Related","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, miRNA-Seq","2 phenotype datasets, 8 variables, 39 samples sequenced, 39 subjects, 65 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Lung Neoplasms; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung",""
"phs000529.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Diffuse Large    B-Cell Lymphoma (HTMCP - DLBCL)","The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Lymphoma, AIDS-Related","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, miRNA-Seq","2 phenotype datasets, 8 variables, 11 samples sequenced, 70 subjects, 77 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Lymphoma, Non-Hodgkin; AIDS Associated Lymphoma; AIDS Lymphoma; AIDS Related Lymphoma; AIDS-Associated Lymphoma; AIDS-Associated Lymphomas",""
"phs000528.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): HIV+ Tumor Molecular Characterization Project - Cervical    Cancer (HTMCP - CC)","The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program includes comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Lymphoma, AIDS-Related","Tumor vs. Matched-Normal","Not Provided","Not Provided","212 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","AIDS Associated Lymphoma; AIDS Lymphoma; AIDS Related Lymphoma; AIDS-Associated Lymphoma; AIDS-Associated Lymphomas; AIDS-Related Lymphoma",""
"phs000527.v18.p6","National Cancer Institute (NCI) Cancer Genome Characterization Initiative    (CGCI): Burkitt Lymphoma Genome Sequencing Project (BLGSP)","The Office of Cancer Genomics at the National Cancer Institute sponsored a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies  in cancer. The CGCI program included comprehensive characterization of the genetic aberrations found in different pediatric and/or adult tumors. All","National Cancer Institute Cancer Genome Characterization Initiative (CGCI) (phs000235.v21.p6)","Lymphoma, Non-Hodgkin","Tumor vs. Matched-Normal","Not Provided","Not Provided","323 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2023-07-11","2013-06-20","Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma",""
"phs003192.v1.p1","ARST17B2-Q Germline and Somatic Genetic Landscape of Pediatric    Rhabdomyosarcoma","Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. While these malignancies display aberrant myogenic differentiation, relatively little is known about genetic susceptibility to RMS, or how genetic  variants influence subsequent somatic events and may be used in risk stratification strategies. A small percentage of cases are associated with","Not Applicable","Rhabdomyosarcoma","Case Set","HumanOmniExpress-24","SNP Genotypes (Array)","4 phenotype datasets, 27 variables, 1 molecular datasets, 920 subjects, 920 samples","European (551), African (5), East Asian (14), African American (117), Hispanic1 (35), Hispanic2 (134), Other Asian or Pacific Islander (22), South Asian (14), Other (28)","NCI","GRU --- General Research Use","2023-06-29","2023-06-29","Not Provided",""
"phs003243.v1.p1","Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment    of a Repository for Related Biologic Studies (10C0086)","This study (10-C-0086) collected and analyzed tumor and circulating tumor omics of pediatric and young adult patients with relapsed rhabdomyosarcoma who were co-enrolled in and receiving treatment on the interventional  study 17-C-0049. We sought to describe the summary genomic findings of tumors, and report on the detection of circulating tumor DNA (ctDNA) in serial","Not Applicable","Rhabdomyosarcoma","Collection","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 17 variables, 66 samples sequenced, 12 subjects, 66 samples","","NCI","GRU --- General Research Use","2023-06-27","2023-06-27","Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Alveolar Rhabdomyosarcomas; Alveolar rhabdomyosarcoma (disease); Monomorphous Round Cell Rhabdomyosarcoma; RHABDOMYOSARCOMA 2","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002262.v2.p1","Characterization of High-Grade Serous Ovarian Cancer Subtypes via    Single-Cell Profiling","We measured gene expression in single-cell RNA sequencing samples from patients with high-grade serous ovarian cancer (HGSOC), for a study on improving HGSOC subtype definition by taking into account varying  cell type proportions within tumors. The initial dataset (added October, 2020) contains 3 samples (3 individuals). The next dataset (added November,","Not Applicable","Carcinoma, Ovarian Epithelial","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 12 variables, 37 samples sequenced, 13 subjects, 37 samples","","NCI","GRU --- General Research Use","2023-06-27","2020-11-10","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003150.v1.p1","International Cancer Proteogenomics Consortium (ICPC): Proteogenomics of    East-Asian Breast Cancer","The incidence of invasive breast cancer is rapidly increasing in East Asia, enriching in younger patients and luminal disease. We presented a deep proteogenomic landscape of a prospectively enrolled early-stage  cohort in Taiwan to uncover the etiology, age-related subtype and oncogenic vulnerabilities underlying the heterogeneous disease. Multilayer","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","WES_markerset_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 24 variables, 1 molecular datasets, 690 samples sequenced, 138 subjects, 690 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2023-06-26","2023-06-26","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002260.v2.p1","Characterization of Immune Evasion in Merkel Cell Carcinoma","Merkel cell carcinoma (MCC) is a rare, neuroendocrine skin carcinoma that is caused by the Merkel cell polyomavirus (MCPyV) in 80% of cases and by ultraviolet (UV) damage in 20%  of cases. MCC should theoretically elicit a strong cytotoxic T cell response due to the high neoantigen and viral antigen burden in MCPyV- and MCPyV+","Not Applicable","Carcinoma, Merkel Cell","Collection","Not Provided","ATAC-seq, Bisulfite-Seq, RNA-Seq, WGS, WXS","4 phenotype datasets, 16 variables, 132 samples sequenced, 49 subjects, 132 samples","","NCI","DS-MCC-IRB-MDS --- Disease-Specific (Merkel cell carcinoma, IRB, MDS)","2023-06-22","2022-06-28","Anaplastic carcinoma of the skin; Cancer, Merkel Cell; Cell Cancer, Merkel; Cutaneous APUDoma; Cutaneous Neuroendocrine Carcinoma; MCC",""
"phs002637.v1.p1","CIDR: The Role of Rare Coding Variation in Prostate Cancer in Men of    African Ancestry - RESPOND Project 2","In RESPOND Project 2, we seek to identify rare genetic factors that are associated with prostate cancer (PCa) risk and aggressiveness in men of African ancestry (AA). We will conduct  exome sequencing of 15,000 prostate cancer cases and 5,000 controls from the RESPOND cohort and the African Ancestry Prostate Cancer Consortium","Not Applicable","Prostatic Neoplasms","Case-Control","WES_markerset_grc37","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 45 variables, 1 documents, 1 molecular datasets, 12155 samples sequenced, 12049 subjects, 12171 samples","","NCI","GRU --- General Research Use, DS-PC-PUB-MDS --- Disease-Specific (Prostate Cancer, PUB, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-CHDSAD-MDS --- Disease-Specific (Cancer, Heart Disease, Stroke, Alzheimer Disease, and Diabetes, MDS), DS-PC --- Disease-Specific (Prostate Cancer), HMB --- Health/Medical/Biomedical, DS-CA-IRB --- Disease-Specific (Cancer, IRB), DS-UC-MDS --- Disease-Specific (Urinary Conditions, MDS), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2023-06-14","2023-06-14","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000450.v5.p1","Whole Exome Sequencing of Primary Mediastinal B-cell Lymphoma","Primary mediastinal large B-cell lymphomas (PMBLs) are aggressive tumors that typically present as large mediastinal masses in young women. PMBLs share clinical, transcriptional, and molecular features with classical Hodgkin lymphoma  (cHL), including constitutive activation of nuclear factor kappaB (NF-kappaB), JAK/STAT signaling, and programmed cell death protein 1","Not Applicable","Primary Mediastinal B-cell Lymphoma","Case Set","WGS_markerset_grc36","SNP Genotypes (NGS), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 517 samples sequenced,  SRA, 361 subjects, 517 samples","","NCI","GRU-NPU-MDS --- General Research Use (NPU, MDS), DS-BLD-MDS --- Disease-Specific (Blood and Lymph Disorders, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB --- Health/Medical/Biomedical","2023-06-08","2013-03-02","Not Provided","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002934.v1.p1","Molecular Biomarkers of Obesity and Metformin Response in Endometrial    Cancer: Analysis of GOG-0286B","The primary endpoint for the phase 2 study was progression free survival (PFS), and the primary endpoint for the phase 3 study was overall survival (OS). Data from phase 2  were included in the phase 3 analysis. Tissue was collected from patients with endometrial cancer who participated in the study (NCT02065687). The","Not Applicable","Endometrial Neoplasms","Case Set","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 11 variables, 738 samples sequenced, 375 subjects, 738 samples","","NCI","DS-ECA --- Disease-Specific (Endometrial Cancer)","2023-06-07","2023-06-07","Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor; Neoplasm of Endometrium; Neoplasm of the Endometrium",""
"phs003186.v1.p1","Tamoxifen Response at Single Cell Resolution in Estrogen Receptor    Positive Primary Human Breast Tumors","Primary breast tissue, normal and cancerous, was collected immediately after resection. The tissue was dissociated and treated with 10uM tamoxifen or control media for 12 hours in suspension. Single cell  libraries were then created using a 10x Genomics gel bead droplet-based kit and sequenced via Illumina sequencing platforms. Differences in cell","Not Applicable","Breast Neoplasms","Case Set","target_markerset_grc38","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 20 variables, 1 molecular datasets, 26 samples sequenced, 13 subjects, 26 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2023-05-30","2023-05-30","Breast Carcinoma In Situ; Carcinoma, Ductal, Breast; LCIS - lobular carcinoma in situ; LCIS, Lobular Carcinoma In Situ; Lobular Carcinoma In Situ; Lobular carcinoma, noninfiltrating",""
"phs003256.v1.p1","Therapy-Induced APOBEC3A Drives Evolution of Resistance to Targeted    Therapies in Non-Small Cell Lung Cancer","The purpose of this study was to identify mechanisms of resistance and associated mutational signatures in non-small cell lung cancers (NSCLCs) treated with targeted therapies. Whole genome sequencing (WGS) and  whole exome sequencing (WES) were performed on tumor tissue or cell lines derived from oncogene-driven NSCLCs before and after treatments with","Not Applicable","Carcinoma, Non-Small-Cell Lung","Tumor vs. Matched-Normal","custom_markerset","SNP Genotypes (NGS), WGS, WXS","4 phenotype datasets, 15 variables, 1 molecular datasets, 94 samples sequenced, 24 subjects, 98 samples","","NCI","GRU --- General Research Use","2023-05-25","2023-05-25","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs002552.v1.p1","Genomic Analysis of Low Grade B-Cell Lymphoma","We included tumors from 64 newly diagnosed or untreated Low Grade B-Cell Lymphoma (LGBCL) patients, consisting of SMZL (n 48), NMZL (n 6), EMZL (n 2), LPL (n 5), and  B-NOS (n 3) in this study. Samples were selected from cases consented to the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo","Not Applicable","Lymphoma, Non-Hodgkin","Case Set","Not Provided","RNA-Seq, WXS","3 phenotype datasets, 14 variables, 183 samples sequenced, 64 subjects, 183 samples","","NCI","GRU --- General Research Use","2023-05-25","2023-05-25","Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003198.v1.p1","Genomic Analyses of Germline and Somatic Variation in High-Grade Serous    Ovarian Cancer","The goal of this study was to identify and characterize germline and somatic genetic variation in women with high grade serous ovarian cancers treated at a single cancer center and  their associations with relapse-free and overall survival. We conducted paired tumor/normal targeted next-generation sequencing of 577 genes in","Not Applicable","Carcinoma, Ovarian Epithelial","Tumor vs. Matched-Normal","OncoScan_CNV_plus","CNV Genotypes, Targeted-Capture","4 phenotype datasets, 27 variables, 1 molecular datasets, 185 samples sequenced, 71 subjects, 185 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2023-05-22","2023-05-22","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian",""
"phs003279.v1.p1","MAITS in HCC","Hepatocellular Carcinoma (HCC) is a leading cause of cancer-related death and can be considered a prototype of inflammation-derived cancer arising from chronic liver injury. The cell composition of the HCC  tumor immune microenvironment (TiME) has a major impact on cancer biology as the TiME can have divergent capacities on tumor initiation, progress,","Not Applicable","Hepatocellular carcinoma; Mucosal-Associated Invariant T Cells;    tumor-associated macrophages; single-cell sequencing","Tumor vs. Matched-Normal","RNAseq_probe_set_grc38","RNA Seq (NGS)","3 phenotype datasets, 10 variables, 1 molecular datasets, 8 subjects, 36 samples","","NCI","GRU --- General Research Use","2023-05-18","2023-05-18","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003257.v1.p1","Investigating the Role of Neddylation in the Repair of Topoisomerase    I-Mediated DNA Damage in Colorectal Cancer","Colorectal cancer is one of the most lethal cancers worldwide. First-line chemotherapy for metastatic CRC (mCRC) entails a combination of irinotecan with 5-fluorouracil and leucovorin (FOLFIRI). Irinotecan is a prodrug  that is converted within the cell to its active metabolite SN38, a potent TOP1 inhibitor. TOP1 relieves DNA torsional strain arising from DNA","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 11 variables, 3 samples sequenced, 3 subjects, 3 samples","","NCI","GRU --- General Research Use","2023-05-16","2023-05-16","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003158.v1.p1","S&#x000e9;zary Syndrome Originates from Heavily Mutated Hematopoietic Progenitors","The pathogenesis of cutaneous T cell lymphoma (CTCL) remains unclear. To study the malignant transformation of CTCL, we collected matched hematopoietic stem cell (HSC) extracts from bone marrow, CD4+CD26- malignant  T cells, CD4+CD26+ normal T cells, and CD34+ HSCs from apheresis performed on 4 patients. To establish the baseline for calling true mutations","Not Applicable","Sezary Syndrome","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 20 variables, 23 samples sequenced, 4 subjects, 23 samples","","NCI","GRU --- General Research Use","2023-05-16","2023-05-16","Lymphoma, T-Cell, Cutaneous; Granulomatous Slack Skin; Slack Skin, Granulomatous; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002845.v1.p1","Expression of Activation Induced Cytidine Deaminase and Risk of    Transformation in Follicular Lymphoma","It is currently unclear how to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression. Building on a prior study demonstrating early transformation in  FLs with high variant allele frequency (VAF) BCL2 mutations at activation-induced cytidine deaminase (AICDA) sites, we examined 11 AICDA mutational","Not Applicable","Lymphoma, Follicular","Case Set","Not Provided","AMPLICON","4 phenotype datasets, 27 variables, 199 samples sequenced, 199 subjects, 199 samples","","NCI","GRU --- General Research Use","2023-05-11","2023-05-11","Cell Transformation, Neoplastic; Risk Factors; Cell Neoplastic Transformation; Cell Neoplastic Transformations; Cell Transformations, Neoplastic; Neoplastic Cell Transformations","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002950.v1.p1","Methylation Profiles of Cell-Free DNA Using Nanopore Sequencing","Epigenetic characterization of cell-free DNA (cfDNA) is an emerging approach for detecting and characterizing diseases such as cancer. We developed a strategy using nanopore-based single-molecule sequencing to measure cfDNA methylomes.  This approach generated up to hundreds of millions of reads for a single cfDNA sample from cancer patients, an order of magnitude improvement over","Not Applicable","Neoplasms","Methods","Not Provided","WGS","65 samples sequenced, 27 subjects, 65 samples","","NCI","GRU --- General Research Use","2023-05-10","2023-05-10","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002935.v1.p1","Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma","The study is a retrospective transcriptomic profiling of oropharyngeal squamous cell carcinoma. The pathologic database was queried for squamous cell carcinoma tumors originating from the anatomic oropharynx (tonsil or tongue  base) with available samples from surgical archives. This retrospective RNA sequencing cohort included cases dating prior to the routine","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","RNAseq_probe_set_grc37","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 13 variables, 1 molecular datasets, 133 samples sequenced, 133 subjects, 133 samples","","NCI","GRU --- General Research Use","2023-05-10","2023-05-10","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003145.v1.p1","Tissue Sampling and Biorepository to improve Cancer Cell Therapy","This study focuses on the elucidation of determinants of response and resistance to anti-CD19 CAR T-cells in large B-cell lymphoma. Plasma samples were collected prior to treatment and serially post  CAR T-cell infusion. Pre-treatment and relapse tumor samples were also obtained as available. Germ-line DNA isolated from Peripheral Blood","Not Applicable","Lymphoma, Non-Hodgkin","Case Set","RNAseq_gene_transcripts","RNA Seq (NGS), Targeted-Capture","4 phenotype datasets, 22 variables, 1 molecular datasets, 694 samples sequenced, 139 subjects, 795 samples","","NCI","DS-LYD-IRB-PUB-COL --- Disease-Specific (Lymphatic Disease, IRB, PUB, COL)","2023-05-09","2023-05-09","Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma",""
"phs003207.v1.p1","Single Cell Colony Whole Genome Sequencing Data From Individuals With    Telomere Syndromes","This is an observational study which examined the phylogenetic evolution of somatic clonal mutations in POT1 mutation carriers. Two individuals with telomere syndromes who carry a heterozygous germline POT1 p.R273Q  variant and one related control who did not carry this variant were studied. Single cell hematopoietic colonies were derived from peripheral blood","Not Applicable","Clonal Hematopoiesis","Cross-Sectional","Not Provided","WGS","5 phenotype datasets, 20 variables, 152 samples sequenced, 3 subjects, 152 samples","","NCI","HMB-IRB-PUB-NPU --- Health/Medical/Biomedical (IRB, PUB, NPU)","2023-05-08","2023-05-08","ARCH; ARCH Age related Clonal Hematopoiesis; ARCH Age-related Clonal Hematopoiesis; Age related Clonal Hematopoiesis; Age-related Clonal Hematopoiesis; Clonal Hematopoiesis, Age-related",""
"phs002476.v3.p1","Immune Profiling in Patients with High-Risk Smoldering Myeloma","Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Multiple Myeloma (SMM). We conducted a Phase II trial of the immunotherapeutic anti-SLAMF7 antibody, Elotuzumab, in  combination with Lenalidomide and Dexamethasone (E-PRISM study), to determine the utility and safety of early immunotherapy in patients with","Not Applicable","Smoldering Multiple Myeloma","Clinical Trial","target_markerset_grc38, RNAseq_probe_set_grc38","OTHER, RNA-Seq, Custom targeted DNA/RNA sequencing, RNA Seq (NGS)","4 phenotype datasets, 22 variables, 2 molecular datasets, 240 samples sequenced, 55 subjects, 240 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-05-03","2023-02-13","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease",""
"phs002207.v2.p1","Genomic and Transcriptomic Profiling of Patients with Malignant Pleural    and Peritoneal Mesothelioma: The NCI Cohort","Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. Better understanding of mesothelioma genomics and transcriptomics could advance novel therapies. We performed whole-exome sequencing (WXS) of  germline and tumors of 122 patients, and RNA-sequencing (RNA-Seq) of tumor samples of 100 patients with pleural, peritoneal, and tunica-vaginalis","Not Applicable","Mesothelioma","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 24 variables, 347 samples sequenced, 122 subjects, 347 samples","","NCI","GRU --- General Research Use","2023-05-03","2023-01-06","",""
"phs003209.v1.p1","Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity    within Individual Tumors and across Evolutionary Time","A key characteristic of osteosarcoma is extensive and complex genomic rearrangements. However, published models explaining how these genomic rearrangements occur disagree about if these rearrangements occur early in tumor progression  and then are stable afterwards, or if there is ongoing genomic instability. Previous studies have employed bulk sequencing technologies to","Not Applicable","Osteosarcoma","Xenograft","target_markerset_grc38, target_markerset_grc38, WGS_markerset_grc38","OTHER, SNP/CNV Genotypes (NGS), SNP/CNV Genotypes (NGS), WGS","3 phenotype datasets, 12 variables, 1 molecular datasets, 19 samples sequenced, 8 subjects, 19 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2023-04-28","2023-04-28","Chromosomal Instability; Sarcoma; Chromosomal Instabilities; Chromosome Instabilities; Chromosome Instability; Instabilities, Chromosomal",""
"phs003228.v1.p1","Genomics of Blastic Plasmacytoid Dendritic Cell Neoplasm","The goal of this study was to understand the genetic evolution and tumor phylogeny of blastic plasmacytoid dendritic cell neoplasm (BPDCN). BPDCN can present in patients with skin tumors of  leukemia cells and no bone marrow or blood involvement, or alternatively, with both skin tumors and blood/bone marrow leukemia cells at the time of","Not Applicable","High-Throughput Nucleotide Sequencing","Tumor vs. Matched-Normal","Not Provided","WGS, WXS","3 phenotype datasets, 13 variables, 25 samples sequenced, 6 subjects, 25 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-04-24","2023-04-24","Not Provided",""
"phs001967.v1.p1","Molecular Biomarkers in Glioma (Mechanisms and Therapeutic Implications    of Hypermutation in Gliomas)","This study seeks to genomically and mechanistically examine the basis for resistance of glioblastoma to chemotherapy, radiation therapy, and targeted therapy including immunotherapies. The study design addresses two Aims. In  Aim 1, we will test the hypothesis that treatment with radiation and temozolomide or other therapies leads to consistent genetic changes in human","Not Applicable","Glioma","Case Set","Not Provided","Targeted-Capture, WGS, WXS","4 phenotype datasets, 18 variables, 90 samples sequenced,  SRA, 3 subjects, 90 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2023-04-21","2023-04-21","Diffuse Intrinsic Pontine Glioma; ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma)",""
"phs003070.v1.p1","Single Cell RNA-Sequencing in Adenoid Cystic Carcinoma","This study of salivary adenoid cystic carcinoma aimed to profile individual malignant and stromal cells in treatment-naive head and neck adenoid cystic carcinoma, with or without metastatic cervical lymph nodes.  Clinical and pathologic information was collected on all patients, in addition to a fresh biopsy sample from the primary tumor and/or metastatic","Not Applicable","Carcinoma, Adenoid Cystic","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 25 variables, 10 samples sequenced, 7 subjects, 10 samples","","NCI","DS-ACC-IRB-MDS --- Disease-Specific (Adenoid Cystic Carcinoma, IRB, MDS)","2023-04-14","2023-04-14","Adenocarcinoma, cylindroid; Adenocystic Carcinoma; Adenocystic Carcinomas; Adenoid Cystic Carcinomas; Carcinoma, Adenocystic; Carcinomas, Adenocystic",""
"phs003140.v1.p1","Genetic Epidemiology of Ovarian Cancer Histotypes","Epithelial ovarian cancer is a highly fatal malignancy with known genetic etiology; however, it is estimated that a substantial portion of narrow sense heritability remains to be discovered. The goal  of this research was to use genetic information from distantly related ovarian cancer cases to identify regions of the genome that may harbor rare","Not Applicable","Ovarian Neoplasms","Case Set","Global_Screening_Array-24","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 molecular datasets, 15 subjects, 15 samples","","NCI","DS-CA-GSO --- Disease-Specific (Cancer, GSO)","2023-04-13","2023-04-13","Carcinoma, Ovarian Epithelial; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian",""
"phs003201.v1.p1","E5103 Correlative Studies","ECOG-ACRIN E5103 (E5103) was a phase III adjuvant breast cancer trial that randomized 4994 patients with node-positive or high-risk node-negative breast cancer to intravenous doxorubicin and cyclophosphamide every 2 or  3 weeks (at the discretion of treating physician), for four cycles of adriamycin and cyclophosphamide (AC) followed by 12 weeks of weekly paclitaxel","Not Applicable","Breast Neoplasms","Case-Control","HumanOmniExpress-12, HumanOmni1-Quad, HumanOmniExpress-12, HumanOmni1-Quad","SNP Genotypes (Array), WXS","4 phenotype datasets, 13 variables, 1 molecular datasets, 672 samples sequenced, 3215 subjects, 3215 samples","European (2546), African (10), East Asian (56), African American (354), Hispanic1 (51), Hispanic2 (127), Other Asian or Pacific Islander (33), South Asian (18), Other (20)","NCI","GRU-COL --- General Research Use (COL)","2023-04-12","2023-04-12","Peripheral Neuropathy; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors",""
"phs003199.v1.p1","RNA-Seq Data From Early Stage Triple Negative Breast Cancer Tumors    Treated With TVEC and Chemotherapy (MCC18621)","This study is a phase 1/phase 2 trial testing the combination of talimogene laherparepvec (TVEC) and neoadjuvant chemotherapy for the treatment of stage II-III triple negative breast cancer. The trial  demonstrated that the addition of TVEC to neoadjuvant chemotherapy was feasible, and resulted in a pathological complete response (pCR) rate of","Not Applicable","Triple Negative Breast Neoplasms","Interventional","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 75 samples sequenced, 45 subjects, 75 samples","","NCI","GRU --- General Research Use","2023-04-07","2023-04-07","ER-Negative PR-Negative HER2-Negative Breast Cancer; Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer",""
"phs003153.v1.p1","Neoantigen-Targeted CD8+ T-Cell Responses 1 With PD-1 Blockade Therapy","Background: The primary target of T-cell responses induced against cancer cells are peptides derived from non-synonymous mutations presented by HLA (neoantigens). However, the large diversity of HLA alleles and restricted  availability of clinical samples have limited the study of the specificity and the evolution over time of the neoantigen-specific T cell responses","Not Applicable","Melanoma","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 18 variables, 33 samples sequenced, 11 subjects, 33 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2023-03-30","2023-03-30","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs002659.v1.p1","Genomics from LCCC1525: A Priming Dose of Cyclophosphamide Prior to    Pembrolizumab to Treat mTNBC","This phase II, single-arm, multicenter study will evaluate pembrolizumab therapy, 200 mg IV, given every 3 weeks (Q3W), following a single priming dose of cyclophosphamide, 300 mg/m2 IV, in patients  with advanced triple-negative breast cancer (TNBC) who have received at least one prior line of therapy. Data uploaded consists of FASTQ sequencing","Not Applicable","Triple Negative Breast Neoplasms","Interventional","RNAseq_probe_set_grc38","AMPLICON, RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 13 variables, 1 molecular datasets, 279 samples sequenced, 33 subjects, 279 samples","","NCI","DS-BRCA-IRB --- Disease-Specific (Breast Cancer, IRB)","2023-03-30","2023-03-30","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003183.v1.p1","The Ultrasound Study of Tamoxifen","The Ultrasound Study of Tamoxifen is a 12-month longitudinal study to describe volumetric breast density change over time among women with and without tamoxifen exposure. Women were enrolled at the  Karmanos Cancer Institute and Henry Ford Health Systems in Detroit, Michigan between 2011-2014. Enrollment included women prescribed tamoxifen for","Not Applicable","Tamoxifen","Prospective Longitudinal Cohort","target_markerset_grc38","AMPLICON, SNP/CNV Genotypes (NGS)","4 phenotype datasets, 14 variables, 1 molecular datasets, 60 samples sequenced, 60 subjects, 60 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2023-03-29","2023-03-29","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002762.v1.p1","Functional Multiomics of Cellular Therapy and Immune Checkpoint Blockade    Therapy for Solid Tumors","Tumor samples were collected from a patient with synovial sarcoma, which acquired resistance to ACT targeting NY-ESO-1. Biopsies (n 3; primary, metastasis, and recurrence) were subjected to bulk tumor DNA  and RNA sequencing, as well as high-dimensional spatial profiling of RNA and protein targets. Bulk tumor whole exome and RNA sequencing corresponding","Not Applicable","Adoptive Transfer","Tumor vs. Matched-Normal","WES_markerset_grc38, RNAseq_probe_set_grc38","RNA-Seq, SNP/CNV Genotypes (NGS), RNA Seq (NGS), WXS","4 phenotype datasets, 17 variables, 2 molecular datasets, 7 samples sequenced, 1 subjects, 7 samples","","NCI","DS-SARC-PUB --- Disease-Specific (Sarcoma, PUB)","2023-03-29","2023-03-29","Synovial Sarcoma; Malignant synovioma; Sarcoma, Synovial; Sarcomas, Synovial; Synovial Sarcomas; Synovialosarcoma",""
"phs001410.v2.p2","Kids First: Pediatric Research Project on Adolescent Idiopathic Scoliosis","Both childhood cancers and structural birth defects are critical and costly conditions associated with substantial morbidity and mortality. Elucidating the underlying genetic etiology of these diseases has the potential to  profoundly improve preventative measures, diagnostics, and therapeutic interventions. For the current study, families with inherited adolescent","Not Applicable","Scoliosis","Prospective Longitudinal Cohort","Not Provided","Not Provided","5 phenotype datasets, 21 variables, 598 subjects, 598 samples","","NCI","HMB --- Health/Medical/Biomedical, DS-MUS-SKEL-IRB --- Disease-Specific (Musculoskeletal Diseases, IRB)","2023-03-29","2018-10-12","Cobb angle greater than ten degrees; Scolioses; Scoliosis,","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs003002.v1.p1","A Platform Study of Combination Immunotherapy for the Neoadjuvant and    Adjuvant Treatment of Patients with Surgically Resectable    Adenocarcinoma of the Pancreas","This is a single-institutional, randomized, open label platform clinical trial testing various immunotherapy combinations. Patients with newly diagnosed and surgically resectable pancreatic ductal adenocarcinoma (PDA) and scheduled to undergo the  Whipple procedure at Johns Hopkins Hospital were eligible to participate in this study. Criteria for determining resectability strictly followed","Not Applicable","Pancreatic Neoplasms","Clinical Trial","WES_markerset_grc37","RNA-Seq, SNP Genotypes (NGS)","5 phenotype datasets, 23 variables, 1 molecular datasets, 79 samples sequenced, 25 subjects, 98 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","2023-03-28","2023-03-28","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas",""
"phs002357.v1.p1","Lineage Plasticity and Immune Cell Heterogeneity Are Coordinately    Dysregulated Through Changes in FOXA1 Expression in Bladder Cancers    with Squamous Differentiation","We performed whole exome sequencing (WES) of paired, macrodissected regions of urothelial carcinoma (UC), not otherwise specified (NOS-UC) and squamous differentiation (SqD) from 21 bladder tumors in which distinct and  separable NOS-UC and SqD regions were present (total 42 exomes, in addition to matched normal exomes). Mean tumor mutational burden (TMB) was higher","Not Applicable","Carcinoma, Transitional Cell","Tumor vs. Matched-Normal","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 19 variables, 1 molecular datasets, 36 samples sequenced, 13 subjects, 36 samples","","NCI","DS-BLADDERCA-PUB-MDS --- Disease-Specific (Bladder Cancer, PUB, MDS)","2023-03-28","2023-03-28","",""
"phs002705.v1.p1","Single Cell Analysis Reveals Immune Dysfunction from the Earliest Stages    of CLL that can be Reversed by Ibrutinib","We applied single cell RNA sequencing to broadly characterize circulating immune cells co-existing with leukemic cells during natural chronic lymphocytic leukemia (CLL) progression. We used peripheral blood mononuclear cells from  patients diagnosed from monoclonal B-lymphocytosis (MBL) and CLL at different time-points, and age-matched healthy donors (HDs). We analyzed the","Not Applicable","Lymphocytosis","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 13 variables, 30 samples sequenced, 16 subjects, 30 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-03-23","2023-03-23","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs003149.v1.p1","Bladder Cancer Organoids as a Functional System to Model Different    Disease Stages and Therapy Response","The study 'Bladder Cancer Organoids as a Functional System to Model Different Disease Stages and Therapy Response' reports the genomic characterization at the single allele level upon Whole Exome Sequencing  of Bladder Cancer (BLCa) Patient Tumor (PT) samples obtained from 18 patients and corresponding Patient Derived Organoids (PDOs), implementing the","Not Applicable","Urinary Bladder Neoplasms","Collection","Not Provided","WXS","4 phenotype datasets, 27 variables, 61 samples sequenced, 18 subjects, 61 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-03-22","2023-03-22","Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder",""
"phs003148.v1.p1","NCT03343197: Clinical Biomarker Data","Patients with IDH1-mutated low-grade glioma were treated with AG-120 (ivosidenib), AG-881 (vorasidenib), or Placebo for 28 days before surgical resection. A portion of the surgical sample was submitted for exome  capture-based transcriptome sequencing (Personalis ACE Whole Transcriptome). Following surgery, subjects had the option to continue (or initiate)","Not Applicable","Glioma","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 41 samples sequenced, 41 subjects, 41 samples","","NCI","DS-GL --- Disease-Specific (Glioma)","2023-03-22","2023-03-22","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs003191.v1.p1","RNA Splicing Dysregulation in the Pathogenesis of Chronic Lymphocytic    Leukemia","RNA splicing dysregulation is a hallmark of cancers, promoting the onset and progression of disease. In chronic lymphocytic leukemia (CLL), spliceosome mutations leading to aberrant splicing occurs in approximately 20%  of patients. However, the underlying mechanism for splicing defects in spliceosome unmutated CLL cases remains elusive. To discover","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case-Control","Not Provided","OTHER, RNA-Seq","4 phenotype datasets, 23 variables, 56 samples sequenced, 48 subjects, 56 samples","","NCI","DS-CLL-PUB-NPU --- Disease-Specific (Chronic Lymphocytic Leukemia, PUB, NPU)","2023-03-21","2023-03-21","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs002435.v1.p1","Development and Validation of Patient-Derived Xenografts from    Fibrolamellar Carcinoma Human Tissue","We developed and validated Patient-Derived Xenografts (PDX) of Fibrolamellar Carcinoma human tissue from surgical resections. Human tissues from primary liver tumor, recurrent liver, and liver metastases were implanted into NOD-SCID-Gamma  (NSG) mice (Jackson laboratories) and monitored for tumor growth. Some of the original tissues were frozen for further analysis including RNA","Not Applicable","Carcinoma, Hepatocellular","Xenograft","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 19 samples sequenced, 5 subjects, 19 samples","","NCI","DS-HCC-IRB-COL --- Disease-Specific (Hepatocellular Carcinoma, IRB, COL)","2023-03-17","2023-03-17","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells",""
"phs003165.v1.p1","Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic    Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer    Brain Metastases","This study is a phase I trial combining ado-trastuzumab emtansine (T-DM1) with Temozolomide (TMZ) for the prevention of additional brain metastases after previous occurrence and local treatment in HER2+ breast  cancer patients. Twelve patients were enrolled in this study. Data includes whole exome sequencing (WES) from patients' cerebrospinal fluid (CSF) and","Not Applicable","Breast Neoplasms","Case Set","target_markerset_grc38","SNP Genotypes (NGS), WXS","4 phenotype datasets, 15 variables, 1 molecular datasets, 69 samples sequenced, 12 subjects, 69 samples","","NCI","GRU --- General Research Use","2023-03-16","2023-03-16","Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002962.v1.p1","Germline Genetics of Myelodysplastic Syndromes (MDS) and Acute Myeloid    Leukemia (AML)","Myelodysplastic syndromes (MDS) are part of a heterogeneous and overlapping group of clonal diseases including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and the hybrid MDS/MPN entities that arise in  hematopoietic stem or progenitor cells. Individuals with MDS have a high risk of progressing to leukemia, with approximately 30% expected to develop","Not Applicable","Myelodysplastic Syndromes","Case-Control","Global_Diversity_Array-8","SNP Genotypes (Array)","5 phenotype datasets, 32 variables, 1 molecular datasets, 1711 subjects, 1711 samples","European (1671), African (1), East Asian (5), African American (11), Hispanic1 (3), Hispanic2 (12), Other Asian or Pacific Islander (4), South Asian (2), Other (2)","NCI","GRU-PUB --- General Research Use (PUB)","2023-03-16","2023-03-16","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs002347.v1.p1","PDAC Prognosis Biomarkers in Genomic and Transcriptomic Molecular Data","Our study was designed to identify biomarkers related to the prognosis of Pancreatic Ductal AdenoCarcinoma (PDAC) patients using genomic variants and gene expression in coding regions of the human genome  (exome). PDAC is the 7th cause of cancer deaths and is among types of cancer having the poorest prognosis. To improve treatment outcomes of PDAC,","Not Applicable","Carcinoma, Pancreatic Ductal","Tumor vs. Matched-Normal","WES_markerset_grc38, WES_markerset_grc38, WES_markerset_grc38","RNA-Seq, SNP Genotypes (NGS), SNV Aggregate (.MAF), WXS","4 phenotype datasets, 24 variables, 1 molecular datasets, 450 samples sequenced, 150 subjects, 450 samples","","NCI","GRU --- General Research Use","2023-03-15","2023-03-15","Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003103.v1.p1","Single Cell Analysis of Sporadic Human Basal Cell Carcinomas","To explore tumor heterogeneity in sporadic human basal cell carcinoma tumors, we profiled three individual patient tumors by scRNA-Seq and scATAC-Seq. Basal cell carcinomas (BCCs) are driven by hedgehog signaling  with GLI1 representing the key downstream transcription factor that drives tumor growth. GLI1 as such is a readout of active hedgehog signaling. We","Not Applicable","Carcinoma, Basal Cell","Case Set","ATAC_DNAseq_probe_set","OTHER, RNA Seq (NGS)","1 molecular datasets, 6 samples sequenced, 3 subjects, 6 samples","","NCI","GRU --- General Research Use","2023-03-09","2023-03-09","Basal Cell Nevus Syndrome; BCNS; BCNS - Basal cell nevus syndrome; BCNS1; Basal cell carcinoma syndrome; Fifth Phacomatoses",""
"phs003195.v1.p1","NSD2 E1099K Drives Relapse in Pediatric Acute Lymphoblastic Leukemia by    Disrupting 3D Chromatin Organization","NSD2 p.E1099K (EK) is a mutation shown to be enriched in patients that relapse with pediatric Acute Lymphoblastic Leukemia (ALL). This work aims to uncover 3D chromatin architecture-related mechanisms responsible  for drug resistance or therapy failure in these patients. We investigated this by performing Hi-C, ATAC-Seq, and RNA-Seq on three B-ALL cell lines","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Clinical Trial","Not Provided","RNA-Seq","3 phenotype datasets, 11 variables, 6 samples sequenced, 6 subjects, 6 samples","","NCI","GRU --- General Research Use","2023-03-08","2023-03-08","ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1",""
"phs002188.v2.p1","Single Cell Genomic Analysis of Lymphoma","Our study aimed to define the extent of heterogeneity between anatomically separated tumor manifestations in follicular lymphoma at single-cell resolution. We subjected single-cell suspensions derived from nodal, synchronously-acquired fine needle  aspirations from two distinct tumor sites to high-throughput microfluidics-based single-cell RNA sequencing. By comparing the relative composition of","Not Applicable","Lymphoma","Case Set","Not Provided","OTHER","4 phenotype datasets, 14 variables, 22 samples sequenced, 10 subjects, 22 samples","","NCI","GRU --- General Research Use","2023-03-03","2021-03-26","Follicular Lymphoma; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002862.v1.p1","Improved T Cell Immunity Following Neoadjuvant Chemotherapy in Ovarian    Cancer","This study characterized the evolution of the peripheral immune cell function and composition across the course of standard of care platinum and taxane chemotherapy in ovarian cancer using bulk and  single cell transcriptomic approaches. Serial blood samples were collected from ten patients with advanced high-grade serous ovarian cancer treated","Not Applicable","Carcinoma, Ovarian Epithelial","Prospective Longitudinal Cohort","Not Provided","OTHER","4 phenotype datasets, 13 variables, 10 samples sequenced, 10 subjects, 10 samples","","NCI","GRU --- General Research Use","2023-03-02","2023-03-02","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian",""
"phs002939.v1.p1","NCI-Maryland Prostate Cancer Case-Control Study","The study seeks to examine the genetic and ancestral basis of prostate cancer-associated inflammation using a genome-wide association approach. The study population are the participants of the NCI Maryland Prostate  Cancer Case-Control study. This study recruited both African American and European American men, and investigated the causes for the excessive burden","Not Applicable","Prostatic Neoplasms","Case-Control","HumanOmni5Exome-4","SNP Genotypes (Array)","4 phenotype datasets, 20 variables, 1 molecular datasets, 1450 subjects, 1450 samples","European (753), African (16), African American (668), Hispanic1 (8), Hispanic2 (1), Other Asian or Pacific Islander (2), Other (2)","NCI","HMB-IRB-PUB-NPU-MDS --- Health/Medical/Biomedical (IRB, PUB, NPU, MDS)","2023-03-01","2023-03-01","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003111.v1.p1","Childhood Cancer Data Initiative (CCDI): Clonal Evolution During    Metastatic Spread in High-Risk Neuroblastoma","The goal of this study is to deliver a detailed characterization of the patterns of disease dissemination at diagnosis, during progression and in response to therapy in high-risk neuroblastoma. Longitudinal  and spatially distinct tumors were collected from patients. Clinical data includes diagnosis and treatment information. Biospecimen data includes","Not Applicable","Rare Diseases","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","2 phenotype datasets, 7 variables, 195 samples sequenced, 129 subjects, 487 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-02-28","2023-02-28","Rare Disease; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs002529.v1.p1","Childhood Cancer Data Initiative (CCDI): Comprehensive Genomic Sequencing    of Pediatric Cancer Cases (CMRI/KUCC)","This study provides paired tumor normal genomic sequencing data from 200 children with cancer, including both solid tumors and leukemias, done by the Children's Mercy Research Institute (CMRI) and University  of Kansas Cancer Center (KUCC). These data include whole genome sequencing (generally, 20x), whole exome sequencing (generally, 300x), bulk RNA","Not Applicable","Whole Genome Sequencing","Tumor vs. Matched-Normal","Not Provided","ATAC-seq, RNA-Seq, WGS, WXS","2 phenotype datasets, 5 variables, 372 samples sequenced, 193 subjects, 372 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2023-02-28","2023-02-28","Leukemia; Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia",""
"phs003177.v1.p1","Comparison Between qPCR and RNA-Seq Reveals Challenges of Quantifying HLA    Expression","Human leukocyte antigen (HLA) class I and HLA class II loci are essential elements of innate and acquired immunity. Their exceptional influence on disease outcome is well documented by GWAS  and candidate gene studies. The impact of HLA allelic variation on human disease through allele-specific presentation of antigenic peptides to T","Not Applicable","HLA Antigens","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 12 variables, 125 samples sequenced, 96 subjects, 125 samples","","NCI","GRU --- General Research Use","2023-02-24","2023-02-24","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs003060.v1.p1","Whole Exome Sequencing of Calcitonin Producing Pancreatic Neuroendocrine    Neoplasms (CT-pNENs) Indicates a Unique Molecular Signature","Calcitonin-producing pancreatic neuroendocrine neoplasms (CT-pNENs), which can mimic clinical and laboratory features of medullary thyroid carcinoma, are an extremely rare clinical entity with approximately 60 cases reported worldwide. The molecular  profile of CT-pNENs is not yet known. Whole-exome sequencing (WES) was performed on tumor and corresponding serum samples of five patients with","Not Applicable","Insulinoma","Tumor vs. Matched-Normal","Not Provided","WGS","3 phenotype datasets, 15 variables, 10 samples sequenced, 5 subjects, 10 samples","","NCI","GRU --- General Research Use","2023-02-24","2023-02-24","Adenoma, beta Cell; Adenoma, beta-Cell; Adenomas, beta-Cell; Beta cell adenoma; Insulinomas; Insuloma",""
"phs001528.v2.p1","Gene Expression of Small Cell Carcinoma of the Ovary-Hypercalcemic Type    (SCCOHT)","Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) is a rare and aggressive form of ovarian cancer afflicting young women at a median age of 24 years. SCCOHTs are characterized  by loss of protein expression of SWI/SNF chromatin remodeling ATPases SMARCA4 and SMARCA2 through mutation and epigenetic silencing, respectively.","Not Applicable","Ovarian Neoplasms","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 23 variables, 9 samples sequenced, 9 subjects, 9 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-02-24","2018-02-22","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001273.v4.p2","Oncoarray Consortium - Lung Cancer Studies","The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in  ONcology (GAME-ON) consortium, and associated with the International Lung Cancer Consortium (ILCCO). Ethics: All participants provided written","Not Applicable","Lung Neoplasms","Case-Control","OncoArray, imputation_panel","SNP Genotypes (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 20 variables, 1 documents, 6 analyses, 3 molecular datasets, 38721 subjects, 39518 samples","European (32953), African (12), East Asian (3553), African American (960), Hispanic1 (245), Hispanic2 (381), Other Asian or Pacific Islander (430), South Asian (22), Other (165)","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB --- Health/Medical/Biomedical, DS-CA --- Disease-Specific (Cancer), DS-CA-GSO --- Disease-Specific (Cancer, GSO), DS-CA-COL-NPU-MDS --- Disease-Specific (Cancer, COL, NPU, MDS), HMB-MDS-GSO --- Health/Medical/Biomedical (MDS, GSO), CHRONIC --- Chronic Diseases (including Cancer), Methods, EPIMEDCA --- Epidemiological and Medical Research on Cancer, Methods, DS-CALD-PUB-NPU --- Disease-Specific (Cancer or Lung Diseases, PUB, NPU), GRU --- General Research Use, LDS --- Lung Disease and Smoking, GRU-COL --- General Research Use (COL), DS-CA-MDS --- Disease-Specific (Cancer, MDS), LCEDOE --- Lung Cancer, Environmental, Diet, Occupational Exposures, HMB-PUB --- Health/Medical/Biomedical (PUB), DS-CA-PUB-NPU --- Disease-Specific (Cancer, PUB, NPU)","2023-02-24","2023-02-24","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs003090.v1.p1","Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model","Progress in the early detection and treatment of cancer requires accurate model systems to further evaluate new, promising discoveries. Small animal and, in particular, mouse model systems are attractive to  researchers for numerous reasons, including their ease of use and well-described platforms. The ability to grow human tumors in immune-deficient mice","Not Applicable","Melanoma","Xenograft","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 17 variables, 40 samples sequenced, 4 subjects, 40 samples","","NCI","GRU --- General Research Use","2023-02-14","2023-02-14","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs003094.v1.p1","Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): a Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study - for Samples Collected at Johns    Hopkins","UC-GENOME is a real-world cohort of patients with metastatic urothelial carcinoma (UC). The study consisted of two co-equal aims: 1) to provide targeted DNA sequencing for clinical decision making at  no cost to patients; and 2) to create a resource for collaborative translational science including a clinically annotated biobank. The submitted data","Not Applicable","Urinary Bladder Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 13 variables, 14 samples sequenced, 8 subjects, 14 samples","","NCI","DS-TCC-IRB-NPU --- Disease-Specific (transitional cell carcinoma, IRB, NPU)","2023-02-09","2023-02-09","Bladder Cancer; Cancer of Urinary Tract; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder",""
"phs003059.v1.p1","Metastatic Colorectal Adenocarcinoma Tumor Purity Assessment from Whole    Exome Sequencing Data","As molecular medicine wields greater and greater influence on cancer patient care, including therapeutic selection, it becomes increasingly important to understand the power and deficiencies of computational tools used in  decision making processes. Here we use a set of unselected metastatic colorectal tumor samples in a head-to-head comparison between the calculation","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","WXS","3 phenotype datasets, 11 variables, 30 samples sequenced, 18 subjects, 30 samples","","NCI","GRU --- General Research Use","2023-02-08","2023-02-08","Neoplasm Metastases; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs001904.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Y","The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and post-treatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 380 variables,  SRA, 31 subjects, 31 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-02-07","2023-02-07","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003154.v1.p1","An Advanced Molecular Medicine Case Report of a Rare Human Tumor Using    Genomics, Pathomics, and Radiomics","The associated data of this study is derived from a single female patient with pulmonary sclerosing pneumocytoma (PSP). The aim of this study is to provide the most comprehensive, multi-modality  sequencing study of a single case of PSP to-date. To this end, the following sequencing experiments were performed: i) RNA-Seq of the primary tumor","Not Applicable","Pulmonary Sclerosing Hemangioma","Case-Control","Not Provided","RNA-Seq, Targeted-Capture, WGS","3 phenotype datasets, 15 variables, 16 samples sequenced, 1 subjects, 16 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2023-02-06","2023-02-06","Hemangioma, Sclerosing, Pulmonary; Lung Sclerosing Angioma; Lung Sclerosing Hemangioma; Lung Sclerosing Hemangiomas; Pneumocytoma; Pulmonary Sclerosing Hemangiomas",""
"phs003042.v1.p1","Novel Strategies to Eliminate Resistance to B-cell Receptor Inhibitor    Therapy in Lymphoid Malignancies","Ibrutinib and acalabrutinib are BTK inhibitors (BTKi) used as frontline therapies for chronic lymphocytic leukemia (CLL). Clonal evolution during ibrutinib treatment has previously been studied, but limited study of clonal  evolution in patients receiving acalabrutinib has been done. Our group analyzed 216 blood samples from 38 CLL patients at multiple time points during","Not Applicable","Clonal Evolution","Case Set","Not Provided","WXS","4 phenotype datasets, 25 variables, 216 samples sequenced, 38 subjects, 216 samples","","NCI","GRU --- General Research Use","2023-02-06","2023-02-06","Evolution, Clonal; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002822.v1.p1","SU2C-MARK Lung Cancer Consortium - Checkpoint Blockade Response Project","Immune checkpoint inhibitors have become a critical part of the armamentarium against advanced Non-Small Cell Lung Cancer (NSCLC). While early studies have identified Tumor Mutation Burden (TMB) and PD-L1 staining  as important biomarkers of response, they remain imperfect predictors. Here we describe a multi-institutional effort as part of the SU2C-MARK Lung","Not Applicable","Carcinoma, Non-Small-Cell Lung","Collection","WES_markerset_grc38","MAF (NGS), Targeted-Capture","4 phenotype datasets, 46 variables, 1 molecular datasets, 463 samples sequenced, 230 subjects, 463 samples","","NCI","DS-CATHLU-MDS --- Disease-Specific (Cancer -Thoracic and Lung, MDS), HMB-MDS --- Health/Medical/Biomedical (MDS), GRU --- General Research Use","2023-02-02","2023-02-02","Adenocarcinoma; Large Cell Carcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs003100.v1.p1","Whole-Genome Sequencing Analysis of Extrachromosomal DNA with Amplicon    Architect","The study is related to our manuscript entitled ""Single-cell genetic heterogeneity linked to immune infiltration in glioblastoma"". Using multiplexed FISH analysis of 3-4 tumor cores from 17 glioblastoma formalin-fixed paraffin-embedded  (FFPE) tumors, we identified two classes of tumors based on single cell co-occurrence of EGFR and CDK4 amplification. Tumors with a low odds ratio","Not Applicable","Glioblastoma","Case Set","Not Provided","WGS","4 phenotype datasets, 27 variables, 6 samples sequenced, 6 subjects, 6 samples","","NCI","GRU --- General Research Use","2023-01-31","2023-01-31","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs003085.v1.p1","RNA-Sequencing of B-Lymphoblastic Leukemia with Glucocorticoids and PI3K    Delta Inhibition","Mononuclear cells were isolated from bone marrow or peripheral blood of 7 pediatric subjects with B-lymphoblastic leukemia at the time of diagnosis. To determine the effect of PI3K delta inhibition  on glucocorticoid-induced gene regulation, B-lymphoblastic leukemia cells were treated with glucocorticoids +/- the PI3K delta inhibitor, idelalisib,","Not Applicable","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Case Set","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 20 variables, 1 molecular datasets, 65 samples sequenced, 7 subjects, 65 samples","","NCI","GRU --- General Research Use","2023-01-31","2023-01-31","Leukemia, Pre B Cell; Leukemia, Pre-B-Cell; Leukemias, Pre-B-Cell; Pre B ALL; Pre B Cell Leukemia; Pre B-ALL",""
"phs003159.v1.p1","Targeted Long-Read Sequencing of the Ewing Sarcoma 6p25.1 Susceptibility    Locus","Ewing Sarcoma (EwS) is rare but the second most common cancer in children, adolescents and young adults. Recent studies suggest germline variation in or around GGAA microsatellites may interact with  fusion oncoprotein binding causing changes in binding affinity and potentially impacting enhancer activity on nearby target genes. This study aims to","Not Applicable","Sarcoma, Ewing","Case-Control","Not Provided","AMPLICON","4 phenotype datasets, 13 variables, 462 samples sequenced, 231 subjects, 462 samples","","NCI","DS-ES --- Disease-Specific (Ewing's Sarcoma)","2023-01-27","2023-01-27","ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor",""
"phs001134.v2.p1","Radiation-Related Genomic Profile of Papillary Thyroid Cancer after the    Chernobyl Accident","The April 26, 1986 accident at the Chernobyl nuclear power plant in northern Ukraine resulted in the release of radioactive contaminants, which were deposited in the surrounding areas in Ukraine,  Belarus, and Russia. The main radiation-related health effect resulting from these exposures is the increased occurrence of thyroid cancer among","Not Applicable","Thyroid Cancer, Papillary","Case Set","HumanOmniExpress-24, HumanOmniExpress-24, HumanOmniExpress-24, HumanOmniExpress-24, HumanOmniExpress-24, HumanOmniExpress-24, MethylationEPIC","SNP Genotypes (Array)","5 phenotype datasets, 23 variables, 2 molecular datasets, 440 subjects, 4615 samples","","NCI","GRU --- General Research Use","2023-01-24","2021-08-03","Neoplasms, Radiation-Induced; Neoplasm, Radiation-Induced; Neoplasms, Radiation Induced; Radiation Induced Neoplasm; Radiation Induced Neoplasms; Radiation-Induced Neoplasm","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003097.v1.p1","Multi-Modal Single-Cell and Whole-Genome Sequencing of Small, Frozen    Clinical Specimens","Clinical application of single-cell sequencing technologies has been hampered by their need for quick processing of relatively large, fresh specimens. Here, we benchmarked the performance of a new technique for  single-cell sequencing from snap-frozen clinical samples, vs. sequencing from fresh samples, on 5 samples from cutaneous melanoma brain metastasis, 6","Not Applicable","Neoplasm Metastasis","Collection","Not Provided","OTHER, WGS, WXS","4 phenotype datasets, 18 variables, 94 samples sequenced, 41 subjects, 94 samples","","NCI","GRU --- General Research Use","2023-01-18","2023-01-18","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell",""
"phs003066.v1.p1","Urothelial Cancer - Genomic Analysis to Improve Patient Outcomes and    Research (UC-GENOME): A Bladder Cancer Advocacy Network (BCAN)-Led    Collaborative Research Pilot Study","UC-GENOME is a real-world cohort of patients with metastatic urothelial carcinoma (UC). The study consisted of two co-equal aims: 1) to provide targeted DNA sequencing for clinical decision making at  no cost to patients; and 2) to create a resource for collaborative translational science including a clinically annotated biobank. The submitted data","Not Applicable","Urinary Bladder Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 13 variables, 353 samples sequenced, 194 subjects, 353 samples","","NCI","DS-UC --- Disease-Specific (Urinary Conditions)","2023-01-12","2023-01-12","Bladder Cancer; Cancer of the Urinary Tract; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder",""
"phs001926.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Q","The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA  sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131).","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 312 variables,  SRA, 35 subjects, 35 samples","","NCI","GRU-COL --- General Research Use (COL)","2023-01-10","2023-01-10","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002622.v1.p1","Aurora US Metastatic Breast Cancer Retrospective Project","The AURORA US Metastatic Breast Cancer project is funded by the Breast Cancer Research Foundation (BCRF) Evelyn H. Lauder Founder's Fund for Metastatic Breast Cancer Research. This multi-center effort conducted  within the Translational Breast Cancer Research Consortium (TBCRC) and cancer researchers to better understand the metastatic process through the","Not Applicable","Breast Neoplasms","Case Set","MethylationEPIC","Methylation (CpG), RNA-Seq, WGS, WXS","5 phenotype datasets, 17 variables, 1 molecular datasets, 325 samples sequenced, 55 subjects, 477 samples","","NCI","GRU --- General Research Use, HMB --- Health/Medical/Biomedical, DS-BRCA --- Disease-Specific (Breast Cancer)","2023-01-06","2023-01-06","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003084.v1.p1","Genome Sequencing of Circulating Tumor Cells for Minimally Invasive    Molecular Characterization of Multiple Myeloma Pathology","&#x0200b;&#x0200b;Multiple Myeloma (MM) develops from well-defined precursor stages known as Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering MM (SMM); however, invasive bone marrow (BM) biopsy limits screening and monitoring  strategies for patients. In this study, we enumerated circulating tumor cells (CTCs) from patients with precursor and overt diseases, and developed a","Not Applicable","Multiple Myeloma","Tumor vs. Matched-Normal","Not Provided","WGS","4 phenotype datasets, 15 variables, 135 samples sequenced, 51 subjects, 135 samples","","NCI","HMB --- Health/Medical/Biomedical","2023-01-05","2023-01-05","Monoclonal Gammopathy of Undetermined Significance; Smoldering Multiple Myeloma; Asymptomatic monoclonal gammopathy; Benign Monoclonal Gammapathies; Benign Monoclonal Gammapathy; Benign Monoclonal Gammopathies",""
"phs003117.v1.p1","Multiregional Single-Cell Transcriptomic Analysis of Liver Cancer","In this study, we performed single-cell transcriptomic profiling of human liver tissues collected from hepatocellular carcinoma and intrahepatic cholangiocarcinoma patients. A total of seven primary liver cancer patients enrolled in  this study. Samples were collected from multiple regions, including tumor core, tumor border and adjacent non-tumor tissue. The 10x Genomics platform","Not Applicable","Carcinoma, Hepatocellular","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 11 variables, 34 samples sequenced, 7 subjects, 34 samples","","NCI","GRU-COL --- General Research Use (COL), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), DS-LCCLD-IRB-NPU --- Disease-Specific (Liver Cancer and Chronic Liver Disease, IRB, NPU)","2023-01-04","2023-01-04","Liver Neoplasms; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells",""
"phs000563.v2.p1","The Genomics of Pilocytic Astrocytoma Formation in Neurofibromatosis Type    1","Neurofibromatosis type 1 (NF1) inherited cancer predisposition syndrome is one of the most common autosomal dominant tumor predisposition syndromes in which affected individuals develop brain tumors. These low-grade glial neoplasms  (pilocytic astrocytomas) typically arise in children younger than 7 years of age and are hypothesized to result from a combination of germline and","Not Applicable","Astrocytoma","Case Set","custom_markerset","Methylation (CpG), WGS","4 phenotype datasets, 14 variables, 1 molecular datasets, 6 samples sequenced, 4 subjects, 10 samples","","NCI","DS-BST-GSO --- Disease-Specific (Brain and Spinal Tumors, GSO)","2022-12-23","2013-07-01","Neurofibromatosis Type 1; Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Glioma",""
"phs002691.v1.p1","The MD Anderson Colorectal Cancer Case Control Study","Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the US. Driven by common disease common variants hypothesis, genome-wide association studies only identified a number of common  susceptibility loci that explained a small portion of CRC heritability. We conducted a case-control study using whole exome sequencing to identify","Not Applicable","Colorectal Neoplasms","Case-Control","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 27 variables, 1 analyses, 1 molecular datasets, 5384 samples sequenced, 5384 subjects, 5384 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2022-12-22","2022-12-22","Family Medical History; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine",""
"phs002866.v1.p1","Circulating Tumor DNA in Intermediate Risk Rhabdomyosarcoma","In this study, we evaluated circulating tumor DNA (ctDNA) as a biomarker in the serum of 124 patients with newly diagnosed intermediate risk rhabdomyosarcoma (IR RMS) from the&#x000a0;Children's Oncology Group&#x000a0;(COG)  biorepository. In addition to pre-treatment serum, we also analyzed matched tumor tissue and germline in a subset of patients. We profiled samples","Not Applicable","Rhabdomyosarcoma","Case Set","Not Provided","Targeted-Capture, WGS","4 phenotype datasets, 13 variables, 295 samples sequenced, 124 subjects, 295 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-12-21","2022-12-21","Not Provided",""
"phs002432.v1.p1","Wistar PDX Development and Trial Center","Overall the outcomes of patients with metastatic melanoma have improved dramatically over the last decade due to an improved understanding of the molecular drivers of this disease. In particular, multiple  targeted therapy regimens have been approved for patients with a BRAFV600E/K mutation, which are present in 50% of cutaneous melanomas. These","Not Applicable","Melanoma","Case Set","Not Provided","Not Provided","4 phenotype datasets, 21 variables, 46 subjects, 185 samples","","NCI","GRU-COL --- General Research Use (COL)","2022-12-21","2022-12-21","Skin Neoplasms; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant",""
"phs002802.v1.p1","Phase IB/II Study of Bazedoxifene in Combination with Palbociclib in    Patients with Endocrine Resistant Hormone Receptor-Positive Breast    Cancer","In this phase Ib/II clinical trial, the investigators evaluated the efficacy and safety of the combination of palbociclib with bazedoxifene in patients with a metastatic endocrine-resistant hormone receptor-positive, HER2-negative breast  cancer. Furthermore, whole exome sequencing of cell-free tumor DNA was done on serial samples from these patients, revealing potential molecular","Not Applicable","Breast Neoplasms","Clinical Trial","Not Provided","WGS, WXS","4 phenotype datasets, 18 variables, 98 samples sequenced, 32 subjects, 98 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-12-15","2022-12-15","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002479.v1.p1","HCI-PDX Trial Center for Breast Cancer Therapy","The HCI-PDX Trial Center for Breast Cancer Therapy study is a collection of patient-tumor samples that are serially established as patient-derived tumor xenografts (human tumor in mouse) and matching organoids.  For this study, we describe valuable methods and resources to generate organoids and use them as cost-effective models for precision drug screens.","Not Applicable","Breast Neoplasms","Xenograft","RNAseq_probe_set_grc38, WES_markerset_grc38, Affymetrix_WG_Array, HumanOmni2.5-8, RNAseq_probe_set_grc38, WES_markerset_grc38","CNV Genotypes, RNA-Seq, SNV (.MAF), RNA Seq (NGS), WXS","4 phenotype datasets, 35 variables, 1 molecular datasets, 152 samples sequenced, 37 subjects, 227 samples","","NCI","GRU --- General Research Use","2022-12-15","2022-12-15","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001286.v3.p2","The Prostate, Lung, Colon, Ovary Screening Trial (PLCO)","The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of  screening on cancer-related mortality and secondary endpoints in over 150,000 men and women aged 55 to 74. The screening component of the trial was","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","OncoArray, HumanOmni5-4, HumanOmni2.5-8, Global_Screening_Array-24, HumanOmniExpress-24, HumanOmni2.5-8, HumanOmni5-4, Global_Screening_Array-24, HumanOmniExpress-24, OncoArray","SNP/CNV (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 13 variables, 2 molecular datasets, 110559 subjects, 112062 samples","European (100737), African (154), East Asian (2749), African American (4481), Hispanic1 (225), Hispanic2 (1379), Other Asian or Pacific Islander (783), South Asian (160), Other (242)","NCI","CADM --- Research relating to adults diseases and methods","2022-12-12","2022-02-14","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002518.v1.p1","Childhood Cancer Data Initiative (CCDI): OncoKids - NGS Panel for    Pediatric Malignancies","This study aimed to systematically collect clinical, registry and genomic data on pediatric cancer patients, and to contribute to the CCDI Pediatric Data Ecosystem. Clinical, treatment and outcome data on  1,039 pediatric cancer patients whose molecular profile was characterized on OncoKids gene panel at Children's Hospital Los Angeles was abstracted","Not Applicable","Neoplasms","Clinical Genetic Testing","Not Provided","AMPLICON","2 phenotype datasets, 5 variables, 2246 samples sequenced, 1039 subjects, 2246 samples","","NCI","GRU --- General Research Use","2022-12-07","2022-12-07","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs003079.v1.p1","Spatiotemporal Evolution of the ccRCC Microenvironment Links    Intra-Tumoral Heterogeneity to Immune Escape CINOMA","We utilize temporal multi-regional multi-omics profiling to uncover the mechanisms of immune escape in clear cell renal cell carcinoma (ccRCC) in 29 patients including 17 patients from a neoadjuvant nivolumab  clinical trial. We observe that tumors can be broadly categorized into intra-tumoral heterogeneity (ITH) high and low, which correlates across","Not Applicable","Carcinoma, Renal Cell","Clinical Trial","Not Provided","AMPLICON, RNA-Seq, WXS","4 phenotype datasets, 28 variables, 449 samples sequenced, 29 subjects, 449 samples","","NCI","GRU --- General Research Use","2022-11-21","2022-11-21","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell",""
"phs002009.v1.p1","Genomic Landscape of Pediatric Germ Cell Tumors","Germ cell tumors (GCTs) are cancers of the testis, ovary and extragonadal sites that occur in infants, children, adolescents, and adults. Post-pubertal (type II) malignant GCTs may present as a  seminoma, non-seminoma or with mixed histologies. In contrast, pre-pubertal (type I) GCTs are limited to (benign) teratomas and (malignant) yolk sac","Not Applicable","Neoplasms, Germ Cell and Embryonal","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 11 variables, 32 samples sequenced, 32 subjects, 32 samples","","NCI","DS-PEDCR --- Disease-Specific (Pediatric Cancer Research)","2022-11-21","2022-11-21","Seminoma; Germ Cell and Embryonal Neoplasms; Germ Cell and Embryonic Neoplasms; Neoplasms, Germ Cell and Embryonic",""
"phs003035.v1.p1","Genomic Analysis of Nucleic Acid Sequences from Pancreatic Cancer","Our study aims to perform multi-omics analysis of pancreatic ductal adenocarcinoma. We performed dual single-cell RNA sequencing and whole genome sequencing on fresh tumor specimens and dual bulk RNA-sequencing and  16S amplicon sequencing on frozen tumor specimens to identify human and non-human nucleic acid sequences. Additionally, we identified microbial","Not Applicable","Carcinoma, Pancreatic Ductal","Case Set","Not Provided","AMPLICON, RNA-Seq, WGS","4 phenotype datasets, 16 variables, 36 samples sequenced, 12 subjects, 36 samples","","NCI","GRU --- General Research Use","2022-11-16","2022-11-16","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas",""
"phs002840.v1.p1","The Transcriptomic Landscape of Oncogenic PI3K Reveals Key Functions in    Splicing and Gene Expression Regulation","This study includes RNA-seq of paired tumor biopsies from PIK3CA-mutated breast cancer patients that underwent treatment with PI3K&#x003b1; inhibitors. Patients with known PIK3CA mutations were enrolled in an open-label, phase  I dose-escalation study of oral daily GDC-0077 alone (Arm A), in combination with endocrine therapy with or without palbociclib (Arm C: GDC-0077 +","Not Applicable","Breast Neoplasms","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 36 samples sequenced, 18 subjects, 36 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2022-11-14","2022-11-14","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002652.v1.p1","Identification of Somatic Changes in Tumors from Fanconi Anemia Patients","This study focused on the identification of genomic signatures present in tumors from Fanconi anemia patients. Fanconi anemia is a rare hereditary disease caused by defects in DNA interstrand crosslink  repair. The primary patient phenotypes are bone marrow failure and cancer predisposition. We concentrated on squamous cell carcinomas and used whole","Not Applicable","Fanconi Anemia","Tumor vs. Matched-Normal","MethylationEPIC","Methylation (CpG), OTHER, RNA-Seq, Synthetic-Long-Read, WGS, WXS","6 phenotype datasets, 56 variables, 1 molecular datasets, 1 images, 131 samples sequenced, 46 subjects, 137 samples","","NCI","GRU --- General Research Use","2022-11-14","2022-11-14","DNA Damage; Genomic Instability; DNA Injuries; DNA Injury; DNA Lesion; DNA Lesions","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002718.v1.p1","Genetics of Prostate Cancer in Africa","African Americans (AA) suffer from the highest rates of Prostate Cancer (CaP) in the world, but while men of African descent around the world suffer disproportionately from CaP compared to  men of other races or ethnicities, our understanding of the reasons for these disparities remains incomplete. To date, few exposure, lifestyle, or","Not Applicable","Prostatic Neoplasms","Case-Control","MADCaP_Array, imputation_panel","SNP Genotypes (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 17 variables, 1 documents, 2 molecular datasets, 4728 subjects, 4728 samples","","NCI","GRU --- General Research Use, DS-CA-IRB --- Disease-Specific (Cancer, IRB), DS-PC --- Disease-Specific (Prostate Cancer)","2022-11-04","2022-11-04","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001003.v3.p1","Prospective Procurement of Solid Tumor Tissue to Identify Novel    Therapeutic Targets","Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A  critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In","Not Applicable","Melanoma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WGS, WXS","5 phenotype datasets, 15 variables, 970 samples sequenced, 210 subjects, 970 samples","","NCI","GRU --- General Research Use","2022-11-04","2020-12-23","Esophageal Neoplasms; Paraneoplastic Syndromes, Ocular; Rectal Neoplasms; Bile duct cancer; CC; CCA","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003043.v1.p1","A Pilot Study to Evaluate Tissue- and Plasma-based DNA Driver Mutations    in a Cohort of Patients with Pancreatic Intraductal Papillary Mucinous    Neoplasms","This is a retrospective study aimed at evaluating concordance between intraductal papillary mucinous neoplasm (IPMN) tissue and patient-matched plasma circulating tumor DNA (ctDNA) using a targeted sequencing approach. Archival solid  tissue genomic DNA was available for 46 patient FFPE blocks patient-matched plasma ctDNA was available from 15 of those patients. All tissues were","Not Applicable","Pancreatic Intraductal Neoplasms","Tumor vs. Matched-Normal","Not Provided","Targeted-Capture","4 phenotype datasets, 14 variables, 61 samples sequenced, 46 subjects, 61 samples","","NCI","HMB-NPU --- Health/Medical/Biomedical (NPU)","2022-11-03","2022-11-03","Cyst, Pancreatic; Intraductal Neoplasm, Pancreatic; Cyst of Pancreas; Cyst of the Pancreas; Cysts, Pancreatic; Multiple pancreatic cysts",""
"phs001971.v1.p1","Kidney Two-Hit Mapping","Germ-line genetic variants identified thus far generally account for only part of the genetic risk predicted for most cancers. A component of the remaining risk may be explained by functionally  consequent genetic variants that are individually very rare (or private to that individual's family). While their identification may be highly","Not Applicable","Kidney Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 13 variables, 108 samples sequenced, 57 subjects, 108 samples","","NCI","DS-KD --- Disease-Specific (Kidney Disease)","2022-11-03","2022-11-03","Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney",""
"phs003020.v1.p1","Molecular Analysis of Short- Versus Long-Term Survivors of High-Grade    Serous Ovarian Carcinoma","The underlying determinants for long-term survival (LTS, &#x02265;10 years) versus short-term survival (STS, 3 years) of patients diagnosed with high-grade serous ovarian carcinoma (HGSC) are largely unknown. The present study  sought to identify molecular predictors of LTS for women with HGSC. A cohort of 24 frozen HGSC samples (12 LTS and 12 STS) were collected and","Not Applicable","Survival Analysis","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 15 variables, 69 samples sequenced, 24 subjects, 69 samples","","NCI","HMB-IRB-PUB-COL --- Health/Medical/Biomedical (IRB, PUB, COL)","2022-11-02","2022-11-02","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs003019.v1.p1","Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the    Oral PARP Inhibitor Olaparib in Patients with Recurrent Triple    Negative Breast Cancer or High Grade Serous Ovarian Cancer","We analyzed massive parallel sequence data from patients with breast and ovarian cancer and identified single base substitution mutational signature 3 (Sig3) - extracted using SigMA - as a biomarker  of homologous recombination deficiency (HRD) and predictive for response to PARP inhibitors. Participants were patients enrolled in clinical trials","Not Applicable","Neoplasms by Site","Clinical Trial","Not Provided","WXS","4 phenotype datasets, 24 variables, 38 samples sequenced, 37 subjects, 38 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-10-27","2022-10-27","Neoplasm Site; Neoplasm Sites; Neoplasms by Sites; Site, Neoplasm; Sites, Neoplasm",""
"phs002162.v2.p1","Kids First: Genetics of Kidney and Urinary Tract Malformations","Congenital defects of the kidney and urinary tract are a common cause of kidney failure in children and adults and elucidation of the genetics of these disorders will provide new  opportunities for diagnosis, risk stratification and prevention of complications. Around 550 trios were selected for whole genome sequencing as part","Not Applicable","Renal Adysplasia","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 1667 subjects, 1673 samples","","NCI","GRU --- General Research Use","2022-10-21","2020-11-25","Hydronephrosis; Vesicoureteral Reflux; Hydronephroses; HEREDITARY RENAL APLASIA; HRA; RENAL AGENESIS","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs003036.v1.p1","Single Cell Genome Variation Induced by Mutational Processes in Cancer -    HGSOC Trios Study","Mutational signatures derived from whole genome sequencing have potential prognostic significance. Identification of high grade serous ovarian cancer patients with deficiency in homologous recombination repair pathways could identify a subset  of patients that would benefit from homologous recombination deficiency-specific treatments independent of identification of a pathological BRCA1/2","Not Applicable","Ovarian Neoplasms","Tumor vs. Matched-Normal","Not Provided","WGS","3 phenotype datasets, 10 variables, 26 samples sequenced, 8 subjects, 26 samples","","NCI","GRU --- General Research Use","2022-10-19","2022-10-19","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs003022.v1.p1","Circulating Tumor DNA Sequencing Provides Comprehensive Mutation    Profiling for Pediatric Central Nervous System Tumors","Tumor molecular profiling is increasingly important for the diagnosis and clinical management of childhood brain tumors, including diffuse midline glioma (DMG). We established a targeted deep sequencing approach using the  TruSight Oncology 500 ctDNA exome panel to detect tumor genomic mutations and copy number variations in circulating tumor DNA from children diagnosed","Not Applicable","Brain Neoplasms","Collection","Not Provided","Targeted-Capture, WXS","4 phenotype datasets, 11 variables, 29 samples sequenced, 10 subjects, 29 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2022-10-19","2022-10-19","Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain; Neoplasm of the Brain",""
"phs002321.v1.p1","Characterizing Advanced Breast Cancer Heterogeneity and Treatment    Resistance through Serial Biopsies and Comprehensive Analytics","This dataset accompanies the manuscript ""Characterizing Advanced Breast Cancer Heterogeneity and Treatment Resistance Through Serial Biopsies and Comprehensive Analytics"". In this study we discuss the clinical implications and consequences of  molecular heterogeneity in a metastatic breast cancer patient identified through serial biopsies, multi-omic analysis, and longitudinal patient","Not Applicable","Breast Neoplasms","Case Set","RNAseq_probe_set_grc38, RNAseq_probe_set_grc38, Reverse-Phase_Protein_Array","Proteomics, RNA-Seq, RNA Seq (NGS)","5 phenotype datasets, 36 variables, 1 molecular datasets, 1 samples sequenced, 1 subjects, 2 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-10-19","2022-10-19","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001239.v1.p1","Integrative Analysis of Lung Adenocarcinoma in EAGLE (Phase 2)","We performed whole genome sequencing and whole exome sequencing of 31 lung adenocarcinoma (LUAD) samples from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. Lung adenocarcinoma cases only  Note for data in GDC: Molecular profiling data from CDDP EAGLE-1 study can be found at The NCI's Genomic Data Commons (GDC)","Not Applicable","Adenocarcinoma of Lung","Case Set","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 50 subjects, 150 samples","","NCI","DS-LDS-MDS --- Disease-Specific (Lung disease or smoking, MDS)","2022-10-18","2022-10-18","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs001859.v1.p1","Genomic Characterization CS-MATCH-0007 Arm Z1D","The CS-MATCH-0007 protocol is a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using  pre-and posttreatment tumor biopsy specimens from all patients enrolled on a treatment arm of the NCI-MATCH Clinical Trial (EAY131). The goal of this","Not Applicable","Neoplasms","Clinical Trial","Not Provided","Not Provided","3 phenotype datasets, 387 variables,  SRA, 36 subjects, 36 samples","","NCI","GRU-COL --- General Research Use (COL)","2022-10-17","2022-10-17","Turcot syndrome; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs002070.v1.p1","Genomic Landscape of High-Grade Neuroendocrine Neoplasms","This project is a multi-omics study of high grade (grade 3) neuroendocrine neoplasms across diverse organs. Genomic analysis using low-pass whole genome sequencing for copy number analysis, whole exome sequencing  and whole transcriptomic sequencing using RNAseq were performed. As high grade neuroendocrine neoplasms are highly lethal with a median survival of","Not Applicable","Carcinoma, Neuroendocrine","Prospective Longitudinal Cohort","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 15 variables, 1 molecular datasets, 69 samples sequenced, 36 subjects, 69 samples","","NCI","GRU --- General Research Use","2022-10-13","2022-10-13","Neuroendocrine Tumors",""
"phs002859.v1.p1","RB1 Loss Triggers Dependence on ESRRG in Retinoblastoma","Retinoblastoma (Rb) is a deadly childhood eye cancer that is classically initiated by inactivation of the RB1 tumor suppressor. Clinical management continues to rely on nonspecific chemotherapeutic agents that are  associated with treatment resistance and toxicity. Here, we analyzed whole exomes from primary Rb tumors to identify novel Rb dependencies. Several","Not Applicable","Retinoblastoma","Tumor vs. Matched-Normal","Not Provided","WXS","5 phenotype datasets, 24 variables, 51 samples sequenced, 31 subjects, 51 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2022-10-11","2022-10-11","Cancer, Retinoblastoma Eye; Cancers, Retinoblastoma Eye; Eye Cancer, Retinoblastoma; Eye Cancers, Retinoblastoma; RB; RB - retinoblastoma",""
"phs003041.v1.p1","Mayo Clinic Adult Diffuse Glioma Illumina OncoArray SNP data","These data are from adult diffuse glioma subjects genotyped on the Illumina OncoArray. Data from this study were used for case control association studies and developing polygenic risk scores. Inclusion  Criteria All subjects were pathologically confirmed to have glioma. Subjects had to be consented at 18 years of age or older. All subjects provided a","Not Applicable","Glioma","Case Set","OncoArray","SNP Genotypes (Array)","4 phenotype datasets, 19 variables, 1 molecular datasets, 794 subjects, 794 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-10-07","2022-10-07","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs003006.v1.p1","Transcriptional and Epigenetic Profiles of Male Breast Cancer at    Single-Cell Resolution Nominate Salient Cancer Specific Enhancers","We performed matched single-cell RNA sequencing (scRNA-seq) and single-cell chromatin accessibility sequencing (scATAC-seq) for two fresh human tumors collected from male breast cancer patients. The integration of these datasets revealed  the intratumoral heterogeneity in both transcription and chromatin accessibility for each male breast cancer patient and allowed for comparisons to","Not Applicable","Carcinoma, Ductal, Breast","Case Set","ATAC_DNAseq_probe_set","ATAC-seq, RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 19 variables, 1 molecular datasets, 4 samples sequenced, 2 subjects, 4 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-10-07","2022-10-07","BREAST CANCER, INVASIVE DUCTAL; Carcinoma, Infiltrating Duct; Carcinoma, Invasive Ductal, Breast; Carcinomas, Infiltrating Duct; Infiltrating Ductal Adenocarcinoma; Infiltrating Ductal Breast Carcinoma",""
"phs002928.v1.p1","Adoptive Cell Therapy of Autologous T cell Receptor-Engineered T Cells    Targeting the p53 Neoantigens in Human Solid Tumors","Adoptive T cell therapy (ACT) using T cell receptor (TCR)-engineered T cells can mediate regression of advanced human cancers. How TCR-transduced T cells change post-ACT in vivo is currently not  well understood. We screened 78 patients for TP53 mutations by whole exome sequencing and whole transcriptome sequencing. Of the 78 patient samples,","Not Applicable","Immunotherapy, Adoptive","Clinical Trial","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 194 samples sequenced, 23 subjects, 194 samples","","NCI","GRU --- General Research Use","2022-10-06","2022-10-06","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002994.v1.p1","BRCA Mutation Status Shapes the Microenvironment of Pancreatic    Adenocarcinoma","This study was established in order to address how the stromal landscape is influenced by BRCA-mutated and BRCA Wild-type (WT) pancreatic ductal adenocarcinoma (PDAC). A primary cohort of 12 PDAC  patients (7 BRCA-WT and 5 germline BRCA-mut) was analyzed by laser-capture microdissection, RNA-sequencing and multiplexed immunofluorescence. Only","Not Applicable","Genes, BRCA2","Collection","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 13 variables, 1 molecular datasets, 12 samples sequenced, 12 subjects, 12 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-10-05","2022-10-05","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas",""
"phs001280.v1.p1","Exome Sequencing of Chordoma Cases","Chordoma is a rare tumor that is believed to develop from notochord remnants. We previously identified germline duplication of the TBXT gene as a major susceptibility mechanism in several chordoma  families. Currently, we are using whole exome sequencing to identify additional susceptibility genes in chordoma families without TBXT duplication as","Not Applicable","Chordoma","Case Set","nCounter_GeneExpressionAssay","AMPLICON, RNA Seq (NGS), WXS","4 phenotype datasets, 13 variables, 1 molecular datasets, 232 samples sequenced, 132 subjects, 374 samples","","NCI","DS-CHR-MDS --- Disease-Specific (Chordoma, MDS)","2022-10-05","2022-10-05","CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to",""
"phs002688.v1.p1","CIDR Estrogen Receptor Negative Breast Cancer in African American Women:    DNA Methylation, Reproductive Events, and Mammary Epithelial Cell    Populations","We conducted methylation profiling of breast tumor DNA from Formalin-Fixed Paraffin-Embedded (FFPE) samples for 1,550 cases from a cohort of Black women from the Black Women's Health Study (BWHS), the  Women's Circle of Health Study (WCHS), and from the Pathways Study using the Illumina MethylationEPIC array. We will examine differentially","Not Applicable","Breast Neoplasms","Case Set","MethylationEPIC","Methylation (CpG)","4 phenotype datasets, 22 variables, 1 molecular datasets, 1550 subjects, 1550 samples","","NCI","HMB-IRB-PUB-NPU-GSO --- Health/Medical/Biomedical (IRB, PUB, NPU, GSO), HMB-COL-NPU-GSO --- Health/Medical/Biomedical (COL, NPU, GSO), HMB-IRB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (IRB, PUB, NPU, MDS, GSO)","2022-10-04","2022-10-04","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003011.v1.p1","APOLLO1: Proteogenomic Analysis of Lung Adenocarcinoma","APOLLO is a proteogenomic study seeking to describe the major genome, transcriptome, proteome and phosphoproteome alterations, subtypes, and molecular predictors of patient outcomes. This study includes 87 lung adenocarcinomas and  matched normal tissues from the Lung Cancer Biospecimen Resource Network (https://lungbio.sites.virginia.edu/). Tumor tissues were profiled by whole","Not Applicable","Adenocarcinoma of Lung","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 5 variables, 87 subjects, 261 samples","","NCI","GRU --- General Research Use","2022-10-03","2022-10-03","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs002809.v1.p1","Genome-Wide Pleiotropy Scan Across Multiple Cancers","A whole-exome sequencing (WES) study was conducted in 3,233 cases diagnosed with multiple primary cancers and 3,229 matched cancer-free controls (90% non-Hispanic white, 3% African-American, 3% East Asian, and 4%  Latino) selected from individuals in the Kaiser Permanente Research Bank (KPRB) who were members of the Kaiser Permanente Northern California (KPNC)","Not Applicable","Neoplasms, Multiple Primary","Case-Control","WES_markerset_grc38","SNP Genotypes (NGS), WXS","4 phenotype datasets, 32 variables, 1 molecular datasets, 5432 samples sequenced, 5432 subjects, 5432 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","2022-10-03","2022-10-03","Multiple Primary Neoplasm; Multiple Primary Neoplasms; Multiple Primary Neoplasms, Synchronous; Neoplasm, Multiple Primary; Neoplasm, Synchronous; Neoplasms, Synchronous",""
"phs001772.v3.p2","A Genomic Approach to Improved Diagnosis and Treatment of Neuroendocrine    Tumors","These are RNA-Seq samples from patients undergoing surgery for small bowel and pancreatic neuroendocrine tumors. Normal tissue, primary tumors, lymph nodes, and liver metastases were collected at surgery and stored  in RNAlater until RNA extraction was carried out for RNA-Seq. Patients having surgery for small bowel and pancreatic neuroendocrine tumors.","Not Applicable","Intestinal Neoplasms","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 24 variables, 210 samples sequenced, 62 subjects, 210 samples","","NCI","HMB-PUB-COL --- Health/Medical/Biomedical (PUB, COL)","2022-10-03","2020-06-19","Neoplasm Metastasis; Intestinal Tumor; Intestinal Tumors; Intestines Neoplasm; Intestines Neoplasms; Neoplasm of Intestines",""
"phs003038.v1.p1","Exploiting New Patterns of Genome Damage in Triple Negative Breast Cancer","Genomic instability, a feature of triple negative breast cancers (TNBC), represents an opportunity for discovery of biologic and clinically relevant subgroups of patients. Owing to TP53 mutation in the majority  of cases, DNA repair deficiency through loss of BRCA1 and BRCA2, and by expression features patterning a basal cell of origin, TNBC represents a","Not Applicable","Triple Negative Breast Neoplasms","Tumor vs. Matched-Normal","other","SNV (.MAF)","3 phenotype datasets, 9 variables, 1 molecular datasets, 16 subjects, 32 samples","","NCI","GRU --- General Research Use","2022-09-30","2022-09-30","Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms",""
"phs001550.v3.p1","The Genetic and Transcriptomic Evolution of Melanoma","The overarching goal of the study was to better understand the evolution of melanoma. To do this, we collected archival tissue of melanomas adjacent to their intact, remnant precursor lesions.  We also collected archival tissue of primary melanomas and their matching metastases. From the formalin-fixed paraffin-embedded (FFPE) blocks, we","Not Applicable","Melanoma","Tumor vs. Matched-Normal","Not Provided","Hi-C, RNA-Seq, Targeted-Capture, WXS, miRNA-Seq","4 phenotype datasets, 19 variables, 361 samples sequenced, 85 subjects, 361 samples","","NCI","DS-M-NPU --- Disease-Specific (Melanoma, NPU)","2022-09-30","2018-03-19","Clonal Evolution; Nevus; Evolution, Clonal; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma",""
"phs002998.v1.p1","Immune Profiles Study","This study assesses glioma patient blood methylation longitudinally beginning pre-surgery through other clinically important timepoints. Progression and survival are studied in relation to methylation derived immunologic profiles and other characteristics.  For this study, patients scheduled for surgery at University of California San Francisco (UCSF) for a possible newly diagnosed glioma (grades 2-4) or","Not Applicable","Glioma","Case Set","MethylationEPIC","Methylation (CpG)","4 phenotype datasets, 14 variables, 1 molecular datasets, 135 subjects, 135 samples","","NCI","GRU --- General Research Use","2022-09-29","2022-09-29","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002977.v1.p1","Functional Analysis of Genetic Variants in African Americans with Breast    Cancer","The goal of this study is to identify and characterize novel genetic variants associated with a predisposition to breast cancer (BCa) in African Americans (AAs) using a family case-family control  study design. Variants of unknown clinical significance (VUS) were characterized using bioinformatics tools. Future studies will further characterize","Not Applicable","Breast Neoplasms","Family/Twin/Trios","Not Provided","WXS","4 phenotype datasets, 19 variables, 88 samples sequenced, 88 subjects, 88 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2022-09-28","2022-09-28","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs003023.v1.p1","Whole-Genome Sequencing Reveals Complex Genomic Features Underlying    Anti-CD19 CAR T-Cell Treatment Failure in Lymphoma","We performed Whole-Genome Sequencing (WGS) on 100 tumor and matched germline samples from 49 CD19-directed chimeric antigen receptor (CAR-19)-treated diffuse large B cell lymphoma (DLBCL) patients. We found that the  presence of complex structural variants, APOBEC (apolipoprotein B mRNA editing enzyme, catalytic polypeptide) mutational signatures, and genomic","Not Applicable","Lymphoma","Tumor vs. Matched-Normal","Not Provided","WGS","4 phenotype datasets, 20 variables, 100 samples sequenced, 49 subjects, 100 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2022-09-22","2022-09-22","Cancer of lymphatic system; Germinoblastic Sarcoma; Germinoblastic Sarcomas; Germinoblastoma; Germinoblastomas; Lymphoma (Hodgkin and Non-Hodgkin)",""
"phs002986.v1.p1","A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant    Therapy in Patients with Locally Advanced Squamous Cell Cancer of the    Head and Neck","This genomic study was an analysis of DNA samples from subjects enrolled in a randomized, interventional, parallel assignment trial of everolimus versus placebo in advanced Head and Neck Cancer. Next  Generation Sequencing was performed on samples obtained from primary tumors before treatment. The purpose was to evaluate potential associations","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 12 variables, 42 samples sequenced, 42 subjects, 42 samples","","NCI","GRU --- General Research Use","2022-09-21","2022-09-21","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002253.v1.p1","CCG Multicentric Italian Lung Detection (MILD)","For the CCG-MILD project, NCI will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations, deletions, amplifications, rearrangements)  and/or gene expression signatures that would be important to the hypothesis(es) submitted by the investigators. The samples will be processed and","Not Applicable","Lung Neoplasms","Case Set","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 160 subjects, 160 samples","","NCI","GRU --- General Research Use","2022-09-21","2022-09-21","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs001554.v2.p1","Detection of Colorectal Cancer Susceptibility Loci Using Genome-Wide    Sequencing","The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort comprised of a coordinating center and scientific researchers from well-characterized cohort and case-control studies. This international consortium  aims to accelerate the discovery of common and rare genetic risk variants for colorectal cancer by conducting large-scale meta-analyses of existing","Not Applicable","Colorectal Neoplasms","Case-Control","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 22 variables, 1 molecular datasets, 2892 samples sequenced, 2892 subjects, 2892 samples","","NCI","GRU --- General Research Use, HMB-IRB --- Health/Medical/Biomedical (IRB), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), CADM --- Cancer in all age groups, other diseases in adults only, and methods","2022-09-19","2018-08-06","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001141.v2.p1","PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of    Castration Resistant Prostate Cancer (CRPC) Patients Treated with    Abiraterone Acetate","The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease. Understanding the  molecular biology behind castration-resistant prostate cancer has led to more treatment options, but there are still no definite conclusions about","Not Applicable","Prostatic Neoplasms, Castration-Resistant","Case Set","WES_markerset_grc37","RNA-Seq, SNP Genotypes (NGS), WXS","4 phenotype datasets, 25 variables, 1 molecular datasets, 398 samples sequenced, 88 subjects, 398 samples","","NCI","GRU --- General Research Use","2022-09-16","2017-02-21","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002429.v1.p1","UNC Tumor Donation Program Set 2021","The goal of this study is to study gene expression patterns in primary, metastatic tumors, and normal tissues. The samples were obtained through the UNC tumor donation program. Inclusion criteria  were UNC patients with metastatic breast cancer with and without treatment options.&#x000a0; Principal Investigator: Charles M. Perou, PhD,","Not Applicable","Breast Neoplasms","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 22 variables, 125 samples sequenced, 30 subjects, 125 samples","","NCI","HMB --- Health/Medical/Biomedical, DS-CA --- Disease-Specific (Cancer)","2022-09-02","2022-09-02","Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors",""
"phs002635.v1.p1","Myelofibrosis Etiology and Transplant Outcomes","The Myelofibrosis Etiology and Transplant Outcomes study is a collaboration between the National Cancer Institute and the Center for International Blood and Marrow Transplant Research (CIBMTR). The study aims to  identify genomic factors affecting myelofibrosis pathogenesis and prognosis. Principal Investigator: Shahinaz Gadalla, PhD, MD, National Institutes","Not Applicable","Primary Myelofibrosis","Case Set","Global_Screening_Array-24, Global_Screening_Array-24, Global_Screening_Array-24","AMPLICON, SNP Genotypes (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 14 variables, 1 molecular datasets, 548 samples sequenced, 548 subjects, 1096 samples","European (473), East Asian (9), African American (29), Hispanic1 (6), Hispanic2 (20), Other Asian or Pacific Islander (6), South Asian (2), Other (3)","NCI","DS-HCTCT-IRB --- Disease-Specific (Hematopoietic Cell Transplantation and Cell Therapy, IRB)","2022-08-30","2022-08-30","AMM; Agnogenic Myeloid Metaplasia; Agnogenic Myeloid Metaplasias; Bone Marrow Fibroses; Bone Marrow Fibrosis; CIMF",""
"phs002865.v1.p1","Accurate Genome-Wide Germline DNA Profiling from Decade-Old Archival    Tissue Specimens","We evaluate the validity of repurposing archival tissue specimens for germline genetic studies. We performed lc-WGS and imputed genotypes on 10 pairs of matching blood and tumor tissue and benchmarked  the accuracy of genome-wide genotypes, HLA haplotypes, and several polygenic risk scores (PRSs). The reported results indicate the high accuracy of","Not Applicable","Neoplasms","Case Set","Not Provided","WGS","4 phenotype datasets, 13 variables, 50 samples sequenced, 50 subjects, 50 samples","","NCI","GRU --- General Research Use","2022-08-25","2022-08-25","Breast Carcinoma In Situ; Carcinoma, Ductal, Breast; Multifactorial Inheritance; LCIS - lobular carcinoma in situ; LCIS, Lobular Carcinoma In Situ; Lobular Carcinoma In Situ",""
"phs001417.v2.p1","Scalable Whole-Exome Sequencing of Cell-Free DNA Reveals High Concordance    with Metastatic Tumors","We performed whole genome sequencing and whole-exome sequencing of cell-free DNA (cfDNA) and whole-exome sequencing of matched tumor biopsies and germline DNA from patients with metastatic cancer. Using ichorCNA, a  software tool that quantifies tumor content in ultra-low pass whole genome sequencing ( 0.1x) of cfDNA without prior genomic characterization of the","Not Applicable","Neoplasms","Case Set","Not Provided","WGS, WXS","4 phenotype datasets, 12 variables, 1722 samples sequenced, 545 subjects, 1722 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS)","2022-08-18","2018-03-27","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize",""
"phs002733.v1.p1","Colon Cancer Family Registry (Colon CFR)","The Colon Cancer Family Registry Cohort (CCFRC www.coloncfr.org) is a cohort of families recruited through six study sites located in the USA, Canada, Australia, and New Zealand. The CCFRC was  formed as a resource to support studies on the etiology, prevention, and clinical management of colorectal cancer. Recruitment protocols fall broadly","Not Applicable","Colorectal Neoplasms","Case-Control","Not Provided","Not Provided","7 phenotype datasets, 1363 variables, 38362 subjects","","NCI","HMB --- Health/Medical/Biomedical, HMB-IRB-COL --- Health/Medical/Biomedical (IRB, COL), DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS), DS-CA-IRB-PUB-NPU-MDS --- Disease-Specific (Cancer, IRB, PUB, NPU, MDS), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), DS-COC-IRB-COL --- Disease-Specific (Colon Cancer, IRB, COL)","2022-08-15","2022-08-15","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs002504.v1.p1","UCSF Database for the Advancement of JMML - Integration of Metadata with    ""Omic"" Data","Juvenile myelomonocytic leukemia (JMML) is a rare and frequently fatal myeloproliferative/myelodysplastic disorder of early childhood with an estimated incidence of 1.2 cases per million. It is associated with a spectrum  of diverse outcomes ranging from spontaneous resolution in rare patients to transformation to acute myeloid leukemia in others. The overwhelming","Not Applicable","Leukemia, Myelomonocytic, Juvenile","Collection","Not Provided","AMPLICON, Bisulfite-Seq, RNA-Seq, WGA, WXS","4 phenotype datasets, 30 variables, 289 samples sequenced, 188 subjects, 328 samples","","NCI","GRU --- General Research Use","2022-08-05","2022-08-05","Neurofibromatosis 1; JCML; JCML - Juvenile chronic myeloid leukemia; JMML; Juvenile Chronic Myelogenous Leukemia; Juvenile Myelomonocytic Leukemias",""
"phs002323.v2.p1","Defining and Overcoming Intrinsic T Cell Dysfunction to Enable Pediatric    Immunotherapy","T-cells from 71 children and young adults with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy were analyzed. These T-cells represent the pre-manufacture T-cells that were subsequently used  for CAR T manufacture. Bulk RNA-Seq was performed on sorted T-cell subsets for all patients, in addition to CITE-Seq and single-cell ATAC-Seq on a","Not Applicable","Immunotherapy","Case Set","RNAseq_probe_set_grc38, RNAseq_probe_set_grc38, RNAseq_probe_set_grc38, custom_probe_set, RNAseq_probe_set_grc38, WES_markerset_grc38","ATAC-seq, RNA-Seq, SNP/CNV Genotypes (NGS), RNA Seq (NGS), RNA Seq (NGS), scRNA_Seq (NGS), WXS","7 phenotype datasets, 36 variables, 2 molecular datasets, 393 samples sequenced, 84 subjects, 393 samples","","NCI","DS-CTOGVHD-IRB-NPU --- Disease-Specific (cancer, cell processing, transplantation outcomes and graft versus host disease, IRB, NPU)","2022-08-03","2022-08-03","Not Provided",""
"phs002496.v1.p1","Germline Whole-Exome Sequencing of Lung Cancer in EAGLE","EAGLE is a large population-based case-control study designed and conducted to investigate the genetic and environmental determinants of lung cancer and smoking persistence using an integrative approach that allows combined  analysis of genetic, environmental, clinical, and behavioral data. Here, we applied whole exome sequencing (WES) to EAGLE study, in a group of 2,777","Not Applicable","Lung Neoplasms","Case-Control","Not Provided","WXS","4 phenotype datasets, 18 variables, 4036 samples sequenced, 4036 subjects, 4036 samples","","NCI","DS-LDS-MDS --- Disease-Specific (Lung disease or smoking, MDS)","2022-08-02","2022-08-02","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs001736.v2.p1","NCI Expanded Genome-Wide Association Study of Renal Cell Carcinoma","The National Cancer Institute (NCI) expanded genome-wide association study (GWAS) of renal cell carcinoma (RCC) was a 2nd GWAS of this cancer performed by NCI to further investigate common genetic  variants associated with RCC risk. The GWAS includes 2,781 cases and 2,940 controls of European background from 13 studies conducted in the US and","Not Applicable","Carcinoma, Renal Cell","Case Set","HumanOmniExpress-12, HumanOmniExpress-12, HumanOmni2.5-4","SNP/CNV Genotypes (imputed), SNP/CNV Genotypes (NGS)","4 phenotype datasets, 19 variables, 3 analyses, 2 molecular datasets, 2385 subjects, 2385 samples","","NCI","GRU --- General Research Use, GRU-IRB-NPU --- General Research Use (IRB, NPU), DS-RCC --- Disease-Specific (Kidney Cancer), CADM --- Cancer in all age groups, other diseases in adults, and methods","2022-08-02","2019-09-27","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002505.v1.p1","CPTAC: Molecular Dissection of Chemotherapy Response in Triple Negative    Breast Cancer","Sporadic Triple Negative Breast Cancer (TNBC) represents 10-15% of breast cancers (BC) worldwide. Non-specific chemotherapy remains the standard of care as there are no targeted agents. In 50% of cases,  pathological complete response (pCR) is not achieved, and these individuals experience poor survival. Predictive markers for chemotherapy have proved","Not Applicable","Triple Negative Breast Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 12 variables, 135 samples sequenced, 48 subjects, 135 samples","","NCI","HMB --- Health/Medical/Biomedical, GRU --- General Research Use","2022-08-01","2022-08-01","Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001570.v3.p1","CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With    Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of    HER2-Positive Primary Breast Cancer","This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer  that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by","Not Applicable","Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 45 variables, 682 samples sequenced, 277 subjects, 682 samples","","NCI","HMB-COL --- Health/Medical/Biomedical (COL)","2022-08-01","2018-09-06","Breast Diseases; Breast Neoplasms, Male; Molecular Mechanisms of Pharmacological Action; Neoplasms by Site; Skin Diseases; Breast Disease, Endocrine",""
"phs002941.v1.p1","CALGB/SWOG 80405 ct DNA Biomarker Evaluation","To investigate treatment-specific mutations that underlie resistance to treatment with chemotherapy +/- bevacizumab or cetuximab in first line metastatic Colorectal Cancer (mCRC) patients, we performed targeted sequencing of circulating free  DNA (cfDNA) from longitudinal plasma samples. These samples were collected at baseline (PRE, n 354), during treatment (OTH, n 259), and/or at","Not Applicable","Colorectal Neoplasms","Clinical Genetic Testing","Not Provided","WXS","3 phenotype datasets, 10 variables, 968 samples sequenced, 367 subjects, 968 samples","","NCI","GRU-COL --- General Research Use (COL), DS-CA-COL --- Disease-Specific (Cancer, COL)","2022-07-29","2022-07-29","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs002835.v1.p1","Breast Cancer Family Registry","The Breast Cancer Family Registry (BCFR) is a multi-center prospective cohort, comprised of over 30,000 women and men from nearly 12,000 families from the United States, Canada, and Australia. Our  BCFR resource has been used, and continues to be used, by breast cancer researchers around the world in order to find new ways to prevent, diagnose,","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","10 phenotype datasets, 996 variables, 2 documents, 32726 subjects","","NCI","DS-CA --- Disease-Specific (Cancer), DS-BOCC-IRB --- Disease-Specific (Breast, Ovary, and/or Colon Cancer, IRB), DS-CA-IRB --- Disease-Specific (Cancer, IRB), DS-CA-PUB-NPU-MDS --- Disease-Specific (Cancer, PUB, NPU, MDS), DS-CA-IRB-MDS --- Disease-Specific (Cancer, IRB, MDS)","2022-07-29","2022-07-29","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002933.v1.p1","Single-Cell RNA-Sequencing Analysis of Responses to Pembrolizumab in    Sezary Syndrome","This phase 2 single arm clinical trial assessed the efficacy of pembrolizumab in patients with previously treated mycosis fungoides or Sezary syndrome. Pembrolizumab was found to have a 38% overall  response rate, and a 27% overall response rate in subjects with Sezary syndrome. We performed single-cell RNA-sequencing on samples collected before","Not Applicable","Sezary Syndrome","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 15 samples sequenced, 6 subjects, 15 samples","","NCI","GRU-COL --- General Research Use (COL)","2022-07-28","2022-07-28","Cutaneous T Cell Lymphoma; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC",""
"phs002769.v1.p1","Multi-Omic Investigation of Beckwith-Wiedemann Syndrome Wilms Tumor","Wilms' Tumor (WT), also known as nephroblastoma, is one of the most common malignant kidney tumors diagnosed in children. One of the most common WT predisposition syndromes is Beckwith-Wiedemann Syndrome  (BWS, OMIM: 130650), which affects approximately 1/10,000 live births. In this study, we perform Whole Exome Sequencing (WES), DNA methylation array,","Not Applicable","Wilms Tumor","Tumor vs. Matched-Normal","MethylationEPIC, RNAseq_probe_set_grc37","Methylation (CpG), RNA Seq (NGS), WXS","4 phenotype datasets, 11 variables, 2 molecular datasets, 18 samples sequenced, 14 subjects, 27 samples","","NCI","GRU-PUB-COL-NPU --- General Research Use (PUB, COL, NPU)","2022-07-27","2022-07-27","Beckwith-Wiedemann Syndrome; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME",""
"phs002903.v1.p1","The Role of CDX2 in Controlling ABCB1 Expression and Chemosensitivity in    Human Colon Cancer","This study reports the results of RNA sequencing (RNA-seq) experiments performed on two human colon cancer cell lines (HT-29, DLD-1) that were genetically engineered to achieve either the constitutive expression  (in HT-29 cells) or the selective inactivation (in DLD-1 cells) of the transcription factor CDX2, a master regulator of embryonic gut development and","Not Applicable","Colonic Neoplasms","Interventional","Not Provided","RNA-Seq","4 phenotype datasets, 17 variables, 12 samples sequenced, 2 subjects, 12 samples","","NCI","GRU --- General Research Use","2022-07-26","2022-07-26","CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002966.v1.p1","Single-Cell Analysis of CD19-Specific CAR T Cell Treatment of    Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia","By leveraging single-cell transcriptome and T cell receptor (TCR) sequencing, we aimed to track the transcriptional signatures of chimeric antigen receptor (CAR) T cell clonotypes throughout the course of treatment  and furthermore identify molecular patterns leading to potent CAR T cell cytotoxicity. The data presented in this study encompass blood and bone","Not Applicable","Allergy and Immunology","Clinical Trial","Not Provided","OTHER, RNA-Seq","4 phenotype datasets, 15 variables, 200 samples sequenced, 16 subjects, 200 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2022-07-25","2022-07-25","Leukemia, B-Cell; B Cell Leukemia; B Lymphocytic Leukemia; B-Cell Leukemia; B-Cell Leukemias; B-Cell Lymphocytic Leukemia",""
"phs002931.v1.p1","Decade-Long Leukemia Remissions with Persistence of CD4+ CAR T-Cells","Two patients with chronic lymphocytic leukemia (CLL) were treated with CD19 targeted CAR T therapy and followed over several years. Peripheral blood from both patients at multiple time points was  collected, and 5' CITE-Seq with TCR profiling was performed on sorted CD3+CAR+ T cells at multiple time points. Here, we deposit the raw sequencing","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 6 samples sequenced, 2 subjects, 6 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-07-22","2022-07-22","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002250.v1.p1","CIDR: Discovery, Biology, and Risk of Inherited Variants in Glioma","This is a gliogene brain tumor family study. This study includes glioma cases with a family history of glioma in a first, second, or third degree relative.&#x000a0; Inclusion criteria: Glioma  cases with a reported family history of glioma Note for data in CDS: The raw sequencing files for this study are available via the NCI Cancer Data","Not Applicable","Glioma","Family/Twin/Trios","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","5 phenotype datasets, 21 variables, 1 molecular datasets, 146 samples sequenced, 151 subjects, 146 samples","European (139), East Asian (2), African American (1), Hispanic1 (1), Hispanic2 (1), South Asian (1), Other (1)","NCI","GRU --- General Research Use","2022-07-22","2022-07-22","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002944.v1.p1","Melanoma Brain Metastasis Single-Cell RNA Sequencing Atlas","Melanoma brain metastasis (MBM) frequently occurs in patients with advanced melanoma, yet our understanding of the underlying salient biology is rudimentary. Here, we performed single-cell/nucleus RNA-seq in 22 treatment-naive MBM  (scRNA-seq n 5; snRNA-seq n 17) and 10 extracranial melanoma metastases (ECM; all snRNA-seq), and matched spatial single-cell transcriptomics (n 16)","Not Applicable","Melanoma","Collection","Not Provided","ATAC-seq, OTHER, RNA-Seq","3 phenotype datasets, 13 variables, 105 samples sequenced, 35 subjects, 105 samples","","NCI","DS-M --- Disease-Specific (Melanoma)","2022-07-13","2022-07-13","Neoplasm Metastasis; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant",""
"phs002925.v1.p1","Genomic Analysis of Extra-Nodal Natural Killer/T-Cell Lymphoma (ENKTCL)","In this study, we performed extensive genetic profiling on 209 extra-nodal natural killer/T-cell lymphoma (ENKTCL) nasal-type cases, including 174 Chinese from four hospitals in China, and 31 Hispanic and 4  Caucasian patients from City of Hope and Eberhard Karls University of T&#x000fc;bingen. All of the cases were reviewed by experienced","Not Applicable","Lymphoma, Extranodal NK-T-Cell","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 27 variables, 209 samples sequenced, 209 subjects, 209 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2022-06-29","2022-06-29","Angiocentric T-Cell Lymphoma; Extranodal NK T Cell Lymphoma, Nasal; Extranodal NK T Cell Lymphoma, Nasal Type; Extranodal NK T Cell Lymphoma, Nasal and Nasal Type; Extranodal NK-T-Cell Lymphoma, Nasal; Extranodal NK-T-Cell Lymphoma, Nasal Type",""
"phs002599.v1.p1","NCI CCSG CCDI Supplement Additional Genomic Submission","The implementation of targeted therapies for acute myeloid leukaemia (AML) has been challenging because of the complex mutational patterns within and across patients as well as a dearth of pharmacologic  agents for most mutational events. This supplement data from the Beat AML program provides Adolescent and Young Adult (AYA) and pediatric tumor","Not Applicable","Leukemia, Myeloid, Acute","Case Set","Not Provided","RNA-Seq, Targeted-Capture, WXS","3 phenotype datasets, 7 variables, 152 samples sequenced, 104 subjects, 203 samples","","NCI","GRU --- General Research Use","2022-06-09","2022-06-09","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002833.v1.p1","A Phase 2 Study of Lamivudine in Patients with p53 Mutant Metastatic    Colorectal Cancer","This was an open-label, single-arm Phase II study of lamivudine in patients who had progressed on systemic therapy for advanced colorectal cancer with TP53 mutations. The phase II study had  a two-stage design, with a target accrual of 20 evaluable patients for the first stage and a total of 32 patients for the whole study. The first 9","Not Applicable","Colorectal Neoplasms","Clinical Trial","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 17 variables, 67 samples sequenced, 31 subjects, 67 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-06-07","2022-06-07","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001813.v3.p1","Integrative Tissue Analysis of Men with Prostate Cancer","Prostate cancer is readily curable if detected early. The goal of this research is to assess the molecular alterations that contribute to prostate cancer development, and how the interaction of  tumor-cell autonomous alterations and immune cell proportions contribute to the predictability of recurrence. Inclusion: Men diagnosed with localized","Not Applicable","Prostatic Neoplasms","Case Set","Not Provided","AMPLICON, RNA-Seq, WGS, WXS","5 phenotype datasets, 20 variables, 1366 samples sequenced, 255 subjects, 1624 samples","","NCI","GRU --- General Research Use","2022-06-07","2019-09-09","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002818.v1.p1","Intercepting Progression from Pre-Invasive to Invasive Lung    Adenocarcinoma","An improved understanding of the biology of lung cancer is needed to intercept the disease at an early point in its progression. In this project we have used multidimensional methods  to profile the tumor microenvironment (TME) and to determine the crosstalk between cancer cells and the TME in pre-invasive to invasive human lung","Not Applicable","Lung Neoplasms","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 18 variables, 84 samples sequenced, 42 subjects, 84 samples","","NCI","GRU --- General Research Use","2022-06-06","2022-06-06","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001977.v1.p1","Large Cancer Fingerprint Screening for Detection of Minimal Residual    Disease.","We describe an approach for large cancer fingerprint screening and its application to cell-free DNA from patients with cancer. Our approach involves tracking somatic mutations identified from patients' tumor biopsies,  in the cell-free DNA from a blood draw. All patients provided written informed consent to allow the collection of blood and/or tumor tissue and","Not Applicable","Neoplasms","Case-Control","Not Provided","Targeted-Capture, WGS, WXS","4 phenotype datasets, 11 variables, 788 samples sequenced, 158 subjects, 788 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS), HMB --- Health/Medical/Biomedical","2022-06-06","2022-06-06","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002380.v1.p1","Characterizing TP53 and PPM1D Mutations as Resistance Drivers to    Radiation Therapy in Diffuse Intrinsic Pontine Gliomas","Pediatric high-grade gliomas (pHGGs), encompassing diffuse midline gliomas (DMGs) and hemispheric tumors, represent the most common cause of cancer-related deaths in children age 0-14 years. Over the last decade, several  landmark papers have revealed recurrent single nucleotide variants (SNVs) in the core histones H3.3 and H3.1, co-occurring with alterations in the","Not Applicable","Brain Neoplasms","Case Set","WGS_markerset_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 17 variables, 1 molecular datasets, 115 samples sequenced, 61 subjects, 122 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-05-26","2022-05-26","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Glioma; Neoplasm of Neuroglia","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002305.v1.p1","Washington University PDX Development and Trial Center","This data set is a collection of patient specimens from common and rare cancers that have been developed into patient-derived xenograft (PDX) models at the Washington University PDX Development and  Trial Center (WU-PDTC). The goal of the PDTC is to develop and characterize PDX models, gaining insight into tumor biology, and validating biomarkers","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","Not Provided","4 phenotype datasets, 27 variables, 127 subjects, 495 samples","","NCI","GRU --- General Research Use, DS-SARC --- Disease-Specific (Sarcoma)","2022-05-26","2022-05-26","Bone Neoplasms; Gastrointestinal Neoplasms; Kidney Neoplasms; Lung Neoplasms; Rectal Neoplasms; Soft Tissue Neoplasms","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001473.v2.p2","Clonal Evolution and Transcriptomic Analysis of Chronic Lymphocytic    Leukemia Treated with Ibrutinib","Disease progression has been increasingly appreciated with the use of ibrutinib to treat chronic lymphocytic leukemia (CLL). Understanding the pattern of clonal evolution and transcriptomic changes during the early treatment  period with ibrutinib may provide insight into the mechanisms of resistance. We performed whole exome sequencing on sequential samples with matched","Not Applicable","Leukemia, Lymphoid","Prospective Longitudinal Cohort","Not Provided","Bisulfite-Seq, RNA-Seq, WXS","4 phenotype datasets, 14 variables, 312 samples sequenced, 77 subjects, 317 samples","","NCI","GRU --- General Research Use","2022-05-25","2021-02-02","Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002804.v1.p1","DNA Double Strand Breaks in KMT2A-Rearranged AML patients","DNA breakage at specific rearrangement-participating genes, which are more sensitive to a range of environmental and chemotherapeutic agents than other regions of the human genome, contributes to the generation of  leukemia-causing rearrangements, and can be used as a predictor of susceptibility to cancer caused by gene rearrangements. As a direct","Not Applicable","DNA Breaks, Double-Stranded","Case-Control","Not Provided","OTHER","4 phenotype datasets, 10 variables, 6 samples sequenced, 6 subjects, 6 samples","","NCI","GRU --- General Research Use","2022-05-19","2022-05-19","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001431.v2.p1","Whole Exome and Whole Genome Profiling as well Genome-Wide Methylation    Profiling from Early to Advanced Chronic Lymphocytic leukemia (CLL),    Genome-Wide Methylation Profiling in Monoclonal B Cell Lymphocytosis    (MBL)","Serial whole exome sequencing of samples collected from 21 patients at multiple time points during progression from early to late chronic lymphocytic leukemia (CLL) and one matching non-tumor tissue sample  from each patient. Additional whole genome sequencing of samples from 3 selected patients. Genome-wide B cell methylation compared between 5 healthy","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","Not Provided","Bisulfite-Seq, RNA-Seq, WGS, WXS","4 phenotype datasets, 14 variables, 227 samples sequenced, 35 subjects, 227 samples","","NCI","GRU --- General Research Use","2022-05-19","2021-12-06","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002852.v1.p1","A Pilot Study of NKTR-214 and Nivolumab in Selected Patients with Locally    Advanced/Metastatic Sarcoma","Study cohort comprises samples derived from patients that received treatment on an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at  Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). Patient tumors include a variety of sarcoma subtypes. Samples include whole exome","Not Applicable","Sarcoma","Clinical Trial","Not Provided","AMPLICON, RNA-Seq, WXS","4 phenotype datasets, 15 variables, 195 samples sequenced, 54 subjects, 195 samples","","NCI","DS-SARC-PUB --- Disease-Specific (Sarcoma, PUB)","2022-05-18","2022-05-18","Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma",""
"phs002734.v1.p1","Rapid Idiosyncratic Mechanisms of Clinical Resistance to KRAS G12C    Inhibition","Using deep RNA and whole exome sequencing of pre- and post-treatment autopsy samples, we reveal diverse clonal populations that occurred through altered cell intrinsic, tumor microenvironment and immunologic remodeling mechanisms  of resistance. Deceased lung cancer patient treated at UNC hospitals Related Genes: KRAS, MAPK1, YAP1 Principal Investigator: Chad Pecot, MD,","Not Applicable","Adenocarcinoma of Lung","Case Set","RNAseq_probe_set_grc38","RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 42 samples sequenced, 1 subjects, 42 samples","","NCI","GRU --- General Research Use","2022-05-18","2022-05-18","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002787.v1.p1","Personalized Breast Cancer Vaccines Based on Genome Sequencing","This study is from a phase I clinical trial of neoantigen DNA vaccines in triple negative breast cancer patients with persistent disease following neoadjuvant chemotherapy. The exome and RNA sequences  used to identify somatic mutations, predict neoantigens, and design vaccines is within. Principal Investigator: William Gillanders, MD, Washington","Not Applicable","Triple Negative Breast Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 16 variables, 54 samples sequenced, 18 subjects, 54 samples","","NCI","GRU --- General Research Use","2022-05-13","2022-05-13","Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002783.v1.p1","Pan Cancer Investigation of Human Leukocyte Antigen Loss of    Heterozygosity","Cancer cells can escape immune recognition through human leukocyte antigen (HLA) loss of heterozygosity (LOH) which results in deletion of HLA alleles, causing a reduction in presentation of tumor neoantigens.  Despite its influence on immunotherapy response, few methods exist to detect HLA LOH, and accuracy of the approaches is poorly defined. Here, we","Not Applicable","HLA Antigens","Case Set","Not Provided","WXS","1118 samples sequenced, 559 subjects, 1118 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2022-05-13","2022-05-13","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs002803.v1.p1","A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and    BRCA2 Wild-Type Patients","The Talazoparib Beyond BRCA (TBB), a phase II proof-of-concept clinical trial, was designed to test the efficacy of talazoparib, a potent, orally bioavailable PARP inhibitor, with an established Phase II  recommended dose, in the treatment of advanced BRCA wildtype (WT), HER2-negative breast cancer and other solid tumors with homologous recombination","Not Applicable","Breast Neoplasms","Clinical Trial","Not Provided","OTHER, WXS","4 phenotype datasets, 43 variables, 89 samples sequenced, 20 subjects, 89 samples","","NCI","GRU --- General Research Use","2022-05-12","2022-05-12","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002847.v1.p1","Circulating Tumor DNA as a Biomarker in Patients with Stage III and IV    Wilms Tumor: Analysis from a Children's Oncology Group Trial, AREN0533","We evaluated the utility of circulating tumor DNA (ctDNA) as a biomarker in the serum and urine of 50 patients with Stage III or Stage IV Wilms tumor (WT) that  were enrolled on Children's Oncology Group&#x000a0;(COG) trial AREN0533. 49 out of 50 patients had matched tumor samples available for comparison. We","Not Applicable","Wilms Tumor","Case Set","Not Provided","Targeted-Capture, WGS","4 phenotype datasets, 12 variables, 149 samples sequenced, 50 subjects, 149 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-05-11","2022-05-11","Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002416.v2.p1","Characterization of CNS Metastases","Metastatic disease to the central nervous system (CNS) is devastating, with a poor prognosis. There are limited treatment options for patients with CNS metastases, and in particular with leptomeningeal carcinomatosis  (LMD). In this study, we evaluated the molecular and cellular features of parenchymal brain metastases and LMD. We used single-cell RNA and cell-free","Not Applicable","Meningeal Carcinomatosis","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 13 variables, 71 samples sequenced, 46 subjects, 71 samples","","NCI","GRU --- General Research Use","2022-05-06","2021-08-23","Leptomeningeal Carcinomatosis; Carcinomatoses, Leptomeningeal; Carcinomatoses, Meningeal; Carcinomatosis of the Meninges; Carcinomatosis, Leptomeningeal; Carcinomatosis, Meningeal","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002867.v1.p1","Blood Somatic Mutations in TCGA Donors Suffering from Solid Tumors","Blood somatic mutations identified across 8,530 solid tumor patients in TCGA cohort. We reasoned that low-coverage whole-genome sequencing of blood samples routinely carried out in cancer genomics projects may be  repurposed to detect clonal hematopoiesis (CH). Thus, inspired by a previous approach to identify early mutations in the development of the","Not Applicable","Clonal Hematopoiesis","Case Set","Somatic_Variant","SNV (.MAF)","3 phenotype datasets, 8 variables, 1 molecular datasets, 8315 subjects, 8315 samples","","NCI","GRU --- General Research Use","2022-05-04","2022-05-04","ARCH; ARCH Age related Clonal Hematopoiesis; ARCH Age-related Clonal Hematopoiesis; Age related Clonal Hematopoiesis; Age-related Clonal Hematopoiesis; Clonal Hematopoiesis, Age-related","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002443.v1.p1","Molecular Signatures of DCIS to Invasive Progression for Basal-Like    Breast Cancers: An Integrated Mouse Model and Human Tumor Study","We studied the genomic signatures of progression in breast ductal carcinoma in situ (DCIS) as it progresses towards triple negative invasive breast cancer (TNBC). Single cell RNA sequencing (scRNAseq) was  performed on the C3Tag genetically engineered mouse model that forms human breast-like DCIS and TNBC. Bulk RNA sequencing was performed on RNA","Not Applicable","Carcinoma, Intraductal, Noninfiltrating","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 16 variables, 18 samples sequenced, 11 subjects, 18 samples","","NCI","GRU --- General Research Use","2022-05-04","2022-05-04","Triple Negative Breast Neoplasms; Breast Ductal Carcinoma In Situ, NOS; Carcinoma, Intraductal; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002620.v1.p1","Feasibility and Clinical Utility of Whole Genome Profiling in Pediatric    and Young Adult Cancers","Comprehensive Whole Genome Sequencing and Whole Transcriptome (RNASeq) analyses from 114 pediatric patients at Memorial Sloan Kettering. This dataset was used as a prospective clinical utility and feasibility study. By  using our Isabl infrastructure for precision medicine, we developed a 2-week end-to-end pipeline to analyze cfDNA, WGS and WTS, which we refer to as","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WGS","3 phenotype datasets, 14 variables, 326 samples sequenced, 114 subjects, 326 samples","","NCI","GRU --- General Research Use","2022-05-02","2022-05-02","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000328.v3.p1","Genome-Wide Analysis of Diffuse Large B-Cell Lymphoma (De Novo and    Derived from the High Grade Transformation of Follicular Lymphoma)","Version 1. Diffuse Large B-cell Lymphoma (DLBCL) represents the most common form of B-cell non-Hodgkin Lymphoma (B-NHL), accounting for 30% of the de novo diagnoses and also arising as a  frequent clinical evolution of Follicular Lymphoma (FL). The molecular pathogenesis of DLBCL is associated with multiple genetic lesions that in part","Not Applicable","Lymphoma, Large B-Cell, Diffuse","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), Targeted-Capture, WGS, WXS","3 phenotype datasets, 12 variables, 2 molecular datasets, 258 samples sequenced, 194 subjects, 333 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2022-04-29","2022-04-29","Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers",""
"phs002765.v1.p1","Transcriptomic Profiles of Neoantigen-Reactive T Cells in Human    Gastrointestinal Cancers","This study explores the transcriptomic profiles of neoantigen-reactive tumor-infiltrating lymphocytes (TILs) from human bile duct and pancreatic cancer. The submitted data are bulk tumor RNA-Seq, tumor and germline whole-exome sequencing  from 10 patients, and single cell RNA-Seq data from TIL of 5 of these patients. Inclusion: patients with gastrointestinal cancer Related Genes: GZMA,","Not Applicable","Gastrointestinal Neoplasms","Case Set","RNAseq_gene_transcripts","AMPLICON, RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 20 variables, 1 molecular datasets, 3134 samples sequenced, 10 subjects, 3134 samples","","NCI","GRU --- General Research Use","2022-04-28","2022-04-28","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001965.v1.p1","MP2PRT: Identification of Genetic Changes Associated with Relapse and/or    Adaptive Resistance in Patients Registered as Favorable Histology    Wilms Tumor on AREN03B2","The Molecular Profiling to Predict Response to Treatment (MP2PRT) program is part of the NCI's Cancer Moonshot Initiative. The aim of this program is the retrospective characterization and analysis of  biospecimens collected from completed NCI-sponsored trials of the National Clinical Trials Network and the NCI Community Oncology Research Program.","Not Applicable","Wilms Tumor","Case Set","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 84 subjects, 84 samples","","NCI","GRU --- General Research Use","2022-04-22","2022-04-22","Embryonal adenosarcoma; Embryonal nephroma; Kidney Nephroblastoma; NEPHROBLASTOMA; Nephroblastoma (Wilms tumor); Nephroblastomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002482.v1.p1","Combined Targeting of CDK4/6 and HER2 Signaling in Orthotopic    Patient-Derived Xenografts of HER2-Positive Breast Cancer Brain    Metastases","Patients with metastatic HER2-positive (HER2+) breast cancer will frequently develop brain metastases (BCBMs). Here, we report that p16INK4A, a tumor suppressor, is deficient in the majority of HER2+ BCBMs. Furthermore,  p16INK4A deficiency, as measured by protein immunohistochemistry, can be a predictive marker associated with response to combined treatment with","Not Applicable","Breast Neoplasms","Collection","Not Provided","RNA-Seq, WXS","3 phenotype datasets, 13 variables, 96 samples sequenced, 39 subjects, 96 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-04-15","2022-04-15","Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001905.v1.p1","CIDR: Molecular Pathological Epidemiology of Colorectal Cancer","Colorectal cancer, the second most commonly diagnosed cancer is a biologically heterogeneous disease. To characterize the molecular attributes of colorectal tumors, we conducted targeted sequencing at the Center for Inherited  Disease Research (CIDR) on 4,518 tumor and matched normal DNA samples from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) and","Not Applicable","Colorectal Neoplasms","Case Set","target_markerset_grc37","SNP/CNV Genotypes (NGS)","5 phenotype datasets, 99 variables, 1 molecular datasets, 3824 subjects, 7825 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB), GRU --- General Research Use, CADM --- Cancer in all age groups, other diseases in adults only, and methods, DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB --- Health/Medical/Biomedical, HMB-IRB-NPU-GSO --- Health/Medical/Biomedical (IRB, NPU, GSO), DS-COC-MDS --- Disease-Specific (Colon Cancer, MDS)","2022-04-14","2022-04-14","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002564.v1.p1","Transcriptional Profiling of Macrophages In Situ in Metastatic Melanoma    Reveals Localization-Dependent Phenotypes and Function","Therapeutic interventions modulating immune function at the tumor site could improve outcomes in cancer. Here we analyzed metastatic melanoma, a tumor type highly responsive to T-cell based therapies, and found  that the tumor-infiltrating T cells are localized closely to CD14+ monocytes/macrophages rather than to melanoma cells. Using novel","Not Applicable","Melanoma","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 21 variables, 64 samples sequenced, 8 subjects, 64 samples","","NCI","GRU --- General Research Use","2022-04-11","2022-04-11","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001939.v3.p1","Count Me In (CMI): The Metastatic Prostate Cancer (MPC) Project    (CMI-MPCproject)","Count Me In - The Metastatic Prostate Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Prostate Cancer Research The Metastatic Prostate Cancer Project (MPCproject; http://mpcproject.org/) is a research study  that empowers men with metastatic and advanced prostate cancer to partner directly with researchers by sharing their samples and clinical","Not Applicable","Prostatic Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","4 phenotype datasets, 11 variables, 63 subjects, 126 samples","","NCI","GRU --- General Research Use","2022-04-07","2020-02-12","Neoplasm Metastasis; Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002683.v1.p1","Combined Tumor and Immune Signals From Genomes or Transcriptomes Predict    Outcomes of Checkpoint Inhibition in Melanoma","Cancer immunotherapy with checkpoint blockade (CPB) leads to improved outcomes in melanoma and other tumor types, but a majority of patients do not respond. High tumor mutation burden (TMB) and  high levels of tumor-infiltrating T cells have been associated with response to immunotherapy, and integrative models using DNA and RNA have improved","Not Applicable","Melanoma","Collection","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 20 variables, 169 samples sequenced, 61 subjects, 169 samples","","NCI","DS-MSC-MDS --- Disease-Specific (Melanoma and Skin Cancer Research, MDS)","2022-04-06","2022-04-06","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001980.v2.p1","University of Texas PDX Development and Trial Center Grant","The goal for the University Texas PDX Development and Trial Center (UTPDTC) is to optimize personalized biomarker-based cancer therapy and identify effective targeted drugs based on the molecular characteristics of  each tumor. Our short-term goals are to establish a biobank of clinically, and molecularly-annotated Patient-Derived Xenografts (PDXs) and to use","Not Applicable","Lung Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 28 variables, 77 samples sequenced, 36 subjects, 77 samples","","NCI","DS-LC-COL --- Disease-Specific (Lung Cancer, COL)","2022-04-01","2021-02-11","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell",""
"phs001951.v2.p1","Relapsed Acute Lymphoblastic Leukemia (ALL): Mutational Landscape","Multi-agent combination chemotherapy can be curative in acute lymphoblastic leukemia (ALL). Still, patients with primary refractory disease or those with relapsed leukemia have a very poor prognosis. Here we report  the mutational landscape of matched diagnostic and relapsed pediatric and adult ALL samples. Our data provides comprehensive annotation of genetic","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Prospective Longitudinal Cohort","Not Provided","WGS, WXS","4 phenotype datasets, 17 variables, 159 samples sequenced, 56 subjects, 159 samples","","NCI","GRU --- General Research Use","2022-04-01","2022-04-01","ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000985.v2.p1","Functional Significance of Prostate Cancer Risk-SNPs","Prostate Cancer (PrCa), the most frequently diagnosed solid tumor in men in the U.S., results in 192,000 new cases and 27,000 deaths per year. Although the variation of PrCa incidence  is likely to be the result of several factors, there is a large body of literature that strongly implicates a genetic etiology. Genome-wide","Not Applicable","Prostatic Neoplasms","Control Set","RNAseq_probe_set_grc37, HumanOmni2.5-8, RNAseq_gene_transcripts","SNP Genotypes (Array), RNA Seq (NGS), miRNA (NGS)","4 phenotype datasets, 29 variables, 8 documents, 3 molecular datasets, 471 subjects, 1383 samples","","NCI","DS-PC-PUB-MDS --- Disease-Specific (Prostate Cancer, PUB, MDS)","2022-03-30","2022-03-30","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs002792.v1.p1","Characterization of Neoantigen-reactive T cells by Single-Cell Analysis","Through CITE-seq and TCR-seq analysis of non-small cell lung cancer (NSCLC) tumor-infiltrating lymphocytes (TIL), we developed a neoantigen-reactive T-cell signature based on clonotype frequency and CD39 protein and CXCL13 mRNA  expression. There are four datasets from four NSCLC cases. Each dataset includes (1) Transcriptome of tumor infiltrating lymphocytes (TIL), (2) Cell","Not Applicable","Lymphocytes, Tumor-Infiltrating","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 48 samples sequenced, 4 subjects, 48 samples","","NCI","GRU --- General Research Use","2022-03-25","2022-03-25","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001920.v1.p1","Genomic Characterization of Brain Metastases from Lung Cancer","Metastatic disease to the brain is associated with a poor prognosis. Our understanding of the genetic drivers of metastasis remain limited. Whole-exome sequencing was performed from brain metastases from lung  adenocarcinoma to identify putative drivers of metastatic progression. We identified patients with brain metastases from lung adenocarcinoma from our","Not Applicable","Neoplasm Metastasis","Prospective Longitudinal Cohort","Not Provided","WXS","3 phenotype datasets, 10 variables, 120 samples sequenced,  SRA, 40 subjects, 120 samples","","NCI","GRU --- General Research Use, DS-BT --- Disease-Specific (Brain Tumors), DS-LCTC-MDS --- Disease-Specific (Lung Cancer and Thoracic Malignancies, MDS)","2022-03-25","2022-03-25","Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize; Neoplasm Metastases","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002283.v2.p1","Selenium Chemoprevention: Benefits and Harms","Selenium is a trace element that may have anti-carcinogenetic effect, but heterogenous treatment effects have been observed. This genome-wide association study investigates if genetic variation modifies the effect of selenium  chemoprevention in the Selenium and Celecoxib Trial, a randomized, double-blind, placebo-controlled trial conducted at the University of Arizona","Not Applicable","Neoplasms, Second Primary","Clinical Trial","Not Provided","SNP Genotypes (Array)","4 phenotype datasets, 27 variables, 1323 subjects, 1323 samples","European (1222), East Asian (9), African American (29), Hispanic1 (5), Hispanic2 (51), Other Asian or Pacific Islander (3), South Asian (4)","NCI","GRU-IRB-COL-NPU --- General Research Use (IRB, COL, NPU)","2022-03-14","2021-01-13","Malignancies, Second; Malignancy, Second; Metachronous Neoplasm; Metachronous Neoplasms; Metachronous Second Primary Neoplasms; Neoplasm, Metachronous",""
"phs001145.v1.p1","Exceptional Responders Initiative","The Exceptional Responders Initiative is a pilot study to investigate the underlying molecular factors driving exceptional treatment responses of cancer patients to drug therapies. Study researchers will examine molecular profiles  of tumors from patients either enrolled in a clinical trial for an investigational drug(s) and who achieved an exceptional response relative to other","Not Applicable","Neoplasms","Case-Control","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 170 subjects, 170 samples","","NCI","GRU --- General Research Use","2022-03-11","2022-03-11","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002653.v1.p1","Tumor Mutation Burden, Expressed Neoantigen and Immune Microenvironment    in Diffuse Gliomas","A consistent correlation between tumor mutation burden (TMB) and tumor immune microenvironment has not been observed in gliomas as in other cancers. Driver germline and somatic mutations, TMB, neoantigen, and  immune cell signatures were analyzed using whole exome sequencing (WES) and transcriptome sequencing of tumor and WES of matched germline DNA in a","Not Applicable","Glioma","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 18 variables, 66 samples sequenced, 48 subjects, 66 samples","","NCI","GRU --- General Research Use","2022-03-09","2022-03-09","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002566.v1.p1","Foregut Microbiome and Risk of Gastric Intestinal Metaplasia, and Gastric    Cancer Risk","The study is composed of two sub-studies. The first study, conducted by NYU Grossman School of Medicine, is a case-control study of 89 cases with gastric intestinal metaplasia (IM) and  89 matched controls who underwent upper gastrointestinal endoscopy at three sites affiliated with NYU Langone Health. Shotgun metagenomic sequencing","Not Applicable","Metaplasia","Case-Control","Not Provided","WGS","7 phenotype datasets, 59 variables, 776 samples sequenced, 679 subjects, 776 samples","","NCI","HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), DS-GICA --- Disease-Specific (Gastric Cancer), DS-GICA-NPU --- Disease-Specific (Gastric Cancer, NPU)","2022-03-09","2022-03-09","CA - Cancer of stomach; Ca lesser curvature - stomach; Cancer of Stomach; Cancer of the Stomach; Cancer, Gastric; Cancer, Stomach",""
"phs002556.v1.p1","Genomic Features of Lung Adenocarcinoma from Individuals with    10    Pack-Year Smoking History","Actionable oncogenic alterations are identified in a subset of lung adenocarcinomas. Many of these driver alterations are enriched in lung adenocarcinomas from individuals with minimal smoking history and are generally  mutually exclusive of one another. We generated whole-exome and RNA-seq data from lung adenocarcinomas obtained from individuals with &#x02264;10","Not Applicable","Adenocarcinoma of Lung","Case Set","RNAseq_probe_set_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 75 samples sequenced, 25 subjects, 75 samples","","NCI","DS-LC --- Disease-Specific (Lung Cancer)","2022-03-08","2022-03-08","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs002498.v1.p1","Integrative Genomic and Transcriptomic Analyses of Refractory Multiple    Myeloma","This study reports results from integrative sequencing analyses that combine capture transcriptome sequencing with a comparative analysis of exome capture between the malignant plasma cells and normal cells of patients  with relapsed and refractory multiple myeloma (RRMM). This approach has enabled the detection of point mutations, insertions/deletions, gene fusions","Not Applicable","Neoplasms","Case Set","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 15 variables, 1530 samples sequenced, 511 subjects, 1530 samples","","NCI","DS-MM --- Disease-Specific (Multiple Myeloma)","2022-03-07","2022-03-07","Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Plasmacytoma; Smoldering Multiple Myeloma; AL; AL AMYLOIDOSIS",""
"phs002231.v1.p1","Germ Cell and Associated Heme Malignancies Evolve from a Common Shared    Precursor","Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15-40. While most patients are cured, those with disease arising in the mediastinum have distinctly  poor outcomes. One in every 17 patients with primary mediastinal non-seminomatous GCTs develop an incurable hematologic malignancy and prior data","Not Applicable","Neoplasms, Germ Cell and Embryonal","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 27 variables, 19 samples sequenced,  SRA, 5 subjects, 19 samples","","NCI","HMB --- Health/Medical/Biomedical","2022-03-07","2022-03-07","Mediastinal Neoplasms; HEMOLYMPHORETICULAR tumor, malignant; Hematopoietic Cancer; Hematopoietic Malignancies; Hematopoietic Malignancy; Hematopoietic Neoplasm","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001323.v3.p1","Multiple Myeloma Genomic Study (MMGS)","Multiple Myeloma (MM) is a plasma cell dyscrasia characterized by bone marrow (BM) infiltration and lytic bone lesions. Recent studies of massive parallel sequencing of tumor cells obtained from the  BM of patients with MM have demonstrated significant clonal heterogeneity in MM. Despite this remarkable clonal heterogeneity, it could be envisioned","Not Applicable","Multiple Myeloma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 15 variables, 1078 samples sequenced, 883 subjects, 1078 samples","","NCI","DS-PCD --- Disease-Specific (plasma cell dyscrasias)","2022-03-07","2020-04-20","Monoclonal Gammopathy of Undetermined Significance; Asymptomatic monoclonal gammopathy; Benign Monoclonal Gammapathies; Benign Monoclonal Gammapathy; Benign Monoclonal Gammopathies; MGUS",""
"phs002748.v1.p1","Transcriptome and TCR Sequencing of T Cells from Metastectomies","T cells were sorted from metastatic tumors (colon, rectal, breast, anal, melanoma primary histologies) following tumor dissociation and single-cell sequencing was performed (RNAseq and TCRseq). For samples from tumors that  had been previously studied, cells were analyzed comparing known neoantigen-reactive TCR-expressing cells to other T cells. For samples without","Not Applicable","Colonic Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 123 samples sequenced, 15 subjects, 123 samples","","NCI","GRU --- General Research Use","2022-03-02","2022-03-02","Anus Neoplasms; Rectal Neoplasms; Anal Neoplasms; Anal Neoplasms, Benign and Malignant; Anal Tumor; Anal Tumors","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002735.v1.p1","Tumor Infiltrating Lymphocytes (TIL) Recognize Unique Somatic Mutations    and Mediate Objective Clinical Responses in Metastatic Breast Cancer","The purpose of this study is to investigate the immunogenicity of tumor mutations in patients with metastatic cancer. Harvest and analysis of progressing metastatic lesions are used for generation of  tumor infiltrating lymphocyte (TIL) cultures and the detections of somatic mutations. In vitro T cell activation assays are used to examine the","Not Applicable","Breast Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 358 samples sequenced, 42 subjects, 358 samples","","NCI","GRU --- General Research Use","2022-02-02","2022-02-02","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001863.v1.p1","Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin    +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by    Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast    Cancer","This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be  removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop","Not Applicable","Breast Neoplasms","Interventional","Not Provided","RNA-Seq","4 phenotype datasets, 53 variables, 2 documents, 389 samples sequenced,  SRA, 389 subjects, 389 samples","","NCI","DS-CA-COL --- Disease-Specific (Cancer, COL)","2022-02-01","2022-02-01","Breast Diseases; Neoplasms by Site; Skin Diseases; Triple Negative Breast Neoplasms; Breast Disease, Endocrine; Breast Diseases, Endocrine",""
"phs002388.v1.p1","Genomic and Transcriptomic Markers Associated with Response to Immune    Checkpoint Blockade","The neoantigen presentation score (NEOPS) study was designed to better understand molecular determinants of response to immunotherapies, including pembrolizumab and nivolumab in stage III or IV melanoma patients. From this  work, we developed a composite approach to predicting neoantigens (NEOPS), which takes into account additional escape mechanisms, including HLA LOH","Not Applicable","Melanoma","Case Set","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 22 variables, 1 molecular datasets, 151 samples sequenced, 52 subjects, 199 samples","","NCI","GRU --- General Research Use","2022-01-25","2022-01-25","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002460.v1.p1","Health Professionals Follow-Up Study","Health Professionals Follow-up Study (HPFS) is a prospective cohort study of men designed to evaluate hypotheses about men's health related to diet and lifestyle to the incidence of serious illnesses,  such as cancer, heart disease, and other vascular diseases. It consisted of 51,529 U.S. male health professionals who were 40-75 years old at","Not Applicable","Diet","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 398 variables, 1 documents, 20064 subjects","","NCI","HMB --- Health/Medical/Biomedical","2022-01-20","2022-01-20","Not Provided","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002396.v1.p1","Integrated Metabolic Profiling and Gene Expression Analysis Reveals    Therapeutic Modalities in Breast Cancer","In this study, we performed metabolite profiling and RNA-sequencing on human breast cancer tumors and normal breast tissue samples, including triple negative breast cancer (TNBC), estrogen receptor positive breast cancer  (ER+) and paired normal samples, and patient-derived xenografts (PDX) samples. Here, we report two distinctive groups defined by metabolites; a","Not Applicable","Triple Negative Breast Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq","5 phenotype datasets, 17 variables, 40 samples sequenced, 26 subjects, 40 samples","","NCI","GRU --- General Research Use","2022-01-13","2022-01-13","Breast Cancer, Triple-Negative; Breast Cancers, Triple-Negative; Breast Neoplasm, Triple-Negative; Breast Neoplasms, Triple-Negative; ER Negative PR Negative HER2 Negative Breast Cancer; ER Negative PR Negative HER2 Negative Breast Neoplasms","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002050.v2.p1","OICR: Molecular Pathological Epidemiology of Colorectal Cancer","Colorectal cancer, the second most commonly diagnosed cancer, is a biologically heterogeneous disease. To characterize the molecular attributes of colorectal tumors, we conducted targeted sequencing at the Ontario Cancer Research  Institution (OICR) of tumor and matched normal DNA samples from 2,542 colorectal cancer cases in the Genetics and Epidemiology of Colorectal Cancer","Not Applicable","Colorectal Neoplasms","Case Set","target_markerset_grc38","SNP Genotypes (NGS), WXS","4 phenotype datasets, 29 variables, 1 molecular datasets, 5056 samples sequenced, 2528 subjects, 5056 samples","","NCI","HMB-IRB-COL --- Health/Medical/Biomedical (IRB, COL), GRU --- General Research Use, HMB-IRB --- Health/Medical/Biomedical (IRB), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS)","2022-01-12","2021-01-15","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002309.v2.p1","Identification and Characterization of Skin-Resident Memory T cells in    Patients with Melanoma-Associated Vitiligo","Metastatic melanoma patients who develop melanoma-associated vitiligo, an autoimmune cutaneous side effect after receiving immunotherapy, have better overall survival than those who do not develop vitiligo. The objective of this  study is to determine the tumor-specific memory T cell responses in the skin, tumor and blood of melanoma patients with vitiligo. Matched melanoma","Not Applicable","Melanoma","Case Set","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), Targeted-Capture","4 phenotype datasets, 19 variables, 2 molecular datasets, 32 samples sequenced, 5 subjects, 32 samples","","NCI","GRU --- General Research Use","2021-12-27","2021-12-27","Vitiligo; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001999.v1.p1","Advanced Genetic and Molecular Analysis of Solid Tumors","This study is designed to understand the role of immunosuppressive regulatory B cells (Breg) in pancreatic cancer. Breg and conventional B cells (Bcon) from patients are compared by RNA sequencing  analysis. Bregs and Bcon were isolated from freshly isolated PBMCs in peripheral blood. These data represent the examination of differentially","Not Applicable","Carcinoma, Pancreatic Ductal","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 2 samples sequenced, 1 subjects, 2 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2021-12-23","2021-12-23","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas",""
"phs002541.v1.p1","Integrated Genomic and Transcriptomic Analysis of Small Cell Lung Cancer    Reveals Inter- and Intratumoral Heterogeneity and a Novel    Chemotherapy-Refractory Subtype","We integrated histology, transcriptome, exome, and treatment outcomes of small cell neuroendocrine cancer (SCNC) from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of neuroendocrine (NE) differentiation  and transcriptomic subtypes (ASCL1, NEUROD1, POU2F3, YAP1 and ATOH1). High NE SCNCs were more likely to benefit from replication stress-targeted","Not Applicable","Small Cell Lung Carcinoma","Cross-Sectional","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 12 variables, 168 samples sequenced, 72 subjects, 168 samples","","NCI","GRU --- General Research Use","2021-12-08","2021-12-08","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002612.v1.p1","Immunogenomics of Malignant Brain Tumors","We performed systematic and comprehensive multi-sector immunogenomic analyses on 93 samples from a cohort of 30 patients with primary or recurrent gliomas or metastatic brain tumors, representing the largest cohort  of these brain cancers studied spatially to date. For each patient, we characterized multiple spatially distinct regions using whole-exome (WES),","Not Applicable","Genetic Heterogeneity","Tumor vs. Matched-Normal","WES_markerset_grc38, RNAseq_probe_set_grc38, WES_markerset_grc38, RNAseq_probe_set_grc38","RNA-Seq, CNV Genotypes, RNA Seq (NGS), WXS","4 phenotype datasets, 22 variables, 2 documents, 1 molecular datasets, 203 samples sequenced, 30 subjects, 203 samples","","NCI","GRU --- General Research Use","2021-12-07","2021-12-07","Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002639.v1.p1","Genomic Analysis of Metastatic Brain Cancer","This study contains targeted exome and transcriptome sequencing of metastatic brain tumors from 68 patients. Sequencing data includes i) targeted Tempus xT exome sequencing from matched tumor/normal from 68 patients,  and ii) whole-transcriptome RNA sequencing from a subset of 65 patients. Related Genes: BRAF, CDKN2A, KRAS, SMAD4, MCL1, NFE2L2, NRAS, PIK3CA, PTEN,","Not Applicable","Neoplasm Metastasis","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 11 variables, 201 samples sequenced, 68 subjects, 201 samples","","NCI","GRU --- General Research Use","2021-12-02","2021-12-02","Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour; Neoplasm of Brain","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002066.v2.p1","Mechanisms of Extreme Genomic Instability at Large Transcribed Genes","Inhibiting DNA replication leads to copy number variant (CNV) formation throughout the genome, especially at chromosome fragile sites (CFSs). We previously showed that these hotspots for genome instability reside in  late-replicating domains associated with large transcribed genes. In this study, we compared aphidicolin (APH)-induced CNV and CFS frequency between","Not Applicable","Chromosome Fragile Sites","Case-Control","Multi-Ethnic_Global, target_markerset_grc38, Multi-Ethnic_Global, target_markerset_grc38","CNV Genotypes, OTHER, RNA-Seq, RNA Seq (NGS), WGS","3 phenotype datasets, 18 variables, 1 documents, 1 molecular datasets, 22 samples sequenced, 2 subjects, 182 samples","","NCI","GRU --- General Research Use","2021-11-22","2020-08-19","Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001689.v1.p1","Multiethnic Cohort Adiposity Phenotype Study (MEC-APS)","A total of 1,861 healthy men and postmenopausal women aged 60-77 years with body mass indexes (BMIs) of 17.1-46.2 kg/m2 were enrolled into the study. Stratified sampling was conducted based  on sex, race/ethnicity, and six BMI categories (18.5-21.9, 22-24.9, 25-26.9, 27-29.9, 30-34.9, and 35-40 kg/m2) to balance the sample size across the","Not Applicable","Intra-Abdominal Fat","Cross-Sectional","MEGA_Consortium_Array","SNP Genotypes (Array)","4 phenotype datasets, 27 variables, 1 molecular datasets, 1849 subjects, 1849 samples","European (412), African (14), East Asian (438), African American (293), Hispanic1 (12), Hispanic2 (370), Other Asian or Pacific Islander (241), Other (69)","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2021-11-22","2021-11-22","Not Provided",""
"phs002587.v1.p1","Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to    Transcriptional CDK Inhibitors through Antagonism of E2F-Driven    Oncogenic Gene Expression","Leiomyosarcoma (LMS) is a smooth muscle-derived mesenchymal cancer commonly found to have recurrent loss of tumor suppressor genes and a poorly defined oncogenic program. Empiric cytotoxic chemotherapy is the standard  systemic treatment for LMS, and while more targeted and effective therapies are urgently needed, insights into therapeutic vulnerabilities in LMS","Not Applicable","Leiomyosarcoma","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 13 variables, 67 samples sequenced, 11 subjects, 67 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-11-18","2021-11-18","Epithelioid Leiomyosarcomas; Leiomyosarcoma, Epithelioid; Leiomyosarcomas, Epithelioid; epithelioid leiomyosarcoma","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002441.v1.p1","High-Throughput and High-Dimensional Single Cell Analysis of    Antigen-Specific CD8+ T Cells","We developed a high-dimensional, tetramer associated T cell receptor sequencing (TetTCR-SeqHD) method to simultaneously profile cognate antigen specificities, TCR sequences, targeted gene-expression, and surface protein expression. Cultured antigen-specific CD8+ T  cell clones were studied as a proof-of-concept experiment. In addition, both the antigen specific CD8+ T cells from healthy subjects and Type I","Not Applicable","Diabetes Mellitus, Type 1","Methods","Not Provided","AMPLICON","4 phenotype datasets, 15 variables, 16 samples sequenced, 22 subjects, 16 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2021-11-18","2021-11-18","DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETES MELLITUS, INSULIN-DEPENDENT, 1; Diabetes Mellitus, Insulin Dependent; Diabetes Mellitus, Juvenile Onset; Diabetes Mellitus, Juvenile-Onset; Diabetes Mellitus, Sudden Onset",""
"phs001928.v1.p1","A Comprehensive Genomic Study of Pediatric Malignancy","Malignancy remains the leading cause of disease-related death in children. DNA sequencing studies have shown a paucity of actionable genomic alterations and a low mutation burden across pediatric cancers at  diagnosis. We perform a comprehensive genomic and epigenomic analysis of pediatric tumor and normal tissues using next-generation sequencing to","Not Applicable","Neuroblastoma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 13 variables, 400 samples sequenced,  SRA, 267 subjects, 401 samples","","NCI","GRU --- General Research Use","2021-11-18","2021-11-18","Desmoplastic Small Round Cell Tumor; Endodermal Sinus Tumor; Hepatoblastoma; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Clear Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002064.v1.p1","Metagenomic Analysis to Identify Novel Infectious Agents in Systemic    Anaplastic Large Cell Lymphoma","Anaplastic large cell lymphoma (ALCL) is a rare T-cell non-Hodgkin lymphoma (NHL). Risk of systemic ALCL is markedly increased among immunosuppressed people, such as those with human immunodeficiency virus (HIV)  infection or solid organ transplant recipients. This increased risk in immunosuppressed populations suggests a viral etiology, given similar","Not Applicable","Lymphoma, Large-Cell, Anaplastic","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 26 samples sequenced,  SRA, 26 subjects, 26 samples","","NCI","GRU --- General Research Use","2021-11-17","2021-11-17","ALCL; Anaplastic Large-Cell Lymphoma; Anaplastic Large-Cell Lymphomas; Anaplastic large cell lymphoma (ALCL) CD30+; Anaplastic large cell lymphoma CD30 positive; Anaplastic large cell lymphoma, CD30+","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001938.v3.p1","Genomic and Genetic Characterization of Prostate Tumors Treated with    Neoadjuvant Intense Androgen Deprivation Therapy","The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging  (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this","Not Applicable","Prostatic Neoplasms","Case Set","Affymetrix_WG_Array","AMPLICON, SNP Genotypes (Array), RNA-Seq, WGS, WXS","5 phenotype datasets, 40 variables, 1 molecular datasets, 450 samples sequenced, 39 subjects, 487 samples","","NCI","GRU-IRB-PUB --- General Research Use (IRB, PUB)","2021-11-15","2021-11-15","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs002457.v1.p1","Comprehensive Analysis of the Immunogenomics of Triple Negative Breast    Cancer Brain Metastases from LCCC1419","Triple negative breast cancer (TNBC) is an aggressive subset of breast cancer that lacks expression of the estrogen and progesterone receptors (ER and PR) and HER2. Nearly 50% of patients  with advanced TNBC will develop brain metastases (BrM), commonly with progressive extracranial disease. Immunotherapy has shown promise in the","Not Applicable","Triple Negative Breast Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 17 variables, 95 samples sequenced, 25 subjects, 95 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-11-10","2021-11-10","Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002238.v1.p1","Genomic Profiling of Relapsed and Refractory Childhood Cancers","Through clinical trials focused on molecularly guided therapy in pediatric cancers (NCT01355679, NCT01802567, NCT02162732), the Beat Childhood Cancer Consortium performed paired tumor/normal whole exome sequencing and/or tumor mRNA sequencing for  202 pediatric or adolescent young adult patients with rare, relapsed and refractory cancers (including neuroblastoma, Ewing sarcoma, osteosarcoma,","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 14 variables, 683 samples sequenced, 202 subjects, 683 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2021-11-09","2021-11-09","Desmoplastic Small Round Cell Tumor; Hepatoblastoma; Sarcoma; Sarcoma, Ewing; Brain Neoplasms; Brain Tumor","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002614.v1.p1","Multi-Omic Investigation of Beckwith-Wiedemann Syndrome Hepatoblastoma","Hepatoblastoma (HB) is the most common malignant liver tumor diagnosed in children under 5 years of age. One of the most common HB predisposition syndromes is Beckwith-Wiedemann Syndrome (BWS, OMIM  130650), which affects approximately 1/10,000 live births. In this study, we perform Whole Exome Sequencing (WES), DNA methylation array, messenger","Not Applicable","Beckwith-Wiedemann Syndrome","Tumor vs. Matched-Normal","RNAseq_probe_set_grc37, MethylationEPIC, RNAseq_probe_set_grc37, MethylationEPIC","Methylation (CpG), RNA Seq (NGS), WXS","4 phenotype datasets, 10 variables, 1 molecular datasets, 16 samples sequenced, 12 subjects, 17 samples","","NCI","GRU-PUB-COL-NPU --- General Research Use (PUB, COL, NPU)","2021-11-08","2021-11-08","Hepatoblastoma; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME",""
"phs002340.v1.p1","A Multi-Omic Single-Cell Atlas of Human Gynecological Malignancies","Matched single-cell transcriptomic sequencing (scRNA-seq) and single-cell chromatin accessibility sequencing (scATAC-seq) were performed for 11 fresh human tumors collected from the endometrium or ovary. More detailed information for each patient  tumor will be provided in selected phenotype/attributes data. Both scRNA-seq and scATAC-seq assays revealed the underlying cellular heterogeneity in","Not Applicable","Carcinoma, Ovarian Epithelial","Case Set","Not Provided","ATAC-seq, RNA-Seq","5 phenotype datasets, 18 variables, 22 samples sequenced, 11 subjects, 22 samples","","NCI","GRU --- General Research Use","2021-11-04","2021-11-04","Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian; Epithelial Cancer, Ovarian","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002346.v1.p1","Characterization of Immune-Related Gene Expression in Lung Cancer","We performed a comprehensive analysis of inter- and intratumor heterogeneity of immune gene expression in 160 lung cancer patients from the Environment And Genetics in Lung cancer Etiology (EAGLE) study.  The transcriptome was profiled with RNA sequencing in 269 tumor samples and 110 normal tissue samples from 160 subjects. Lung cancer cases only","Not Applicable","Lung Neoplasms","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 16 variables, 378 samples sequenced, 160 subjects, 378 samples","","NCI","DS-LDS-MDS --- Disease-Specific (Lung disease or smoking, MDS)","2021-11-03","2021-11-03","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs002407.v1.p1","A Single Cell Atlas of MMRd and MMRp Colorectal Cancer","Immune responses to cancer vary across cancer types and patients. Colorectal cancer tumors with mismatch repair-deficiency (MMRd) show an elevated immune cell activity as compared to mismatch repair proficient (MMRp)  tumors. To understand the immune response patterns in these two types of colorectal cancer, we transcriptionally profiled 371,223 tumor and adjacent","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","RNA-Seq","5 phenotype datasets, 40 variables, 181 samples sequenced, 62 subjects, 181 samples","","NCI","GRU --- General Research Use","2021-10-27","2021-10-27","Microsatellite Instability; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002434.v1.p1","Mentored Patient Oriented Research in Lymphoma","Significant racial differences have been observed in the incidence and clinical outcomes of diffuse large B-cell lymphoma (DLBCL) in the United States, but to the authors' knowledge it remains unclear  whether genomic differences contribute to these disparities. To understand the influences of genetic ancestry on tumor genomic alterations, the","Not Applicable","Lymphoma, Large B-Cell, Diffuse","Case Set","Not Provided","Not Provided","Not Provided","","NCI","","2021-10-18","","Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma",""
"phs002344.v1.p1","Study of Tumor Recurrence Related to the Expression of the PAX3-FOXO1    Oncogenic Transcription Factor in Fusion-Positive Rhabdomyosarcoma","Alveolar rhabdomyosarcoma (ARMS) is a highly aggressive pediatric soft tissue cancer characterized by a recurrent 2;13 chromosome translocation. This translocation generates a PAX3-FOXO1 (P3F) fusion gene, which encodes a chimeric  transcription factor with oncogenic activity. Using a human myoblast system that models targeted therapy directed against P3F, we demonstrated that","Not Applicable","Rhabdomyosarcoma","Case Set","custom_markerset","SNP/CNV (Array)","1 molecular datasets, 17 subjects, 17 samples","","NCI","GRU --- General Research Use","2021-10-14","2021-10-14","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001710.v1.p1","Transplant Outcomes in Aplastic Anemia (TOAA)","The TOAA study is a research collaboration between the National Cancer Institute and the Center for International Blood and Marrow Transplant Research. The study aims to identify molecular predictors of  outcomes after hematopoietic cell transplant in patients with severe aplastic anemia. Principal Investigator: Shahinaz Gadalla, MD, PhD, National","Not Applicable","Anemia, Aplastic","Prospective Longitudinal Cohort","Not Provided","SNP Genotypes (Array)","4 phenotype datasets, 15 variables, 1 molecular datasets,  SRA, 416 subjects, 416 samples","","NCI","DS-HCTCT-IRB --- Disease-Specific (Hematopoietic Cell Transplantation and Cell Therapy, IRB)","2021-10-07","2021-10-07","",""
"phs002001.v1.p1","Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance    Mechanisms in EGFR Mutant Lung Cancer","Current understanding of acquired resistance to osimertinib in EGFR-mutant lung cancer is largely based on the use of targeted sequencing platforms and cell-free DNA. In this study we examined the  clonal evolution and heterogeneity of acquired resistance mechanisms to osimertinib through whole exome and RNA-sequencing of prospectively collected","Not Applicable","Lung Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 19 variables, 133 samples sequenced, 15 subjects, 133 samples","","NCI","GRU --- General Research Use","2021-09-30","2021-09-30","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001027.v4.p1","Epigenomics Studies in Acute Myeloid Leukemia (AML)","Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease  that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through","Not Applicable","Leukemia, Myeloid, Acute","Tumor vs. Matched-Normal","target_markerset_grc37, WES_markerset_grc37, target_markerset_grc37, WES_markerset_grc37","Bisulfite-Seq, RNA-Seq, SNP/CNV Genotypes (NGS), Targeted-Capture, WGS, WXS","5 phenotype datasets, 29 variables, 1 molecular datasets, 910 samples sequenced, 155 subjects, 961 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2021-09-23","2021-05-18","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs001497.v2.p1","UCSF Adult Glioma Study","The UCSF Adult Glioma Study is a case-control study conducted at the University of California, San Francisco. The goals of the study were to discover inherited (genetic), developmental, immunologic and  other risk factors for glioma and to determine molecular level tumor markers that would be helpful in classifying glioma into more homogeneous","Not Applicable","Glioma","Case-Control","OncoArray, HumanCNV370-Duo, HumanMethylation450, OncoArray, HumanCNV370-Duo, HumanMethylation450","Methylation (CpG), SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 2 molecular datasets, 3173 subjects, 3173 samples","European (1842), African (1), East Asian (60), African American (69), Hispanic1 (20), Hispanic2 (93), Other Asian or Pacific Islander (41), South Asian (17), Other (32)","NCI","GRU --- General Research Use, DS-BT-CA-MDS --- Disease-Specific (Brain tumors and all cancer, MDS)","2021-09-22","2021-09-22","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs002421.v1.p1","Transcriptomic Profiling of Patient Derived Alternative Lengthening of    Telomeres (ALT) and Non-MYCN-Amplified Neuroblastoma Cell Lines","Patient derived neuroblastoma cell lines are excellent tools to study biology of the disease. While many previous studies sequenced neuroblastoma cell lines, there are very few ALT and non-MYCN-amplified neuroblastoma  cell lines that were sequenced previously. Here, we present raw RNA sequencing data for 3 ALT (CHLA-90, SK-N-FI, COG-N-515) and 8 non-MYCN-amplified","Not Applicable","Neuroblastoma","Collection","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS)","3 phenotype datasets, 14 variables, 1 molecular datasets, 11 samples sequenced, 11 subjects, 11 samples","","NCI","GRU --- General Research Use","2021-09-20","2021-09-20","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002545.v1.p1","Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable    (MSS) and Microsatellite Instable (MSI) High Colorectal and Pancreatic    Cancer","This is a single-arm, non-randomized, phase 2 trial (NCT03104439) combining radiation, ipilimumab and nivolumab in patients with metastatic MSS Colorectal Cancer (CRC; n 40) and Pancreatic Ductal Adenocarcinoma Cancer (PDAC;  n 25). Patients were previously treated population, and the primary endpoint was disease control rate. Pre- and post-treatment samples were subjected","Not Applicable","Immunotherapy","Case Set","Not Provided","WXS","5 phenotype datasets, 19 variables, 58 samples sequenced, 26 subjects, 72 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-09-17","2021-09-17","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001882.v1.p1","OncoArray: Follow-up of Ovarian Cancer Genetic Association and    Interaction Studies (FOCI)","The Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). FOCI represents a collective effort that builds upon the strengths and history of","Not Applicable","Carcinoma, Ovarian Epithelial","Case-Control","OncoArray-500K","SNP Genotypes (Array)","4 phenotype datasets, 49 variables, 1 molecular datasets, 50315 subjects, 50671 samples","European (38518), African (79), East Asian (6355), African American (1730), Hispanic1 (191), Hispanic2 (808), Other Asian or Pacific Islander (881), South Asian (244), Other (267)","NCI","GRU --- General Research Use, DS-BCEMOPCA-NPU-MDS --- Disease-Specific (Breast, Colorectal, Endometrial, Melanoma, Ovarian, and/or Prostate Cancer, NPU, MDS), DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), GRU-NPU --- General Research Use (NPU), GRU-PUB-NPU --- General Research Use (PUB, NPU), HMB --- Health/Medical/Biomedical, HMB-PUB --- Health/Medical/Biomedical (PUB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS), GRU-COL --- General Research Use (COL), CADM --- Cancer in all age groups, other diseases in adults only, and methods, DS-BROC --- Disease-Specific (Breast and Ovarian cancer), DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), DS-CA-MDS --- Disease-Specific (Cancer, MDS), OVCA --- Ovarian Cancer Only, DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2021-09-13","2021-09-13","Genital Neoplasms, Female; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002462.v1.p1","Circulating Tumor Cell Heterogeneity in Neuroendocrine Prostate Cancer by    Single Cell Copy Number Analysis","Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. Combined loss  of tumor suppressors RB1, TP53, PTEN are frequent in NEPC but also present in a subset of prostate adenocarcinomas. Most clinical and preclinical","Not Applicable","Prostatic Neoplasms","Case Set","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 13 variables, 1 molecular datasets, 215 samples sequenced, 12 subjects, 215 samples","","NCI","DS-PC-IRB --- Disease-Specific (Prostate Cancer, IRB)","2021-09-09","2021-09-09","Carcinoma, Neuroendocrine; NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic",""
"phs002377.v1.p1","A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed    Hematologic Malignancies After Allogeneic Hematopoietic Cell    Transplantation","Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is characterized by poor outcomes and novel therapeutic options are urgently needed. Immune checkpoint blockade using CTLA-4 and PD-1 blocking antibodies are  a potential concept for reinstating a dormant graft-versus-leukemia (GvL) effect.This study investigated transcriptomic changes in biopsies obtained","Not Applicable","Hematologic Neoplasms","Clinical Trial","Not Provided","RNA-Seq","3 phenotype datasets, 13 variables, 78 samples sequenced, 36 subjects, 78 samples","","NCI","HMB-COL --- Health/Medical/Biomedical (COL)","2021-09-03","2021-09-03","Relapse; HEMOLYMPHORETICULAR tumor, malignant; Hematopoietic Cancer; Hematopoietic Malignancies; Hematopoietic Malignancy; Hematopoietic Neoplasm",""
"phs002229.v1.p1","Germ Cell Tumor Molecular Heterogeneity Revealed through Analysis of    Primary and Metastasis Pairs","Purpose: While primary germ cell tumors (GCTs) have been extensively characterized, molecular analysis of metastatic sites has been limited. We performed whole-exome sequencing and targeted next-generation sequencing on paired primary  and metastatic GCT samples in a patient cohort enriched for cisplatin-resistant disease. Experimental Design: Tissue sequencing was performed on 100","Not Applicable","Neoplasms, Germ Cell and Embryonal","Case Set","Not Provided","WXS","4 phenotype datasets, 48 variables, 30 samples sequenced,  SRA, 10 subjects, 30 samples","","NCI","GRU --- General Research Use","2021-08-30","2021-08-30","Testicular Neoplasms; Germ Cell and Embryonal Neoplasms; Germ Cell and Embryonic Neoplasms; Neoplasms, Germ Cell and Embryonic; Neoplasm of Testis; Neoplasm of the Testis","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002056.v1.p1","Genetic Factors associated with Conversion from Active Surveillance to    Treatment for Prostate Cancer","This is a genome-wide association study (GWAS) of conversion from active surveillance (AS) for prostate cancer (PC) to treatment. AS is the monitoring with screening tests and/or biopsies over time  of men usually with low-risk, early-stage PC to avoid harmful side effects of PC treatment. ""Conversion"" refers to patients who withdraw from AS","Not Applicable","Prostatic Neoplasms","Case Set","Multi-Ethnic_Global, imputation_panel","SNP/CNV (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 57 variables, 2 molecular datasets, 6323 subjects, 6577 samples","European (5370), African (40), East Asian (134), African American (407), Hispanic1 (63), Hispanic2 (127), Other Asian or Pacific Islander (35), South Asian (91), Other (56)","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB-IRB-MDS --- Health/Medical/Biomedical (IRB, MDS), HMB-MDS --- Health/Medical/Biomedical (MDS), HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS), DS-PC --- Disease-Specific (Prostate Cancer), DS-PC-IRB-MDS --- Disease-Specific (Prostate Cancer, IRB, MDS), DS-PC-IRB-PUB-MDS --- Disease-Specific (Prostate Cancer, IRB, PUB, MDS), DS-PC-IRB-NPU-MDS --- Disease-Specific (Prostate Cancer, IRB, NPU, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-PC-PUB-MDS --- Disease-Specific (Prostate Cancer, PUB, MDS), DS-PC-PUB-NPU-MDS --- Disease-Specific (Prostate Cancer, PUB, NPU, MDS), GRU --- General Research Use","2021-08-25","2021-08-25","Death; Neoplasm Metastasis; Neoplasm Recurrence, Local; Deceased; End Of Life; End-Of-Life","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002437.v1.p1","Metformin for Oral Cancer Prevention","The M4OC-PREVENT clinical trial addressed whether metformin has utility in the prevention of oral cancer. It is a phase IIa clinical trial of metformin ER 2,000 mg per day given  for 12-14 weeks to individuals with oral premalignant lesions, either oral leukoplakia or erythroplakia (which are precursors to oral cancer). The","Not Applicable","Leukoplakia, Oral","Case Set","Not Provided","WXS","4 phenotype datasets, 22 variables, 34 samples sequenced, 17 subjects, 34 samples","","NCI","GRU --- General Research Use","2021-08-24","2021-08-24","Erythroplasia; Leukoplakia; Erythroplasias; erythroplakia; Keratotic Plaque; Lesion, Leukoplakic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001806.v1.p1","Kids First: Whole Genome Sequencing of Nonsyndromic Craniosynostosis","Nonsyndromic craniosynostosis (NCS) is a common, major structural birth defect - due to the premature fusion of one or more cranial sutures - that requires extensive surgical correction and is  associated with considerable ongoing medical problems and health care costs. Because little is known about the causes of NCS, whole genome sequencing","Not Applicable","Craniosynostoses","Cross-Sectional","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 974 subjects, 1036 samples","","NCI","GRU --- General Research Use, HMB-GSO --- Health/Medical/Biomedical (GSO)","2021-08-19","2021-08-19","Craniofacial Abnormalities; Abnormalities, Craniofacial; Abnormality, Craniofacial; Craniofacial Abnormality; CRANIOSTENOSIS; CRS","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002419.v1.p1","Integrative Molecular Characterization of Breast Cancer","We have performed integrative analyses of breast cancer tumors, including whole exome sequencing of tumor & normal pairs, whole transcriptome sequencing, and single-cell/nucleus RNA sequencing, to determine molecular correlates of  response to novel and immune therapies. We have focused on dissecting the role of anticancer immunity in response to these therapies and","Not Applicable","Breast Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 15 variables, 159 samples sequenced, 58 subjects, 159 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-08-18","2021-08-18","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001785.v1.p1","Gabriella Miller Kids First Pediatric Research Program for Infantile    Hemangiomas Associated with Multi-Organ Structural Birth Defects","Infantile hemangiomas are the most common benign vascular tumor in infants, affecting 4-5% of children. Thirty percent of segmental infantile hemangiomas on the face and scalp are associated with birth  defects of multiple organs. This condition is known as PHACE, an acronym for posterior fossa brain malformations, segmental facial hemangiomas,","Not Applicable","Hemangioma","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 274 subjects, 274 samples","","NCI","HMB --- Health/Medical/Biomedical, DS-PHACE --- Disease-Specific (PHACE Syndrome)","2021-08-17","2021-08-17","Abnormality of cardiac morphology; Abnormality of the heart; Abnormality, Heart; Abnormally shaped heart; Cardiac abnormalities; Cardiac abnormality","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002444.v1.p1","Germline Genetic Variants in Cancer-Susceptibility Genes in Patients with    Osteosarcoma","We conducted whole-exome sequencing of germline DNA from patients with osteosarcoma to estimate the frequency of pathogenic/likely pathogenic germline genetic variants in known cancer-susceptibility genes in a large population of  osteosarcoma patients unselected for family history. Osteosarcoma cases of all ages unselected for family history from 10 international centers or","Not Applicable","Osteosarcoma","Case Set","Not Provided","WXS","4 phenotype datasets, 13 variables, 720 samples sequenced, 720 subjects, 720 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-08-11","2021-08-11","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002436.v1.p1","Transcriptome and Epigenome of TIL Infusion for Cancer Immunotherapy","Adoptive T cell therapy (ACT) using ex vivo&#x02013;expanded autologous tumor-infiltrating lymphocytes (TILs) can mediate complete regression of certain human cancers. The impact of TIL phenotypes on clinical success of TIL-ACT  is currently unclear. Samples were analyzed from TIL infusion products from metastatic melanoma human patients who responded to TIL-ACT (responders)","Not Applicable","Melanoma","Case Set","Not Provided","ATAC-seq, RNA-Seq","4 phenotype datasets, 15 variables, 36 samples sequenced, 13 subjects, 36 samples","","NCI","GRU --- General Research Use","2021-07-21","2021-07-21","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002311.v1.p1","GATA2 Deficiency","The aim of this study is to identify somatic mutations that contribute to the progression of GATA2 Deficiency patients from bone marrow failure to myelodysplastic syndrome (MDS) to acute myeloid  leukemia (AML) or chronic myelomonocytic leukemia (CMML). We investigated somatic mutations in 100 patients by whole exome and myeloid malignancy","Not Applicable","Neoplasms","Case Set","other","SNV (.MAF), Targeted-Capture, WXS","5 phenotype datasets, 21 variables, 1 molecular datasets, 294 samples sequenced, 106 subjects, 294 samples","","NCI","GRU --- General Research Use","2021-07-09","2021-07-09","Immune System Diseases; Disease, Immune; Disease, Immune System; Disease, Immunologic; Disease, Immunological; Diseases of Immune System","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002394.v1.p1","Chromatin Accessibility Landscape of Human Pancreatic Ductal    Adenocarcinoma (PDAC)","Therapeutic options in pancreatic ductal adenocarcinoma (PDAC) are largely limited to cytotoxic chemotherapy without the benefit of molecular markers predicting response. By ATAC-seq analyses of EpCAM+ PDAC malignant epithelial cells  sorted from 54 freshly resected human tumors, we discovered a signature of 1092 chromatin loci displaying differential accessibility between patients","Not Applicable","Pancreatic Neoplasms","Case Set","Not Provided","ATAC-seq, OTHER","5 phenotype datasets, 28 variables, 174 samples sequenced, 53 subjects, 174 samples","","NCI","DS-PACA-PUB --- Disease-Specific (Pancreatic Cancer, PUB)","2021-07-08","2021-07-08","Recurrence; Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas",""
"phs002002.v1.p1","Landscape of Intratumoral NK Cell and ILC in Head and Neck Squamous Cell    Carcinoma","In this study, total innate lymphoid cells (ILCs), including natural killer (NK) cells, were FACS-sorted from eight dissociated primary head and neck squamous cell carcinoma (HNSCC) tumors. In addition, ILCs  and NK cells were sorted from peripheral blood of tumor patients. The ILCs and NK cells were analyzed by single-cell RNA sequencing (scRNA-seq) using","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 2747 samples sequenced, 8 subjects, 2747 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2021-07-07","2021-07-07","Pharyngeal Neoplasms; Tongue Neoplasms; Neoplasia of the pharynx; Neoplasm of Pharynx; Neoplasm of the Pharynx; Neoplasm, Pharyngeal",""
"phs000720.v4.p1","Genomic sequencing of Pediatric Rhabdomyosarcoma","Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood accounting for approximately 350 newly diagnosed cases yearly in the United States. With the development of multimodal chemotherapy regimens,  relapse-free survival rates have improved to 70-80% in patients with localized disease albeit with significant toxicity. Unfortunately, despite","Not Applicable","Rhabdomyosarcoma","Case Set","HumanOmni2.5-4, HumanOmni2.5-4, HumanOmni2.5-4, HumanOmni2.5-8, HumanOmni5-4","SNP Genotypes (Array), RNA-Seq, Targeted-Capture, WGS, WXS","4 phenotype datasets, 18 variables, 1 molecular datasets, 953 samples sequenced,  SRA, 807 subjects, 953 samples","","NCI","GRU-PUB-MDS --- General Research Use (PUB, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2021-07-02","2019-10-07","Rhabdomyosarcoma, Alveolar; Rhabdomyosarcoma, Embryonal; Alveolar Rhabdomyosarcomas; Alveolar rhabdomyosarcoma (disease); Monomorphous Round Cell Rhabdomyosarcoma; RHABDOMYOSARCOMA 2",""
"phs002034.v1.p1","Genomic Evolution of Low- and High-Grade Glioma","Malignant transformation (MT) of IDH-mutant low-grade glioma (LGG) to aggressive high-grade tumors is an event of major clinical significance, eventually leading to death in the majority of LGG patients. While  patients with primary glioblastoma (GBM) have benefited from increased overall survival due to treatment with the alkylating chemotherapy","Not Applicable","Glioma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 17 variables, 157 samples sequenced,  SRA, 42 subjects, 157 samples","","NCI","HMB-MDS-GSO --- Health/Medical/Biomedical (MDS, GSO)","2021-07-01","2021-07-01","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs001163.v1.p1","CRU-Ukrainian National Research Center for Radiation Medicine Trio Study","Data on transgenerational effects following nuclear accidents are important for understanding fully the consequences of parental exposure to ionizing radiation. Few studies to date have had adequate statistical power to  detect effects of the magnitude expected based on animal data, and most have not been of low-dose, protracted exposures associated with nuclear","Not Applicable","Germ-Line Mutation","Family/Twin/Trios","Not Provided","Not Provided","5 phenotype datasets, 27 variables,  SRA, 340 subjects, 340 samples","","NCI","GRU --- General Research Use","2021-06-17","2021-06-17","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002398.v1.p1","Genomics of Prostate Cancer","This dataset includes genomic data from patients with prostate cancer. Specimens include archival active surveillance biopsies, radical prostatectomy specimens selected based on evidence of PD-L1 expression and/or T lymphocyte infiltrates,  and rapid autopsy material from patients deceased of prostate cancer. These data include low pass whole genome sequencing and targeted sequencing","Not Applicable","Prostatic Neoplasms","Cross-Sectional","Not Provided","OTHER, WGS","4 phenotype datasets, 21 variables, 129 samples sequenced, 43 subjects, 129 samples","","NCI","GRU --- General Research Use","2021-06-11","2021-06-11","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001327.v2.p1","Childhood Cancer Survivor Study (CCSS)","Background and Rationale for the Childhood Cancer Survivor Study (CCSS) Over the last several decades, advances in treatments for childhood and adolescent cancer have substantially improved survival following diagnosis. These  improvements gave rise to the responsibility for investigating long-term treatment-associated morbidity and mortality. Early efforts to describe late","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","imputation_panel","SNP/CNV Genotypes (imputed)","21 phenotype datasets, 1158 variables, 6 documents, 1 molecular datasets, 30716 subjects, 11363 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2021-06-04","2021-06-04","Bone Diseases; Cardiovascular Diseases; Cognitive Dysfunction; Dwarfism, Pituitary; Heart Failure; Infertility","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002176.v2.p1","Notch Signaling and Efficacy PD-1/PD-L1 Blockade in Relapsed Small Cell    Lung Cancer","Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine (NE) cancer that accounts for approximately 15% of all lung cancer, with an annual incidence of more than 34,000 in  the United States alone. SCLC is characterized by loss of function of p53 and RB and high tumor mutational burden, which suggests that these tumors","Not Applicable","Small Cell Lung Carcinoma","Clinical Trial","Not Provided","OTHER, RNA-Seq, WXS","4 phenotype datasets, 20 variables, 101 samples sequenced, 38 subjects, 101 samples","","NCI","GRU --- General Research Use","2021-06-01","2021-03-09","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002408.v1.p1","The Role of CTCF in the Organization of the Centromeric 11p15 Imprinted    Domain Interactome","Beckwith-Wiedemann Syndrome (BWS) is the most common human imprinting disorder and comprises a spectrum of overgrowth phenotypes. While approximately 35% of BWS cases are caused by isolated loss of methylation  (LOM) at the human imprinting center 2 (IC2) on chromosome 11p15, only around 5% of patients develop BWS due to structural alterations to the IC2","Not Applicable","Beckwith-Wiedemann Syndrome","Case-Control","target_markerset_grc38","ChIP_Seq (NGS), WGS","4 phenotype datasets, 11 variables, 1 molecular datasets, 2 samples sequenced, 7 subjects, 9 samples","","NCI","GRU-PUB-COL-NPU --- General Research Use (PUB, COL, NPU)","2021-05-27","2021-05-27","BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME; EMG Syndromes",""
"phs001500.v2.p1","National Cancer Institute (NCI) Primary Human Melanocyte QTL Study","In order to create a melanocyte-specific QTL resource, we obtained primary human melanocyte cultures isolated from foreskin of 106 healthy newborn males predominantly of European descent. Melanocytes were cultured in  lot-matched culture medium in randomized batches to minimize variability that could be introduced by culturing conditions. RNA sequencing and direct","Not Applicable","Melanocytes","Methods","RNAseq_probe_set_grc37, HumanOmniExpress-24, HumanMethylation450","Methylation (CpG), SNP Genotypes (Array), RNA-Seq, RNA Seq (NGS)","5 phenotype datasets, 26 variables, 3 molecular datasets, 106 samples sequenced,  SRA, 106 subjects, 106 samples","","NCI","GRU --- General Research Use","2021-05-27","2021-05-27","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1)"
"phs002387.v1.p1","Ghana Breast Health Study","The Ghana Breast Health Study (GBHS) was a multi-disciplinary, population-based case-control study conducted in Accra and Kumasi, Ghana that was designed to investigate breast cancer etiology in the West Africa  region. The study enrolled 1,126 invasive breast cancer cases and 2,106 frequency matched population-based controls using census-based sampling. GHBS","Not Applicable","Breast Neoplasms","Case-Control","Global_Screening_Array-24","SNP/CNV (Array)","4 phenotype datasets, 23 variables, 1 molecular datasets, 2529 subjects, 2529 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-05-20","2021-05-20","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001800.v2.p1","Genomics of Pediatric Renal Medullary Carcinomas","Version 1 We derived faithful cancer cell lines from patients with a diagnosis of renal medullary carcinomas (RMC). These models have been sequenced with whole genome, exome and transcriptome technologies  along with the patient's primary germline and tumor samples. We took these faithful models and performed loss-of-function genetic perturbation","Not Applicable","SMARCB1 Protein","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 14 variables, 30 samples sequenced, 15 subjects, 30 samples","","NCI","HMB --- Health/Medical/Biomedical, DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use","2021-05-20","2019-06-14","Kidney Neoplasms; Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001825.v1.p1","Study of 5'UTR Mutations in Prostate Cancer","The 5' untranslated region (5' UTR) of mRNA controls the translation of specific transcripts through encoded cis-regulatory elements. Yet exceedingly little is known about the prevalence and function of 5'  UTR mutations in cancer. We have uncovered many 5' UTR mutations in our analysis of localized and castration resistant prostate cancer patients, and","Not Applicable","Prostatic Neoplasms","Xenograft","Not Provided","WXS","4 phenotype datasets, 25 variables, 164 samples sequenced,  SRA, 82 subjects, 164 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2021-05-19","2021-05-19","Prostatic Neoplasms, Castration-Resistant; NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic",""
"phs001474.v1.p1","Single Cell RNA-Seq Reveals Malignant and Stromal Programs Associated    with Metastasis in Head and Neck Cancer","This study of head and neck cancer aimed to profile individual malignant, stromal, and immune cells in treatment-naive oral cavity squamous cell carcinoma, with or without matched metastatic cervical lymph  nodes. Clinical and pathologic information was collected on all patients, in addition to a fresh biopsy sample from the primary tumor and/or","Not Applicable","Carcinoma, Squamous Cell","Prospective Longitudinal Cohort","Somatic_Variant","RNA-Seq, SNP Genotypes (NGS), WXS","4 phenotype datasets, 29 variables, 1 molecular datasets, 24 samples sequenced,  SRA, 18 subjects, 24 samples","","NCI","GRU --- General Research Use","2021-05-18","2021-05-18","Neoplasm Metastasis; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002304.v1.p1","Germline and Somatic Genetic Landscape of Pediatric Rhabdomyosarcoma","Dynamic approaches that integrate population-based research and molecular biology are needed to explain the mechanisms underlying pediatric rhabdomyosarcoma (RMS) and to determine novel prevention strategies. RMS, the most common soft-tissue  sarcoma in children and adolescents, has one of the poorest 5-year survival rates among all pediatric cancers (less than 65%). One of the strongest","Not Applicable","Rhabdomyosarcoma","Case Set","Not Provided","WXS","4 phenotype datasets, 15 variables, 621 samples sequenced, 621 subjects, 621 samples","","NCI","GRU --- General Research Use","2021-05-12","2021-05-12","Sarcoma; Blastoma; CA; CA - Cancer; Cancer; MT","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001404.v1.p1","Molecular Profiling of Gallbladder Cancer (MPOG)","The purpose of this study is to investigate the underlying genetic factors involved in gallbladder cancer. All cases from the Shanghai Biliary Cancer Study and the Chile Gallbladder Cancer Pilot  Study with fresh frozen tissue that were included in the molecular profiling analysis. Principal Investigator: Jill Koshiol, PhD, National Institutes","Not Applicable","Gallbladder Neoplasms","Case Set","MethylationEPIC, MethylationEPIC","CNV Genotypes, Methylation (CpG), RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 157 variables, 2 molecular datasets, 274 samples sequenced,  SRA, 158 subjects, 433 samples","","NCI","GRU --- General Research Use","2021-05-10","2021-05-10","Gallbladder Cancer; Bladder Cancer, Gall; Bladder Cancers, Gall; Cancer of Gallbladder; Cancer of the Gallbladder; Cancer, Gall Bladder","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001942.v1.p1","Molecular Genetics of Secondary Histiocytic/Dendritic Sarcoma","This is a comprehensive genomic analysis of a rare set of secondary histiocytic/dendritic sarcomas from the consult service of the Hematopathology section of the Laboratory of Pathology, NCI, NIH. All  archived consult cases with a confirmed pathologic diagnosis of secondary histiocytic/dendritic sarcoma were eligible for this study. Principal","Not Applicable","Histiocytic Sarcoma","Case Set","WGS_markerset_grc38","SNV (.MAF), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 19 samples sequenced, 16 subjects, 19 samples","","NCI","GRU --- General Research Use","2021-05-05","2021-05-05","Histiocytic Lymphoma, True; Histiocytic Lymphomas, True; Histiocytic Sarcomas; Histiocytoses, True Malignant; Histiocytosis, True Malignant; Lymphoma, True Histiocytic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001982.v1.p1","Rb and p53-Deficient Pleomorphic Myofibroblastic Sarcomas Require Skp2","Myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) are highly genetically complex soft tissue sarcomas. Up to 50% of patients develop distant metastases, but current systemic therapies have limited efficacy. MFS  and UPS have recently been shown to commonly harbor copy number alterations or mutations in the tumor suppressor genes RB1 and TP53. As these","Not Applicable","Sarcoma","Case Set","Not Provided","WXS","5 phenotype datasets, 16 variables, 62 samples sequenced,  SRA, 62 subjects, 62 samples","","NCI","GRU --- General Research Use","2021-04-23","2021-04-23","Histiocytoma, Malignant Fibrous; Sarcoma, Soft Tissue; Fibrohistiocytic Tumor, Malignant; Fibrohistiocytic Tumors, Malignant; Fibrous Histiocytoma, Malignant; Fibrous Histiocytomas, Malignant","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002061.v1.p1","Genomic Damage in HIV-Uninfected Children with In Utero Zidovudine    Exposure","Zidovudine (ZDV) is a nucleoside reverse transcriptase inhibitor (NRTI) which competitively inhibits HIV reverse transcriptase and is incorporated into the viral DNA, resulting in DNA chain termination. It was the  first approved antiretroviral medication used for preventing HIV transmission from mother to child. However, in vitro and animal studies have","Not Applicable","HIV","Prospective Longitudinal Cohort","WES_markerset_grc38","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 11 variables, 1 molecular datasets, 185 samples sequenced,  SRA, 186 subjects, 364 samples","European (14), African (7), African American (68), Hispanic1 (42), Hispanic2 (24), Other Asian or Pacific Islander (3), Other (21)","NCI","DS-HIV-COL --- Disease-Specific (Human Immunodeficiency Virus, COL)","2021-04-22","2021-04-22","Not Provided",""
"phs002301.v1.p1","Whole Genome Sequencing of Skull-Based Chordoma","Chordoma is a rare bone tumor, which is believed to originate from notochordal remnants. Based on the United States Surveillance Epidemiology and End Results (SEER) data, the incidence of chordoma  varies by gender and race; however, little is known about the etiologic factors that predispose to it. Genomic profiling studies of chordoma are","Not Applicable","Chordoma","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 14 variables, 198 samples sequenced, 80 subjects, 198 samples","","NCI","DS-CHR --- Disease-Specific (Chordoma)","2021-04-14","2021-04-14","CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to",""
"phs001349.v2.p1","Identification of 22 Novel Loci Associated with Susceptibility to    Testicular Germ Cell Tumors","Testicular germ cell tumors (TGCT) are the most common cancers in young men of European ancestry aged 20 to 39 years. The Testicular Cancer Consortium (TECAC) has brought together the  largest genome-wise association study (GWAS) study of TGCT to date. We conducted a GWAS of 5,602 cases and 5,006 controls aggregated from 12","Not Applicable","Testicular Germ Cell Tumor","Case-Control","HumanCore-24_plus","SNP Genotypes (Array)","4 phenotype datasets, 27 variables, 1 documents, 2 analyses, 1 molecular datasets, 10608 subjects, 10608 samples","European (10576), Hispanic1 (11), Hispanic2 (4), South Asian (1), Other (16)","NCI","DS-TGCT-PUB-MDS --- Disease-Specific (Testicular Cancer, PUB, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB --- Health/Medical/Biomedical, DS-TGCT-MDS --- Disease-Specific (Testicular Cancer, MDS)","2021-04-14","2022-10-03","Cryptorchidism; Nonseminomatous germ cell tumor; Cryptorchidism (unilateral or bilateral); Cryptorchidism, Unilateral Or Bilateral; Cryptorchism; IDT - Imperfectly descended testis","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001120.v2.p2","ELLIPSE Prostate Cancer Meta-Analysis and Genotyping","The ELLIPSE Consortium is an international effort to discover risk loci for prostate cancer. It includes the meta-analysis of existing GWAS data as well as novel GWAS, exome, and iCOGS  genotyping. The GWAS meta-analysis includes the following cases and controls from studies of European ancestry: UK GWAS stage 1 (Illumina Infinium","Not Applicable","Prostatic Neoplasms","Case-Control","OncoArray, HumanExome-12, HumanOmni2.5-8","Not Provided","2 phenotype datasets, 10 variables, 5 analyses, 12947 subjects, 12947 samples, 2 substudies","","NCI","DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-PC --- Disease-Specific (Prostate Cancer)","2021-04-14","2017-03-31","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001125.v2.p2","ELLIPSE Prostate Cancer Genotyping","The Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium is an international effort to discover risk loci for prostate cancer. The following de novo genotyping was performed. The OMNI  2.5M genotyping was conducted for 977 prostate cancer cases from UKGPCS. The Exome SNP array genotyping was conducted for 4741 subjects from UKGPCS.","ELLIPSE Prostate Cancer Meta-Analysis and Genotyping (phs001120.v2.p2)","Prostatic Neoplasms","Case-Control","OncoArray, HumanExome-12, HumanOmni2.5-8","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 3 molecular datasets, 12947 subjects, 12947 samples","European (11012), African (4), East Asian (1), African American (12), Hispanic1 (13), Hispanic2 (2), South Asian (12), Other (16)","NCI","DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-PC --- Disease-Specific (Prostate Cancer)","2021-04-14","2017-03-31","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001081.v2.p2","ELLIPSE Prostate Cancer Meta-Analysis","The Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium is an international effort to discover risk loci for prostate cancer. It includes the meta-analysis of existing GWAS data. The  GWAS meta-analysis includes the following cases and controls from studies of European ancestry: UK GWAS stage 1 (Illumina Infinium HumanHap 550","ELLIPSE Prostate Cancer Meta-Analysis and Genotyping (phs001120.v2.p2)","Prostatic Neoplasms","Case-Control","Not Provided","Not Provided","2 analyses","","NCI","DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-PC --- Disease-Specific (Prostate Cancer)","2021-04-14","2017-03-31","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001307.v1.p1","Inherited Genetic Variation and Predisposition to Testicular Germ Cell    Tumor: UPenn Local TGCT Study","Testicular germ cell tumors (TGCT) are the most common cancer in men ages 20-40. The incidence of TGCT has more than doubled over the past forty years, without clear etiology.  Both genetic effects and environmental exposures, specifically during the pre-natal period, are likely to play an important role in determining TGCT","Not Applicable","Testicular Germ Cell Tumor","Case-Control","Not Provided","SNP Genotypes (Array)","4 phenotype datasets, 40 variables, 1 molecular datasets, 1397 subjects, 1400 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2021-04-13","2021-04-13","Seminoma",""
"phs002365.v1.p1","Derivation and Investigation of The First Human Cell-Based Model of    Beckwith-Wiedemann Syndrome","Beckwith-Wiedemann Syndrome (BWS) is the most common human imprinting disorder, and phenotypes include hepatomegaly and hepatoblastoma development. In approximately 20% of patients, this syndrome is caused by uniparental isodisomy of  the paternal allele across chromosome 11p15 (pUPD11). From fibroblasts cultured from 2 BWS patients with pUPD11, we derived induced pluripotent stem","Not Applicable","Beckwith-Wiedemann Syndrome","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 10 variables, 18 samples sequenced, 4 subjects, 18 samples","","NCI","GRU --- General Research Use","2021-04-07","2021-04-07","BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME; EMG Syndromes","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001819.v2.p1","Whole Genome Sequencing to Discover Familial Myeloma Risk Genes","We identified germline KDM1A truncating mutations in patients with multiple myeloma (MM), and loss of heterozygosity (LOH) in tumors. KDM1A mutation burden is higher in sporadic MM patients than in  controls, and mRNA levels are lower in MM compared with normal plasma cells. KDM1A pharmacological inhibition in vitro promotes myeloma cell","Not Applicable","Multiple Myeloma","Case Set","WES_markerset_grc37","SNP Genotypes (NGS)","4 phenotype datasets, 15 variables, 1 molecular datasets, 39 subjects, 39 samples","","NCI","GRU --- General Research Use, DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2021-03-31","2019-12-13","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001697.v1.p1","Integrative Analysis of Lung Adenocarcinoma in Never Smokers","We performed whole genome sequencing of lung cancers from never smoker subjects from Institut universitaire de cardiologie et de pneumologie de Qu&#x000e9;bec - Universit&#x000e9; Laval (IUCPQ-UL) (N 125), Universit&#x000e9; C&#x000f4;te  d'Azur (Nice) (N 47), the Environment And Genetics in Lung cancer Etiology (EAGLE) study (N 27), Yale University (N 22), and Moffitt Cancer Cente (N","Not Applicable","Lung Neoplasms","Case Set","Not Provided","WGS","4 phenotype datasets, 21 variables, 464 samples sequenced,  SRA, 232 subjects, 464 samples","","NCI","DS-LD --- Disease-Specific (Lung Disease), DS-LDS-MDS --- Disease-Specific (Lung disease or smoking, MDS), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB)","2021-03-31","2021-03-31","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002313.v1.p1","Copy-Number Analysis of Understudied Black Women Ovarian Cancers","Two general types of genetic alterations drive cancer progression: mutations and copy number alterations (CNAs). With the exception of p53, single nucleotide variant mutations (here, simply ""mutations"") are not drivers  of 80% of tumors within the most frequent and deadly histotype of ovarian cancer: serous ovarian cancer (SOC). Rather, CNAs are more prevalent in SOC","Not Applicable","Neoplasms","Case Set","WGS_markerset_grc37","CNV Genotypes, WXS","4 phenotype datasets, 18 variables, 1 molecular datasets, 21 samples sequenced, 20 subjects, 21 samples","","NCI","GRU --- General Research Use","2021-03-23","2021-03-23","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002089.v1.p1","Dynamics of Genomic and Immune Responses During Primary Immunotherapy    Resistance in Mismatch Repair Deficient Tumors","We study a patient with dMMR lung cancer refractory to immunotherapy. Post-treatment tumor demonstrated compound heterozygous frameshift deletions located upstream of the kinase domain in the gene encoding JAK1 protein,  downregulation of JAK1 and mediators of its signal transduction, and total loss of JAK1 phosphorylation. Importantly, one of the JAK1 mutations,","Not Applicable","Small Cell Lung Carcinoma","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 16 variables, 6 samples sequenced, 1 subjects, 6 samples","","NCI","GRU --- General Research Use","2021-03-23","2021-03-23","Turcot syndrome; Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002273.v1.p1","Analysis of Recurrently Protected Genomic Regions in Urine Cell-Free DNA","This study investigated fragmentation patterns in urine and plasma cell-free DNA and evaluated the relevance of such analysis for cancer diagnostics using urine samples. Specifically, we performed whole-genome sequencing at  variable depths and evaluated genome-wide coverage in urine and plasma samples, relative to known genome annotation features. Tumor/germline exome","Not Applicable","Cell-Free Nucleic Acids","Methods","Not Provided","WGS, WXS","3 phenotype datasets, 13 variables, 89 samples sequenced, 60 subjects, 89 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2021-03-22","2021-03-22","Not Provided",""
"phs001264.v1.p1","A Super-Enhancer Associated with CD47 in Breast Cancer","CD47 is a cell surface molecule that inhibits phagocytosis of cells that express it by binding to its receptor, SIRP&#x003b1;, on macrophages and other immune cells. CD47 is expressed at  different levels in normal cells, however, in cancer cells, CD47 transcript and protein expression is aberrantly increased. Here we sought to uncover","Not Applicable","Breast Neoplasms","Xenograft","Not Provided","ChIP-Seq","4 phenotype datasets, 24 variables, 4 samples sequenced,  SRA, 4 subjects, 4 samples","","NCI","GRU --- General Research Use, DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS)","2021-03-17","2021-03-17","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001374.v2.p1","VA APOLLO Project - Research for Precision Oncology (RePOP)","The Research for Precision Oncology Program (RePOP) is a research activity that establishes a cohort of Veterans diagnosed with cancer and who have had genomic analyses performed on their tumor  tissue as part of standard of care. All data relevant to a patient's cancer and cancer care will be collected under RePOP, including patient","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 170 subjects, 170 samples","","NCI","GRU --- General Research Use","2021-03-15","2018-08-22","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002295.v1.p1","Cross-site Concordance Evaluation of Tumor DNA and RNA Sequencing    Platforms of CIMAC-CIDC Network","The Cancer Immune Monitoring and Analysis Centers (CIMACs) and the Cancer Immunologic Data Commons (CIDC)&#x000a0; has engaged in efforts to harmonize Whole-exome (WES) and RNA-sequencing (RNA-seq) data from three different  experimental platforms (MD Anderson, NCI MoCha lab, and Broad Institute) and are using a series of developed pipelines to process the early trial","Not Applicable","Carcinoma, Non-Small-Cell Lung","Case Set","WES_markerset_grc38, RNAseq_probe_set_grc38","SNV (.MAF), RNA Seq (NGS)","3 phenotype datasets, 12 variables, 2 molecular datasets, 8 subjects, 234 samples","","NCI","GRU --- General Research Use","2021-03-11","2021-03-11","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002252.v1.p1","Cellular and Molecular Characterization of Renal Cell Carcinoma","We are performing a comprehensive cellular and molecular characterization of renal cell carcinoma. This work includes an initial cohort of patients whose tumors (and adjacent normal tissue) underwent single cell  analysis. Single-cell RNA sequencing (scRNA-seq) and TCR sequencing (scTCR-seq) analysis of untreated clear cell renal cell carcinoma tumor and","Not Applicable","Carcinoma, Renal Cell","Tumor vs. Matched-Normal","Not Provided","OTHER, WXS","4 phenotype datasets, 21 variables, 52 samples sequenced, 13 subjects, 53 samples","","NCI","DS-RCCA-MDS --- Disease-Specific (Renal Cell Carcinoma, MDS)","2021-03-11","2021-03-11","Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell",""
"phs002342.v1.p1","Optimized Polyepitope Neoantigen DNA Vaccines Elicit Neoantigen-Specific    Immune Responses in Preclinical Models and in Clinical Translation","A patient with Lynch syndrome and a neuroendocrine tumor sequenced with exome, whole genome, and bulk RNAseq. Sequence data was used to create a personalized cancer vaccine. Principal Investigator: William  Gillanders, MD, Washington University School of Medicine, St Louis, MO, USA","Not Applicable","Carcinoma, Neuroendocrine","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 16 variables, 5 samples sequenced, 1 subjects, 5 samples","","NCI","GRU --- General Research Use","2021-03-09","2021-03-09","","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002335.v1.p1","Dana-Farber Cancer Institute (DFCI) Wu Lab/Avicenne CLL RNA-Seq Study","Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by accumulation of CD5+ B cells in peripheral lymphoid organs, bone marrow and blood. Recently, the advent of large-scale whole-exome sequencing  of hundreds of CLL samples has led to gain a comprehensive understanding of the mutational landscape of this clonal B cell malignancy, but the","Not Applicable","Leukemia","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 14 samples sequenced, 12 subjects, 14 samples","","NCI","HMB-NPU-MDS --- Health/Medical/Biomedical (NPU, MDS)","2021-03-09","2021-03-09","Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias",""
"phs002334.v1.p1","Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic    Response In Vivo","Oncogenic alterations in EGFR frequently co-occur with additional genetic alterations in EGFR-driven lung adenocarcinoma (LUAD), but how specific combinations of mutations affect tumor phenotypes and responses to targeted therapy is  yet unknown. We leveraged a genetically engineered mouse model of EGFR mutant/Trp53-deficient LUAD to study the consequences of inactivating 10","Not Applicable","Adenocarcinoma of Lung","Collection","Not Provided","WXS","4 phenotype datasets, 20 variables, 78 samples sequenced, 29 subjects, 78 samples","","NCI","DS-LCTC-MDS --- Disease-Specific (Lung Cancer and Thoracic Malignancies, MDS)","2021-03-09","2021-03-09","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs002210.v1.p1","Comprehensive Analysis of Structural Variants in Breast Cancer Genomes    Using Single Molecule Sequencing","This study used the SKBR3 breast cell line and tumor/normal organoids derived from breast tissue to explore the utility of long read sequencing for detecting structural variants in complex samples.  Three technologies were used to characterize the samples: Illumina/10X, Pacific Biosciences, and Oxford Nanopore. Methylation results were derived","Not Applicable","Breast Neoplasms","Case Set","target_markerset_grc38","CNV (NGS), WGS","4 phenotype datasets, 15 variables, 1 molecular datasets, 7 samples sequenced, 2 subjects, 7 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2021-03-05","2021-03-05","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs002065.v1.p1","Integrative Somatic and Germline Molecular Characterization of    Genitourinary Cancers","We have performed integrative bulk (whole exome sequencing of tumor and normal paired and whole transcriptome sequencing) and single cell analysis of primary and metastatic non-prostate genitourinary cancer specimens, such  as renal and bladder tumors. Principal Investigator: Eliezer M. Van Allen, MD, Dana-Farber Cancer Institute, Boston, MA, USA Funding Sources: R37","Not Applicable","Urinary Bladder Neoplasms","Case-Control","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 17 variables, 18 samples sequenced, 8 subjects, 18 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-03-05","2021-03-05","Bladder Neoplasms; Kidney Neoplasms; Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002294.v1.p1","Evolution of Core Archetypal Phenotypes in High-Grade Serous Ovarian    Cancer (HGSOC)","The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells in response to chemotherapy is only partially understood. To uncover phenotypic changes associated with chemotherapy resistance, we performed single-cell  RNA-sequencing (scRNA-seq) or whole-genome sequencing of 23 total patients, with longitudinal samples collected from 9, treatment-na&#x000ef;ve","Not Applicable","Ovarian Neoplasms","Tumor vs. Matched-Normal","Not Provided","OTHER, WGS","3 phenotype datasets, 11 variables, 72 samples sequenced, 23 subjects, 72 samples","","NCI","GRU --- General Research Use","2021-03-04","2021-03-04","Carcinoma, Ovarian Epithelial; Cancer, Epithelial Ovarian; Cancer, Ovarian Epithelial; Carcinoma of Ovary; Carcinoma of the Ovary; Carcinoma, Epithelial Ovarian","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001935.v1.p1","National Cancer Institute Clinical and Laboratory Analysis of Familial    Cancer","The purpose of this study is to continue the analysis begun on 09C0079 which was focused on identification of the genetic mutation associated with a new gastric polyposis syndrome, Gastric  Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS). GAPPS, first described in 2012, is an autosomal dominant gastric polyposis syndrome","Not Applicable","Stomach Neoplasms","Case Set","Not Provided","WXS","5 phenotype datasets, 24 variables, 6 samples sequenced,  SRA, 6 subjects, 12 samples","","NCI","GRU --- General Research Use","2021-03-03","2021-03-03","Adenocarcinoma; Polyposis, Gastric; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs002289.v1.p1","Yale SPORE in Skin Cancer Project 2","Understanding the relationship between tumor and peripheral immune environments could allow longitudinal immune monitoring in cancer. Here, we examined whether T cells that share the same TCRab and are found  in both tumor and blood can be interrogated to gain insight into the ongoing tumor T cell response. Paired transcriptome and TCRab repertoire of","Not Applicable","Single-Cell Analysis","Case Set","RNAseq_probe_set_grc38","RNA-Seq, RNA Seq (NGS)","5 phenotype datasets, 29 variables, 1 molecular datasets, 26 samples sequenced, 13 subjects, 50989 samples","","NCI","HMB --- Health/Medical/Biomedical","2021-02-26","2021-02-26","Not Provided","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002327.v1.p1","Therapeutic Targeting of ATR Yields Durable Regressions in High    Replication Stress Tumors","Patients with relapsed or recurrent small cell lung cancer or extra-pulmonary small cell cancers were enrolled on an investigator-initiated, single-arm, phase 2 trial (NCT02487095) combining an ATR inhibitor M6620 (VX-970,  berzosertib) administered at 210 mg/m2 intravenously over 60 minutes on day 2 and day 5, and topotecan 1.25 mg/m2 intravenously over 30 minutes every","Not Applicable","Small Cell Lung Carcinoma","Clinical Trial","RNAseq_gene_transcripts, other, RNAseq_gene_transcripts, other, other","RNA-Seq, SNV (.MAF), RNA Seq (NGS), MAF (NGS), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 24 samples sequenced, 24 subjects, 24 samples","","NCI","GRU --- General Research Use","2021-02-22","2021-02-22","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001140.v1.p1","ALCHEMIST Study","The ALCHEMIST study will accrue patients that are potentially eligible for the Intergroup adjuvant studies and perform central EGFR and ALK genotyping using a central reference laboratory certified by the  Clinical Laboratory Improvement Amendments of 1988 (CLIA). Patients may either present prior to surgery with resectable NSCLC, may present following","Not Applicable","Carcinoma, Non-Small-Cell Lung","Case Set","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 5731 subjects, 5731 samples","","NCI","GRU --- General Research Use","2021-02-17","2021-02-17","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002037.v1.p1","Methylation Biomarker Study of Magnesium Deficiency and Colorectal Cancer","Five US studies using the Mg tolerance test, the ""gold standard"" test of Mg status, indicated that 50% participants had Mg deficiency. In our ongoing US trial, we have found  a similar result. In growing recognition of the importance of Mg in human health, very recently, Mg was selected by the US Federal Dietary Reference","Not Applicable","Magnesium Deficiency","Clinical Trial","MethylationEPIC","Methylation (CpG)","4 phenotype datasets, 16 variables, 1 molecular datasets, 238 subjects, 476 samples","","NCI","GRU --- General Research Use","2021-02-10","2021-02-10","DNA Methylation; Deficiencies, Magnesium; Deficiency, Magnesium; Magnesium Deficiencies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002290.v1.p1","Tumor Fraction Guided Cell-Free DNA Profiling in Metastatic Cancer    Patients","Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay sensitivity  and the fraction of circulating DNA in plasma that is tumor-derived (i.e cfDNA tumor fraction). We hypothesized that cfDNA tumor fraction could","Not Applicable","Cell-Free Nucleic Acids","Tumor vs. Matched-Normal","Not Provided","WGS, WXS","4 phenotype datasets, 13 variables, 131 samples sequenced, 118 subjects, 131 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2021-02-05","2021-02-05","Not Provided",""
"phs002083.v1.p1","Role of Tobacco Smoke in Clear Cell Renal Cell Carcinoma","Background. Clear cell renal cell carcinoma (ccRCC) is the most common histologically defined renal cancer. However, it is not a uniform disease and includes several genetic subtypes with different prognoses.  ccRCC is also characterized by distinguished metabolic reprogramming. Tobacco smoking (TS) is an established risk factor for ccRCC with unknown","Not Applicable","Carcinoma, Renal Cell","Collection","Not Provided","RNA-Seq","4 phenotype datasets, 22 variables, 50 samples sequenced, 32 subjects, 50 samples","","NCI","GRU --- General Research Use","2021-02-05","2021-02-05","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001748.v1.p1","Molecular Genetics of Histiocytic Sarcoma","This is a comprehensive genomic analysis of a rare set of histiocytic sarcomas from the consult service of the Hematopathology section of the Laboratory of Pathology, NCI, NIH. The study  identifies two distinct groupings of these tumors based on the site of disease, their mutational spectrum, and proliferation signature. All archived","Not Applicable","Histiocytic Sarcoma","Case Set","RNAseq_probe_set_grc37, WES_markerset_grc37","RNA-Seq, SNV (.MAF), RNA Seq (NGS), WXS","4 phenotype datasets, 15 variables, 2 molecular datasets, 44 samples sequenced, 25 subjects, 54 samples","","NCI","GRU --- General Research Use","2021-02-05","2021-02-05","Histiocytic Lymphoma, True; Histiocytic Lymphomas, True; Histiocytic Sarcomas; Histiocytoses, True Malignant; Histiocytosis, True Malignant; Lymphoma, True Histiocytic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001857.v1.p1","Genetics of Mammographic Density in Ashkenazi Jews","Mammographic density (MD) is a strong risk factor for breast cancer and is also a highly heritable trait with 60-70% of the variance due to genetic factors, based on twin  studies. MD is also higher in families with a strong history of breast cancer. Genome-wide association studies (GWAS), which focus on common genetic","Not Applicable","Breast Density","Cross-Sectional","Multi-Ethnic_Global","SNP Genotypes (Array)","5 phenotype datasets, 46 variables, 1 molecular datasets, 677 subjects, 677 samples","European (667), African American (1), Hispanic2 (3), Other Asian or Pacific Islander (1), Other (5)","NCI","DS-MDBRCA-MDS --- Disease-Specific (Mammographic Density and Breast Cancer Risk, MDS)","2021-02-03","2021-02-03","Mammographic Breast Density; Breast Densities, Mammographic; Breast Density, Mammographic; Density, Mammographic; Mammographic Breast Densities; Mammographic Densities",""
"phs002062.v1.p1","Polygenic Risk Score for the Prediction of Breast Cancer Is Related to    Lesser Terminal Duct Lobular Unit Involution of the Breast","The Susan G. Komen Tissue Bank (KTB) at the Indiana University Simon Cancer Center is an annotated biobank, which has recruited healthy women who provided demographic, lifestyle, and cancer-related information  via self-administered questionnaire, blood samples and normal breast tissues. H&E slides of the normal breast tissues were scanned for image analysis","Not Applicable","Breast Neoplasms","Cross-Sectional","Not Provided","Not Provided","4 phenotype datasets, 25 variables, 1089 subjects, 1089 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2021-01-28","2021-01-28","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001962.v1.p1","Genomic Profiling of Peripheral T-cell Lymphoma","Peripheral T-cell lymphomas (PTCLs) are malignant and highly aggressive hematologic tumors arising from mature post-thymic T cells. The diagnosis of PTCL includes diverse lymphoma subgroups, altogether accounting for about 15%  of all non-Hodgkin lymphomas. Despite recent advances in uncovering the mutational landscape of PTCLs, the prognoses of most PTCLs remain poor. To","Not Applicable","Lymphoma, T-Cell, Peripheral","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 12 variables, 20 samples sequenced,  SRA, 20 subjects, 20 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2021-01-28","2021-01-28","Lymphoma, Non-Hodgkin; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology",""
"phs001744.v1.p1","Genome-Wide Association Study of HCC in Non-Asian USA Population","This GWAS of HCC relied on existing biological and data resources from 7 USA sites and one Canadian site which allows for the integration of genetic and environmental data. Total  of 2199 case patients and 1103 non cancer controls were genotyped. Case patients are defined as patients with pathological or radiological diagnosis","Not Applicable","Liver Neoplasms","Case-Control","HumanOmniExpressExome-8, imputation_panel","SNP Genotypes (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 19 variables, 2 molecular datasets, 3225 subjects, 3352 samples","European (2849), African (1), East Asian (3), African American (147), Hispanic1 (39), Hispanic2 (172), Other Asian or Pacific Islander (3), South Asian (1), Other (10)","NCI","DS-LCCLD-MDS --- Disease-Specific (Liver Cancer and Chronic Liver Disease, MDS), DS-HCC-IRB --- Disease-Specific (Hepatocellular Carcinoma, IRB)","2021-01-27","2021-01-27","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells",""
"phs002287.v1.p1","Evolution of Resistance in ER+ Breast Cancer","While the combination of endocrine therapy and CDK4/CDK6 inhibitors has been shown to be effective in the metastatic ER+ breast cancer setting, to test whether it is effective in an  earlier stage neoadjuvant setting, the FELINE trial (NCT02712723) was established to test the efficacy of letrozole and ribociclib in a ER-positive,","Not Applicable","Breast Neoplasms","Tumor vs. Matched-Normal","Not Provided","WXS","5 phenotype datasets, 18 variables, 72 samples sequenced, 24 subjects, 72 samples","","NCI","GRU --- General Research Use","2021-01-15","2021-01-15","Drug Resistance; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002060.v1.p1","Pharmacogenomic Analysis of Microtubule Targeting Agent Response and    Toxicity","Microtubule targeting agents are commonly prescribed for early and metastatic breast cancer and other solid tumors. However, interindividual variability in microtubule targeting drug response and toxicity can cause limited therapeutic  benefit and impact quality of life. In the present study, genome-wide analyses were performed to investigate how genetic factors can be used to","Not Applicable","Peripheral Nervous System Diseases","Prospective Longitudinal Cohort","WES_markerset_grc38, HumanOmniExpress-12, HumanOmniExpress-12, WES_markerset_grc38","SNP Genotypes (Array), SNP/CNV Genotypes (NGS)","4 phenotype datasets, 34 variables, 1 molecular datasets, 624 subjects, 624 samples","European (483), African (6), East Asian (8), African American (77), Hispanic1 (13), Hispanic2 (22), Other Asian or Pacific Islander (12), South Asian (1), Other (2)","NCI","HMB --- Health/Medical/Biomedical","2020-12-22","2020-12-22","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001787.v1.p1","Discovery of Colorectal Cancer Susceptibility Genes in High-Risk Families","Colorectal cancer remains one of the most common cancers in the US with 146,970 new diagnoses and 49,920 deaths estimated for 2009. Colon cancer is also one of the most  familial of cancers. Individuals with a first-degree relative with colon cancer have a 2- to 3-fold increased risk, and those with more than one","Not Applicable","Colorectal Neoplasms, Hereditary Nonpolyposis","Case Set","HumanOmniExpressExome-8","SNP Genotypes (Array), WXS","4 phenotype datasets, 17 variables, 1 molecular datasets, 159 samples sequenced,  SRA, 51 subjects, 206 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2020-12-22","2020-12-22","Familial Nonpolyposis Colon Cancer",""
"phs001846.v1.p1","Kids First: The Intersection of Childhood Cancer and Birth Defects","Birth defects and childhood cancer share biological pathways that are important for cell growth and division. We propose that sequencing pediatric patients suffering both conditions will allow us to discover  the underlying genes and in turn advance our understanding of the causes of these devastating diseases. 1806 samples were selected for whole genome","Not Applicable","Neoplasms","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 1805 subjects, 1805 samples","","NCI","GRU --- General Research Use","2020-12-21","2020-12-21","Congenital Abnormalities; Abnormalities, Congenital; Abnormality, Congenital; Birth Defect; Birth Defects; CM - Congenital malformation","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002286.v1.p1","A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7    for HPV-Associated Cancers","This is a phase I clinical trial testing the safety and efficacy of gene-engineered T cells expressing a T-cell receptor targeting an HLA-A 02:01-restricted epitope of HPV-16 E7 (E7 TCR  T cells) in patients with metastatic HPV-16+ epithelial cancers. A total of 12 patients were treated. The maximum tested dose was tolerated. Side","Not Applicable","Neoplasms","Clinical Trial","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 21 variables, 17 samples sequenced, 6 subjects, 17 samples","","NCI","GRU --- General Research Use","2020-12-16","2020-12-16","Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases; Otorhinolaryngologic Diseases; Virus Diseases; Genitourinary Disease, Male; Genitourinary Diseases, Male","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002161.v1.p1","Kids First: Genomic Analysis of Esophageal Atresia and Tracheoesophageal    Fistulas and Associated Congenital Anomalies","The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller","Not Applicable","Tracheoesophageal Fistula","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 410 subjects, 410 samples","","NCI","GRU --- General Research Use","2020-12-16","2020-12-16","Abnormal connection between trachea and esophagus; Abnormal connection between trachea and oesophagus; Esophageal Atresia and/or Tracheoesophageal Fistula; Esophageal Atresia/Tracheoesophageal Fistula; Esophageal atresia with or without tracheoesophageal fistula; Esophagotracheal Fistula","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002071.v1.p1","Multimodal Mapping of the Immune Landscape in Human Pancreatic Cancer","Pancreatic ductal adenocarcinoma (PDA) is characterized by an immune-suppressive tumor microenvironment that has rendered it largely refractory to immunotherapy. We used single-cell RNA sequencing on patient tumors and matched blood,  and we uncovered a previously unappreciated, complex environment of immune-suppressive cellular interactions. These experiments reveal immune","Not Applicable","Carcinoma, Pancreatic Ductal","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","3 phenotype datasets, 18 variables, 41 samples sequenced,  SRA, 25 subjects, 41 samples","","NCI","HMB --- Health/Medical/Biomedical","2020-12-14","2020-12-14","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001758.v1.p1","Identification of Rare Germline Variants in Familial Patients with    Non-medullary Thyroid Cancer","As the most common malignancy of the endocrine system, thyroid cancer is classified into two major categories, non-medullary thyroid cancer (NMTC) and medullary thyroid cancer (MTC) according to the origins  and clinical features. NMTC includes papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), and anaplastic thyroid cancer (ATC). Sporadic","Not Applicable","Thyroid Cancer, Papillary","Case Set","Not Provided","WGS","5 phenotype datasets, 18 variables, 10 samples sequenced, 10 subjects, 10 samples","","NCI","GRU --- General Research Use","2020-12-14","2020-12-14","Cancer, Papillary Thyroid; Cancers, Papillary Thyroid; Carcinoma, Papillary Thyroid; Carcinomas, Papillary Thyroid; Familial Papillary Thyroid Carcinoma; NONMEDULLARY THYROID CARCINOMA, PAPILLARY","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001831.v1.p1","Elucidating Transcription Regulation by Epigenetics in Neuroblastoma","PURPOSE Whole-genome profiles of the epigenetic modification 5-hydroxymethylcytosine (5-hmC) are robust diagnostic biomarkers in adult patients with cancer. We investigated if 5-hmC profiles would serve as novel prognostic markers in  neuroblastoma, a clinically heterogeneous pediatric cancer. Because this DNA modification facilitates active gene expression, we hypothesized that","Not Applicable","Neuroblastoma","Prospective Longitudinal Cohort","Not Provided","OTHER, RNA-Seq","4 phenotype datasets, 32 variables, 287 samples sequenced,  SRA, 189 subjects, 287 samples","","NCI","GRU --- General Research Use","2020-12-09","2020-12-09","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002019.v1.p1","WES and RNA-Seq Analysis in Paired Sun-Exposed Epidermis and SCCIS    Samples","Squamous cell carcinoma in situ (SCCIS) is a prevalent precancerous lesion that can progress to cutaneous squamous cell carcinoma (cSCC). Although SCCIS is common, its pathogenesis remains poorly understood. To  better understand SCCIS development, we performed laser-captured microdissection of human SCCIS and adjacent epidermis to isolate genomic DNA and RNA","Not Applicable","Carcinoma in Situ","Case-Control","WES_markerset_grc38","RNA-Seq, SNP Genotypes (NGS), WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 22 samples sequenced,  SRA, 11 subjects, 22 samples","","NCI","HMB --- Health/Medical/Biomedical","2020-12-04","2020-12-04","Cancer in situ; Carcinoma, Intraepithelial; Carcinoma, Preinvasive; Intraepithelial Carcinoma; Non-invasive Carcinoma; Preinvasive Carcinoma","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs002244.v1.p1","A Model for Predicting Response to PD-1 Inhibitors in NSCLC","Whole exome sequencing was used to examine the impact of human leukocyte antigen B44 in a non-small cell lung cancer cohort treated with single agent pembrolizumab with over five years  of follow-up. Study participants were treated on clinical trials with single-agent pembrolizumab at the University of California, Los Angeles who","Not Applicable","Carcinoma, Non-Small-Cell Lung","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 26 variables, 66 samples sequenced, 33 subjects, 66 samples","","NCI","DS-CA-IRB-PUB-NPU --- Disease-Specific (Cancer, IRB, PUB, NPU)","2020-11-19","2020-11-19","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs002130.v1.p1","Gabriella Miller Kids First Pediatric Research Program in Craniofacial    Microsomia","Craniofacial microsomia (CFM), also termed hemifacial microsomia or oculo-auricular-vertebral spectrum, is the third most common congenital craniofacial condition. CFM comprises a variable phenotype and the most common features include malformations  of the ear (i.e. microtia) and lower jaw (i.e. mandibular hypoplasia) on one or both sides. Microtia in the absence of other anomalies is believed to","Not Applicable","Goldenhar Syndrome","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 4 variables, 278 subjects, 278 samples","","NCI","DS-CFD --- Disease-Specific (Craniofacial Disorders)","2020-11-13","2020-11-13","Congenital Microtia; Hemifacial Microsomia; Microtia-Anotia; Bilateral microtia; Hypoplasia of the external ear; Hypoplastic ears",""
"phs001761.v1.p1","Genomic Characteristics of MPNs in IR-Exposed Patients","The study ""Genomic Characteristics of Myeloproliferative Neoplasms in Patients Exposed to Ionizing Radiation following the Chernobyl Nuclear Accident"" was designed as case-control study. We studied genomic characteristics of chronic Philadelphia  chromosome-negative myeloproliferative neoplasm (MPNs) in Ukrainian patients who were previously exposed to Ionizing Radiation (IR) due to Chernobyl","Not Applicable","Primary Myelofibrosis","Case-Control","target_markerset_grc38, WES_markerset_grc37, target_markerset_grc38, WES_markerset_grc37","SNV (.MAF), Targeted-Capture, WXS","4 phenotype datasets, 22 variables, 1 molecular datasets, 155 samples sequenced,  SRA, 155 subjects, 155 samples","","NCI","GRU --- General Research Use","2020-11-05","2020-11-05","Acquired primary erythrocytosis; Disease, Osler-Vaquez; Erythremia; Erythremias; Osler Vaquez Disease; Osler-Vaquez Disease","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002269.v1.p1","A New Pipeline to Predict and Confirm Tumor Neoantigens Predicts Better    Response to Checkpoint Blockade","Mutations that drive oncogenesis in cancer can generate neoantigens that may be recognized by the immune system. Identification of these neoantigens remains challenging due to the complexity of the major  histocompatibility complex (MHC) antigen and T-cell receptor interaction. Here we describe the development of a systematic approach to efficiently","Not Applicable","Antigens, Neoplasm","Case Set","Not Provided","WXS","3 phenotype datasets, 9 variables, 37 samples sequenced, 37 subjects, 37 samples","","NCI","GRU --- General Research Use","2020-11-04","2020-11-04","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001925.v1.p1","Characterization of Clonal Evolution in Microsatellite Unstable    Metastatic Cancers through Multi-Regional Tumor Sequencing","Whole exome sequencing was performed on blood and multiple tumor samples from six patients with known microsatellite unstable tumors. Subclones within each tumor site were identified and within each subclone,  differing microsatellite instability was characterized. Inclusion Criteria: 1) A histologically or cytologically confirmed diagnosis of cancer 2)","Not Applicable","Microsatellite Instability","Case Set","Not Provided","WXS","4 phenotype datasets, 14 variables, 38 samples sequenced, 6 subjects, 38 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2020-11-04","2020-11-04","Clonal Evolution; Evolution, Clonal; Error Phenotype, Replication; Error Phenotypes, Replication; Phenotype, Replication Error; Phenotypes, Replication Error",""
"phs001786.v1.p1","SU2C GEMM Trial","The goal of the GEMM Trial is to ascertain if comprehensive and systematic interrogation of a patient's tumor molecular profile improves outcomes compared to the current practice of physician's choice  for metastatic melanoma patients who have progressed following first line therapy. The data shared here includes tumor/normal exome and tumor RNAseq","Not Applicable","Melanoma","Case Set","WES_markerset_grc37, RNAseq_probe_set_grc37","CNV (NGS)","4 phenotype datasets, 17 variables, 2 molecular datasets,  SRA, 36 subjects, 137 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2020-11-03","2020-11-03","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001912.v1.p1","Somatic Genome Dynamics of Barrett's Esophagus Patients with Non-Cancer    and Cancer Outcomes","A case-control study was designed with 80 participants diagnosed with Barrett's Esophagus (BE) selected from a larger case-cohort study (Li et al., 2014, PMID: 24253313) within the Seattle Barrett's Esophagus  Program (SBEP) at the Fred Hutchinson Cancer Research Center. The study included 40 cases with BE with non-cancer outcomes, ""NCO"", who did not","Not Applicable","Barrett Esophagus","Case-Control","HumanOmni2.5-8","SNP Genotypes (Array), WGS","4 phenotype datasets, 56 variables, 1 molecular datasets, 427 samples sequenced,  SRA, 80 subjects, 427 samples","","NCI","DS-BE-EA --- Disease-Specific (Barrett's Esophagus or EA)","2020-10-19","2020-10-19","BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome; Barrett esophagus/esophageal adenocarcinoma",""
"phs001866.v1.p1","RNA Sequence-Based Analysis Used to Compare Breast Primary and Metastatic    Tumor Pairs","The goal of this study is to capture the transcriptome landscape of luminal and basal-like metastatic breast tumors. We will aim to show the importance of using the most up-to-date  cancer biopsy for detecting cancer drivers that were often not present in the primary tumor. RNA-Seq data are available through dbGaP's Authorized","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 26 variables, 166 samples sequenced, 166 subjects, 166 samples","","NCI","GRU --- General Research Use","2020-10-19","2020-10-19","Metastases; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002053.v1.p1","Neoadjuvant Pazopanib in Renal Cell Carcinoma","This study examined the tissue of patients who received oral pazopanib prior to nephrectomy. Patients were consented and underwent a pre-treatment biopsy. Pretreatment samples for analysis were preserved as available.  Subjects underwent a proscribed course of treatment with pazopanib. At the completion of treatment, subjects underwent a planned nephrectomy, and","Not Applicable","Carcinoma, Renal Cell","Prospective Longitudinal Cohort","Not Provided","OTHER, RNA-Seq","4 phenotype datasets, 10 variables, 36 samples sequenced,  SRA, 22 subjects, 36 samples","","NCI","DS-KD-IRB --- Disease-Specific (Kidney Disease, IRB)","2020-10-13","2020-10-13","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell",""
"phs001290.v1.p1","CIDR: NCI Genome Wide Predictors of Survival in Colorectal Cancer","CIDR/Molecular Correlates: This study genotyped archived blood samples from colorectal cancer cases participating in clinical trials. The goals of this project were to identify genetic variants associated with survival outcomes  treatment and treatment-related severe adverse events among patients with colorectal cancer. Another goal was to examine the impact of adding","Not Applicable","Colorectal Neoplasms","Clinical Trial","HumanOmniExpressExome-8, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 37 variables, 2 molecular datasets, 6077 subjects, 6371 samples","European (5107), African (20), East Asian (172), African American (397), Hispanic1 (65), Hispanic2 (205), Other Asian or Pacific Islander (53), South Asian (18), Other (40)","NCI","GRU-PUB --- General Research Use (PUB), GRU-COL-NPU --- General Research Use (COL, NPU), GRU-COL --- General Research Use (COL)","2020-10-07","2020-10-07","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001133.v1.p1","Follow-up of Ovarian Cancer Genetic Association and Interaction Studies    (FOCI)","(Excerpted/paraphrased from original grant application): FOCI seeks to expand our understanding of epithelial ovarian cancer through a coordinated and comprehensive approach. Project 1 will focus on discovery, expansion, and replication.  By pooling GWAS, we expect to identify new associations and achieve independent replication, explore whether there are risk variants specific for","Not Applicable","Ovarian Neoplasms","Case-Control","Axiom_Biobank_plus, imputation_panel, HumanOmni2.5-8, meta_analysis_markerset","Not Provided","2 phenotype datasets, 7 variables, 14796 subjects, 16783 samples, 4 substudies","","NCI","GRU --- General Research Use, DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), OVCARES --- Ovarian Cancer Only, GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2020-09-24","2020-09-24","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001150.v1.p1","FOCI Mayo 2.5M","This sub-study phs001150 Mayo 2 5M contains genotype data generated using 2.5M genotyping array and selected phenotype of subjects available from the phs001150 study. Summary level phenotypes for the NCI  FOCI Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data","Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) (phs001133.v1.p1)","Ovarian Neoplasms","Case-Control","HumanOmni2.5-8","SNP/CNV (Array), SNP/CNV (Array)","2 phenotype datasets, 15 variables, 1 molecular datasets, 1000 subjects, 1021 samples","European (971), East Asian (4), African American (7), Hispanic1 (1), Hispanic2 (9), Other Asian or Pacific Islander (4), Other (2)","NCI","GRU --- General Research Use, DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), OVCARES --- Ovarian Cancer Only, GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2020-09-24","2020-09-24","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs001142.v1.p1","FOCI Mayo OmniExpress","This sub-study phs001142 Mayo Omni Express contains genotype data and selected phenotype of subjects available from the phs001142 study. Summary level phenotypes for the NCI FOCI Cohort study participants can  be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data for all FOCI Cohort top-level study","Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) (phs001133.v1.p1)","Ovarian Neoplasms","Case Set","imputation_panel","SNP Genotypes (imputed), SNP Genotypes (imputed)","2 phenotype datasets, 10 variables, 1 molecular datasets, 171 subjects, 171 samples","","NCI","GRU --- General Research Use, DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), OVCARES --- Ovarian Cancer Only, GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2020-09-24","2020-09-24","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs001132.v1.p1","FOCI GWAS Meta-Analysis","This sub-study phs001132 GWAS Meta Analysis contains genotype data pulled from several GWAS studies and selected phenotype of subjects available from the phs001132 study. Summary level phenotypes for the NCI  FOCI Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data","Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) (phs001133.v1.p1)","Ovarian Neoplasms","Case-Control","meta_analysis_markerset","CNV Genotypes, CNV Genotypes","2 phenotype datasets, 10 variables, 6 analyses, 1 molecular datasets, 2818 subjects, 2818 samples","","NCI","GRU --- General Research Use, DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), OVCARES --- Ovarian Cancer Only, GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2020-09-24","2020-09-24","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs001131.v1.p1","FOCI Affymetrix Exome Chip","This sub-study phs001131&#x000a0;Affymetrix Exome Chip contains genotype data generated using exome genotyping array and selected phenotype of subjects available from the phs001131 study. Summary level phenotypes for the NCI FOCI  Cohort study participants can be viewed at the top-level study page phs001133 FOCI Cohort. Individual level phenotype data and molecular data for all","Follow-up of Ovarian Cancer Genetic Association and Interaction Studies (FOCI) (phs001133.v1.p1)","Ovarian Neoplasms","Case-Control","Axiom_Biobank_plus","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 13 variables, 1 molecular datasets, 12773 subjects, 12773 samples","","NCI","GRU --- General Research Use, DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), OVCARES --- Ovarian Cancer Only, GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-OVCA --- Disease-Specific (Ovarian Cancer), DS-OVCA-MDS --- Disease-Specific (Ovarian Cancer, MDS), DS-OVCA-MDS-GSO --- Disease-Specific (Ovarian Cancer, MDS, GSO), DS-OVCA-NPU --- Disease-Specific (Ovarian Cancer, NPU), DS-OVCA-NPU-MDS --- Disease-Specific (Ovarian Cancer, NPU, MDS), DS-OVTU --- Disease-Specific (Ovarian Tumors)","2020-09-24","2020-09-24","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs002049.v1.p1","Memorial Sloan Kettering (MSKCC) Single Cell Mutational Profiling in    Myeloid Malignancies","Myeloid malignancies have previously been characterized by large scale bulk molecular profiling studies on patient samples. These studies, while clinically informative, are unable to delineate mutation order as well as  clonal architecture and complexity. To investigate the clonal framework of myeloid malignancies, the Single Cell Mutational Profiling in Myeloid","Not Applicable","Leukemia, Myeloid, Acute","Prospective Longitudinal Cohort","target_markerset_grc38","AMPLICON, SNP/CNV Genotypes (NGS)","4 phenotype datasets, 14 variables, 1 molecular datasets, 148 samples sequenced,  SRA, 117 subjects, 148 samples","","NCI","HMB --- Health/Medical/Biomedical","2020-09-23","2020-09-23","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001110.v3.p1","Kids First: Pediatric Research Project on the Genomic Analysis of    Congenital Diaphragmatic Hernia","The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller","Not Applicable","Hernias, Diaphragmatic, Congenital","Family/Twin/Trios","WGS_markerset_grc37","CNV Genotypes, SNP Genotypes (NGS)","5 phenotype datasets, 26 variables, 1 molecular datasets,  SRA, 2312 subjects, 2358 samples","","NCI","GRU --- General Research Use","2020-09-16","2017-05-25","Agenesis of Hemidiaphragm; CDH; CDH - Congenital diaphragmatic hernia; Congenital Diaphragmatic Defect; Congenital Diaphragmatic Defects; Congenital Diaphragmatic Hernia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001993.v1.p1","WES, RNASeq and CNV Analysis of NF1-Associated Atypical Neurofibromas","Neurofibromatosis type 1 (NF1) is a tumor-predisposition disorder caused by germline mutations in NF1. NF1 patients have an 8-16% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST),  a highly aggressive soft-tissue sarcoma, often arising from pre-existing benign plexiform neurofibromas (PN) and atypical neurofibromas (ANF). ANF","Not Applicable","Neurofibromatosis 1","Prospective Longitudinal Cohort","WES_markerset_grc38","RNA-Seq, CNV Genotypes, WXS","5 phenotype datasets, 29 variables, 1 molecular datasets, 69 samples sequenced,  SRA, 69 subjects, 74 samples","","NCI","GRU --- General Research Use","2020-09-15","2020-09-15","Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I; NEUROFIBROMATOSIS, TYPE I, SOMATIC","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001903.v1.p1","dbGaP submission of CORECT OncoArray GWAS data","This analysis represents the genome-wide association study results of several international case-control studies of colorectal cancer. Inclusion Criteria In general, for cases: (1) age 18 years (some studies capped age  at 69, and others did not), (2) newly-diagnosed CC (stages I-III), (3) English or German or Spanish speaking dependent on study locale, and (4)","Not Applicable","Colorectal Neoplasms","Case-Control","OncoArray-500K","SNP Genotypes (Array)","4 phenotype datasets, 37 variables, 1 analyses, 1 molecular datasets, 37437 subjects, 37437 samples","European (31101), African (24), East Asian (3646), African American (591), Hispanic1 (1142), Hispanic2 (350), Other Asian or Pacific Islander (292), South Asian (54), Other (237)","NCI","EPIMEDCA-MDS --- Epidemiological and Medical Research on Cancer and Methods, DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), GRU-PUB --- General Research Use (PUB), DS-COC-MDS --- Disease-Specific (Colon Cancer, MDS), HMB --- Health/Medical/Biomedical, DS-CC --- Disease-Specific (Colorectal Cancer), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), DS-COC-PUB-NPU --- Disease-Specific (Colon Cancer, PUB, NPU), DS-CC-PUB --- Disease-Specific (Colorectal Cancer, PUB), CHRONIC-MDS --- Chronic Diseases (including Cancer) and Methods, GRU --- General Research Use, CADM --- Cancer in all age groups, other diseases in adults only, and methods, CRCSTATS --- Colorectal Cancer and Statistical Methods, DS-CA-GSO --- Disease-Specific (Cancer, GSO), DS-CC-COL-NPU --- Disease-Specific (Colorectal Cancer, COL, NPU), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB-COL --- Health/Medical/Biomedical (IRB, COL), DS-COC-IRB-COL --- Disease-Specific (Colon Cancer, IRB, COL), DS-CA-IRB-PUB-NPU-MDS --- Disease-Specific (Cancer, IRB, PUB, NPU, MDS), DS-BCEMOPCA-NPU-MDS --- Disease-Specific (Breast, Colorectal, Endometrial, Melanoma, Ovarian, and/or Prostate Cancer, NPU, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2020-09-15","2020-09-15","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001875.v1.p1","Determinants of Venetoclax Resistance","The study aimed to identify genetic determinants of resistance to Venetoclax, a recently approved BCL-2 inhibitor for patients with chronic lymphocytic leukemia (CLL). Whole exome sequencing of tumor samples from  6 CLL patients relapsing on Venetoclax revealed clonal evolution when comparing pre- and post-Venetoclax samples. Genetic screens for genes involved","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 23 variables, 19 samples sequenced,  SRA, 6 subjects, 19 samples","","NCI","GRU --- General Research Use","2020-09-10","2020-09-10","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001870.v1.p1","Genomic Changes in Breast Cancer Among Chinese Women in Hong Kong","Recently, tumor sequencing and profiling analyses have improved molecular classification and refined existing breast cancer subtypes. However, epidemiologic data are absent in most somatic profiling studies even in extensively studied  Western populations. The expansion of genomic studies to understudied populations with the integration of etiologic factors will allow the capture of","Not Applicable","Breast Neoplasms","Case Set","MethylationEPIC","Methylation (CpG), RNA-Seq, WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 247 samples sequenced, 92 subjects, 340 samples","","NCI","DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS)","2020-09-10","2020-09-10","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001493.v2.p1","Whole Exome Predictors Immune Checkpoint Therapy Response in Renal Cell    Carcinoma","Immune checkpoint therapies, including monoclonal antibodies to programmed cell death-1 (PD-1) and cytotoxic % lymphocyte associated protein-4 (CTLA-4), yield durable clinical responses across many tumor types, including metastatic melanoma, non-small  cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, predictors of response to these therapies in RCC are still unknown. Genomic","Not Applicable","Carcinoma, Renal Cell","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 17 variables, 143 samples sequenced,  SRA, 71 subjects, 143 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use","2020-08-26","2018-02-02","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001169.v2.p1","Integrative Analysis of Lung Adenocarcinoma (Version 2)","We performed a comprehensive analysis of intratumor heterogeneity of somatic mutations in cancer driver genes, copy number aberrations and DNA methylation in 292 tumor samples from 84 lung adenocarcinoma (LUAD)  patients from the Environment And Genetics in Lung cancer Etiology (EAGLE) study. SNVs of 37 established lung cancer driver genes were profiled by","Not Applicable","Adenocarcinoma of Lung","Case Set","HumanOmniExpress-12, HumanOmniExpress-12, HumanMethylation450, HumanOmniExpress-12, HumanMethylation450","SNP Genotypes (Array), RNA-Seq, Methylome sequencing, Targeted-Capture, WXS","4 phenotype datasets, 14 variables, 2 molecular datasets, 512 samples sequenced,  SRA, 132 subjects, 1114 samples","","NCI","DS-LDS-MDS --- Disease-Specific (Lung disease or smoking, MDS)","2020-08-24","2020-08-24","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs002000.v1.p1","The Genomic Landscape of Mongolian Hepatocellular Carcinoma","Background and Hypotheses: Mongolia has the highest reported incidence of - and mortality from - hepatocellular carcinoma (HCC) in the world, which is between three and seven times higher than  that observed in other high-incidence populations, such as South Korea, Thailand, and China. Although its causative factors and underlying tumor","Not Applicable","Carcinoma, Hepatocellular","Case Set","Not Provided","Targeted-Capture","5 phenotype datasets, 34 variables, 142 samples sequenced, 76 subjects, 142 samples","","NCI","GRU --- General Research Use","2020-08-19","2020-08-19","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells",""
"phs002022.v1.p1","Genomic Analysis of Primary Plasma Cell Leukemia","Primary plasma cell leukemia (pPCL) is a rare and aggressive form of multiple myeloma (MM) that is characterized by poor overall survival despite advances in anti-MM therapy. The disease biology  as well as molecular mechanisms that distinguish pPCL from non-pPCL MM remain poorly understood. In an attempt to identify key biological mechanisms","Not Applicable","Leukemia, Plasma Cell","Prospective Longitudinal Cohort","Not Provided","WXS","5 phenotype datasets, 16 variables, 46 samples sequenced,  SRA, 23 subjects, 46 samples","","NCI","GRU --- General Research Use","2020-08-18","2020-08-18","Leukemia Plasmacytic; Leukemia, Plasmacytic; Leukemias, Plasma Cell; Leukemias, Plasmacytic; PCL; Plasma Cell Leukemia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002051.v1.p1","DNA Methylation in Rhabdomyosarcoma PDX and PDX-Derived Primary Cells","Conditions to maintain primary tumor cells in culture are largely unknown for most tumor entities including rhabdomyosarcoma. In this collaborative study with Dr. Beat Sch&#x000e4;fer's laboratory, we performed DNA methylation  profiles of rhabdomyosarcoma patient-derived xenograft (PDX) and their matching PDX-derived primary cells (PPC), where the PPCs were developed and","Not Applicable","Rhabdomyosarcoma","Case Set","Cytogenetic_Arrays, MethylationEPIC, Cytogenetic_Arrays, MethylationEPIC","CNV Genotypes, Methylation (CpG), WXS","3 phenotype datasets, 12 variables, 1 molecular datasets, 31 samples sequenced,  SRA, 39 subjects, 99 samples","","NCI","GRU --- General Research Use","2020-08-17","2020-08-17","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002021.v1.p1","Chemotherapy and Unrelated Donor SCT for Blood and Immune System Cancers","Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without an HLA tissue-matched sibling and graft-versus-host disease (GVHD), a serious  side effects of immune-suppressing chemotherapy that is given to bring the cancer under control before SCT. In GVHD, the patient's immune system","Not Applicable","Graft vs Host Disease","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 27 variables, 2 samples sequenced,  SRA, 2 subjects, 2 samples","","NCI","GRU --- General Research Use","2020-08-14","2020-08-14","Blood Protein Disorders; Bone Marrow Diseases; Cardiovascular Diseases; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001714.v1.p1","Gabriella Miller Kids First Pediatric Research Program: An Integrated    Clinical and Genomic Analysis of Treatment Failure in Pediatric    Osteosarcoma","Although the survival of children with relapsed osteosarcoma is very poor, little is known about the etiology of treatment failure in this disease. The purpose of this project is to  perform whole genome sequencing on serial samples from patients with osteosarcoma obtained before treatment, after treatment, and at","Not Applicable","Osteosarcoma","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 84 subjects, 311 samples","","NCI","GRU --- General Research Use","2020-08-14","2020-08-14","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002045.v1.p1","Intraductal Transplantation Models of PDAC Reveal Progression of Subtypes","Pancreatic ductal adenocarcinoma (PDAC) is the most lethal common malignancy, with little improvement in patient outcomes over the past few decades. Recently, subtypes of pancreatic cancer with different prognoses have  been elaborated. However, the inability to model these subtypes has precluded mechanistic investigation of their origins. Here, we present an","Not Applicable","Carcinoma, Pancreatic Ductal","Case Set","custom_markerset, custom_markerset, custom_markerset","RNA-Seq, CNV Genotypes, RNA Seq (NGS), WGS","4 phenotype datasets, 26 variables, 1 molecular datasets, 70 samples sequenced,  SRA, 15 subjects, 70 samples","","NCI","GRU --- General Research Use","2020-08-10","2020-08-10","Pancreatic Intraductal Neoplasms; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001856.v1.p1","CORECT: Affymetrix Axiom GWAS Data","This study is part 1 of 2 for Schumacher et al, Nat Commun. 2015 Jul 7;6:7138. Part 1 is the original GWAS data for 9,259 participants on the Affymetrix Axiom  platform of the studies listed below in the Inclusion Criteria. Inclusion Criteria The CORECT consortium coordinated the analysis of six","Not Applicable","Colorectal Neoplasms","Case-Control","Axiom_Array","SNP Genotypes (Array)","4 phenotype datasets, 13 variables, 1 analyses, 1 molecular datasets, 9924 subjects, 9924 samples","","NCI","GRU --- General Research Use, DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), DS-CC --- Disease-Specific (Colorectal Cancer), DS-COC-IRB-COL --- Disease-Specific (Colon Cancer, IRB, COL), HMB --- Health/Medical/Biomedical, HMB-IRB-COL --- Health/Medical/Biomedical (IRB, COL), DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-CA-IRB-PUB-NPU-MDS --- Disease-Specific (Cancer, IRB, PUB, NPU, MDS)","2020-08-10","2020-08-10","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001793.v1.p1","Pharmacogenomic Interactions in Glioblastoma Cell Line Models","Glioblastoma (GBM) is a lethal disease without effective treatments. To advance toward effective therapeutic approaches that are biomarker-driven, there is a need for new targeted agents and to develop accurate  preclinical models that encompass its cellular and molecular diversity. Historical cell line models poorly represent molecular diversity of GBMs, so","Not Applicable","Glioma","Case Set","Not Provided","WXS","4 phenotype datasets, 21 variables, 34 samples sequenced,  SRA, 33 subjects, 34 samples","","NCI","HMB --- Health/Medical/Biomedical","2020-08-06","2020-08-06","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001648.v2.p1","Genomic Characterization of Metastatic Castration Resistant Prostate    Cancer","Biopsies of castration resistant prostate cancer metastases were subjected to whole genome sequencing (WGS), along with RNA-sequencing (RNA-Seq). The overarching goal of the study is to illuminate molecular mechanisms of  acquired resistance to therapeutic agents, and particularly androgen signaling inhibitors, in the treatment of metastatic castration resistant","Not Applicable","Prostatic Neoplasms, Castration-Resistant","Prospective Longitudinal Cohort","Not Provided","Bisulfite-Seq","4 phenotype datasets, 13 variables, 100 samples sequenced,  SRA, 101 subjects, 311 samples","","NCI","GRU --- General Research Use","2020-07-28","2019-05-02","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001835.v1.p1","Whole-Exome Sequencing and Targeted DNA Sequencing of Matched Ocular    Melanocytosis and Uveal Melanoma","Ocular melanocytosis is the most important predisposing condition for the eye cancer uveal melanoma (UM). Here we used whole-exome and deep targeted sequencing to identify for the first time a  clonal Gq pathway mutation in ocular melanocytosis, which gave rise to UM. Additionally, we elucidated the order in which canonical genetic","Not Applicable","Uveal melanoma","Case Set","Not Provided","WXS","3 phenotype datasets, 17 variables, 3 samples sequenced, 1 subjects, 3 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-07-21","2020-07-21","Not Provided",""
"phs000480.v1.p1","Familial Breast Cancer Study (FBCS)","Breast cancer has a significant genetic component. The strongest epidemiologic risk factor is family history of the disease. Familial studies have identified a number of genes contributing to increased risk.  Of these, the highly penetrant BRCA1 and BRCA2 genes account for the majority of families in whom disease-causal mutations have been identified.","Not Applicable","Breast Neoplasms","Family/Twin/Trios","WES_markerset_grc37","SNP/CNV Genotypes (NGS), WXS","5 phenotype datasets, 24 variables, 1 documents, 1 molecular datasets, 126 samples sequenced,  SRA, 136 subjects, 129 samples","","NCI","DS-BRCA --- Disease-Specific (Breast Cancer)","2020-07-21","2020-07-21","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001573.v1.p1","Intra-Tumor Heterogeneity and Clonal Evolution of Papillary Renal Cell    Carcinoma","Limited knowledge of intratumor heterogeneity (ITH), and clonal evolution of papillary renal cell carcinoma (pRCC) and rare kidney tumor subtypes hinders understanding of tumorigenesis and therapeutic efficacy. We conducted an  integrative genomic and epigenomic ITH analysis and studied clonal evolutionary history of pRCC and rare kidney tumor subtypes. We dissected multiple","Not Applicable","Carcinoma, Renal Cell","Case Set","HumanMethylation450, HumanOmniExpress-24, HumanMethylation450, HumanOmniExpress-24","Methylation (CpG), SNP Genotypes (Array), Targeted-Capture, WGS","4 phenotype datasets, 13 variables, 1 molecular datasets, 263 samples sequenced,  SRA, 39 subjects, 502 samples","","NCI","GRU --- General Research Use","2020-07-14","2020-07-14","Sarcoma; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell",""
"phs000723.v1.p1","Sequencing of Cervical Cancer","Precision mapping of genetic alterations in cancer can enable better selection of therapies and improved outcomes when combined with new sequencing diagnostics. We describe whole-exome sequences from cervical adenocarcinomas and  paired normal samples in Hong Kong Chinese women. These data uncover a heterogeneous genomic landscape but identify commonly aberrant loci including","Not Applicable","Uterine Cervical Neoplasms","Case-Control","Not Provided","Targeted-Capture","4 phenotype datasets, 29 variables, 29 samples sequenced,  SRA, 15 subjects, 29 samples","","NCI","GRU-NPU-MDS --- General Research Use (NPU, MDS)","2020-07-14","2020-07-14","Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms",""
"phs001994.v1.p1","Smoking and Tumor Immune Microenvironment in HNSCC","This study was designed to measure immune cell differences between HNSCC patients according to smoking history. We measured CD3, CD8, FoxP3, PD-1 and PD-L1 for immune markers and Pancytokeratin to  distinguish between tumor and surrounding tissue. We observed that current smokers have significantly lower numbers of immune cells surrounding the","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 26 variables, 120 samples sequenced,  SRA, 61 subjects, 120 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2020-07-09","2020-07-09","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx",""
"phs002023.v1.p1","Drug Screening of Patient-Derived Organoids from Colorectal Peritoneal    Metastases","Colorectal cancer (CRC) patients with peritoneal metastases (CRPM) have limited treatment options and the lowest CRC survival rates. We trialed the possibility of organoid directed precision treatment for CRPM patients.  CRPM organoids (peritonoids) isolated from patients underwent next-generation sequencing and medium-throughput drug panel testing ex vivo to identify","Not Applicable","Peritoneal Neoplasms","Prospective Longitudinal Cohort","Not Provided","WXS","5 phenotype datasets, 16 variables, 30 samples sequenced,  SRA, 14 subjects, 30 samples","","NCI","GRU --- General Research Use","2020-07-08","2020-07-08","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001883.v1.p1","Whole Exome Sequencing of DNA in Breast Cancers Enrolled in the S0800    Trial","Purpose: The purpose of this study was to assess the somatic mutation landscape of breast tumors before and after neoadjuvant chemotherapy. The data includes whole exome sequencing of pre- and  post- tissues that were collected in the context of an already published clinical trial SWOG S0800 (ZA Nahleh et al. Breast Cancer Research and","Not Applicable","Breast Neoplasms","Clinical Trial","Not Provided","WXS","5 phenotype datasets, 20 variables, 45 samples sequenced, 29 subjects, 45 samples","","NCI","GRU-COL --- General Research Use (COL)","2020-07-08","2020-07-08","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001829.v1.p1","Molecular Characterization of Response to Rectal Chemoradiation","Pre-operative chemoradiation (CRT) followed by resection is the standard of care option for patients with locally advanced rectal adenocarcinoma. Pathologic downstaging after CRT is associated with improved outcomes, but molecular  predictors of response are poorly understood. We performed whole exome sequencing, gene expression profiling, and immune infiltrate analysis on","Not Applicable","Rectal Neoplasms","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 19 variables, 48 samples sequenced,  SRA, 17 subjects, 48 samples","","NCI","DS-GID-MDS --- Disease-Specific (Gastrointestinal Diseases, MDS)","2020-07-06","2020-07-06","CA - Cancer of rectum; Cancer of Rectum; Cancer of the Rectum; Cancer, Rectal; Cancer, Rectum; Carcinoma of Rectum",""
"phs001979.v1.p1","Genomic Landscape of Human Skin at a Single-Cell Resolution","Every cell in the human body has a unique set of somatic mutations, yet it remains difficult to comprehensively genotype an individual cell. Here, we developed solutions to overcome this  obstacle in the context of normal human skin, thus offering the first glimpse into the genomic landscapes of melanocytes at single-cell resolution.","Not Applicable","Melanoma","Cross-Sectional","RNAseq_gene_transcripts","RNA-Seq, RNA Seq (NGS), Targeted-Capture, WXS","4 phenotype datasets, 21 variables, 1 molecular datasets, 355 samples sequenced,  SRA, 7 subjects, 355 samples","","NCI","GRU --- General Research Use","2020-07-01","2020-07-01","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001969.v1.p1","Cellular Origins and Genetic Landscape of Cutaneous GD T Cell Lymphoma","Cutaneous gamma-delta T cell lymphomas are a rare and aggressive subtype of cutaneous lymphoma. In the present study, we analyzed these cancers by DNA and RNA sequencing in order to  illuminate the genetic landscape for this rare disease. We obtained tumor samples from multiple institutions, including Northwestern University","Not Applicable","Lymphoma, T-Cell, Cutaneous","Case Set","Not Provided","OTHER, RNA-Seq, Targeted-Capture, WGS, WXS","4 phenotype datasets, 18 variables, 37 samples sequenced,  SRA, 20 subjects, 37 samples","","NCI","GRU --- General Research Use","2020-06-24","2020-06-24","Granulomatous Slack Skin; Slack Skin, Granulomatous","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001738.v1.p1","Kids First Pediatric Research Study in Familial Predisposition to    Hematopoietic Malignancies (SJFAMILY-HM)","Acute lymphoblastic leukemia (ALL) is the commonest childhood tumor and a leading cause of cancer death in children, adolescents and young adults. Hodgkin and non-Hodgkin lymphoma are also important hematologic  malignancies (HM) that occur in children. Each are genetic diseases with growing evidence for a germline predisposition of both familial and sporadic","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 5 variables,  SRA, 366 subjects, 373 samples","","NCI","GRU --- General Research Use","2020-06-18","2020-06-18","Hodgkin Disease; Lymphoma, Non-Hodgkin; CHL; Classic Hodgkin disease; Disease, Hodgkin; Disease, Hodgkin's","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001794.v1.p1","Beckwith-Wiedemann Syndrome (BWS) Study","miRNA data from Beckwith-Wiedemann syndrome patients was compared with samples from large overgrowth syndrome animals (GSE117015). Tongue samples from patients with Beckwith-Wiedemann Syndrome were included. Principal Investigator: Jennifer Kalish, MD,  PhD, Children's Hospital of Philadelphia, Philadelphia, PA, USA Funding Sources: K08 CA193915, National Institutes of Health, Bethesda, MD, USA","Not Applicable","Beckwith-Wiedemann Syndrome","Prospective Longitudinal Cohort","Not Provided","miRNA-Seq","4 phenotype datasets, 14 variables, 12 samples sequenced,  SRA, 12 subjects, 12 samples","","NCI","GRU --- General Research Use","2020-06-16","2020-06-16","Macroglossia; BWS; Beckwith Wiedemann Syndrome; Beckwith's syndrome; Beckwith-Wiedemann syndrome chromosome region; EMG SYNDROME","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001970.v1.p1","DNA Methylation in Rhabdomyosarcoma","Rhabdomyosacoma (RMS) is a common pediatric soft tissue tumor that is associated with the skeletal muscle lineage. RMS comprises two major subtypes: fusion-positive (FP, most commonly PAX3- FOXO1 or PAX7-FOXO1)  and fusion-negative (FN, frequently associated with mutations in RAS pathway). Our previous study demonstrated that FP and FN tumors exhibit distinct","Not Applicable","Rhabdomyosarcoma","Case Set","HumanMethylation450","Methylation (CpG)","3 phenotype datasets, 12 variables, 1 molecular datasets, 134 subjects, 134 samples","","NCI","GRU --- General Research Use","2020-06-12","2020-06-12","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001997.v1.p1","Kids First: Genomics of African and Asian Orofacial Clefts Triads","The focus of this study is to identify novel risk variants for OFC in Africa and Asian OFC case-parent triads through analysis of Whole Genome Sequencing data. About 300 Case-parent  trio samples were selected for this whole genome sequencing as part of the Gabriella Miller Kids First Orofacial Clefts Projects. Samples of","Not Applicable","Cleft Lip","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 6 variables,  SRA, 791 subjects, 791 samples","","NCI","DS-OC-PUB-MDS --- Disease-Specific (Oral Clefts, PUB, MDS), GRU --- General Research Use","2020-05-22","2020-05-22","Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001954.v1.p1","Early Stage Lung Adenocarcinoma","Lung cancer in East Asia is characterized by high percentage of never-smokers, early-onset and predominant EGFR mutations. To provide an insight into the molecular phenotype of this demographically distinct disease,  we have performed a proteogenomics study on a prospectively collected cohort representing early stage lung adenocarcinomas in Taiwan. The distinct","Not Applicable","Adenocarcinoma of Lung","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 20 variables, 354 samples sequenced, 89 subjects, 356 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2020-05-19","2020-05-19","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs001890.v1.p1","Single Molecule Molecular Inversion Probe Capture Developed Using CIViC","This study evaluated the use of the Clinical Interpretations of Variants in Cancer database (CIViC) to develop an Open-sourced CIViC Annotation Pipeline (OpenCAP). OpenCAP is a resource that allows users  to develop a clinical capture panel that can be linked back to clinical summaries within the CIViC database. This method for capture panel","Not Applicable","Database Management Systems","Tumor vs. Matched-Normal","Not Provided","AMPLICON","4 phenotype datasets, 14 variables, 31 samples sequenced,  SRA, 17 subjects, 31 samples","","NCI","GRU --- General Research Use, GRU-IRB --- General Research Use (IRB), DS-CA --- Disease-Specific (Cancer), DS-LC-IRB --- Disease-Specific (Lung Cancer, IRB)","2020-05-07","2020-05-07","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs002012.v1.p1","SEER Remote Access Pilot Test Data (2018)","This is a limited use Surveillance, Epidemiology, and End Results (SEER) file for use in a pilot test of remote data access. The SEER Program of the National Cancer Institute  (NCI) is an authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer","Not Applicable","SEER Program","Methods","Not Provided","Not Provided","Not Provided","","NCI","GRU --- General Research Use","2020-05-05","","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001943.v1.p1","Hereditary Cancer Predisposition Syndromes and Uveal Melanoma","Uveal melanoma (UM) is a subtype of melanoma characterized by the strong contribution of genetic rather than environmental factors in the pathogenesis of the disease, making it an ideal model  disease to study the genetic basis of cancer. The long-term goal of our laboratory is to determine the genes and mechanisms responsible for","Not Applicable","Uveal melanoma","Prospective Longitudinal Cohort","Not Provided","WXS","5 phenotype datasets, 19 variables, 34 samples sequenced,  SRA, 34 subjects, 34 samples","","NCI","DS-CA-PUB-NPU-MDS-GSO --- Disease-Specific (Cancer, PUB, NPU, MDS, GSO)","2020-05-01","2020-05-01","Cancer Syndrome, Hereditary; Cancer Syndromes, Hereditary; Cancer predisposition; Familial Neoplastic Syndrome; Familial Tumor Syndrome; Germline Neoplastic Syndrome",""
"phs001868.v1.p1","Genetic Architecture of Susceptibility to Melanoma","Most genetic susceptibility to cutaneous melanoma (CM) remains to be discovered. Meta-analysis genome-wide association study (GWAS) of 36,760 melanoma cases (67% newly-genotyped) and 375,188 controls identified 54 significant loci with  68 independent SNPs. Analysis of risk estimates across geographical regions and host factors suggests the acral melanoma subtype is uniquely","Not Applicable","Melanoma","Case-Control","HumanOmniExpress-24","SNP Genotypes (Array)","4 phenotype datasets, 24 variables, 1 analyses, 1 molecular datasets, 11234 subjects, 11234 samples","","NCI","GRU --- General Research Use","2020-04-24","2020-04-24","Nevus; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001743.v1.p1","Contribution of Systemic and Somatic Factors to Clinical Response and    Resistance in Urothelial Cancer","Patients with metastatic urothelial cancer (n 29) were treated with atezolizumab (anti-PD-L1). All 29 patients had T-cell receptor sequencing (TCR-seq) of the pre-treatment blood; 24 also had TCR-seq on at  least one post-treatment blood sample. 24 patients had TCR-seq of their pre-treatment tumors. TCR-seq data can be found at","Not Applicable","Urologic Neoplasms","Prospective Longitudinal Cohort","WES_markerset_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 37 variables, 1 molecular datasets, 78 samples sequenced,  SRA, 29 subjects, 78 samples","","NCI","DS-BLADDERCA-GSO --- Disease-Specific (Bladder Cancer, GSO)","2020-04-24","2020-04-24","Neoplasm of Urinary System; Neoplasm of the Urinary System; Neoplasm, Urinary Tract; Neoplasm, Urologic; Neoplasm, Urological; Neoplasms, Urinary Tract",""
"phs002011.v1.p1","PLCO - Limited Use Pilot Test Data","This is a sample of Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial data for limited use in a pilot test for remote data access. The PLCO is a  randomized, controlled trial of screening tests for prostate, lung, colorectal and ovarian cancers. Approximately 155,000 participants were enrolled","Not Applicable","Early Detection of Cancer","Clinical Trial","Not Provided","Not Provided","Not Provided","","NCI","CADM --- Research relating to adults diseases and methods","2020-04-21","","Not Provided",""
"phs001947.v1.p1","Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma    Evaluated After Starting Hu14.18-IL2 Predicts Outcome","Background: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune  and/or tumor biomarkers in melanoma patients at high risk for recurrence. Methods: Patients were randomized to receive the first of 3 monthly-courses","Not Applicable","Melanoma","Prospective Longitudinal Cohort","Not Provided","Not Provided","5 phenotype datasets, 31 variables,  SRA, 23 subjects, 23 samples","","NCI","GRU --- General Research Use","2020-04-21","2020-04-21","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001940.v2.p1","Genomic Determinants of Response to Immunotherapy","This study evaluates integrated genomic models of response to immune checkpoint blockade for lung cancer patients. A computationally adjusted tumor mutation burden was combined with HLA class I genetic variation,  mutational smoking signature and activating mutations in receptor tyrosine kinase genes to generate a prognostic classifier that outperforms tumor","Not Applicable","Carcinoma, Non-Small-Cell Lung","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 18 variables, 72 samples sequenced,  SRA, 36 subjects, 72 samples","","NCI","HMB-IRB --- Health/Medical/Biomedical (IRB)","2020-04-17","2020-01-13","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs000876.v2.p1","Transdisciplinary Research Into Cancer of the Lung (TRICL)","The study was conducted under the auspices of the Transdisciplinary Research In Cancer of the Lung (TRICL) Research Team, which is a part of the Genetic Associations and MEchanisms in  ONcology (GAME-ON) consortium, and associated with the International Lung Cancer Consortium (ILCCO). Ethics All participants provided written","Not Applicable","Lung Neoplasms","Case-Control","WES_markerset_grc37, Axiom_GW_Human_Origins","Not Provided","2 phenotype datasets, 11 variables, 2030 samples sequenced, 12178 subjects, 12225 samples, 3 substudies","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), HMB-MDS --- Health/Medical/Biomedical (MDS), LCRF --- Lung Cancer Risk Factors, DS-LCS-RD --- Disease-Specific (Lung Cancer or Smoking, RD), GRU-COL --- General Research Use (COL), DS-CA-PUB --- Disease-Specific (Cancer, PUB), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-04-10","2020-04-10","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001681.v1.p1","Transdisciplinary Research Into Cancer of the Lung (TRICL) - Affymetrix","This sub-study phs001681 Affy Axiom Array contains genotype, sequence data, and selected phenotype of subjects available from the phs001681 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research  Cohort study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level","Transdisciplinary Research Into Cancer of the Lung (TRICL) (phs000876.v2.p1)","Lung Neoplasms","Case-Control","Axiom_GW_Human_Origins","SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 10195 subjects, 10195 samples","European (8923), East Asian (385), African American (10), Hispanic1 (67), Hispanic2 (268), Other Asian or Pacific Islander (317), South Asian (15), Other (193)","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), HMB-MDS --- Health/Medical/Biomedical (MDS), LCRF --- Lung Cancer Risk Factors, DS-LCS-RD --- Disease-Specific (Lung Cancer or Smoking, RD), GRU-COL --- General Research Use (COL), DS-CA-PUB --- Disease-Specific (Cancer, PUB), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-04-10","2020-04-10","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs000878.v2.p1","Transdisciplinary Research Into Cancer of the Lung (TRICL) - Exome Plus    Targeted Sequencing","This sub-study phs000878 CIDR Lung Cancer contains genotype, sequence data, and selected phenotype of subjects available from the phs000878 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research  Cohort study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level","Transdisciplinary Research Into Cancer of the Lung (TRICL) (phs000876.v2.p1)","Lung Neoplasms","Case-Control","WES_markerset_grc37","SNP/CNV Genotypes (NGS), WXS, SNP/CNV Genotypes (NGS), WXS","2 phenotype datasets, 14 variables, 1 molecular datasets, 2030 samples sequenced,  SRA, 1942 subjects, 2030 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), HMB-MDS --- Health/Medical/Biomedical (MDS), LCRF --- Lung Cancer Risk Factors, DS-LCS-RD --- Disease-Specific (Lung Cancer or Smoking, RD), GRU-COL --- General Research Use (COL), DS-CA-PUB --- Disease-Specific (Cancer, PUB), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-04-10","2020-04-10","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs000877.v2.p1","Transdisciplinary Research Into Cancer of the Lung (TRICL) - Meta    Analysis","This sub-study phs000877 Meta Analysis contains genotype, sequence data, and selected phenotype of subjects available from the phs000877 study. Summary level phenotypes for the NCI Lung Cancer Transdisciplinary Research Cohort  study participants can be viewed at the top-level study page phs000876 Lung Cancer Transdisciplinary Research Cohort. Individual level phenotype data","Transdisciplinary Research Into Cancer of the Lung (TRICL) (phs000876.v2.p1)","Lung Neoplasms","Case-Control","Not Provided","Not Provided","3 analyses","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), HMB-MDS --- Health/Medical/Biomedical (MDS), LCRF --- Lung Cancer Risk Factors, DS-LCS-RD --- Disease-Specific (Lung Cancer or Smoking, RD), GRU-COL --- General Research Use (COL), DS-CA-PUB --- Disease-Specific (Cancer, PUB), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-04-10","2020-04-10","Adenocarcinoma; Neoplasms, Squamous Cell; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant",""
"phs001964.v1.p1","Women's Health Study Accelerometry Dataset","Background The Women's Health Study (WHS) was a randomized trial testing low-dose aspirin and vitamin E for preventing cancer and CVD among 39,876 women aged &#x02265;45 years throughout the US  from 1992-2004. When the trial ended as planned, women who were willing to participate continued in an observational follow-up study. Participants in","Not Applicable","Exercise","Prospective Longitudinal Cohort","Not Provided","Not Provided","5 phenotype datasets, 90 variables, 9 documents, 17062 subjects","","NCI","GRU --- General Research Use","2020-03-19","2020-03-19","Sedentary Behavior; Behavior, Sedentary; Lifestyle, Sedentary; Sedentary Behaviors; Sedentary Lifestyle; Sedentary life style","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001722.v1.p1","Understanding the Progression of Metastatic Colorectal Cancer","This study is to understand (1) the clonal evolution of metastatic colorectal cancer using DNA sequencing and (2) long non-coding RNAs associated with metastatic colon cancer using RNA sequencing. Our  goal is to better understand the progression of aggressive colorectal cancer. All metastatic colon cancer patients coming in for surgery were","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture, WGS, WXS","219 samples sequenced, 20 subjects, 219 samples","","NCI","GRU --- General Research Use","2020-03-17","2020-03-17","Neoplasm Metastasis; CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001919.v1.p1","PAK4 Inhibition Improves PD-1 Blockade Immunotherapy","Introduction with rationale and aims for study Immune checkpoint blockade therapies have significantly altered the current landscape of cancer treatment. However, this immunotherapy still fails more often than it succeeds.  There are now evidences that the lack of tumour infiltration by immune cells is the main mechanism of primary resistance to PD&#x02010;1 blockade","Not Applicable","Melanoma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","5 phenotype datasets, 27 variables, 60 samples sequenced,  SRA, 39 subjects, 60 samples","","NCI","HMB-PUB-NPU-MDS --- Health/Medical/Biomedical (PUB, NPU, MDS)","2020-03-13","2020-03-13","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001221.v1.p1","ProHealth: Kaiser Permanente Genome-wide Association Study of Prostate    Cancer","A genome-wide association study (GWAS) of prostate cancer (PCa) was conducted in Kaiser Permanente (KP) Northern California health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0%  East Asian, and 7.8% Latino) [PMID: 26034056]. The data for these members were drawn from three KP cohort studies: Research Program in Genes,","Not Applicable","Prostatic Neoplasms","Prospective Longitudinal Cohort","Axiom_GW_EUR, Axiom_GW_EAS, Axiom_GW_EUR, Axiom_Exome_plus, Axiom_GW_AFR, Axiom_GW_LAT, Axiom_GW_EAS, Axiom_GW_LAT, Axiom_GW_AFR, Axiom_Exome_plus, imputation_panel","SNP/CNV (Array), SNP/CNV Genotypes (imputed)","6 phenotype datasets, 72 variables, 2 molecular datasets, 34736 subjects, 34736 samples","","NCI","DS-PC-IRB-NPU-MDS --- Disease-Specific (Prostate Cancer, IRB, NPU, MDS)","2020-03-12","2020-03-12","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001861.v1.p1","Single Cell Analysis Reveals New Evolutionary Complexity in Uveal    Melanoma","Uveal melanoma (UM) is a rare eye cancer that is highly aggressive and leads to metastatic death in up to half of patients. Here, we conduct droplet-based single-cell RNA sequencing  of 59,915 neoplastic and non-neoplastic cells from 8 primary and 3 metastatic UMs. Single-cell VDJ sequencing of RNA is conducted to determine","Not Applicable","Uveal melanoma","Case Set","Not Provided","RNA-Seq, WGA","3 phenotype datasets, 15 variables, 24 samples sequenced,  SRA, 11 subjects, 24 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2020-03-11","2020-03-11","Not Provided",""
"phs001177.v2.p1","Rare Germline Variations in Familial Melanoma","Although a number of high-risk melanoma genes have been identified, they account for melanoma risk in less than 40% of melanoma-prone families. The major goals of our research are to  identify novel high-penetrance genes for familial melanoma in melanoma-prone families without known mutations and to identify modifier factors,","Not Applicable","Melanoma, Cutaneous Malignant","Family/Twin/Trios","HumanOmniExpress-12","SNP Genotypes (Array), RNA-Seq, Targeted-Capture, WXS","5 phenotype datasets, 21 variables, 1 molecular datasets, 3381 samples sequenced,  SRA, 3357 subjects, 3495 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2020-03-09","2017-03-30","CMM; Cutaneous Malignant Melanoma; Cutaneous Malignant Melanomas; Cutaneous melanoma; MELANOMA, MALIGNANT; MM (malignant melanoma) of skin","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001895.v2.p1","Genome Sequencing of Lung Cancer in European Americans and African    Americans","The goal of this study is to compare the somatic mutation landscape between European Americans and African Americans. It includes various histological forms of lung cancer. In LUAD, we find  increased prevalence of PTPRT and JAK2 mutations among African Americans. These proteins function in the same pathway and as such, this may be a new","Not Applicable","Lung Neoplasms","Case-Control","OncoScan_CNV_plus","CNV Genotypes, Targeted-Capture","4 phenotype datasets, 17 variables, 1 molecular datasets, 356 samples sequenced,  SRA, 286 subjects, 578 samples","","NCI","GRU --- General Research Use","2020-03-05","2020-03-05","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001858.v1.p1","Germline Variants of Clinical Cancer Specimens","These clinical specimens represent solid tumors and matched blood controls that were collected as part of patients' routine care at Memorial Sloan Kettering Cancer Center. They were sequenced on the  targeted platform MSK-IMPACT. Here, we performed germline variant calling on the normal blood specimens and assessed their zygosity in the","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","other","SNV (.MAF)","4 phenotype datasets, 16 variables, 1 molecular datasets,  SRA, 17152 subjects, 34304 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2020-02-25","2020-02-25","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001461.v1.p1","Temporal and Clonal Progression in Pediatric Ependymoma","Whole genome and exome-based DNA sequencing of germline and tumor specimens from serial samples of a single patient's ependymoma. The findings reveal the extent to which treatment with radiation and  chemotherapies resulted in the diversification of the tumor subclonal architecture and shaped the neo-antigen landscape, and provide new insights","Not Applicable","Ependymoma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 16 variables, 11 samples sequenced, 1 subjects, 11 samples","","NCI","DS-BT-PUB-NPU-MDS --- Disease-Specific (Brain Tumors, PUB, NPU, MDS)","2020-02-24","2020-02-24","Supratentorial Neoplasms; Cellular Ependymoma; Clear Cell Ependymoma; Brain Neoplasms, Supratentorial; Neoplasm, Supratentorial; Neoplasms, Supratentorial",""
"phs001853.v1.p1","MGH Gastrointestinal Malignancies Resistance Initiative","Tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique molecular resistance alterations in different metastatic lesions in an individual patient, under the selective pressure of therapy1-3. Studies  have suggested that liquid biopsy may better capture the heterogeneity of acquired resistance, but systematic, direct comparisons of post-progression","Not Applicable","Colorectal Neoplasms","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 21 variables, 44 samples sequenced, 15 subjects, 44 samples","","NCI","DS-GICA-MDS --- Disease-Specific (Gastric Cancer, MDS)","2020-02-21","2020-02-21","Esophageal Neoplasms; Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular",""
"phs001953.v1.p1","Genomic Profiling of Metastatic Uveal Melanoma","Up to 50% of patients with uveal melanoma (UM) develop metastatic disease, for which there is no effective systemic treatment. This study aimed to evaluate the safety and efficacy of  the orally available protein kinase C inhibitor, AEB071, in patients with metastatic UM, and to perform genomic profiling of metastatic tumor","Not Applicable","Uveal Neoplasms","Clinical Trial","Not Provided","WXS","3 phenotype datasets, 11 variables, 89 samples sequenced,  SRA, 89 subjects, 89 samples","","NCI","DS-UM-GSO --- Disease-Specific (Uveal Melanoma, GSO)","2020-02-14","2020-02-14","Eye Neoplasms; Neoplasm Metastasis; Cancer of Eye; Cancer of the Eye; Cancer, Eye; Cancers, Eye",""
"phs001931.v1.p1","Count Me In: Angiosarcoma Project (CMI-ASCproject)","Count Me In - The Angiosarcoma Project: A Patient-Partnered Research Initiative to Accelerate Research in a Rare Sarcoma The Angiosarcoma Project (ASCproject) is a research study that directly engages angiosarcoma  patients online and empowers them to accelerate cancer research by sharing medical information and clinical samples. Angiosarcoma is an exceedingly","Not Applicable","Sarcoma","Prospective Longitudinal Cohort","Not Provided","Not Provided","4 phenotype datasets, 10 variables,  SRA, 36 subjects, 84 samples","","NCI","GRU --- General Research Use","2020-02-14","2020-02-14","Angiosarcoma; Angiosarcomas; Hemangioendothelial sarcoma; Hemangiosarcomas; Malignant hemangioendothelioma; angiosarcoma (disease)","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001811.v1.p1","Molecular Determinants of Tumor Behavior in Early Lung Adenocarcinoma","Lung adenocarcinoma is the leading cause of cancer death worldwide and a heterogeneous disease with poor survival in the advanced stage. Given that the frequency of early diagnosis is increasing,  the investigation of the molecular determinants of disease progression is paramount. Prediction of whether the tumor is indolent or aggressive has","Not Applicable","Adenocarcinoma of Lung","Prospective Longitudinal Cohort","Not Provided","Targeted-Capture","4 phenotype datasets, 24 variables, 102 samples sequenced,  SRA, 102 subjects, 102 samples","","NCI","DS-LC-NPU --- Disease-Specific (Lung Cancer, NPU)","2020-02-12","2020-02-12","Adenocarcinoma in Situ; AIS; AIS - Adenocarcinoma in situ; Adenocarcinoma in Situs; Adenocarcinoma, Intraepithelial; Adenocarcinoma, Preinvasive",""
"phs001936.v1.p1","Genome, Exome, and Transcriptome Sequencing of Gastric Cancer","The integration of exogenous DNA into the human genome can cause somatic mutations associated with oncogenesis. For example, the insertion of HPV DNA into human chromosomes is the single most  important event leading to tumorigenesis in cervical cancer. It is also now preventable with vaccines against HPV. In contrast to viral DNA","Not Applicable","Gastrointestinal Neoplasms","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 15 variables, 19 samples sequenced,  SRA, 9 subjects, 19 samples","","NCI","DS-GICA-PUB-NPU-MDS --- Disease-Specific (Gastric Cancer, PUB, NPU, MDS)","2020-01-30","2020-01-30","Cancer of Gastrointestinal Tract; Cancer of the Gastrointestinal Tract; Cancer, Gastrointestinal; Cancers, Gastrointestinal; Gastrointestinal Cancer; Gastrointestinal Cancers",""
"phs001885.v1.p1","Endometrial Cancer Association Consortium - OncoArray Genotypes","The data come from 9 studies participating in the Endometrial Cancer Association Consortium (ECAC). ECAC data included in this dbGaP submission include OncoArray data from 4486 endometrial cancer cases genotyped  at the Center for Inherited Disease Research (CIDR). Samples were genotyped using the Illumina OncoArray beadchip 500K SNP custom array. Details of","Not Applicable","Endometrial Neoplasms","Case Set","OncoArray-500K","SNP Genotypes (Array)","4 phenotype datasets, 13 variables, 1 molecular datasets, 4486 subjects, 4486 samples","European (4425), Hispanic1 (3), Hispanic2 (8), South Asian (22), Other (28)","NCI","GRU --- General Research Use, GRU-NPU --- General Research Use (NPU), ENDTU-MDS --- Endometrial Tumors (MDS), DS-BCEMOPCA-NPU-MDS --- Disease-Specific (Breast, Colorectal, Endometrial, Melanoma, Ovarian, and/or Prostate Cancer, NPU, MDS)","2020-01-27","2020-01-27","Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor; Neoplasm of Endometrium; Neoplasm of the Endometrium","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001580.v1.p1","MGH/Broad Hurthle Cell Carcinoma Whole Exome Sequencing Study","In this study, we performed whole-exome sequencing of 41 patients with Hurthle cell carcinoma, a thyroid cancer variant with abundant mitochondria. We were able to identify recurrent somatic mutations in  both the nuclear and mitochondrial genomes of Hurthle cell carcinoma. Our study identifies mutations in DAXX (GeneID: 1616), TP53 ( GeneID:7157),","Not Applicable","Thyroid cancer, Hurthle cell","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 13 variables, 111 samples sequenced,  SRA, 41 subjects, 111 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2020-01-15","2020-01-15","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001917.v1.p1","DNA Methylation Markers and Pancreatic Cancer Risk","Pancreatic cancer is the 4th leading cause of cancer deaths in the US. Due to the lack of early symptoms, pancreatic cancer is difficult to identify at early stages and  no screening is available for the general population. Identifying pancreatic cancer at earlier stages could significantly improve survival with","Not Applicable","Pancreatic Neoplasms","Case-Control","MethylationEPIC","Methylation (CpG)","4 phenotype datasets, 21 variables, 1 molecular datasets, 824 subjects, 824 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2020-01-08","2020-01-08","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas",""
"phs001921.v1.p1","DNA Methylation and Prostate Cancer","The study cohort includes 525 Caucasian and African American prostate cancer (PCa) patients who underwent radical prostatectomy (RP) as primary therapy for clinically localized adenocarcinoma of the prostate. These patients  were previously enrolled in one of two population-based studies: 1) men 40-64 years of age, diagnosed between January 1993 and December 1996; and, 2)","Not Applicable","Prostatic Neoplasms","Prospective Longitudinal Cohort","HumanMethylation450","Methylation (CpG)","4 phenotype datasets, 19 variables, 1 molecular datasets, 525 subjects, 525 samples","","NCI","DS-PRD-PUB-NPU-MDS --- Disease-Specific (Prostate Disease, PUB, NPU, MDS)","2019-12-27","2019-12-27","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001907.v1.p1","CPTAC: Microscaled Proteogenomic Methods for Precision Oncology","Cancer proteogenomics combines genomics, transcriptomics and mass spectrometry-based proteomics to gain insights into cancer biology and treatment outcomes. To promote clinical investigation, we developed a ""microscaled"" proteogenomics approach for tumor-rich  frozen core needle biopsies. Tissue-sparing specimen processing (""Biopsy Trifecta EXTraction"", BioTExt) and microscaled proteomics (MiProt) generated","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","other","RNA-Seq, SNV (.MAF), WXS","3 phenotype datasets, 15 variables, 1 molecular datasets, 58 samples sequenced, 14 subjects, 58 samples","","NCI","HMB-NPU --- Health/Medical/Biomedical (NPU)","2019-12-27","2019-12-27","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001805.v1.p1","Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer, including    KRAS and Her2","Neoantigen-specific T cell responses were characterized in 4 patients with non-small cell lung cancer. Candidate neoantigens were identified by sequencing tumor and normal DNA from each patient, and ranking single  nucleotide variants by expression. Multiple T cell responses were isolated, and in two patients with lung adenocarcinoma, CD4+ T cell responses to","Not Applicable","Adenocarcinoma of Lung","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 16 variables, 10 samples sequenced,  SRA, 4 subjects, 10 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2019-12-26","2019-12-26","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs001713.v1.p1","LCCC 1108 (UNCseqTM)","The primary objective of this specimen correlative study was two-fold: to provide a mechanism for the association of known molecular alterations with clinical outcomes, and to provide rapid genetic profiling  of alterations with known clinical utility using tumor and germline specimens to support treatment decisions. Inclusion Criteria: 1.Current or","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","Targeted-Capture","4 phenotype datasets, 14 variables, 3558 samples sequenced,  SRA, 2074 subjects, 3558 samples","","NCI","GRU --- General Research Use","2019-12-26","2019-12-26","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000178.v11.p8","The Cancer Genome Atlas (TCGA)","The Cancer Genome Atlas (TCGA) is a comprehensive and coordinated effort to accelerate our understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale  genome sequencing. TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), which are","Not Applicable","Neoplasms","Tumor vs. Matched-Normal","WGS_markerset_grc37","Not Provided","3 phenotype datasets, 8 variables, 11429 subjects, 11467 samples, 1 substudies","","NCI","GRU --- General Research Use","2019-12-18","2018-08-17","Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Esophageal Neoplasms; Invasive Ductal Carcinoma, Breast","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000854.v3.p8","Genome-Wide Analysis of Noncoding Regulatory Mutations in Cancer","Large-scale sequencing of human tumor samples has transformed the identification of somatic genetic alterations that drive the cancer phenotype. However, most efforts have focused on the protein-coding exome, which comprises  less than 2% of the human genome. Here, we analyzed whole genome sequences from The Cancer Genome Atlas with a focus on recurrently mutated","National Institutes of Health The Cancer Genome Atlas (TCGA) (phs000178.v11.p8)","Neoplasms","Tumor vs. Matched-Normal","WGS_markerset_grc37","SNV Aggregate (.MAF)","2 phenotype datasets, 4 variables, 1 molecular datasets, 356 subjects, 356 samples","","NCI","GRU --- General Research Use","2019-12-18","2018-08-17","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001906.v1.p1","Altered topology drives oncogenic programs in SDH-deficient GIST","Metabolic lesions with pleiotropic effects on epigenetic regulation and other cellular processes are widely implicated in cancer, yet their oncogenic mechanisms remain poorly understood. Succinate dehydrogenase (SDH) deficiency causes a  subset of gastrointestinal stromal tumors (GISTs) with DNA hyper-methylation. Here we associate this hyper-methylation with changes in chromosome","Not Applicable","Gastrointestinal Stromal Tumors","Case Set","Not Provided","Bisulfite-Seq, ChIP-Seq, RNA-Seq","5 phenotype datasets, 18 variables, 84 samples sequenced,  SRA, 22 subjects, 84 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), HMB --- Health/Medical/Biomedical","2019-12-17","2019-12-17","GI stroma tumor; GI stroma tumour; GIST; GIST - Gastrointestinal stromal tumor; Gastrointestinal Stromal Neoplasm; Gastrointestinal Stromal Neoplasms","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001877.v1.p1","Genetics of Cutaneous T-Cell Lymphoma","Mycosis fungoides (MF) is a common extranodal T-cell lymphoma primarily arising in the skin. In early disease stages, MF presents as skin patches and plaques that in some cases may  progress to tumor and disperse to lymph nodes and other internal organs. The 10-year overall survival is 50% in advanced stages. Early diagnosis is","Not Applicable","Mycosis Fungoides","Case-Control","Not Provided","WXS","4 phenotype datasets, 15 variables, 82 samples sequenced, 31 subjects, 82 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2019-12-16","2019-12-16","Lymphoma, T-Cell, Cutaneous; Granulomatous Slack Skin; Slack Skin, Granulomatous",""
"phs001337.v1.p1","AACR Project GENIE","AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international pancancer registry of real-world data assembled through data sharing between 19 leading international cancer centers with the goal of  improving clinical decision-making. The registry leverages ongoing clinical sequencing efforts (CLIA/ISO-certified) at participating cancer centers","Not Applicable","Neoplasms","Case Set","Not Provided","Not Provided","2 phenotype datasets, 6 variables, 46510 subjects, 48447 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2019-12-09","2019-12-09","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001854.v1.p1","Human Pilocytic Astrocytoma Single Cell RNA Sequencing","Pilocytic astrocytoma (PA), the most common childhood brain tumor, is a low-grade glioma with a single driver BRAF rearrangement. Here, we perform scRNAseq in six PAs using methods that enabled  detection of the rearrangement. When compared to higher-grade gliomas, a strikingly higher proportion of the PA cancer cells exhibit a","Not Applicable","Astrocytoma","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 11 variables, 1234 samples sequenced,  SRA, 6 subjects, 1234 samples","","NCI","DS-NDR-MDS --- Disease-Specific (Neurological Disorders Research, MDS)","2019-12-03","2019-12-03","ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas",""
"phs001433.v1.p1","Non-coding RNAs Activated in Hepatoblastoma","Hepatoblastoma (HB) is the most common pediatric liver tumor, affecting mostly children under 3 years of age. This rare tumor represents 1% of all pediatric cancers. Genetic studies have shown  that HB is characterized by high frequency mutations of the CTNNB1 gene encoding beta-catenin (around 75%) and relative genomic stability. Here we","Not Applicable","Hepatoblastoma","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 42 samples sequenced, 21 subjects, 42 samples","","NCI","HMB --- Health/Medical/Biomedical","2019-11-27","2019-11-27","","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001910.v1.p1","Enhancer Signatures of Neuroendocrine Tumors","Most pancreatic neuroendocrine tumors (PNETs) do not produce symptoms of hormonal excess and are hence considered &#x0201c;non-functional&#x0201d;. Their clinical behaviors vary widely, emphasizing the need for a robust classification with  prognostic power. Using enhancer maps to infer regulatory programs, we find that the large majority of non-functional PNETs fall into two major","Not Applicable","Neuroendocrine Tumors","Case Set","Not Provided","ChIP-Seq, RNA-Seq","5 phenotype datasets, 16 variables, 62 samples sequenced, 46 subjects, 62 samples","","NCI","HMB --- Health/Medical/Biomedical, DS-PACA-MDS --- Disease-Specific (Pancreatic Cancer, MDS), DS-PACA-NPU-MDS --- Disease-Specific (Pancreatic Cancer, NPU, MDS)","2019-11-25","2019-11-25","","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001797.v1.p1","UW TAN Study of Metastatic Urothelial Carcinoma","Patients with metastatic urothelial carcinoma treated at our institution, who elected to undergo rapid autopsy at the time of death, are included in this study. These patients agreed to submit  their tissue (normal samples for germline analysis [kidney or liver] as well as primary and metastatic tumor sites [urothelial carcinoma]) and the","Not Applicable","Urogenital Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 30 variables, 46 samples sequenced, 7 subjects, 46 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2019-11-21","2019-11-21","Genito-urinary Neoplasm; Genito-urinary Neoplasms; Genitourinary Neoplasm; Genitourinary tract neoplasia; Genitourinary tract neoplasm; Genitourinary tract tumors",""
"phs001083.v1.p1","99 Cases of Small Cell Lung Cancer Study","Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however,  much still remains unknown, particularly in the Asian patient population. Here we conducted whole exome sequencing (WES) and transcriptomic","Not Applicable","Small Cell Lung Carcinoma","Case Set","Not Provided","WXS","99 samples sequenced, 99 subjects, 99 samples","","NCI","GRU-PUB-MDS --- General Research Use (PUB, MDS)","2019-11-21","2019-11-21","Carcinoma, Small Cell Lung; Lung Small Cell Neuroendocrine Carcinoma; Lung oat cell carcinoma; Oat Cell Carcinoma of Lung; Oat Cell Lung Cancer; SCCL",""
"phs001045.v1.p1","Molecular Epidemiology of Colorectal Cancer (MECC) Metastasis Study","This study compared Ashkenazi Jewish individuals with Stage IV metastatic colon cancer to those with non-metastatic Stage I or II colon cancers. A genome-wide association study, using a 2-stage design,  identified a significant association with rs60745952. Inclusion Criteria Cases Diagnosis with a primary colorectal cancer Stage IV, Stage I, Stage II","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 molecular datasets, 323 subjects, 323 samples","","NCI","DS-CC --- Disease-Specific (Colorectal Cancer)","2019-11-21","2019-11-21","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001924.v1.p1","Case Study of Acquired Resistance to FGFR Inhibition in    Cholangiocarcinoma","Targeted sequencing was performed on blood, tumor, and cell free DNA samples from an FGFR2-fusion positive cholangiocarcinoma patient before and after treatment with an FGFR targeted therapy. Inclusion Criteria: 1.  A histologically or cytologically confirmed diagnosis of cancer 2. Patients with any malignancy 3. Patients must have tumor suitable for research","Not Applicable","Cholangiocarcinoma","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 15 variables, 8 samples sequenced,  SRA, 1 subjects, 8 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2019-11-15","2019-11-15","Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular; Cholangiocar.- intra/extrahepatic",""
"phs001742.v2.p1","Clonal Mapping of Multi-Organ Metastasis and Chemoresistance in Triple    Negative Breast cancer","Clonal dynamics during metastasis were studied in two patient-derived xenograft (PDX) models established from treatment-naive primary breast tumors from TNBC patients diagnosed with concurrent metastatic disease. Genomic sequencing and barcode-mediated  clonal tracking revealed robust alterations in clonal architecture between primary tumors and metastases. Polyclonal seeding and maintenance of","Not Applicable","Triple Negative Breast Neoplasms","Case-Control","Not Provided","RNA-Seq, Targeted-Capture, WXS","4 phenotype datasets, 21 variables, 113 samples sequenced,  SRA, 4 subjects, 113 samples","","NCI","GRU --- General Research Use","2019-11-15","2019-11-15","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000929.v1.p1","High-Risk Breast Cancer GWAS","The GWAS includes High Risk Women from the following epidemiological studies of breast cancer, comprising a total of 3,719 cases and 3,642 controls (cases/controls: MEC, 0/200; ABCFR, 326/418; FCCC, 56/3;  BCFR-UT, 66/32; CNIO-BC, 87/92; GESBC, 65/0; LIFE, 164/0; MARIE, 41/105; MAYO, 208/210; MNYR, 293/409; MSKCC, 310/0; NC-BCFR, 234/233; OFBCR,","Not Applicable","Breast Neoplasms","Case-Control","OncoArray, imputation_panel","SNP Genotypes (Array), SNP/CNV Genotypes (imputed)","4 phenotype datasets, 25 variables, 2 molecular datasets, 7258 subjects, 7369 samples","European (6974), African (6), East Asian (28), African American (63), Hispanic1 (82), Hispanic2 (46), Other Asian or Pacific Islander (12), South Asian (20), Other (27)","NCI","GRU --- General Research Use, HMB-PUB --- Health/Medical/Biomedical (PUB), DS-CA-IRB-PUB-COL-NPU-MDS-GSO --- Disease-Specific (Cancer, IRB, PUB, COL, NPU, MDS, GSO), DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), CABNHD-MDS --- Cancer, Benign Neoplasms, or Hematopoietic Diseases (MDS), DS-BROC-GSO --- Disease-Specific (Breast and Ovarian cancer, GSO), DS-CA-GSO --- Disease-Specific (Cancer, GSO), DS-BRCA-PUB-MDS --- Disease-Specific (Breast Cancer, PUB, MDS), DS-BRD --- Disease-Specific (Breast Diseases), DS-CA-PUB --- Disease-Specific (Cancer, PUB)","2019-11-13","2019-11-13","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000828.v1.p1","Genomic Analysis of Hepatocellular Carcinoma","Fibrolamellar hepatocellular carcinoma (FL-HCC) is a very rare and distinct subtype of hepatocellular carcinoma that occurs in the previously healthy livers of adolescents and young adults. The low incidence rate  has kept FL-HCC an understudied cancer, thus the list of FL-HCC markers is limited and the genetic alterations driving its growth have remained","Not Applicable","Fibrolamellar hepatocellular carcinoma","Case Set","WGS_markerset_grc37","RNA-Seq, SNP Genotypes (NGS), WGS, WXS","3 phenotype datasets, 14 variables, 1 molecular datasets, 5 samples sequenced,  SRA, 1 subjects, 5 samples","","NCI","DS-PLC-GSO --- Disease-Specific (Pediatric Liver Cancer, GSO)","2019-11-13","2019-11-13","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells",""
"phs001444.v2.p1","Genomic Variation in Diffuse Large B Cell Lymphomas","Integrative analysis of genetic lesions in 574 diffuse large B cell lymphomas (DLBCL). The study investigates genomic structural variation, genetic alteration and its effect on the development and biology of  lymphomas by using high throughput sequencing, gene expression, and methylation status. Clinically diagnosed as DLBCL Note: Controlled datasets at","Not Applicable","Lymphoma, Large B-Cell, Diffuse","Case Set","Not Provided","Not Provided","2 phenotype datasets, 7 variables, 489 subjects, 1916 samples","","NCI","GRU --- General Research Use","2019-11-08","","Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001465.v1.p1","Multiregion Sequencing of Localized Prostate Cancer","Ten patients with treatment-na&#x000ef;ve, locally advanced or localized prostate cancer underwent radical prostatectomy. Pathological stage ranged from T2aN0 to T3bN1, and Gleason scores from 3+4 to 4+5. Tumor foci were  mapped, and DNA was extracted from multiple (5-9) regions from a single, contiguous index focus. Whole exome sequencing was performed to identify","Not Applicable","Prostatic Neoplasms","Case Set","other","SNV (.MAF), WGS, WXS","4 phenotype datasets, 44 variables, 1 molecular datasets, 153 samples sequenced,  SRA, 10 subjects, 153 samples","","NCI","DS-CA-IRB-NPU --- Disease-Specific (Cancer, IRB, NPU)","2019-11-04","2019-11-04","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001499.v1.p1","CORECT: Meta-analysis","This study is part 2 of 2 for Schumacher et al, Nat Communication. 2015 Jul 7;6:7138. Part 2 is the pooled meta-analysis of 29 different studies of 37,955 European (18,299  Cases/19,656 Controls) participants using eight different genotyping platforms/variations. Study Name Participants Platform CFR-1 2976 Illumina 1M,","Not Applicable","Colorectal Neoplasms","Case-Control","Not Provided","Not Provided","1 analyses","","NCI","DS-CC --- Disease-Specific (Colorectal Cancer)","2019-10-25","2019-10-25","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001534.v1.p1","Pathways Study","The Pathways Study (NCI R01 CA105274, PI: Kushi), is a prospective cohort study of a diverse population of recently diagnosed breast cancer survivors in KPNC. The aims are to examine  the effect on recurrence and survival of 1) lifestyle factors such as diet, physical activity, and use of complementary and alternative therapies and","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","MEGA_Consortium_Array_plus, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 34 variables, 2 molecular datasets, 4383 subjects, 4576 samples","European (2993), African (11), East Asian (334), African American (324), Hispanic1 (32), Hispanic2 (384), Other Asian or Pacific Islander (196), South Asian (49), Other (53)","NCI","DS-BRCA-IRB-PUB-NPU-MDS --- Disease-Specific (Breast Cancer, IRB, PUB, NPU, MDS)","2019-10-18","2019-10-18","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000897.v1.p1","Mayo Clinic and Illumina Collaborative Early Stage Ovarian Cancer (ESOC)    Study","Twenty five patients with early stage carcinoma (Stage I and II) of the ovary were consented for this study. As part of a collaborative agreement with Illumina Inc, Tumor-DNA and  patient matched normal DNA from blood underwent whole genome sequencing and microarray genotyping and RNA underwent RNASeq. Tissue also underwent IHC","Not Applicable","Cystadenocarcinoma, Serous","Case Set","HumanHap650Y","SNP Genotypes (Array), RNA-Seq, WGS","4 phenotype datasets, 63 variables, 1 molecular datasets, 32 samples sequenced,  SRA, 16 subjects, 142 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2019-10-18","2019-10-18","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001847.v1.p1","Understanding RNA Biology and Therapeutics in Hematopoiesis and Leukemia","Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and is expected to increase in frequency as the population ages. Most subtypes of AML are  difficult to treat, in part due to a lack of understanding of possible molecular targets. Furthermore, the peak incidence of AML is in the sixth","Not Applicable","Leukemia, Myeloid, Acute","Prospective Longitudinal Cohort","Not Provided","WGS","4 phenotype datasets, 15 variables, 4 samples sequenced, 2 subjects, 4 samples","","NCI","GRU --- General Research Use","2019-10-17","2019-10-17","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001799.v1.p1","Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis","Chronic neutrophilic leukemia (CNL), atypical chronic myeloid leukemia (aCML), and unclassified myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN-U) are a group of rare, heterogeneous myeloid disorders. There is strong morphologic resemblance amongst these  distinct diagnostic entities as well as lack of specific molecular markers and limited understanding of disease pathogenesis, which has made their","Not Applicable","Leukemia","Prospective Longitudinal Cohort","Not Provided","Not Provided","3 phenotype datasets, 9 variables, 176 subjects, 238 samples","","NCI","DS-LEU --- Disease-Specific (Leukemia)","2019-10-17","2019-10-17","Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia; Leucocythemias",""
"phs001864.v1.p1","MAP Kinase-Mutant Hematologic Malignancies and Their Therapeutic    Resistance","The Mitogen-Activated Protein Kinase (MAPK) signaling pathway has been critically important in understanding pathology and developing targeted therapy for many cancers, but high frequency mutations in this pathway in hematopoietic  malignancies were unknown until a series of sequencing studies from our group and others revealed a high frequency of activating mutations in BRAF","Not Applicable","Histiocytosis","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 15 variables, 22 samples sequenced, 22 subjects, 22 samples","","NCI","DS-HIST-MDS --- Disease-Specific (Histiocytoses, MDS)","2019-10-08","2019-10-08","Dendritic Cell Sarcoma, Interdigitating; Erdheim-Chester Disease; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Histiocytosis, Non-Langerhans-Cell; Leukemia, Hairy Cell",""
"phs001597.v1.p1","Genomic Analysis of Bevacizumab-induced Hypertension","Bevacizumab use in the treatment of cancer can lead to the development of hypertension in some patients, and high-grade toxicity can limit therapy or lead to cardiovascular complications. The factors  that contribute to interindividual variability in blood pressure rise during bevacizumab treatment are not well understood. In the present study,","Not Applicable","Hypertension","Case-Control","WES_markerset_grc37","SNP Genotypes (NGS)","4 phenotype datasets, 22 variables, 2 analyses, 1 molecular datasets,  SRA, 62 subjects, 62 samples","","NCI","DS-CA-COL --- Disease-Specific (Cancer, COL)","2019-10-08","2019-10-08","Arterial hypertension; BP - High blood pressure; BP+ - Hypertension; Blood Pressure, High; Blood Pressures, High; HBP - High blood pressure",""
"phs001709.v1.p1","Count Me In: Metastatic Breast Cancer Project (CMI-MBCproject)","Count Me In - The Metastatic Breast Cancer Project: A Patient-Driven Research Initiative to Accelerate Metastatic Breast Cancer Research The Metastatic Breast Cancer Project (MBCproject; mbcproject.org) is a research study  that directly engages patients with metastatic breast cancer via social media and advocacy groups and empowers them to accelerate cancer research by","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 11 variables, 454 samples sequenced,  SRA, 200 subjects, 478 samples","","NCI","GRU --- General Research Use","2019-10-04","2019-10-04","Neoplasm Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001839.v1.p1","Deep Sequencing of 3 Cancer Cell Lines on 2 Sequencing Platforms","To test the performance of a new sequencing platform, develop an updated somatic calling pipeline and establish a reference for future benchmarking experiments, we performed whole-genome sequencing of 3 common  cancer cell lines (COLO-829, HCC-1143 and HCC-1187) along with their matched normal cell lines to great sequencing depths (up to 278X coverage) on","Not Applicable","Neoplasms","Case Set","Not Provided","WGS","4 phenotype datasets, 19 variables, 12 samples sequenced, 3 subjects, 12 samples","","NCI","GRU --- General Research Use","2019-09-27","2019-09-27","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001436.v1.p1","Discovering the Genetic Basis of Human Neuroblastoma: A Gabriella Miller    Kids First Pediatric Research Program (Kids First) Project","Children with disseminated neuroblastoma have a very high risk of treatment failure and death despite receiving intensified chemotherapy, radiation therapy and immunotherapy. The long-term goal of our research program is  to ultimately improve neuroblastoma cure rates by first comprehensively defining the genetic basis of the disease. The central hypothesis to be","Not Applicable","Neuroblastoma","Tumor vs. Matched-Normal","Not Provided","Not Provided","2 phenotype datasets, 6 variables,  SRA, 1694 subjects, 2281 samples","","NCI","GRU --- General Research Use","2019-09-25","2019-09-25","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001632.v1.p1","African American Multiple Myeloma GWAS","The case set is from a case-control study designed to identify common genetic risk factors for multiple myeloma in African Americans, the population with the highest risk for this cancer.  We conducted two GWAS and combined each of these with convenience controls consisting of unaffected African American participants in cohorts with","Not Applicable","Multiple Myeloma","Case Set","HumanCoreExome-12, MEGA_Consortium_Array, HumanCoreExome-12, MEGA_Consortium_Array","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 molecular datasets, 1408 subjects, 1408 samples","European (2), African (43), African American (1348), Hispanic1 (8), Other (7)","NCI","GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), GRU-NPU --- General Research Use (NPU), GRU-PUB-NPU --- General Research Use (PUB, NPU), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), DS-MM-MDS --- Disease-Specific (Multiple Myeloma, MDS), DS-CA-IRB-GSO --- Disease-Specific (Cancer, IRB, GSO)","2019-09-06","2019-09-06","Smoldering Multiple Myeloma; Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001687.v1.p1","West Africa Breast Cancer Study (WABCS)","Differences in breast cancer incidence and mortality rates between North American Caucasian and African American women are well-described and transcend socioeconomic issues. Black women are diagnosed with breast cancer at  a younger median age; have more clinically aggressive disease and stage-for-stage; and have higher mortality rates than age-matched Caucasian women.","Not Applicable","Breast Neoplasms","Case-Control","Not Provided","Not Provided","4 phenotype datasets, 63 variables,  SRA, 294 subjects, 722 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2019-08-29","2019-08-29","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001705.v1.p1","NCI-Epidemiology of Burkitt Lymphoma in East African Children and Minors    (EMBLEM)","A genome-wide analysis of genetic structure, gene flow, and natural selection was conducted in populations in the endemic Burkitt lymphoma (eBL) belt in Ghana and Northern Uganda, both subject to  a high incidence of falciparum malaria and eBL. These populations have different ethnolinguistic ancestries and are located 2400 miles apart in","Not Applicable","Burkitt Lymphoma","Case-Control","HumanOmni5Exome-4","SNP Genotypes (Array)","4 phenotype datasets, 15 variables, 1 molecular datasets, 568 subjects, 568 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2019-08-15","2019-08-15","Malaria; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma",""
"phs001781.v1.p1","Proteogenomic Landscape of Squamous Cell Lung Cancer","To provide a detailed analysis on how genomic and transcriptomic alterations related to proteome level changes in squamous cell lung cancer (SCC), we performed an integrated analysis incorporating DNA copy  number, somatic mutations, expression RNA-sequencing, and expression proteomics in 108 SCC nested within clinical outcome, tumor pathology, and other","Not Applicable","Carcinoma, Non-Small-Cell Lung","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 18 variables, 108 samples sequenced,  SRA, 108 subjects, 108 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2019-08-14","2019-08-14","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001428.v1.p1","GWAS for Breast Cancer Chemotherapy Toxicities in S0221","When undergoing treatment for breast cancer, many women experience severe side effects, some of which result in treatment-related death and some that can persist for years. Little is understood regarding  factors that may predict drug toxicities. Pharmacogenetics, the investigation of variants in candidate genes in drug metabolism pathways, has been","Not Applicable","Peripheral Nervous System Diseases","Clinical Trial","HumanOmni1-Quad","SNP Genotypes (Array)","4 phenotype datasets, 24 variables, 1 molecular datasets, 1847 subjects, 1847 samples","European (1465), African (5), East Asian (46), African American (161), Hispanic1 (24), Hispanic2 (106), Other Asian or Pacific Islander (29), South Asian (6), Other (5)","NCI","DS-BRCATOX-COL-MDS-GSO --- Disease-Specific (Breast Cancer Treatment Toxicities, COL, MDS, GSO)","2019-08-13","2019-08-13","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001568.v1.p1","Genetic Epidemiology of CLL","Chronic lymphocytic leukemia (CLL) is a subtype of B-cell lymphoproliferative disorders (LPD), and is the most common form of adult leukemia in Caucasians in the United States. Small lymphocytic lymphoma  (SLL) is also a B-cell LPD and is typically considered to be the same disease as CLL, based on pathology. We consider CLL and SLL as the same disease","Not Applicable","Leukemia, Lymphoid","Case-Control","HumanOmni1-Quad","SNP Genotypes (Array)","3 phenotype datasets, 12 variables, 1 molecular datasets, 715 subjects, 715 samples","European (701), East Asian (3), African American (2), Hispanic2 (8), Other Asian or Pacific Islander (1)","NCI","DS-HM-GSO --- Disease-Specific (Hematological Malignancies, GSO)","2019-08-12","2019-08-12","Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia",""
"phs001823.v1.p1","Genome and Transcriptome Analysis of Lung Cancer Cell Lines","We have used a ""chemistry first"" approach to discover druggable acquired vulnerabilities that arised in the pathogenesis of non-small cell lung cancer (NSCLC). We screened chemical libraries ( 200,000 compounds)  for chemical toxins that killed subsets of NSCLC but not normal human lung epithelial cells (HBECs). We first screened a panel of 12 NSCLC lines that","Not Applicable","Carcinoma, Non-Small-Cell Lung","Prospective Longitudinal Cohort","RNAseq_probe_set_grc38, WES_markerset_grc38","RNA-Seq, SNV (.MAF), RNA Seq (NGS), WXS","4 phenotype datasets, 19 variables, 2 molecular datasets, 813 samples sequenced, 279 subjects, 813 samples","","NCI","DS-LC-IRB --- Disease-Specific (Lung Cancer, IRB)","2019-08-09","2019-08-09","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs001284.v1.p1","NCI Waldenstrom Macroglobulinemia Genome-Wide Association Study","A discovery GWAS is performed, consisting of genotyping 221 Waldenstrom macroglobulinemia (WM) cases on the Illumina Omni Express 12v1.1 platform and analyzing the genotypes together with those of 3798 previously  genotyped controls in a model taking into account gender, age, and principal components of ancestry (i.e., significant eigenvectors). Directly","Not Applicable","Waldenstrom Macroglobulinemia","Case-Control","HumanOmniExpress-12, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 17 variables, 2 molecular datasets, 217 subjects, 217 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use","2019-08-09","2019-08-09","Lymphoplasmacytoid Lymphoma; Lymphoma, Lymphocytic, Plasmacytoid; Lymphoma, Lymphoplasmacytoid; Lymphomas, Lymphoplasmacytoid; Lymphoplasmacytoid Lymphomas; Macroglobulinaemia, Waldenstrom's","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001830.v1.p1","Tumor Heterogeneity and Drug Resistance in FGFR2-Fusion    Cholangiocarcinoma","Whole exome sequencing was performed on blood and tumor specimens (collected from biopsy or rapid research autopsy) from a patient with FGFR2 fusion positive cholangiocarcinoma. Inclusion Criteria: 1) A histologically  or cytologically confirmed diagnosis of cancer 2) Patients with any malignancy 3) Patients must have tumor suitable for research tumor biopsy (as","Not Applicable","Cholangiocarcinoma","Case Set","WES_markerset_grc37","CNV Genotypes, WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 12 samples sequenced,  SRA, 1 subjects, 12 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2019-08-06","2019-08-06","Clonal Evolution; Bile duct cancer; CC; CCA; Carcinoma, Cholangiocellular; Carcinomas, Cholangiocellular",""
"phs001680.v1.p1","T Cell States Associated with Response to Checkpoint Blockade in Melanoma","Checkpoint blockade therapy using antibodies targeting CTLA4, PD1 or PDL1 have changed the way cancer patients with advanced disease are being treated, as evident by their FDA approval in a  wide variety of malignancies, and their ability to induce high response rates when compared to conventional therapies (e.g. chemotherapy). However,","Not Applicable","Immunotherapy","Prospective Longitudinal Cohort","Not Provided","ATAC-seq, RNA-Seq, WXS","5 phenotype datasets, 19 variables, 92 samples sequenced, 32 subjects, 98 samples","","NCI","DS-MSC-MDS --- Disease-Specific (Melanoma and Skin Cancer Research, MDS), DS-CA-IRB-PUB --- Disease-Specific (Cancer, IRB, PUB)","2019-07-23","2019-07-23","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant",""
"phs001840.v1.p1","Single-Cell Analysis of Human Pancreatic Ductal Adenocarcinoma","Cancer-associated fibroblasts (CAFs) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma (PDAC). CAFs constitute a diverse cell population consisting of several recently described subtypes, although  the extent of CAF heterogeneity has remained undefined. Here we employ single-cell RNA-sequencing to thoroughly characterize the neoplastic and tumor","Not Applicable","Carcinoma, Pancreatic Ductal","Prospective Longitudinal Cohort","RNAseq_probe_set_grc37","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 15 variables, 1 molecular datasets, 9 samples sequenced, 6 subjects, 9 samples","","NCI","GRU --- General Research Use","2019-07-17","2019-07-17","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001784.v1.p1","Functional Genomics and Molecular Imaging of Liver Disease and Cancer","Molecular imaging with 18F-fluorocholine PET/CT reveals two distinct imaging phenotypes for hepatocellular carcinoma (HCC) as a potential source of non-invasive insight into its molecular heterogeneity. Using gene set enrichment analyses,  we found 18F-fluorocholine-avid tumors to be significantly enriched by genes comprising a subset of previously published HCC-related gene signatures.","Not Applicable","Carcinoma, Hepatocellular","Case Set","HumanHT-12","mRNA Expression (Array)","4 phenotype datasets, 21 variables, 1 molecular datasets,  SRA, 41 subjects, 41 samples","","NCI","DS-LCCLD-COL --- Disease-Specific (Liver Cancer and Chronic Liver Disease, COL)","2019-07-15","2019-07-15","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells",""
"phs001776.v1.p1","NCI LTG Human Pancreas QTL Study","We created a human histologically normal pancreas eQTL resource using 91 fresh frozen tissue samples from patients diagnosed with pancreatic cancer (Mayo Clinic and Memorial Sloan Kettering Cancer Center) or  from organ donors without a history of pancreatic cancer (Penn State University) by RNA-Sequencing. Genome wide genotyping was done using blood","Not Applicable","Pancreas","Case-Control","HumanOmni1-Quad, HumanOmniExpress-12, HumanOmniExpress-12, HumanOmniExpress-24, HumanOmni1-Quad, HumanOmniExpress-12, HumanOmniExpress-12, HumanOmniExpress-24","SNP Genotypes (Array), RNA-Seq","4 phenotype datasets, 16 variables, 1 molecular datasets, 91 samples sequenced,  SRA, 91 subjects, 182 samples","","NCI","DS-PACA-IRB-MDS --- Disease-Specific (Pancreatic Cancer, IRB, MDS), GRU-IRB-PUB-NPU --- General Research Use (IRB, PUB, NPU)","2019-07-12","2019-07-12","Not Provided",""
"phs000740.v1.p1","Whole Genome Sequencing of Waldenstrom's Macroglobulinemia","Whole genome sequencing was conducted on 10 tumor/germline paired samples along with 20 additional unpaired tumor samples from patients with Waldesntrom's macroglobulinemia. Tumor lymphoplasmacytic lymphoma cells were obtained from CD19+  selected bone marrow mononuclear cells. Germline tissue was obtained from CD19 depleted peripheral blood mononuclear cells. High molecular weight DNA","Not Applicable","Waldenstrom Macroglobulinemia","Case-Control","Not Provided","WGS","4 phenotype datasets, 19 variables, 35 samples sequenced,  SRA, 30 subjects, 40 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2019-07-11","2019-07-11","Lymphoma, Lymphocytic, Plasmacytoid; Lymphoma, Lymphoplasmacytoid; Lymphomas, Lymphoplasmacytoid; Lymphoplasmacytoid Lymphoma; Lymphoplasmacytoid Lymphomas; Macroglobulinaemia, Waldenstrom's","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001824.v1.p1","RNASeq of Plasmacytoid Dendritic Cells in Head and Neck Squamous Cell    Cancer","Plasmacytoid dendritic cells (pDC) are a subset of dendritic cells with unique immunophenotypic properties and functions. While their role in antiviral immunity through production of type I interferons is well-established,  their contributions to anti-tumor immunity are less clear. While some evidence demonstrates that pDC in the tumor microenvironment (TME) may drive","Not Applicable","Dendritic Cells","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 19 samples sequenced,  SRA, 7 subjects, 19 samples","","NCI","GRU --- General Research Use","2019-06-28","2019-06-28","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001611.v1.p1","Pancreas Cancer Organoid Profiling","We generated a collection of patient-derived pancreatic normal and cancer organoids. We performed whole genome sequencing, targeted exome sequencing, and RNA sequencing on organoids as well as matched tumor and  normal tissue if available. This dataset is a valuable resource for pancreas cancer researchers, and those looking to compare primary tissue to","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","Not Provided","4 phenotype datasets, 16 variables, 1 documents,  SRA, 71 subjects, 188 samples","","NCI","GRU --- General Research Use","2019-06-21","2019-06-21","Carcinoma, Pancreatic Ductal; Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001420.v1.p1","Kids First: Genomics of Orofacial Cleft Birth Defects in Latin American    Families","The Kids First study of nonsyndromic orofacial cleft (OFC) birth defects in Latin American families is a whole genome sequencing study of 283 Latin-American parent-case trios drawn from ongoing collaborations  led by Dr. Mary L. Marazita of the University of Pittsburgh Center for Craniofacial and Dental Genetics, and including a collaboration with Dr. Lina","Not Applicable","Cleft Lip","Family/Twin/Trios","Not Provided","Not Provided","2 phenotype datasets, 7 variables,  SRA, 828 subjects, 828 samples","","NCI","DS-OBDR-RD --- Disease-Specific (Orofacial birth defects and related phenotypes, RD)","2019-06-14","2019-06-14","Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip",""
"phs001432.v1.p1","Rapid Autopsy in Thoracic Malignancy Cancer Patients to Investigate Tumor    Heterogeneity","Integrated proteo-genomics studies to characterize tumor heterogeneity of metastatic lung adenocarcinoma and thymic carcinoma are lacking. We carried out whole exome sequencing, RNA sequencing, copy number estimation and mass spectrometry-based  proteomics of 40 tumors from five rapid/warm autopsy patients. We found highly variable mutational heterogeneity that was largely driven by","Not Applicable","Adenocarcinoma of Lung","Case Set","WES_markerset_grc37, RNAseq_probe_set_grc37, WES_markerset_grc37, RNAseq_probe_set_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), RNA Seq (NGS), WXS","4 phenotype datasets, 31 variables, 1 molecular datasets, 86 samples sequenced,  SRA, 6 subjects, 86 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2019-05-28","2019-05-28","Mesothelioma; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001596.v1.p1","Acral Melanoma Targeted Sequencing Study (UCSF)","Acral melanoma affects world populations irrespective of skin color. It has comparatively few single nucleotide mutations, but exhibits genomic instability characterized by structural rearrangements and amplifications. As acral melanoma harbors  BRAF (GeneID:673) mutations at low frequencies, we searched for alternative therapeutic targets. We performed targeted deep sequencing of","Not Applicable","Melanoma","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 14 variables, 37 samples sequenced,  SRA, 37 subjects, 37 samples","","NCI","DS-M-NPU --- Disease-Specific (Melanoma, NPU)","2019-05-22","2019-05-22","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001526.v1.p1","Next Generation Sequencing of Diffuse Intrinsic Pontine Glioma Samples","Diffuse intrinsic pontine glioma (DIPG) is an extremely rare ( 350 cases/year) and universally fatal childhood brain cancer. Standard clinical strategies such as chemotherapy and radiotherapy show only transient improvement  in patient condition and result in negligible change in survival, DIPG remains at below 1% survival after 5 years. Prioritization of panobinostat","Not Applicable","Glioma","Prospective Longitudinal Cohort","other","RNA-Seq, RNA Seq (NGS), WXS","4 phenotype datasets, 27 variables, 1 molecular datasets, 52 samples sequenced,  SRA, 14 subjects, 52 samples","","NCI","GRU --- General Research Use, GRU-COL --- General Research Use (COL), GRU-COL-NPU --- General Research Use (COL, NPU)","2019-05-06","2019-05-06","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs001483.v1.p1","DRIVE Breast Cancer Whole Genome Sequencing","This study consists of whole genome sequencing (target: average 30x coverage) of 110 European-ancestry (EA), early-onset, family-history-positive breast cancer cases, 21 Asian cases, 25 African-American cases, and 24 controls from  six studies participating in the Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) consortium, part of the NCI's Genetic","Not Applicable","Breast Neoplasms","Case Set","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 20 variables, 1 molecular datasets, 79 samples sequenced,  SRA, 180 subjects, 180 samples","","NCI","DS-CA-PUB --- Disease-Specific (Cancer, PUB), GRU --- General Research Use, DS-BRD-MDS --- Disease-Specific (Breast Diseases, MDS), DS-BRD --- Disease-Specific (Breast Diseases), DS-COBC-NPU-MDS --- Disease-Specific (Colorectal, ovarian, and/or breast cancer, NPU, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), HMB-PUB --- Health/Medical/Biomedical (PUB)","2019-05-01","2019-05-01","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001666.v1.p1","Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Castration    Resistant and Neuroendocrine Prostate Cancer","Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression.  Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth. In","Not Applicable","Adenocarcinoma","Case Set","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 14 variables, 64 samples sequenced,  SRA, 49 subjects, 64 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2019-04-25","2019-04-25","Neuroendocrine Tumors; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma",""
"phs001168.v2.p2","Kids First: Genomic Studies of Orofacial Cleft Birth Defects","The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller","Not Applicable","Cleft Lip","Family/Twin/Trios","Not Provided","WGS","5 phenotype datasets, 23 variables, 1117 samples sequenced,  SRA, 1378 subjects, 1311 samples","","NCI","DS-OBDR-MDS --- Disease-Specific (Orofacial birth defects and related phenotypes, MDS), DS-OBD-MDS --- Disease-Specific (Orofacial birth defects, MDS), DS-OC-PUB-MDS --- Disease-Specific (Oral Clefts, PUB, MDS), HMB-MDS --- Health/Medical/Biomedical (MDS), GRU --- General Research Use","2019-04-05","2018-03-20","Cleft Palate; CL - Cleft lip; Cheiloschisis; Cheiloschisis of upper lip; Cleft Lips; Cleft of upper lip","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001628.v1.p1","Clinical Crenolanib Resistance in AML","FLT3 mutations are commonly detected in Acute Myeloid Leukemia (AML) patients and are associated with poor prognosis. Crenolanib, a potent type I pan-FLT3 (GeneID:2322) inhibitor, is effective against both internal  tandem duplications (ITD) and resistance-conferring tyrosine kinase domain (TKD) mutations. While crenolanib monotherapy has demonstrated significant","Not Applicable","Leukemia, Myeloid, Acute","Prospective Longitudinal Cohort","Not Provided","Not Provided","2 phenotype datasets, 6 variables,  SRA, 56 subjects, 119 samples","","NCI","DS-LEU --- Disease-Specific (Leukemia)","2019-03-29","2019-03-29","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs001415.v1.p1","Uncovering the Genetic Architecture of Colorectal Cancer with Focus of    Rare and Less Frequent Variants","The Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort comprised of a coordinating center and scientific researchers from well-characterized cohort and case-control studies conducted in North  America and Europe. This international consortium aims to accelerate the discovery of common and rare genetic risk variants for colorectal cancer by","Not Applicable","Colorectal Neoplasms","Case-Control","OncoArray-500K_plus, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 29 variables, 3 molecular datasets, 29540 subjects, 30487 samples","European (25853), African (85), East Asian (762), African American (1990), Hispanic1 (98), Hispanic2 (107), Other Asian or Pacific Islander (410), South Asian (55), Other (180)","NCI","GRU --- General Research Use, DS-CA-IRB --- Disease-Specific (Cancer, IRB), RCV-CRC-MDS --- Rare and common variants associated with colorectal cancer risk, and methods, CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-GSO --- Health/Medical/Biomedical (PUB, NPU, GSO), HMB-COL-GSO --- Health/Medical/Biomedical (COL, GSO), HMB --- Health/Medical/Biomedical, HMB-IRB --- Health/Medical/Biomedical (IRB), HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), HMB-PUB --- Health/Medical/Biomedical (PUB), DS-BOCA --- Disease-Specific (Bowel Cancer), GRU-GSO --- General Research Use (GSO), DS-CEC-IRB --- Disease-Specific (Colorectal and Endometrial Cancer, IRB)","2019-03-27","2019-03-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000748.v7.p4","Multiple Myeloma CoMMpass Study","The Multiple Myeloma Research Foundation (MMRF) CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) trial (NCT01454297) is a longitudinal observation study of 1000 newly diagnosed myeloma  patients receiving various standard approved treatments that aim at collecting tissue samples, genetic information, Quality of Life (QoL) and various","Not Applicable","Multiple Myeloma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 29 variables, 5118 samples sequenced,  SRA, 1014 subjects, 5118 samples","","NCI","GRU-MDS --- General Research Use (MDS), DS-MCRD-MDS --- Disease-Specific (Myeloma and other cancer-related disorders, MDS)","2019-03-20","2014-10-07","Neoplasms, Plasma Cell; Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001594.v1.p1","Mucosal Melanoma Targeted Sequencing Study (UCSF)","Mucosal melanoma is a deadly disease that carries the worst prognosis amongst subtypes of melanoma. Like all melanomas, mucosal melanomas are frequently driven by activating mutations in the MAPK and/or  PI3K pathways; however, unlike melanomas that arise on sun-exposed skin, mucosal melanomas harbor few point mutations. Instead, most somatic","Not Applicable","Melanoma","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 15 variables, 4 documents, 43 samples sequenced,  SRA, 38 subjects, 43 samples","","NCI","DS-M-NPU --- Disease-Specific (Melanoma, NPU)","2019-03-19","2019-03-19","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001178.v1.p1","UCLA/Gabriella Miller Kids First Disorders of Sex Development Study","The Gabriella Miller Kids First Pediatric Research Program (Kids First) is a trans-NIH effort initiated in response to the 2014 Gabriella Miller Kids First Research Act and supported by the  NIH Common Fund. This program focuses on gene discovery in pediatric cancers and structural birth defects and the development of the Gabriella Miller","Not Applicable","Disorders of Sex Development","Family/Twin/Trios","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 20 variables, 1 molecular datasets, 300 samples sequenced,  SRA, 300 subjects, 300 samples","","NCI","GRU --- General Research Use","2019-03-19","2019-03-19","46, XX Testicular Disorders of Sex Development; 46, XY Disorders of Sex Development; Hypospadias; Mullerian aplasia; Omphalocele exstrophy imperforate anus; Ovotesticular Disorders of Sex Development","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001589.v1.p1","Breast Cancer Family Registry Early-onset Breast Cancer GWAS","In order to enhance our understanding of the genetic etiology of breast cancer, this study analyzed 1,265,548 Hapmap3 single-nucleotide polymorphisms (SNP) among a discovery set of 3,523 EOBC incident cases  and 2,702 age-matched population control women, all of whom were age 50 or younger at enrollment. Subjects were recruited from the eight sites, some","Not Applicable","Breast Neoplasms","Case-Control","Not Provided","Not Provided","2 analyses","","NCI","GRU --- General Research Use","2019-03-07","2019-03-07","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001495.v2.p1","DAXX Suppression of ALT","Many tumors maintain chromosome ends through a telomerase-independent, homologous recombination based mechanism called alternative lengthening of telomeres (ALT). While ALT occurs in only a subset of tumors, it is strongly  associated with mutations in the genes encoding components of the histone H3.3 chaperone complex, ATRX and DAXX. To date the mechanistic role of ATRX","Not Applicable","Osteosarcoma","Case Set","Not Provided","OTHER, RNA-Seq","4 phenotype datasets, 20 variables, 14 samples sequenced,  SRA, 5 subjects, 14 samples","","NCI","GRU --- General Research Use","2019-03-06","2018-02-02","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001765.v1.p1","Genomic Characterization of Parathyroid Cancer","Here we performed genomic characterization of twenty-nine sporadic parathyroid cancers using next generation whole exome sequencing. Thirty-three novel candidate driver genes for sporadic parathyroid cancer were proposed, in addition to  previously known driver genes CDC73 and MEN1. All patients undergoing surgical resection for sporadic parathyroid cancer at a tertiary cancer center","Not Applicable","Parathyroid Neoplasms","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 20 variables, 41 samples sequenced, 41 subjects, 41 samples","","NCI","GRU --- General Research Use","2019-02-27","2019-02-27","Neoplasm of Parathyroid; Neoplasm of Parathyroid Gland; Neoplasm of the Parathyroid; Neoplasm of the Parathyroid Gland; Neoplasm, Parathyroid; Neoplasms, Parathyroid","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001660.v1.p1","Lung Cancer Pharmacogenomics (LUPG)","Lung cancer is frequently treated with paclitaxel in combination with several other agents; however, paclitaxel treatment is often ineffective or limited by treatment-related toxicities. Heritable variants in genes associated with  absorption, distribution, metabolism, and elimination may predict paclitaxel clinical outcome and toxicity. We designed a prospective","Not Applicable","Paclitaxel","Case Set","Affymetrix_expression_array","SNP Genotypes (Array)","4 phenotype datasets, 274 variables, 1 molecular datasets, 103 subjects, 103 samples","","NCI","GRU-IRB --- General Research Use (IRB), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-IRB --- Disease-Specific (Cancer, IRB)","2019-02-22","2019-02-22","Lung Neoplasms; Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung",""
"phs001645.v1.p1","Genomic Landscape of Cutaneous Diffuse Large B Cell Lymphoma","Cutaneous diffuse large B cell lymphomas (DLBCL) are aggressive lymphomas with a poor prognosis. To elucidate their genetic bases, we performed whole exome capture and massively parallel sequencing on 19  tumor samples of diffuse large B cell lymphoma, leg type (DLBCL-LT) and 6 samples of secondary cutaneous diffuse large B cell lymphoma, not otherwise","Not Applicable","Lymphoma, Large B-Cell, Diffuse","Case Set","Not Provided","WXS","4 phenotype datasets, 22 variables, 25 samples sequenced, 25 subjects, 25 samples","","NCI","HMB-NPU --- Health/Medical/Biomedical (NPU)","2019-02-19","2019-02-19","Lymphoma, B-Cell; Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma",""
"phs000915.v2.p2","Integrative Clinical Sequencing Analysis of Metastatic Castration    Resistant Prostate Cancer Reveals a High Frequency of Clinical    Actionability","Most prostate cancer deaths are caused by metastatic, castration resistant disease (mCRPC). To develop a precision medicine framework for mCRPC, we established a multi-institutional, international clinical sequencing infrastructure to enroll  and carry out prospective whole exome and transcriptome sequencing of tumors from a cohort of mCRPC patients. We obtained high quality DNA and RNA","Not Applicable","Prostatic Neoplasms","Case Set","other","RNA-Seq, SNV (.MAF), WXS","4 phenotype datasets, 10 variables, 1 molecular datasets, 749 samples sequenced,  SRA, 274 subjects, 763 samples","","NCI","DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS), GRU --- General Research Use, HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU)","2019-02-08","2016-01-15","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001175.v2.p2","CTSP: Clinical Trial Sequencing Project","For the Clinical Trials Sequencing Project (CTSP), National Cancer Institute (NCI) will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent  genetic alterations (mutations, deletions, amplifications, rearrangements) and/or gene expression signatures that would be important to the","Not Applicable","Breast","Collection","Not Provided","Not Provided","2 phenotype datasets, 6 variables,  SRA, 366 subjects, 366 samples, 1 substudies","","NCI","GRU --- General Research Use","2019-01-29","2018-04-11","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001184.v2.p2","CTSP Diffuse Large B-Cell Lymphoma (DLBCL) CALGB 50303","For the CTSP-DLBCL sub-project, National Cancer Institute (NCI) will utilize whole genome sequencing and/or whole exome sequencing in conjunction with transcriptome sequencing to try to identify recurrent genetic alterations (mutations,  deletions, amplifications, rearrangements) and/or gene expression signatures that would be important to the hypothesis(es) submitted by the","CTSP: Clinical Trial Sequencing Project (phs001175.v2.p2)","Lymphoma, Large B-Cell, Diffuse","Case Set","Not Provided","Not Provided","366 samples","","NCI","GRU --- General Research Use","2019-01-29","2018-04-11","Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma",""
"phs001193.v1.p1","Hispanic Colorectal Cancer Study","Genome-wide association studies (GWAS) of colorectal cancer (CRC) have been instrumental in identifying a number of common susceptibility loci in Non Hispanic (NH)-White populations, and a NCI priority is to  extend GWAS findings to other populations to address racial/ethnic disparities in cancer susceptibility. Currently, GWA studies of CRC in NH-Whites,","Not Applicable","Colorectal Neoplasms","Case-Control","HumanOmni2.5-8","SNP Genotypes (Array)","4 phenotype datasets, 17 variables, 7 documents, 1 molecular datasets, 1597 subjects, 1597 samples","European (81), African (1), African American (6), Hispanic1 (20), Hispanic2 (1438), Other Asian or Pacific Islander (10), Other (41)","NCI","GRU --- General Research Use, DS-CA --- Disease-Specific (Cancer), HMB-MDS --- Health/Medical/Biomedical (MDS)","2018-12-27","2018-12-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001621.v1.p1","The Platinum Study","The Platinum Study is an R01-funded, multicenter study of testicular cancer survivors that characterizes both long-term cisplatin-induced peripheral neuropathy (CisIPN) and cisplatin-associated ototoxicity, i.e., permanent, bilateral hearing loss. We collected  data abstracted from medical records (e.g., cumulative cisplatin dose), conducted audiometric examinations, and administered self-report","Not Applicable","Cisplatin","Cross-Sectional","imputation_panel, HumanOmniExpress-12","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 28 variables, 2 molecular datasets, 680 subjects, 680 samples","","NCI","GRU --- General Research Use","2018-12-21","2018-12-21","Not Provided","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001704.v1.p1","Enhancer Mapping in Chronic Lymphocytic Leukemia","In this study we profile the epigenomic enhancer landscapes of CLL B cells (CD19+/CD5+) harvested from peripheral blood of patients from our Center. Included are results of ChIPseq profiling using  chromatin immunoprecipitation of the enhancer histone mark H3K27ac (acetylated lysine 27 on histone H3), and open chromatin profiles using ATAC-seq","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case-Control","Not Provided","ATAC-seq, ChIP-Seq, RNA-Seq","4 phenotype datasets, 19 variables, 66 samples sequenced,  SRA, 28 subjects, 66 samples","","NCI","DS-CLL --- Disease-Specific (Chronic Lymphocytic Leukemia)","2018-12-18","2018-12-18","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs001658.v1.p1","Tumor Heterogeneity in Metastatic Adrenocortical Tumors","We have analyzed 33 human metastatic adrenocortical tumors from 14 patients with advanced metastases and performed whole exome sequencing to identify novel signatures in these tumors. We observed tumor heterogeneity  in these tumors coming from the same metastatic tissue site across different patients while the different metastatic tumor sites coming from the same","Not Applicable","Adrenocortical Carcinoma","Prospective Longitudinal Cohort","other","SNV (.MAF), WXS","3 phenotype datasets, 22 variables, 1 molecular datasets, 33 samples sequenced,  SRA, 14 subjects, 33 samples","","NCI","GRU --- General Research Use","2018-12-04","2018-12-04","ACC; Adenoid Cystic Carcinoma; Adrenal Cortex Adenocarcinoma; Adrenal Cortex Cancer; Adrenal Cortex Carcinoma; Adrenal Cortical Adenocarcinoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001654.v1.p1","NSAIDS and Somatic Mutations in Barrett's Esophagus","Background: Use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to protect against tetraploidy, aneuploidy, and chromosomal alterations in the metaplastic condition Barrett's esophagus (BE) and to  lower the incidence and mortality of esophageal adenocarcinoma (EA). The esophagus is exposed to both intrinsic and extrinsic mutagens resulting from","Not Applicable","Barrett Esophagus","Case-Control","HumanOmniExpress-12","OTHER, SNP/CNV Genotypes (NGS)","4 phenotype datasets, 20 variables, 1 molecular datasets, 164 samples sequenced,  SRA, 82 subjects, 164 samples","","NCI","DS-BE --- Disease-Specific (Barrett's Esophagus)","2018-11-28","2018-11-28","BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome; Barrett esophagus/esophageal adenocarcinoma",""
"phs001696.v1.p1","Genomic Studies for Understanding Etiology of Esophageal Adenocarcinoma    (EsophagealAdenocarcinoma_Chinese)","While the incidence of esophageal adenocarcinoma (EAC) has risen drastically in Western countries over the last 40 years, a similar trend has not been observed for EAC in China. Here  we analyzed mutational spectrum, copy number alterations, and structural variants from whole-genome sequencing of ten Chinese EAC tumor samples and","Not Applicable","Esophageal Neoplasms","Case Set","WGS_markerset_grc37","SNP Genotypes (NGS), WGS","4 phenotype datasets, 26 variables, 1 molecular datasets, 20 samples sequenced,  SRA, 10 subjects, 20 samples","","NCI","DS-E-C-NPU --- Disease-Specific (Esophageal Cancer, NPU)","2018-11-27","2018-11-27","Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm",""
"phs001078.v1.p1","Common Variant GWAS, GECCO","Genetics & Epidemiology of Colorectal Cancer Consortium (GECCO) is a collaborative effort which aims to accelerate the discovery of colorectal cancer-related variants by discovering, replicating and fine-mapping Genome Wide Association  Study (GWAS) findings, conducting a meta-analysis of GWAS data, and investigating how genetic variants are modified by environmental risk factors.","Not Applicable","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12, HumanOmniExpress-12, Not Provided, Not Provided, Not Provided","Not Provided","2 phenotype datasets, 9 variables, 17766 subjects, 18509 samples, 12 substudies","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001171.v1.p1","Multiethnic Cohort Study (MEC)","This study phs001171 MEC Colorectal Cancer contains genotype and phenotype of subjects available from the phs001171 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed  at the top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 722 subjects, 735 samples","European (674), African (1), East Asian (1), African American (2), Hispanic1 (7), Hispanic2 (15), Other Asian or Pacific Islander (13), Other (6)","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC --- Health/Medical/Biomedical (PUB), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001170.v1.p1","Hawai'i Colorectal Cancer Studies 2&3 (Colo2&3)","This study phs001170 Colo2and3 contains genotype and phenotype of subjects available from the phs001170 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 225 subjects, 232 samples","European (214), East Asian (1), Hispanic1 (3), Hispanic2 (3), Other Asian or Pacific Islander (4)","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001129.v1.p1","Nurses' Health Study (NHS)","This study phs001129 NHS contains genotype and phenotype of subjects available from the phs001129 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 2606 subjects, 2660 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001128.v1.p1","Physicians' Health Study (PHS)","This study phs001128 PHS contains genotype and phenotype of subjects available from the phs001128 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Prospective Longitudinal Cohort","HumanOmniExpress-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 806 subjects, 817 samples","European (775), East Asian (12), African American (4), Hispanic1 (1), Hispanic2 (4), Other Asian or Pacific Islander (5), South Asian (3), Other (2)","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001114.v1.p1","Health Professionals Follow-up Study (HPFS)","This study phs001114 HPFS contains genotype and phenotype of subjects available from the phs001114 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 1497 subjects, 1539 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001113.v1.p1","Darmkrebs: Chancen der Verhutung durch Screening (DACHS)","This study phs001113 DACHS contains genotype and phenotype of subjects available from the phs001113 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","Not Provided, Not Provided, HumanCytoSNP-12, Not Provided","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 4686 subjects, 5125 samples","European (3496), African (1), East Asian (3), African American (1), Hispanic1 (4), South Asian (2), Other (4)","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC --- Health/Medical/Biomedical (PUB), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001104.v1.p1","French Association STudy Evaluating RISK for Sporadic Colorectal Cancer    (ASTERISK)","This study phs001104 ASTERISK contains genotype and phenotype of subjects available from the phs001104 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortioum. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 1937 subjects, 2005 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001094.v1.p1","Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO)","This study phs001094 PLCO contains genotype and phenotype of subjects available from the phs001094 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Prospective Longitudinal Cohort","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 1123 subjects, 1189 samples","European (917), African (3), East Asian (58), African American (108), Hispanic1 (5), Hispanic2 (15), Other Asian or Pacific Islander (14), South Asian (1), Other (2)","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001092.v1.p1","Postmenopausal Hormones Supplementary Study to the Colon Cancer Family    Registry (PMH-CCFR)","This study phs001092 PMH CCFR contains genotype and phenotype of subjects available from the phs001092 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at  the top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 450 subjects, 463 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001077.v1.p1","Women's Health Initiative (WHI)","This study phs001077 WHI Colorectal Cancer contains genotype and phenotype of subjects available from the phs001077 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed  at the top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 2191 subjects, 2191 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001056.v1.p1","Diet, Activity, and Lifestyle Study (DALS)","This study phs001056 DALS contains genotype and phenotype of subjects available from the phs001056 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 880 subjects, 916 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs000965.v1.p1","VITamins And Lifestyle (VITAL)","This study phs000965 VITAL contains genotype and phenotype of subjects available from the phs000965 study. Summary level phenotypes for the NCI GECCO Consortium study participants can be viewed at the  top-level study page phs001078 GECCO Consortium. Individual level phenotype data and molecular data for all GECCO Consortium top-level study and","Common Variant GWAS, Genetics &amp; Epidemiology of Colorectal Cancer Consortium (GECCO) (phs001078.v1.p1)","Colorectal Neoplasms","Case-Control","HumanCytoSNP-12","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 11 variables, 1 molecular datasets, 607 subjects, 637 samples","","NCI","GRU --- General Research Use, HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU), CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO), DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-MDS --- Disease-Specific (Colorectal Cancer, MDS), HMB-IRB --- Health/Medical/Biomedical (IRB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-11-27","2018-11-27","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001678.v1.p1","High-Throughput Determination of the Antigen Specificities of T cell    Receptors in Single Cells","High-throughput linking of T cell receptor (TCR) sequences to their binding antigens is vital for immune profiling, yet challenging. We present Tetramer associated TCR Sequencing (TetTCR-Seq) to address this challenge.  Binding is determined using a library of DNA-barcoded antigen tetramers that are rapidly and inexpensively generated using an in vitro","Not Applicable","Humans","Methods","Not Provided","RNA-Seq","4 phenotype datasets, 15 variables, 88 samples sequenced,  SRA, 10 subjects, 144 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","2018-11-23","2018-11-23","Not Provided",""
"phs001629.v1.p1","Single Patient BRAF Mutant Brain Tumor, Pre- and Post-dabrafenib WES.","A single adolescent patient with a BRAF V600E mutated brain tumor was treated with dabrafenib and had a complete response, followed by progression. The pre-treatment and post-progression tumors were both  sequenced in order to identify potential drivers of resistance. The patient had both pre-treatment and post-progression specimens available for","Not Applicable","Ganglioglioma","Case Set","Somatic_Variant","SNV (.MAF), WXS","4 phenotype datasets, 25 variables, 1 molecular datasets, 2 samples sequenced,  SRA, 1 subjects, 2 samples","","NCI","GRU-IRB-PUB --- General Research Use (IRB, PUB)","2018-11-08","2018-11-08","ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas",""
"phs001674.v1.p1","The Genomic Landscape of Endocrine Resistant Advanced Breast Cancers.","The genomic evolution of breast cancers exposed to systemic therapy and its effects on clinical outcome have not been broadly characterized. We integrated the genomic sequencing of 1918 breast cancers,  including 1501 hormone receptor-positive tumors, with detailed clinical information and treatment outcomes. Functional mutations in ERBB2 and","Not Applicable","Breast Neoplasms","Case Set","Not Provided","WXS","3 phenotype datasets, 17 variables, 95 samples sequenced,  SRA, 30 subjects, 95 samples","","NCI","HMB --- Health/Medical/Biomedical","2018-11-05","2018-11-05","Neoplasm Metastasis; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001372.v1.p1","Integrated Single-Cell Analysis in Chronic Lymphocytic Leukemia","Intratumoral genetic heterogeneity has been characterized across cancers by genome sequencing of bulk tumors, including chronic lymphocytic leukemia (CLL). In order to more accurately identify subclones, define phylogenetic relationships, and  probe genotype-phenotype relationships, we developed methods for targeted mutation detection in DNA and RNA isolated from thousands of single cells","Not Applicable","Leukemia, Lymphoid","Case Set","target_markerset_grc37, RNAseq_probe_set_grc37","SNP Genotypes (NGS), RNA Seq (NGS)","4 phenotype datasets, 15 variables, 2 molecular datasets,  SRA, 5 subjects, 1567 samples","","NCI","GRU --- General Research Use","2018-10-18","2018-10-18","Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001234.v1.p1","Sequence of Primary ER+ Breast Tumors Treated with 5 Years of Tamoxifen","Targeted massively parallel sequencing analysis was conducted on DNA extracted from archived 22-28 year old, formalin-fixed primary breast tumors from 625 patents from British Columbia treated with five years of  adjuvant tamoxifen monotherapy and followed for over 10 years. Genes were selected for targeted sequencing by review of existing large-scale breast","Not Applicable","Breast Neoplasms","Case Set","Not Provided","WXS","3 phenotype datasets, 12 variables, 625 samples sequenced,  SRA, 625 subjects, 625 samples","","NCI","DS-CA-IRB --- Disease-Specific (Cancer, IRB)","2018-10-16","2018-10-16","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001304.v1.p1","NCI Biospecimen Pre-analytical Variables (BPV) Analysis","The Biospecimen Pre-analytical Variables (BPV) Program is a National Cancer Institute-sponsored study to systematically assess the effects of pre-analytical factors on the molecular profile of biospecimens. A robust biospecimen collection  infrastructure was established to prospectively collect biospecimens using rigorous standard operating procedures to control for most variables while","Not Applicable","Carcinoma, Renal Cell","Case Set","SNP-PCR, Cytogenetic_Arrays, custom_markerset","Not Provided","3 phenotype datasets, 466 variables, 341 samples sequenced,  SRA, 153 subjects, 1554 samples, 7 substudies","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001640.v1.p1","TumorStorage","This study phs001640 Tumor Storage contains molecular data and phenotype of subjects available from the phs001640 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","custom_markerset","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 156 variables, 1 molecular datasets,  SRA, 53 subjects, 340 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001639.v1.p1","NGS","This study phs001639 NGS contains molecular data and phenotype of subjects available from the phs001639 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be viewed  at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","Not Provided","RNA-Seq, WXS, miRNA-Seq, RNA-Seq, WXS, miRNA-Seq","1 phenotype datasets, 129 variables, 341 samples sequenced,  SRA, 35 subjects, 341 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001638.v1.p1","mRNA_TaqMan","This study phs001638 mRNA TaqMan contains molecular data and phenotype of subjects available from the phs001638 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","SNP-PCR","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 124 variables, 1 molecular datasets,  SRA, 20 subjects, 100 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001637.v1.p1","GlobalMetaboliteProfiling","This study phs001637 Global Metabolite Profiling contains molecular data and phenotype of subjects available from the phs001637 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can  be viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","custom_markerset","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 49 variables, 1 molecular datasets,  SRA, 40 subjects, 240 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001636.v1.p1","FixationDelay","This study phs001636 Fixation Delay contains molecular data and phenotype of subjects available from the phs001636 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","custom_markerset","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 116 variables, 1 molecular datasets,  SRA, 20 subjects, 95 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001635.v1.p1","CNV_aCGH","This study phs001635 CNV aCGH contains molecular data and phenotype of subjects available from the phs001635 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV cohort. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","Cytogenetic_Arrays","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 168 variables, 1 molecular datasets,  SRA, 38 subjects, 229 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001634.v1.p1","CIT_mRNA","This study phs001634 CIT mRNA contains molecular data and phenotype of subjects available from the phs001634 study. Summary level phenotypes for the NCI Biospecimen PV cohort study participants can be  viewed at the top-level study page phs001304 Biospecimen PV study. Individual level phenotype data and molecular data for all Biospecimen PV cohort","National Cancer Institute (NCI) Biospecimen Pre-analytical Variables (BPV) Analysis (phs001304.v1.p1)","Carcinoma, Renal Cell","Case Set","SNP-PCR","Legacy Genotypes, Legacy Genotypes","1 phenotype datasets, 131 variables, 1 molecular datasets,  SRA, 40 subjects, 209 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2018-10-12","2018-10-12","Fallopian Tube Neoplasms; ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung",""
"phs001572.v1.p1","Pan-Tumor Genomic Biomarkers for PD-1 Based Immunotherapy","Tumor mutation burden (TMB) and a T-cell-inflamed gene expression profile (GEP) independently predict clinical outcome in pembrolizumab-treated patients in 22 indications and stratify distinct targets of resistance biology. TMB was  evaluated by whole exome sequencing (WES) of germline and tumor DNA from formalin-fixed paraffin-embedded (FFPE) pre-treatment samples in multiple","Not Applicable","Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 15 variables, 624 samples sequenced,  SRA, 312 subjects, 624 samples","","NCI","DS-CA-IRB --- Disease-Specific (Cancer, IRB)","2018-10-11","2018-10-11","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001527.v1.p1","Oral Microbiome in Esophageal Adenocarcinoma","The purpose of our study was to assess the influence of oral microbiota on the development of esophageal cancer. Our preliminary case-control studies reported a global alteration of foregut microbiome  in esophageal adenocarcinoma with the strongest changes found in the oral microbiome. We hypothesise that commensal oral bacteria are capable of","Not Applicable","Esophageal Neoplasms","Case-Control","Not Provided","WGS","4 phenotype datasets, 18 variables, 219 samples sequenced,  SRA, 219 subjects, 219 samples","","NCI","HMB-IRB-PUB-COL --- Health/Medical/Biomedical (IRB, PUB, COL)","2018-09-28","2018-09-28","Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm",""
"phs001643.v1.p1","Chordoma Genomics","In this study, we performed paired tumor/normal whole exome and shallow long insert whole genome sequencing, as well as tumor RNAseq, from archival chordoma specimens collected from four patients at  the Barrow Neurological Institute in Phoenix, AZ. The purpose of this analysis was to identify potential therapeutic targets. In three patients, we","Not Applicable","Chordoma","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 15 variables, 8 samples sequenced,  SRA, 4 subjects, 8 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-09-25","2018-09-25","CHDM; Chordomas; Notochordal sarcoma; chordoma (disease); chordoma, malignant; chordoma, susceptibility to",""
"phs001006.v1.p1","Intra-Lesion Heterogeneity and Clonality of Lobular Carcinomas In Situ","This study comprises prospectively accrued, microdissected fresh frozen samples of multifocal lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), invasive lobular carcinoma and invasive ductal carcinoma from patients  undergoing prophylactic or therapeutic mastectomies after a diagnosis on LCIS diagnosed and managed at Memorial Sloan Kettering Cancer Center","Not Applicable","Carcinoma, Lobular","Collection","Not Provided","WXS","4 phenotype datasets, 26 variables, 94 samples sequenced,  SRA, 24 subjects, 94 samples","","NCI","GRU --- General Research Use","2018-09-13","2018-09-13","Carcinoma in Situ; Cancer in situ; Carcinoma, Intraepithelial; Carcinoma, Preinvasive; Intraepithelial Carcinoma; Non-invasive Carcinoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001577.v1.p1","Structural Alterations in Castration-Resistant Prostate Cancer","Adapted from manuscript in review: Nearly all prostate cancer deaths are from metastatic castration-resistant prostate cancer (mCRPC) but there have been few whole genome sequencing (WGS) studies of this disease  state. We performed linked-read WGS on 23 mCRPC biopsy specimens and analyzed cell-free DNA sequencing data from 86 patients with mCRPC. In addition","Not Applicable","Prostatic Neoplasms, Castration-Resistant","Prospective Longitudinal Cohort","Not Provided","WGS","4 phenotype datasets, 11 variables, 2 samples sequenced,  SRA, 20 subjects, 43 samples","","NCI","DS-MDS --- Disease-Specific (Cancer, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS)","2018-09-12","2018-09-12","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001481.v1.p1","Inherited Bone Marrow Failure Syndromes Study","Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders. Mutations in IBMFS genes are relevant to  carcinogenesis in sporadic cancers. Patients with IBMFS who develop cancer differ in their genetic and/or environmental features from patients with","Not Applicable","Bone Marrow Failure Disorders","Prospective Longitudinal Cohort","Not Provided","WXS","5 phenotype datasets, 19 variables, 456 samples sequenced, 456 subjects, 456 samples","","NCI","GRU --- General Research Use","2018-09-06","2018-09-06","Bone Marrow Failure Syndromes; Dyskeratosis Congenita; Anemia, Fanconi; Anemia, Fanconi's; Anemias, Fanconi; FA","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001549.v1.p1","Genome-Wide Association Study and Meta-Analysis of Ewing Sarcoma","We combined a set of 122 French Ewing sarcoma (EWS) cases from the Institut Curie, 19 EWS cases from the National Cancer Institute (NCI) Center for Cancer Research (CCR), and  29 EWS cases from the NCI Bone Disease and Injury Study. All EWS cases were confirmed by medical record review and the presence of a specific","Not Applicable","Sarcoma, Ewing","Case-Control","imputation_panel, HumanOmniExpress-12","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 13 variables, 2 molecular datasets, 170 subjects, 170 samples","","NCI","DS-BONE --- Disease-Specific (Bone Cancers), DS-ES --- Disease-Specific (Ewing's Sarcoma), GRU --- General Research Use","2018-08-31","2018-08-31","ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor",""
"phs001247.v1.p1","GMKF: Kids First Pediatric Research Program on Congenital Cranial    Dysinnervation Disorders and Related Birth Defects","Goals of this ongoing study are to identify novel ""congenital cranial dysinnervation disorder"" (CCDD) genes and define the role of the wildtype and mutant genes in normal and aberrant development.  The umbrella term (CCDD) refers to congenital birth defects with malformation of one or more cranial nerves, typically resulting in limitations of","Not Applicable","Cranial Nerve Diseases","Family/Twin/Trios","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","6 phenotype datasets, 41 variables, 1 molecular datasets, 899 samples sequenced,  SRA, 899 subjects, 899 samples","","NCI","DS-EMD --- Disease-Specific (Eye Movement Disorders), DS-ELMD --- Disease-Specific (Eye and Lid Movement Disorders), DS-CCDD-RD --- Disease-Specific (Congenital Cranial Dysinnervation Disorders, RD)","2018-08-24","2018-08-24","Abducens Nerve Diseases; Facial Nerve Diseases; Oculomotor Nerve Diseases; Trochlear Nerve Diseases; Abducens Nerve Disease; Abducens nerve weakness",""
"phs001618.v1.p1","Dormant TILs and Sensitivity to Immune Checkpoint Blockers in Lung Cancer","The biological determinants of sensitivity and resistance to immune checkpoint inhibitors are not completely understood. To elucidate the role of intratumoral T-cells and its association with the tumor genomic landscape,  we perform paired whole exome DNA sequencing and multiplexed quantitative immunofluorescence (QIF) in pre-treatment samples from non-small cell lung","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","WES_markerset_grc37","SNP Genotypes (NGS), WXS","4 phenotype datasets, 20 variables, 1 molecular datasets, 84 samples sequenced,  SRA, 49 subjects, 84 samples","","NCI","GRU --- General Research Use, DS-LCTC-MDS --- Disease-Specific (Lung Cancer and Thoracic Malignancies, MDS)","2018-08-03","2018-08-03","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001513.v1.p1","Mechanisms of Chemotherapy Resistance in T-ALL","The goals of this study are to unravel the molecular mechanisms underlying leukemic transformation and chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL). Towards this end, a cohort of T-ALL  lymphoblast specimens was collected at the time of initial T-ALL diagnosis (prior to the start of therapy) from children enrolled on contemporary","Not Applicable","Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, Targeted-Capture","4 phenotype datasets, 17 variables, 109 samples sequenced,  SRA, 109 subjects, 109 samples","","NCI","DS-LEU --- Disease-Specific (Leukemia)","2018-08-02","2018-08-02","Acute T Cell Leukemia; Acute T Cell Lymphoblastic Leukemia; Acute T-Cell Leukemia; Acute T-Cell Leukemias; Acute T-Cell Lymphoblastic Leukemia; Acute T-Lymphocytic Leukemia",""
"phs001566.v1.p1","Mutations in Breast Cancer Patient with Neurofibromatosis","Targeted genetic sequencing was performed on a 41-year-old female with metaplastic breast cancer (MBC) and neurofibromatosis type I (NF1). A custom panel capturing 279 cancer related genes was used to  identify a germline pathogenic SNV in NF1, as well several other somatic alterations. Single case report Related Genes: NF1 Principal Investigator:","Not Applicable","Neurofibromatosis 1","Case Set","target_markerset_grc37","SNP Genotypes (NGS)","4 phenotype datasets, 24 variables, 1 molecular datasets, 1 subjects, 2 samples","","NCI","GRU --- General Research Use","2018-07-25","2018-07-25","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001565.v1.p1","Pre-treatment Molecular Characterizations of Tumors from Patients Who    Receive Immune Checkpoint Therapies","Immune checkpoint inhibitors yield clinical benefit in many cancer types, but molecular predictors of response have not yet been robustly characterized. In this study, we pursued whole exome sequencing (WES)  of pre-treatment tumors from patients treated with immune checkpoint therapies - including monoclonal antibodies targeting programmed cell death-1","Not Applicable","Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 14 variables, 142 samples sequenced, 71 subjects, 142 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-BLADDERCA-MDS --- Disease-Specific (Bladder Cancer, MDS), DS-CATHLU-MDS --- Disease-Specific (Cancer -Thoracic and Lung, MDS), GRU --- General Research Use","2018-07-03","2018-07-03","Carcinoma, Transitional Cell; Lung Neoplasms; Urinary Bladder Neoplasms; Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma",""
"phs001381.v1.p1","Gut Microbiome and Types of Colorectal Polyps","Colorectal cancer is a heterogeneous disease arising from at least two precursors-the conventional adenoma and the serrated polyp. This dataset was used to test the relationship of the gut microbiota  to specific colorectal polyp types. We included samples from two independent study populations based at colonoscopy clinics: the Centers for Disease","Not Applicable","Colonic Polyps","Cross-Sectional","Not Provided","AMPLICON","4 phenotype datasets, 43 variables, 667 samples sequenced, 667 subjects, 667 samples","","NCI","GRU --- General Research Use","2018-06-15","2018-06-15","Adenomatous Polyps","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001399.v1.p1","Development of Precision Neoadjuvant-Adjuvant Therapies","In clinical trials assessing neoadjuvant androgen deprivation therapy plus next-generation androgen receptor axis inhibitors, a subset of patients fail to demonstrate a complete pathologic response following treatment and radical prostatectomy.  We performed exome and transcriptome analyses on laser capture microdissected foci of residual tumor from these patients. Patients with residual","Not Applicable","Prostatic Neoplasms","Case Set","Not Provided","WXS","5 phenotype datasets, 23 variables, 50 samples sequenced,  SRA, 19 subjects, 69 samples","","NCI","DS-CA-NPU --- Disease-Specific (Cancer, NPU)","2018-05-31","2018-05-31","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001315.v1.p1","GECCO: Detecting Common and Rare Genetic Loci and GxE Interactions in    Colorectal Cancer","COLON, Colorectal Cancer: Longitudinal Observational study on Nutritional and lifestyle factors that influence colorectal tumor recurrence, survival and quality of life: The COLON study is a multi-center prospective cohort study  to assess the role of diet and other lifestyle factors in cancer recurrence and survival among incident colorectal cancer patients in the","Not Applicable","Colorectal Neoplasms","Case-Control","HumanOmniExpressExome-8, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 24 variables, 2 molecular datasets, 8725 subjects, 9101 samples","European (8607), African (1), East Asian (17), African American (23), Hispanic1 (11), Hispanic2 (6), Other Asian or Pacific Islander (18), Other (42)","NCI","GRU --- General Research Use, DS-CC-NPU-GSO --- Disease-Specific (Colorectal Cancer, NPU, GSO), DS-CC-PUB-NPU --- Disease-Specific (Colorectal Cancer, PUB, NPU), HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-05-23","2018-05-23","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001396.v1.p1","Genetics of Pigmentation in Eastern and Southern African Populations    Study","The goal of this study was to identify genes and loci associated with pigmentation in African populations. It comprises 1,593 participants from Ethiopia, Tanzania, and Botswana. Sexes are evenly represented  (768 males and 825 females) and self reported ages ranged from 18 to 103. Mean age was used for individuals without ages. For each participant, a DSM","Not Applicable","Skin Pigmentation","Cross-Sectional","HumanOmni2.5-8, WGS_markerset_grc37, Not Provided, WGS_markerset_grc37","SNP Genotypes (Array), SNP Genotypes (NGS), WGS","4 phenotype datasets, 14 variables, 1 molecular datasets, 135 samples sequenced,  SRA, 1573 subjects, 1573 samples","","NCI","GRU-NPU --- General Research Use (NPU)","2018-05-15","2018-05-15","Not Provided",""
"phs001219.v1.p1","Detection of Genes Predisposing to Hematologic Malignancies","We have been conducting genetic studies on families at high risk of different hematologic malignancies, in order to define the related tumors in the families, define precursor and other related  conditions, and map and identify susceptibility genes. We have focused mainly on four types of lymphoid malignancies: chronic lymphocytic leukemia","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Family/Twin/Trios","Not Provided","WXS","5 phenotype datasets, 26 variables, 475 samples sequenced,  SRA, 475 subjects, 475 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2018-05-10","2018-05-10","Hodgkin Disease; Leukemia, Hairy Cell; Leukemia, Myelomonocytic, Juvenile; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; CHL",""
"phs001391.v1.p1","OncoArray: Prostate Cancer","Original description of the study: From ELLIPSE (linked to the PRACTICAL consortium), we contributed 78,000 SNPs to the OncoArray. A large fraction of the content was derived from the GWAS  meta-analyses in European ancestry populations (overall and aggressive disease; 27K SNPs). We also selected just over 10,000 SNPs from the","Not Applicable","Prostatic Neoplasms","Case-Control","OncoArray","SNP Genotypes (Array)","4 phenotype datasets, 15 variables, 1 molecular datasets, 99622 subjects, 99622 samples","European (87794), African (1216), East Asian (390), African American (6686), Hispanic1 (361), Hispanic2 (2309), Other Asian or Pacific Islander (212), South Asian (276), Other (378)","NCI","GRU --- General Research Use, CADM --- Cancer in all age groups, other diseases in adults only, and methods, CHRONIC --- Chronic Diseases (including Cancer), Methods, DS-BCEMOPCA-NPU-MDS --- Disease-Specific (Breast, Colorectal, Endometrial, Melanoma, Ovarian, and/or Prostate Cancer, NPU, MDS), DS-CA --- Disease-Specific (Cancer), DS-CA-MDS-GSO --- Disease-Specific (Cancer, MDS, GSO), DS-CA-NPU --- Disease-Specific (Cancer, NPU), DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), DS-PC-MDS-GSO --- Disease-Specific (Prostate Cancer, MDS, GSO), DS-PCP --- Disease-Specific (Prostate Cancer Predisposition), GRU-IRB --- General Research Use (IRB), DS-PC-PUB-MDS --- Disease-Specific (Prostate Cancer, PUB, MDS), GRU-NPU --- General Research Use (NPU), MHNSI-MDS --- Men's Health and Nutrition in Serious Illnesses (MDS), PC-RITPC --- Prostate Cancer or Radiation-induced Toxicity in Prostate Cancer Patients, HMB-PUB --- Health/Medical/Biomedical (PUB), DS-CA-PUB --- Disease-Specific (Cancer, PUB), DS-CA-MDS --- Disease-Specific (Cancer, MDS), EPIMEDCA --- Epidemiological and Medical Research on Cancer, Methods, DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS), PC-MDS-NOCTRL --- Prostate Cancer, Methods, Non-control, HMB-NPU --- Health/Medical/Biomedical (NPU), DS-CHDSAD-MDS --- Disease-Specific (Cancer, Heart Disease, Stroke, Alzheimer Disease, and Diabetes, MDS), HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), DS-PC --- Disease-Specific (Prostate Cancer), HMB --- Health/Medical/Biomedical","2018-03-21","2018-03-21","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001064.v1.p1","Whole Exome Sequencing of Signet Ring/Plasmacytoid Variant Bladder Cancer","In this study, six plasmacytoid bladder cancers were analyzed by whole exome sequencing. The results show loss of the CDH1 gene in every sample and correlate with E-cadherin loss of  expression by immunohistochemistry. A separate validation cohort of plasmacytoid samples showed loss of E-cadherin expression by CDH1 mutation or","Not Applicable","Carcinoma, Signet Ring Cell","Case Set","other","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 15 variables, 1 molecular datasets, 12 samples sequenced,  SRA, 6 subjects, 12 samples","","NCI","DS-BLADDERCA --- Disease-Specific (Bladder Cancer)","2018-03-12","2018-03-12","Urinary Bladder Neoplasms; Signet Ring Cell Adenocarcinoma; Signet Ring Cell Carcinoma; Signet cell adenocarcinoma; Signet ring carcinoma; Signet-Ring Cell Carcinoma",""
"phs001447.v1.p1","Metastatic Castrate-Resistant Prostate Cancer Study (MCRPCS)","We examined genetic resistance to second generation androgen targeting therapies (abiraterone acetate or enzalutamide) by analyzing whole exome sequencing of patient-matched pre-treatment and post-resistance tumors from a series of castrate-resistant  prostate cancer (CRPC) patients. Abiraterone resistant tumors harbored alterations in AR and MYC, whereas patients treated with enzalutamide had","Not Applicable","Prostatic Neoplasms","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 12 variables, 21 samples sequenced, 7 subjects, 21 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS)","2018-03-07","2018-03-07","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001405.v1.p1","Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212","In this study the investigators looked at adaptive reprogramming impact on the kinome when a MEK inhibitor called GSK1120212 (trametinib) was administered in a ""window of opportunity"" trial. GSK1120212 is  not yet approved by the FDA for use in breast cancer patients. The investigators gave GSK1120212 for a short period of time (one week) to examine MEK","Not Applicable","Triple Negative Breast Neoplasms","Clinical Trial","Not Provided","RNA-Seq","5 phenotype datasets, 32 variables, 5 documents, 28 samples sequenced,  SRA, 12 subjects, 28 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2018-03-07","2018-03-07","Breast Diseases; Molecular Mechanisms of Pharmacological Action; Neoplasms by Site; Skin Diseases; Breast Disease, Endocrine; Breast Diseases, Endocrine",""
"phs001389.v1.p1","Gene Expression and Histone Modification Profiles in GBM Tumors","The primary goal of this study was to collect and analyze genomic data from primary glioblastoma multiforme tumors. Our collaborators at St David's Medical Center (SDMC) obtained informed consent from  patients undergoing surgery to remove a tumor in the brain. After consent was obtained, specimens were removed from the operating suite and flash","Not Applicable","Glioblastoma","Case Set","Not Provided","ChIP-Seq, RNA-Seq","4 phenotype datasets, 23 variables, 109 samples sequenced,  SRA, 13 subjects, 109 samples","","NCI","HMB --- Health/Medical/Biomedical","2018-03-06","2018-03-06","ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001469.v1.p1","High Response Rate to Anti PD-1 Therapy in Desmoplastic Melanoma","Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet  light DNA damage. We analysed 60 patients with advanced DM treated with programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1) blocking antibody","Not Applicable","Immunotherapy","Case-Control","WES_markerset_grc37","SNV (.MAF), WXS","4 phenotype datasets, 24 variables, 1 molecular datasets, 34 samples sequenced,  SRA, 17 subjects, 34 samples","","NCI","HMB-PUB-NPU-MDS --- Health/Medical/Biomedical (PUB, NPU, MDS)","2018-03-01","2018-03-01","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma; Melanoma, Malignant",""
"phs000676.v2.p2","Sequence-Based Analysis of Human Breast Tumors","The goal of this study is to study gene expression patterns in tumors, normal tissues, and cell lines. Principal Investigator: Charles Perou, PhD, Lineberger Comprehensive Cancer Center, University of North  Carolina at Chapel Hill,Chapel Hill, NC, USA Funding Source: P50-CA058223, P50-CA058223","Not Applicable","Breast Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","5 phenotype datasets, 37 variables, 232 samples sequenced,  SRA, 28 subjects, 232 samples","","NCI","GRU-MDS --- General Research Use (MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2018-02-28","2014-10-29","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001084.v1.p1","Differential Mutations in Matched Primary and Metastatic Colorectal    Cancers","This study compares DNA mutations detected in matched primary and metastatic colorectal cancer samples from 18 individuals across 1,321 genes. We found many more mutations were shared between tumor pairs  (avg. 33.3 mutations/tumor) than were discordant (avg. 2.3 mutations / tumor). Nearly all tumors showed at least one discordance, and these were","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 14 variables, 38 samples sequenced, 18 subjects, 38 samples","","NCI","GRU --- General Research Use","2018-02-20","2018-02-20","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001421.v1.p1","Whole Exome Sequencing and Methylation Profiling of Uveal Melanoma","Uveal melanoma (UM) is the most common primary cancer of the eye and frequently leads to metastatic death. Metastatic risk can be stratified into low, intermediate and high based on  the presence of mutually exclusive mutations in EIF1AX, SF3B1 and BAP1, respectively. The purpose of this study was to comprehensively profile the","Not Applicable","Uveal melanoma","Prospective Longitudinal Cohort","HumanMethylation450","Methylation (CpG), WXS","1 molecular datasets, 57 samples sequenced, 37 subjects, 64 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2018-01-25","2018-01-25","Methylation",""
"phs000950.v1.p1","NCI SEER Formalin Fixed Paraffin Embedded (FFPE) Tissue Feasibility Study","Next Generation Sequencing (NGS) technologies are being used for detection of somatic mutations in tumors and studies of germline variation. However, most NGS studies used DNA isolated either from whole  blood or fresh frozen tissue specimens. Meanwhile, the tissue specimens available from most National Cancer Institute (NCI) funded cohorts and the","Not Applicable","Neoplasms","Case Set","WES_markerset_grc37","RNA-Seq, SNP Genotypes (NGS), WXS","4 phenotype datasets, 21 variables, 1 molecular datasets, 127 samples sequenced,  SRA, 59 subjects, 129 samples","","NCI","GRU --- General Research Use, HMB-MDS --- Health/Medical/Biomedical (MDS)","2018-01-04","2018-01-04","Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001385.v1.p1","Ancestry Admixture among Chileans","The purpose of this study is to investigate ancestry admixture among Chileans with and without gallbladder cancer. All cases from the Chile Gallbladder Cancer Pilot and Expansion studies with available  genotype data. Principal Investigator: Jill Koshiol, PhD, National Institutes of Health, Bethesda, MD, USA Funding Source: Z01 CP010218, National","Not Applicable","Gallbladder Neoplasms","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 17 variables, 1 molecular datasets, 189 subjects, 204 samples","","NCI","GRU --- General Research Use","2017-12-28","2017-12-28","Bladder Cancer, Gall; Bladder Cancers, Gall; Cancer of Gallbladder; Cancer of the Gallbladder; Cancer, Gall Bladder; Cancer, Gallbladder","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001159.v1.p1","Genetic Analysis to Interrogate Tumor Heterogeneity in Lung    Adenocarcinoma","We employed next-generation sequencing to identify somatic alterations in multiple metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient during his seven year course of ERBB2-directed therapies. The degree of  heterogeneity was unprecedented, with 1% similarity between somatic alterations of the lung and lymph nodes. One novel translocation, PLAG1-ACTA2,","Not Applicable","Adenocarcinoma of Lung","Case Set","WGS_markerset_grc37, Somatic_Variant","SNP/CNV Genotypes (NGS), WGS, WXS","3 phenotype datasets, 22 variables, 2 molecular datasets, 4 samples sequenced,  SRA, 1 subjects, 4 samples","","NCI","HMB-IRB-PUB --- Health/Medical/Biomedical (IRB, PUB)","2017-12-12","2017-12-12","ADENOCARCINOMA OF LUNG; Adenocarcinoma of lung, somatic; Adenocarcinoma of the Lung; Adenocarcinoma, Lung; Adenocarcinomas, Lung; Lung Adenocarcinoma",""
"phs001403.v1.p1","WES and CNV analysis of NF1-Associated Plexiform Neurofibromas","Neurofibromatosis type 1 (NF1) is a common tumor-predisposition disorder due to germline mutations in the tumor suppressor gene NF1. A virtually pathognomonic finding of NF1 is the plexiform neurofibroma (PN),  a benign, likely congenital tumor that arises from biallelic inactivation of NF1. PN can undergo transformation to a malignant peripheral nerve","Not Applicable","Neurofibromatosis 1","Case-Control","HumanOmni2.5-8","SNP Genotypes (Array), WXS","5 phenotype datasets, 26 variables, 1 molecular datasets, 44 samples sequenced, 21 subjects, 44 samples","","NCI","GRU --- General Research Use","2017-11-30","2017-11-30","Neurofibromatosis Type I; Molluscum Fibrosum; Multiple non-ossifying fibromatosis; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMATOSIS, PERIPHERAL TYPE; NEUROFIBROMATOSIS, TYPE I","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001241.v1.p1","Clonal Architectures and Driver Mutations in Metastatic Melanomas","This study contains sequence data from 15 patients with stage IV melanoma, including the whole genome sequence of 15 metastatic tumors and corresponding normal blood samples from 13 cases, and  targeted capture sequence of four synchronous metastatic samples from two additional cases. These data provide a comprehensive survey of the clonal","Not Applicable","Melanoma","Case Set","Not Provided","WGS, WXS","4 phenotype datasets, 14 variables, 36 samples sequenced, 15 subjects, 36 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2017-11-20","2017-11-20","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001088.v1.p1","Shanghai Breast Cancer Genetics Study (SBCGS)","The Shanghai Breast Cancer Genetics Study (SBCGS) includes data from four population-based studies conducted among Chinese women in urban Shanghai: the Shanghai Breast Cancer Study (SBCS), the Shanghai Breast Cancer  Survival Study (SBCSS), the Shanghai Women's Health Study (SWHS), and the Shanghai Endometrial Cancer Study (SECS, contributing controls only).","Not Applicable","Breast Neoplasms","Case-Control","HumanExome-12","SNP Genotypes (Array)","4 phenotype datasets, 16 variables, 1 molecular datasets,  SRA, 2392 subjects, 2392 samples","","NCI","HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU)","2017-11-14","2017-11-14","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001448.v1.p1","Sub-Saharan Sophageal Squamous Cell Carcinoma Molecular Analysis","Esophageal squamous cell carcinoma (ESCC) occurs as much as 20x more frequently in sub-Saharan Africa than Western countries. Through the UNC-Malawi project collaboration we obtained whole-exome matched tumor/normal and RNA  sequencing of 59 ESCC from Malawi between 2011-2012. DNA analysis revealed similar mutations as other cohorts, while RNA analysis revealed three","Not Applicable","Esophageal Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 35 variables, 177 samples sequenced,  SRA, 59 subjects, 177 samples","","NCI","DS-E-C --- Disease-Specific (Esophageal Cancer)","2017-10-27","2017-10-27","Esophageal Neoplasm; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinoma, Squamous Cell; Carcinomas, Epidermoid",""
"phs001303.v1.p1","GWAS of Sporadic and Familial Testicular Germ Cell Tumors","Case-Control Study: Testicular germ cell cancer has been increasing among men during most of the 20th century. Despite this increase, the etiology of testicular cancer is poorly understood. To better  understand the molecular epidemiology of testicular cancer, the National Cancer Institute and the Department of Defense are conducting a case-control","Not Applicable","Germinoma","Case-Control","HumanHap550","SNP Genotypes (Array)","4 phenotype datasets, 18 variables, 1 molecular datasets, 1509 subjects, 1556 samples","European (1354), East Asian (10), African American (40), Hispanic1 (24), Hispanic2 (64), Other Asian or Pacific Islander (10), South Asian (1), Other (6)","NCI","GRU --- General Research Use, DS-TGCT-COL-MDS --- Disease-Specific (Testicular Cancer, COL, MDS)","2017-10-26","2017-10-26","","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000554.v1.p1","Mutational Landscape of Lethal Castrate Resistant Prostate Cancer","Exome sequencing of matched pairs of tumor / normal genomic DNA was performed from high risk localized prostate cancer or lethal, metastatic, castrate resistant prostate cancer (CRPC). Exome libraries were  prepared using Illumina Paired_End Genome DNA Sample Prep Kit and captured using Agilent SureSelect Capture Library or Roche EZ Exome capture","Not Applicable","Prostatic Neoplasms","Tumor vs. Matched-Normal","Not Provided","WXS","5 phenotype datasets, 30 variables, 120 samples sequenced,  SRA, 59 subjects, 120 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2017-10-17","2017-10-17","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001424.v1.p1","Genomic Analysis of Pre-Treatment and Autopsy Glioblastoma Specimens","We performed whole exome sequencing data of pre-treatment glioblastoma specimens, matched to post-treatment recurrent intracranial autopsy samples and metastatic extracranial post-treatment autopsy samples. We identified early genetic events common to  the evolutionary ancestry of both pre-treatment glioblastoma and later recurrences. We demonstrated that there were no protein-coding mutations as","Not Applicable","Glioblastoma","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 12 variables, 36 samples sequenced,  SRA, 12 subjects, 36 samples","","NCI","DS-NDC-MDS --- Disease-Specific (Neurological Disorders and Cancer, MDS)","2017-10-13","2017-10-13","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme",""
"phs000260.v4.p2","Foregut Microbiome in Development of Esophageal Adenocarcinoma","The distal esophagus is an important anatomical area where gastric acid reflux can cause reflux esophagitis (RE), Barrett's esophagus (BE) (intestinal metaplasia), and esophageal adenocarcinoma (EA). The incidence of EA  has increased 6-fold in the U.S. since the 1970s, parallel to a significant increase in the prevalence of gastroesophageal reflux diseases (GERD).","Not Applicable","Adenocarcinoma Of Esphophagus","Case-Control","Not Provided","AMPLICON, WGS","4 phenotype datasets, 20 variables, 5 documents, 575 samples sequenced,  SRA, 110 subjects, 575 samples","","NCI","HMP --- Human Microbiome Research","2017-10-13","2011-07-01","Adenocarcinoma Of Esophagus; Barrett's Esophagus; GERD; Adenocarcinoma of the Esophagus; Esophageal adenocarcinoma; Esophagus Adenocarcinoma",""
"phs001454.v1.p1","Genomic Regions Associated with Susceptibility to Barrett's Esophagus and    Esophageal Adenocarcinoma in African Americans: The Cross BETRNet    Admixture Study","Differences in rates of diseases between different populations with similar environments are presumed to be secondary to variability in population frequencies of disease causing alleles. Recently admixed populations such as  African Americans (AAs) provide a natural opportunity to identify disease-causing variants by examining the ancestry of long chromosomal haplotypes.","Not Applicable","Adenocarcinoma Of Esophagus","Case Set","HumanOmni2.5-8","SNP Genotypes (Array)","3 phenotype datasets, 11 variables, 1 molecular datasets, 28 subjects, 28 samples","","NCI","GRU-IRB --- General Research Use (IRB)","2017-10-10","2017-10-10","Barrett Esophagus; Esophageal Neoplasms; Adenocarcinoma of the Esophagus; Esophageal adenocarcinoma; Esophagus Adenocarcinoma; adenocarcinoma - esophagus",""
"phs001464.v1.p1","Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. The purpose of this study was to investigate whether alterations in genes encoding components of the HLA Class  I antigen processing and presentation machinery or interferon signaling pathways play a role in acquired resistance to PD-1 or PD-L1 antagonistic","Not Applicable","Carcinoma, Non-Small-Cell Lung","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 24 variables, 63 samples sequenced, 14 subjects, 63 samples","","NCI","DS-LCTC-MDS --- Disease-Specific (Lung Cancer and Thoracic Malignancies, MDS)","2017-10-06","2017-10-06","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs000782.v1.p1","Post-Liver Transplant Recurrent Human Hepatocellular Carcinoma Study    (RHCCS)","The whole exome sequencing showed that HERC5 deletion and under-expression associates with shorter: time to tumor recurrence, progression-free, and overall survival in hepatocellular carcinoma (HCC) in two independent studies (p1  0.004, HR1 1.80; p2 0.018, HR2 3.31) totaling 286 HCC patients. Matched primary and recurrent tumors indicated a clonal selection advantage in","Not Applicable","Carcinoma, Hepatocellular","Prospective Longitudinal Cohort","WES_markerset_grc37","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 26 variables, 1 molecular datasets, 20 samples sequenced,  SRA, 16 subjects, 46 samples","","NCI","GRU-PUB-MDS --- General Research Use (PUB, MDS)","2017-10-06","2017-10-06","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells",""
"phs000978.v1.p1","WGS of a Malignant GCT with Metabolic Response to Pazopanib","We report one case study of a malignant granular cell tumor patient with metabolic response to pazopanib. In this study, we used whole-genome sequencing of the tumor with the matched  blood to characterize the somatic mutation profile in this tumor. This is the first reported whole-genome sequencing study of the rare malignant","Not Applicable","Granular Cell Tumor","Case-Control","Not Provided","WGS","3 phenotype datasets, 22 variables, 2 samples sequenced,  SRA, 1 subjects, 2 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2017-10-02","2017-10-02","Abrikosoff's granulous cell tumor; Abrikosoff's granulous cell tumour; Abrikosoff's tumor; Abrikosoff's tumour; Abrikosovâs tumor; Abrikosovâs tumour",""
"phs001173.v1.p1","Head and Neck Cancer Genome-Wide Association Study","Head and neck cancers have well-documented associations with tobacco and alcohol exposure, but the disease develops in only a small fraction of users, which implies an important role for genetic  susceptibility. Therefore, head and neck cancers are an excellent model for studying genetic susceptibility to environmental carcinogens. The primary","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 20 variables, 1 molecular datasets, 3333 subjects, 3333 samples","European (3301), African American (1), Hispanic1 (3), Hispanic2 (22), Other Asian or Pacific Islander (3), Other (3)","NCI","GRU --- General Research Use","2017-09-27","2017-09-27","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001384.v1.p1","Time Lapse to Cancer-Defining the Transition from Polyp to Cancer","In the US, CRC incidence has declined with uptake in colonoscopy for early detection and removal of polyps, the precursor lesion, can stop a cancer from developing but in spite  of this, CRC remains the second leading cause of cancer death in the United States. One third of people who undergo screening colonoscopy will have","Not Applicable","Colorectal Neoplasms","Case Set","WGS_markerset_grc37","Bisulfite-Seq, RNA-Seq, SNP Genotypes (NGS), WGS","4 phenotype datasets, 19 variables, 1 molecular datasets, 268 samples sequenced,  SRA, 31 subjects, 268 samples","","NCI","HMB --- Health/Medical/Biomedical","2017-09-20","2017-09-20","Adenoma; Adenoma, Microcystic; Adenomas, Microcystic; Microcystic Adenomas; microcystic adenoma; microcystic adenoma (morphologic abnormality)","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001407.v1.p1","HNPCC-Sys: Molecular Characterization of Lynch Syndromes","Lynch Syndrome (LS) tumors are characterized by constitutional mutations in DNA mismatch-repair genes. Colorectal cancers (CRCs) are the predominant tumor type in patients with LS. Here, we have used whole-genome  and transcriptome sequencing of LS- CRC to find similarities and differences of mutation and gene expression characteristics between LS-CRC and","Not Applicable","Colorectal Neoplasms, Hereditary Nonpolyposis","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 30 variables, 46 samples sequenced,  SRA, 11 subjects, 46 samples","","NCI","DS-LYN-PUB-NPU --- Disease-Specific (Lynch Syndrome, PUB, NPU)","2017-09-18","2017-09-18","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal",""
"phs001261.v1.p1","DNA Inverted Repeats as an At-risk Motif for Palindromic Gene    Amplification","DNA Inverted Repeats as an At-risk Motif for Palindromic Gene Amplification defines oncogene amplification that is configured as a series of inverted duplications (palindromic gene amplification). To study the impact  of palindromic gene amplification in cancer genomes, we developed an approach to enrich DNA palindromes from genomic DNA (Genome-wide Analysis of","Not Applicable","Neoplasms by Site","Case Set","Affymetrix_WG_Array","SNP Genotypes (Array), OTHER, WGS","4 phenotype datasets, 21 variables, 1 molecular datasets, 9 samples sequenced,  SRA, 8 subjects, 17 samples","","NCI","DS-BRCA-NPU-MDS --- Disease-Specific (Breast Cancer, NPU, MDS)","2017-09-13","2017-09-13","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001321.v1.p1","Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) - OncoArray    Genotypes","The data come from 40 studies participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). CIMBA recruits individuals with pathogenic mutations in BRCA1 or BRCA2. The majority of  carriers were recruited through cancer genetics clinics offering genetic testing, and were enrolled into national or regional studies. The remainder","Not Applicable","Breast Neoplasms","Prospective Longitudinal Cohort","OncoArray","SNP Genotypes (Array)","4 phenotype datasets, 19 variables, 1 molecular datasets, 11841 subjects, 11841 samples","European (11666), East Asian (125), Hispanic1 (13), Hispanic2 (8), South Asian (1), Other (28)","NCI","GRU --- General Research Use, GRU-IRB --- General Research Use (IRB), GRU-NPU --- General Research Use (NPU), CABNHD-MDS --- Cancer, Benign Neoplasms, or Hematopoietic Diseases (MDS), DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS), DS-BROC-MDS-GSO --- Disease-Specific (Breast and Ovarian cancer, MDS, GSO), DS-BROC-NPU --- Disease-Specific (Breast and Ovarian cancer, NPU), DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-CA-MDS-GSO --- Disease-Specific (Cancer, MDS, GSO)","2017-09-11","2017-09-11","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001425.v1.p1","Melanoma Sequential Immune Checkpoint Blockade Treatment Sequencing Study","Blockade of T cell coinhibitory molecules such as CTLA-4 and PD-1, can activate T cell antitumor response. Although these immune checkpoint blockades (CTLA-4 blockade and PD-1 blockade) have shown durable  response, response rate is modest. Therefore, there is a need to find stable biomarkers predictive of response to immune checkpoint blockades and to","Not Applicable","Melanoma","Case Set","Not Provided","WXS","4 phenotype datasets, 20 variables, 85 samples sequenced, 34 subjects, 85 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2017-08-24","2017-08-24","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001179.v1.p1","Foundation Medicine Adult Cancer Clinical Dataset (FM-AD)","The Foundation Medicine adult cancer clinical dataset consists of 18,004 unique solid tumor samples that underwent genomic profiling on a single uniform platform as part of standard clinical care. The  dataset is derived from the FoundationOne&#x000ae; genomic profiling assay version 2 that interrogates exonic regions of 287 cancer-related genes and","Not Applicable","Neoplasms","Case Set","Not Provided","Not Provided","2 phenotype datasets, 4 variables,  SRA, 18004 subjects, 18004 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2017-07-31","2017-07-31","Abdominal Neoplasms; Digestive System Neoplasms; Endocrine Gland Neoplasms; Nervous System Neoplasms; Skin Neoplasms; Thoracic Neoplasms",""
"phs001199.v1.p1","TIGER-LC OncoVar Sequencing","Intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are clinically disparate primary liver cancers with etiological and biological heterogeneity. We performed targeted sequencing of Thai ICC and HCC among the Thailand  Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) cohort using the OncoVar platform. Incident cases residing in Thailand of","Not Applicable","Carcinoma, Hepatocellular","Case Set","Not Provided","WXS","4 phenotype datasets, 19 variables, 394 samples sequenced,  SRA, 197 subjects, 394 samples","","NCI","GRU --- General Research Use","2017-07-03","2017-07-03","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells",""
"phs000768.v2.p1","Genomic Sequencing of Ewing's Sarcoma","The Ewing sarcoma family of tumors (EFT) is a group of malignant small round blue cell tumors that arise in bone or soft tissue. Ewing sarcoma (ES) is the second  most common type of primary bone tumor to affect children and adolescents and accounts for 2.9% of all childhood cancers. This data set reports","Not Applicable","Sarcoma, Ewing","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 21 variables, 99 samples sequenced,  SRA, 93 subjects, 99 samples","","NCI","GRU --- General Research Use","2017-06-29","2016-07-28","Neuroectodermal Tumors, Primitive, Peripheral; (pPNET) Peripheral Primitive Neuroectodermal Tumors; Ewing sarcoma / PNET; Extracranial Primitive Neuroectodermal Tumor; Neuroectodermal Neoplasm, Peripheral Primitive; Neuroectodermal Tumor, Peripheral","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001265.v1.p1","DRIVE Breast Cancer OncoArray Genotypes","Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). GAME-ON's overall goal was to foster an intra-disciplinary and collaborative approach to","Not Applicable","Breast Neoplasms","Case-Control","OncoArray","SNP Genotypes (Array)","4 phenotype datasets, 27 variables, 1 molecular datasets, 60015 subjects, 60015 samples","European (58491), African (541), African American (812), Hispanic1 (54), Hispanic2 (53), South Asian (3), Other (61)","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods, HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU), DS-BROC --- Disease-Specific (Breast and Ovarian cancer), DS-BRCA-PUB --- Disease-Specific (Breast Cancer, PUB), DS-BCEMOPCA-NPU-MDS --- Disease-Specific (Breast, Colorectal, Endometrial, Melanoma, Ovarian, and/or Prostate Cancer, NPU, MDS), DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-CA --- Disease-Specific (Cancer), DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), GRU --- General Research Use, HMB-PUB --- Health/Medical/Biomedical (PUB)","2017-06-12","2017-06-12","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000773.v1.p1","CTLA4:CD28 in Sezary Syndrome","We sequenced two tumor and one normal whole genome libraries for a Sezary syndrome patient and also sequenced RNA libraries for each tumor. We identified a novel, highly expressed CTLA4:CD28  gene fusion that is predicted to results in a leading to stimulatory T-cell signaling in the presence of an inhibitory signal. Principal","Not Applicable","Sezary Syndrome","Prospective Longitudinal Cohort","WGS_markerset_grc37","RNA-Seq, SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 15 variables, 1 molecular datasets, 7 samples sequenced, 3 subjects, 7 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2017-06-12","2017-06-12","CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC; SS","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001255.v1.p1","Molecular Evolution of Cancer","Recently developed methods that utilize partitioning of long genomic DNA fragments, and barcoding of shorter fragments derived from them, have succeeded in retaining long-range information in short sequencing reads. These  so-called read cloud approaches represent a powerful, accurate, and cost-effective alternative to single-molecule long-read sequencing. We developed","Not Applicable","Liposarcoma","Tumor vs. Matched-Normal","Not Provided","WGS","3 phenotype datasets, 11 variables, 8 samples sequenced, 1 subjects, 8 samples","","NCI","DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS)","2017-06-09","2017-06-09","DDLPS; DDLS; Dedifferentiated Liposarcomas; Liposarcoma, Dedifferentiated; dedifferentiated liposarcoma",""
"phs001257.v2.p1","Genetic Analysis of Tumor Samples","Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-&#x003b3;, which  is a critical cytokine for host immune responses. However, the role of IFN-&#x003b3; signaling in tumor cells in the setting of anti-CTLA-4 therapy","Not Applicable","Melanoma","Case Set","Not Provided","WXS","4 phenotype datasets, 21 variables, 44 samples sequenced,  SRA, 22 subjects, 44 samples","","NCI","DS-M-PUB-NPU --- Disease-Specific (Melanoma, PUB, NPU)","2017-04-12","2017-01-18","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001192.v1.p1","Thoracic Patient-Derived Xenografts","Targeted capture sequencing of 341 cancer associated genes in thoracic patient-derived xenografts. Principal Investigator: John Thomas Poirier, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA Funding Source: P01  CA129243-09, National Institutes of Health, Bethesda, MD, USA","Not Applicable","Lung Neoplasms","Case Set","Not Provided","Targeted-Capture","3 phenotype datasets, 19 variables, 4 samples sequenced,  SRA, 1 subjects, 4 samples","","NCI","DS-LC-PUB-NPU --- Disease-Specific (Lung Cancer, PUB, NPU)","2017-04-11","2017-04-11","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs000795.v1.p1","Gastric Cancer Genetic Analysis of Metastasis","To identify candidate drivers involved in oncogenesis and tumor evolution, we conducted an extensive genome sequencing analysis of metastatic progression in diffuse gastric cancer. This involved a comparison between a  primary tumor from a Hereditary Diffuse Gastric Cancer Syndrome proband and its subsequent recurrence as an ovarian metastasis. Principal","Not Applicable","Stomach Neoplasms","Case-Control","Not Provided","WGS, WXS","5 phenotype datasets, 23 variables, 6 samples sequenced, 17 subjects, 6 samples","","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2017-04-11","2017-04-11","Krukenberg Tumor; Carcinoma, Krukenberg; Krukenbergâs tumor; Krukenbergâs tumour; Krukenberg Carcinoma; Krukenberg Neoplasm",""
"phs001210.v1.p1","NCI Lung Cancer and Smoking Phenotypes in African-American Subjects","This is a two-stage case-control study designed to evaluate the association between common genetic variants and the risk of lung cancer. The stage 1 studies included 1737 cases and 3602  controls from the following studies: MD Anderson Lung Cancer Epidemiology Study, The Multiethnic Cohort Study (MEC), NCI-MD Lung Cancer-Case Control","Not Applicable","Lung Neoplasms","Case-Control","Human1M-Duo","SNP Genotypes (Array)","4 phenotype datasets, 20 variables, 1 molecular datasets, 5339 subjects, 5644 samples","European (1), African (133), African American (5102), Hispanic1 (86), Other (17)","NCI","DS-CA --- Disease-Specific (Cancer), GRU --- General Research Use, GRU-IRB --- General Research Use (IRB), DS-CA-PUB-NPU-RD --- Disease-Specific (Cancer, PUB, NPU, RD), DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2017-04-07","2017-04-07","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001249.v1.p1","Chemosensitive Relapse in Small Cell Lung Cancer Patient-Derived    Xenografts","Genetic and epigenetic analysis of patient-derived xenograft models of acquired chemoresistance in small cell lung cancer. Principal Investigator: John Thomas Poirier, PhD, Memorial Sloan Kettering Cancer Center, New York, NY,  USA Funding Source: R01 CA197936, National Institutes of Health, Bethesda, MD, USA","Not Applicable","Lung Neoplasms","Case Set","Not Provided","ChIP-Seq, RNA-Seq, WGS, WXS","3 phenotype datasets, 21 variables, 110 samples sequenced, 10 subjects, 110 samples","","NCI","HMB-PUB --- Health/Medical/Biomedical (PUB)","2017-04-03","2017-04-03","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs001319.v1.p1","Glioma International Case Control Study (GICC)","The main goals of the GICC Study were: 1) to identify novel genetic risk variants for glioma, as well as validate variants implicated by previous genome-wide association studies of glioma;  and 2) to explore biologically relevant gene-gene and gene-environment interactions in glioma susceptibility. The GICC Study includes participants","Not Applicable","Glioma","Case-Control","OncoArray","SNP Genotypes (Array)","4 phenotype datasets, 16 variables, 1 molecular datasets, 7566 subjects, 7566 samples","European (7500), Hispanic1 (18), Hispanic2 (26), South Asian (1), Other (21)","NCI","GRU --- General Research Use, DS-BT --- Disease-Specific (Brain Tumors), DS-GL-PUB --- Disease-Specific (Glioma, PUB), DS-GL --- Disease-Specific (Glioma), GRU-COL --- General Research Use (COL), DS-CA --- Disease-Specific (Cancer), DS-GLRC --- Disease-Specific (Glioma and Related Conditions)","2017-03-31","2017-03-31","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001181.v1.p1","Single-Cell DNA and RNA Sequencing over A 29-Year Period of A CLL Patient","Chronic lymphocytic leukemia (CLL) is a frequent B-cell malignancy characterized by recurrent somatic chromosome alterations and a low level of point mutations. Here we present single nucleotide polymorphism (SNP) microarray  analyses of a single CLL patient over 29-years of observation and treatment, and transcriptome and whole genome sequencing at selected timepoints. We","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Case Set","HumanOmniExpress-12","SNP Genotypes (Array), RNA-Seq, WGS","4 phenotype datasets, 15 variables, 1 molecular datasets, 8 samples sequenced,  SRA, 1 subjects, 16 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2017-03-24","2017-03-24","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs001121.v1.p1","Integrated Genetic and Pharmacologic Interrogation of Rare Cancers","Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated  sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen.","Not Applicable","Sarcoma","Prospective Longitudinal Cohort","other","RNA-Seq, SNV Aggregate (.MAF), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 3 samples sequenced, 1 subjects, 3 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2017-03-21","2017-03-21","Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma",""
"phs001263.v1.p1","DRIVE Breast Cancer GWAS Meta-Analysis","Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) was one of five projects funded in 2010 as part of the NCI's Genetic Associations and Mechanisms in Oncology  (GAME-ON) initiative (http://epi.grants.cancer.gov/gameon/). GAME-ON's overall goal was to foster an intra-disciplinary and collaborative approach to","Not Applicable","Breast Neoplasms","Case-Control","Not Provided","Not Provided","1 documents, 2 analyses","","NCI","DS-BRCA-MDS --- Disease-Specific (Breast Cancer, MDS)","2017-03-09","2017-03-09","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001036.v1.p1","Genomic Characterization of Acral Melanoma","In this study, we performed paired tumor/normal long insert whole genome and exome sequencing and tumor RNA sequencing on primary or metastatic acral melanoma tumors collected from 34 patients. Patients  were enrolled from either Vanderbilt University or the Memorial Sloan-Kettering Cancer Center. We report an integrated analysis of DNA and RNA","Not Applicable","Melanoma","Tumor vs. Matched-Normal","other","RNA-Seq, SNV Aggregate (.MAF), WGS, WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 109 samples sequenced,  SRA, 34 subjects, 109 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2017-03-01","2017-03-01","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001271.v1.p1","Pooled Genome-Wide Analysis of Kidney Cancer Risk (KIDRISK)","Incidence rates of renal cell carcinoma (RCC) are rising and the latest estimates show that it accounts for over 300,000 cases and 120,000 deaths worldwide each year. Mechanisms underlying RCC  occurrence are not fully understood and a large part of the disease heritability remains unexplained. The study aimed at augmenting the size of","Not Applicable","Carcinoma, Renal Cell","Case-Control","HumanOmni5-4","SNP Genotypes (Array)","4 phenotype datasets, 17 variables, 1 molecular datasets, 5307 subjects, 5307 samples","European (5208), Hispanic1 (6), Hispanic2 (1), South Asian (3), Other (89)","NCI","HMB-PUB-NPU-MDS --- Health/Medical/Biomedical (PUB, NPU, MDS), DS-CA-NPU-GSO --- Disease-Specific (Cancer, NPU, GSO), DS-RCC-MDS --- Disease-Specific (Kidney Cancer, MDS)","2017-02-28","2017-02-28","Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell",""
"phs000882.v1.p1","Prostate Cancer Genome-Wide Association Study for Uncommon Susceptibility    Loci (PEGASUS)","This genome-wide association study was funded by the National Cancer Institute (NCI) to identify uncommon susceptibility loci for prostate cancer. A total of 4,600 prostate cancer cases and 2,840 controls  of European ancestry from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were genotyped using the Illumina HumanOmni2.5","Not Applicable","Prostatic Neoplasms","Case-Control","HumanOmni2.5-4","SNP Genotypes (Array)","4 phenotype datasets, 18 variables, 1 molecular datasets, 7440 subjects, 7639 samples","","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods","2017-01-24","2017-01-24","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000907.v1.p1","Brain Metastases in Squamous Cell Lung Cancers","Putative oncogenic pathways in squamous cell lung cancer have been recently characterized, although their biologic repercussions in patients is largely unknown. This study sought to discover potential clinical manifestations of  major pathways in squamous cell lung cancer, particularly the PI3K pathway. Two key findings emerged: patients with stage IV squamous cell lung","Not Applicable","Carcinoma, Squamous Cell","Case Set","other","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 28 variables, 1 molecular datasets, 13 samples sequenced,  SRA, 5 subjects, 13 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2016-12-22","2016-12-22","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell",""
"phs000973.v1.p1","The Genomic Landscape of Juvenile Myelomonocytic Leukemia","This study analyzed samples from 29 patients with juvenile myelomonocytic leukemia (JMML) using whole exome sequencing. Each patient had a paired germline tissue along with a diagnostic leukemia sample. Germline  tissue types included buccal mucosa, cordblood, Epstein-Barr virus immortalized cell lines and fibroblasts from either skin or bone marrow. Leukemia","Not Applicable","Leukemia, Myelomonocytic, Juvenile","Collection","WES_markerset_grc37","SNV (.MAF), WXS","4 phenotype datasets, 24 variables, 1 molecular datasets, 65 samples sequenced,  SRA, 29 subjects, 65 samples","","NCI","DS-CA-NPU-MDS --- Disease-Specific (Cancer, NPU, MDS)","2016-12-21","2016-12-21","JCML; JCML - Juvenile chronic myeloid leukemia; JMML; Juvenile Chronic Myelogenous Leukemia; Juvenile Myelomonocytic Leukemias; Juvenile chronic myelomonocytic leukemia",""
"phs001243.v1.p1","Genetic Basis of Breast Cancer Resistance in BRCA1 Mutation Carrier","Our study addressed a specific question in NCI RFA-CA-12-022: ""What underlying causal events - e.g., genetic, epigenetic, biologic, behavioral, or environmental - allow certain individuals to survive beyond the expected  limits of otherwise highly lethal cancers?"". A germline mutation in BRCA1 (BRCA1+) is the most penetrant genetic predisposition for breast cancer.","Not Applicable","Breast Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 14 variables, 54 samples sequenced, 54 subjects, 54 samples","","NCI","GRU-PUB --- General Research Use (PUB)","2016-12-15","2017-06-15","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000804.v1.p1","Genomic Sequencing of Ewing Sarcoma","Pediatric Ewing sarcoma is a pediatric cancer that primarily arises from the bone. It is characterized by chimeric fusions of the EWS gene and an ETS family transcription factor. In  this study, we performed massively parallel sequencing of a larger collection of Ewing sarcoma tumors to define the genomic landscape of this","Not Applicable","Sarcoma, Ewing","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WGS, WXS","4 phenotype datasets, 18 variables, 1 molecular datasets, 132 samples sequenced, 102 subjects, 132 samples","","NCI","GRU --- General Research Use, DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2016-12-13","2016-12-13","ES; Ewing Sarcoma; Ewing Tumor; Ewing tumour; Ewing's Sarcoma; Ewing's Tumor","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001185.v1.p1","Genome-Wide Scan of Early-onset Prostate Cancer","This is a genome-wide association scan of 931 early-onset prostate cancer cases of European ancestry. The samples were selected from prostate cancer studies at the University of Michigan. Controls were  previously genotyped individuals selected from the Cancer Genetics Markers of Susceptibility (CGEMS) and Illumina's iControlDB database. All subjects","Not Applicable","Prostatic Neoplasms","Case-Control","Human660W-Quad","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 molecular datasets, 931 subjects, 931 samples","","NCI","DS-CA --- Disease-Specific (Cancer)","2016-11-03","2016-11-03","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs001223.v1.p1","Analysis of AR Gene Rearrangements in Prostate Cancer","Molecularly-targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signaling undermines therapeutic efficacy and promotes progression to  lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone","Not Applicable","Prostatic Neoplasms","Case Set","Not Provided","OTHER, RNA-Seq","57 samples sequenced, 42 subjects, 57 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2016-10-31","2016-10-31","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000893.v1.p1","Genome-Wide Association Study of Endometrial Cancer in E2C2","Endometrial cancer, the most common gynecological malignancy in the United States, has both an environmental and genetic component. To this end, we conducted a genome-wide association study to identify genes  involved in endometrial cancer using studies from the NCI-supported Epidemiology of Endometrial Cancer Consortium (E2C2). For the discovery stage we","Not Applicable","Carcinoma, Endometrioid","Case-Control","HumanExome-12, Human660W-Quad, HumanOmniExpress-12","SNP Genotypes (Array)","5 phenotype datasets, 34 variables, 1 molecular datasets, 8622 subjects, 8622 samples","","NCI","GRU-MDS --- General Research Use (MDS), GRU-COL-MDS --- General Research Use (COL, MDS), DS-CA --- Disease-Specific (Cancer), DS-EC-MDS --- Disease-Specific (Endometrial Carcinoma, MDS), DS-ENDOMETRIAL-MDS --- Disease-Specific (Endometrial Diseases, MDS), DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), DS-CHRONIC --- Disease-Specific (Chronic Diseases), CADM --- Cancer in all age groups, other disease in adults only and methods, HMB-PUB-NPU-MDS-GSO --- Health/Medical/Biomedical (PUB, NPU, MDS, GSO)","2016-10-27","2016-10-27","Uterine Neoplasms; Endometrial Neoplasms; Endometrial Tumor; Endometrial neoplasm; Endometrium Neoplasm; Endometrium Tumor","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000669.v1.p1","AMBER Consortium","The AMBER Consortium Study was formed to pool interview data, questionnaire data, and biological samples from epidemiological studies of breast cancer in African-American women to discover the potential causes of  early-onset and aggressive breast cancer in African-American women. AMBER is funded through a Program Project grant from the National Cancer","Not Applicable","Breast Neoplasms","Case-Control","imputation_panel, Not Provided","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 23 variables, 2 molecular datasets, 6830 subjects, 7127 samples","European (5), African (151), African American (3782), Hispanic1 (42), Other (19)","NCI","DS-BRCA-COL-MDS-GSO --- Disease-Specific (Breast Cancer, COL, MDS, GSO)","2016-10-21","2016-10-21","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs001072.v1.p1","Genomic Analysis of Relapsed Pediatric Acute Lymphoblastic Leukemia","Although multi-agent combination chemotherapy is curative in a significant fraction of childhood acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die due to chemo-refractory disease. Here we  used whole-exome and whole-genome sequencing to analyze the mutational landscape and pattern of clonal evolution at relapse in pediatric ALL cases.","Not Applicable","Leukemia, Lymphoid","Tumor vs. Matched-Normal","Not Provided","WGS, WXS","4 phenotype datasets, 21 variables, 179 samples sequenced,  SRA, 57 subjects, 179 samples","","NCI","DS-CA-PUB-MDS-GSO --- Disease-Specific (Cancer, PUB, MDS, GSO)","2016-10-11","2016-10-11","Lymphoblastic Leukemia, Acute, T-Cell; Precursor B-Cell Lymphoblastic Leukemia; Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia",""
"phs000801.v2.p1","NCI Non-Hodgkin Lymphoma GWAS","Within the framework of the International Lymphoma Epidemiology Consortium (InterLymph) Consortium and NCI-sponsored Cohort Consortium, investigators from 22 studies came together to conduct a genome-wide association study (GWAS) of non-Hodgkin  lymphoma (NHL). The goal of the study was to identify common genetic variants associated with the risk of NHL. As described previously (Berndt SI et","Not Applicable","Lymphoma, Non-Hodgkin","Prospective Longitudinal Cohort","HumanOmniExpressExome-8, HumanOmniExpress-12, HumanOmniExpress-12","Not Provided","2 phenotype datasets, 7 variables, 10491 subjects, 10791 samples, 5 substudies","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","Lymphoma, Follicular; B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade",""
"phs000891.v1.p1","NCI Non-Hodgkin Lymphoma GWAS: MZL","This sub-study phs000891 NCI Non-Hodgkin Lymphoma GWAS: MZL contains genotype and subject and sample phenotype of subjects available from the phs000891 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Marginal zone lymphoma (MZL) encompasses a","National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS) (phs000801.v2.p1)","Lymphoma, Non-Hodgkin","Case Set","HumanOmniExpress-12","SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 1 molecular datasets, 825 subjects, 839 samples","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","Lymphoma, B-Cell, Marginal Zone; Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue; Extranodal marginal zone B-cell lymphoma; Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma); Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue; Immunocytoma",""
"phs000890.v1.p1","NCI Non-Hodgkin Lymphoma GWAS: FL","This sub-study phs000890 NCI Non-Hodgkin Lymphoma GWAS: FL contains genotype and subject and sample phenotype of subjects available from the phs000890 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Genome-wide association studies (GWAS) of","National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS) (phs000801.v2.p1)","Lymphoma, Non-Hodgkin","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 1 molecular datasets, 2142 subjects, 2186 samples","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","Lymphoma, Follicular; Non-Hodgkin Lymphoma; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers",""
"phs000889.v1.p1","NCI Non-Hodgkin Lymphoma GWAS: DLBCL","This sub-study phs000889 NCI Non-Hodgkin Lymphoma GWAS: DLBCL contain genotype and subject and sample phenotype of subjects available from the phs000889 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Diffuse large B-cell lymphoma (DLBCL) is a","National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS) (phs000801.v2.p1)","Lymphoma, Non-Hodgkin","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 1 molecular datasets, 2661 subjects, 2706 samples","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma; Diffuse Histiocytic Lymphoma",""
"phs000818.v2.p1","NCI Non-Hodgkin Lymphoma GWAS: Controls","This sub-study phs000818 NCI Non-Hodgkin Lymphoma GWAS: Controls contains genotype and subject and sample phenotype of subjects available from the phs000818 study. Summary level phenotypes for the NCI Non-Hodgkin Lymphoma  GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Within the framework of the International","National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS) (phs000801.v2.p1)","Lymphoma, Non-Hodgkin","Prospective Longitudinal Cohort","HumanOmniExpressExome-8","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 1 molecular datasets, 2685 subjects, 2835 samples","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology; Reticulum-Cell Sarcoma",""
"phs000802.v2.p1","NCI Non-Hodgkin Lymphoma GWAS: CLL","This sub-study phs000802 NCI Non-Hodgkin Lymphoma GWAS: CLL contains genotype and subject and sample phenotype data from subjects available from the phs000802 study. Summary level phenotypes for the NCI Non-Hodgkin  Lymphoma GWAS study participants can be viewed at the top-level study page phs000801 NCI Non-Hodgkin Lymphoma GWAS. Individual level phenotype data","National Cancer Institute (NCI) Non-Hodgkin Lymphoma Genome-wide Association Study (GWAS) (phs000801.v2.p1)","Lymphoma, Non-Hodgkin","Prospective Longitudinal Cohort","HumanOmniExpressExome-8","SNP Genotypes (Array), SNP Genotypes (Array)","2 phenotype datasets, 10 variables, 1 molecular datasets, 2178 subjects, 2225 samples","","NCI","DS-CA-IRB-NPU-GSO --- Disease-Specific (Cancer, IRB, NPU, GSO), DS-NHL-NPU-GSO --- Disease-Specific (non-Hodgkin Lymphoma, NPU, GSO), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2016-09-22","2016-09-22","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs001111.v1.p1","A Prognostic Role of APC in Colorectal Cancers","Colorectal cancer (CRC) is a highly heterogeneous disease, for which prognosis has been relegated to clinic-pathologic staging for decades. There is a need to molecularly stratify subpopulations of CRC to  better predict outcome and assign therapies. Here we report targeted exome sequencing of 1,321 cancer-related genes on 468 tumor specimens, which","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","Targeted-Capture","4 phenotype datasets, 29 variables, 468 samples sequenced,  SRA, 468 subjects, 468 samples","","NCI","GRU --- General Research Use","2016-09-21","2016-09-21","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001044.v1.p1","Breast Cancer Risk Pathways","We sought to identify genomic variants that differed between individuals who developed familial breast cancer and individuals who had a family history of breast cancer but who had not developed  breast cancer. We aggregated these data at the pathway level to identify pathways that play a role in familial breast cancer development. We profiled","Not Applicable","Breast Neoplasms","Case-Control","WES_markerset_grc37","SNP/CNV Genotypes (NGS), WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 35 samples sequenced,  SRA, 35 subjects, 35 samples","","NCI","GRU --- General Research Use","2016-09-19","2016-09-19","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000937.v1.p1","The Landscape of Antisense Gene Expression in Human Cancers","High throughput RNA Sequencing has revealed that the human genome is widely transcribed. However, the extent of natural antisense transcription, the molecular mechanisms by which natural antisense transcripts (NATs) might  affect their cognate sense genes, and the role of NATs in cancer are less well understood. Here, we use strand-specific paired-end RNA sequencing","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 376 samples sequenced, 376 subjects, 376 samples","","NCI","DS-CA-NPU-MDS --- Disease-Specific (Cancer, NPU, MDS), DS-LC-MDS --- Disease-Specific (Lung Cancer, MDS)","2016-08-24","2016-08-24","Carcinoma, Merkel Cell; Hodgkin Disease; Lung Neoplasms; Meningioma; Sarcoma; ADENOCARCINOMA OF LUNG",""
"phs001112.v1.p1","Chromosome X Mosaicism Methylation Study","This study investigates methylation patterns in promoter regions on the X chromosomes of females with X chromosome mosaicism in an effort to phase mosaic events to either the active or  inactive X chromosome. Females with genotyping array detected X mosaic events greater than 2 Mb in size and with available DNA Principal","Not Applicable","Neoplasms","Case Set","HumanMethylation450","Methylation (CpG)","4 phenotype datasets, 14 variables, 1 molecular datasets, 33 subjects, 33 samples","","NCI","O-MDS_ONLY --- Methods Only","2016-07-01","2016-07-01","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs001115.v1.p1","Tissue Specimens from Patients with Melanoma for Genetic Analysis","The purpose of this study was to obtain tissue specimens derived from patients with melanoma to generate research tools to advance our understanding of the genetics, pathogenesis, and therapeutics of  melanoma. Briefly, tissue was obtained from metastatic lesions and used to generate clonal primary cell lines from melanoma cells and fibroblasts","Not Applicable","Melanoma, Cutaneous Malignant","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 20 variables, 1 documents, 6 samples sequenced,  SRA, 3 subjects, 6 samples","","NCI","GRU --- General Research Use","2016-06-27","2016-06-27","CMM; Cutaneous Malignant Melanoma; Cutaneous Malignant Melanomas; Cutaneous melanoma; MELANOMA, MALIGNANT; MM (malignant melanoma) of skin","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000932.v1.p1","Somatic Reference Standard for Cancer Sequencing","In this study, we separately performed PCR-free whole genome sequencing on the paired tumor/normal melanoma COLO-829 and lymphoblastoid COLO-829BL cell lines across three separate institutions (TGen, Illumina, Genome Sciences Centre  at the British Columbia Cancer Agency). We performed a meta-analysis of all data, in combination with the originally reported analysis of these cell","Not Applicable","Melanoma","Tumor vs. Matched-Normal","WGS_markerset_grc37","SNP Genotypes (NGS), WGA","4 phenotype datasets, 17 variables, 1 molecular datasets, 8 samples sequenced,  SRA, 1 subjects, 8 samples","","NCI","GRU --- General Research Use","2016-06-15","2016-06-15","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs001041.v1.p1","Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma","Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall  survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. We obtained tumor tissue from patients","Not Applicable","Melanoma","Prospective Longitudinal Cohort","other","SNP Genotypes (NGS), WXS","4 phenotype datasets, 41 variables, 1 molecular datasets, 128 samples sequenced,  SRA, 64 subjects, 128 samples","","NCI","HMB-PUB-NPU-MDS --- Health/Medical/Biomedical (PUB, NPU, MDS)","2016-06-10","2016-06-10","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs001107.v1.p1","Patient-Specific Factors Influence Somatic Variations in VHL Tumors","Patients affected with von Hippel-Lindau disease are at risk of developing multiple independent clear cell renal carcinomas. This study performed whole genome sequencing on 40 tumors from 6 VHL patients  to compare somatic variation patterns within and between patients. Although tumors from the same patient showed many differences, within-patient","Not Applicable","von Hippel-Lindau Disease","Tumor vs. Matched-Normal","WES_markerset_grc37","SNP Genotypes (NGS), WGS","4 phenotype datasets, 33 variables, 1 molecular datasets, 51 samples sequenced,  SRA, 6 subjects, 51 samples","","NCI","DS-RCC-IRB --- Disease-Specific (Kidney Cancer, IRB)","2016-06-08","2016-06-08","Angiomatoses, Familial Cerebello-Retinal; Angiomatoses, Familial Cerebelloretinal; Angiomatosis Retinae; Angiomatosis, Familial Cerebello-Retinal; Angiomatosis, Familial Cerebelloretinal; Cerebello-Retinal Angiomatoses, Familial",""
"phs001066.v1.p1","DNA and RNA Sequence of an Acute Lymphoblastic Leukemia","We used massively parallel sequencing technology to profile the genomic DNA and RNA of tumor cells (leukemic bone marrow) and normal cells (skin biopsy) obtained from a single patient with  Acute Lymphoblastic Leukemia (ALL), referred to throughout this study as 'ALL1'. Included in this study are samples obtained from a primary tumor,","Not Applicable","Neoplasms","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 13 variables, 23 samples sequenced,  SRA, 1 subjects, 23 samples","","NCI","HMB --- Health/Medical/Biomedical","2016-05-19","2016-05-19","Leukemia; Blood (Leukemia); Blood cancer; Leucocythaemia; Leucocythaemias; Leucocythemia","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs001063.v1.p1","Genomic Characterization of PDX Models for Breast Cancer Brain Metastases","We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel  combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived","Not Applicable","Breast Neoplasms","Case Set","WES_markerset_grc37","SNP Genotypes (NGS), WXS","4 phenotype datasets, 20 variables, 1 molecular datasets, 12 samples sequenced,  SRA, 12 subjects, 12 samples","","NCI","GRU-IRB-PUB --- General Research Use (IRB, PUB)","2016-05-12","2016-05-12","Neoplasm Metastasis; Brain Neoplasms; Brain Tumor; Brain Tumors; Brain neoplasm; Brain tumour",""
"phs001054.v1.p1","Genomic Characterization of Pediatric Low-Grade Gliomas","Pediatric low-grade gliomas (PLGGs) are the most common pediatric brain-tumor, with more than ten histologic subtypes recognized by the World Health Organization. We performed a genomic analysis of 230 PLGGs  of which 73 had whole genome/RNA sequencing performed and show that MYB-QKI fusions define the seizure associated tumor, Angiocentric Glioma (AG).","Not Applicable","Glioma","Case Set","Not Provided","ChIP-Seq, RNA-Seq, WGS, WXS","4 phenotype datasets, 13 variables, 92 samples sequenced,  SRA, 80 subjects, 93 samples","","NCI","GRU --- General Research Use, DS-NTT --- Disease-Specific (Nervous Tissue Tumors)","2016-04-06","2016-04-06","ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000942.v1.p1","Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic","Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members  of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n 176) and those without (n 82). Initial analysis of potentially pathogenic","Not Applicable","Neoplasms","Prospective Longitudinal Cohort","WGS_markerset_grc37","SNP/CNV Genotypes (NGS), WGS","4 phenotype datasets, 31 variables, 1 molecular datasets, 235 samples sequenced,  SRA, 258 subjects, 258 samples","European (214), African American (14), Hispanic1 (3), Hispanic2 (17), Other Asian or Pacific Islander (1), South Asian (4), Other (4)","NCI","GRU-PUB-MDS --- General Research Use (PUB, MDS)","2016-03-03","2016-03-03","Adenomatous Polyposis Coli; Bile Duct Neoplasms; Colonic Polyps; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hemangioblastoma",""
"phs001038.v1.p1","DNA Methylation Inhibitors in Immunotherapy","We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway and re-expression of epigenetically silenced endogenous retrovirus. In melanoma patients treated with an  immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi","Not Applicable","Melanoma","Case Set","RNAseq_probe_set_grc37","RNA-Seq, RNA Seq (NGS)","4 phenotype datasets, 38 variables, 1 molecular datasets, 20 samples sequenced,  SRA, 20 subjects, 20 samples","","NCI","HMB-PUB-NPU-MDS --- Health/Medical/Biomedical (PUB, NPU, MDS)","2016-03-02","2016-03-02","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs000994.v1.p1","The Mutational Landscape of CTCL and Sezary Syndrome.","Sezary syndrome is a leukemic and aggressive form of cutaneous T-cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4+ T cells. To identify new genetic alterations  involved in Sezary syndrome and CTCL transformation we performed whole-exome sequencing of tumor-normal sample pairs from 26 Sezary syndrome and 16","Not Applicable","Sezary Syndrome","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 21 variables, 84 samples sequenced,  SRA, 84 subjects, 84 samples","","NCI","DS-CA-IRB-PUB --- Disease-Specific (Cancer, IRB, PUB)","2016-01-15","2016-01-15","Mycosis Fungoides; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC",""
"phs001034.v1.p1","New England-Based Case-Control Study of Ovarian Cancer (NECC)","The case-control data provided to dbGaP were collected under NCI grant number CA54419 which had 3 enrollment phases: I (1992-1997), II (1998-2002) and III (2003-2008). Altogether, CA54419 funded 15 years  of data and specimen collection, resulting in one of the longest running population based case-control studies of ovarian cancer. The study goal was","Not Applicable","Ovarian Neoplasms","Case-Control","Not Provided","Not Provided","2 phenotype datasets, 84 variables, 3 documents, 4141 subjects","","NCI","GRU-NPU --- General Research Use (NPU)","2016-01-14","2016-01-14","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs001007.v1.p1","The Genetic Landscape of Metastasis and Recurrence in HNSCC","Recurrence and/or metastasis occur in more than half of patients with head and neck squamous cell carcinoma (HNSCC) and pose the greatest threats to long-term survival. The genetic alterations underlying  recurrent/metastatic HNSCC are unknown. This study represents the first whole exome sequencing (WES) cohort study of patient-matched tumor pairs in","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","Not Provided","WXS","4 phenotype datasets, 26 variables, 65 samples sequenced, 23 subjects, 65 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2015-12-02","2015-12-02","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx",""
"phs000975.v1.p1","Nurses' Health Study (NHS)","The Nurses' Health Study is an on-going prospective cohort study of women that was initiated in 1976. This specific study was part of a larger study to advance our knowledge  of breast cancer etiology, expand the current knowledge of mammographic density, and clarify the relationship between mammographic density and breast","Not Applicable","Breast Density","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 26 variables, 1 molecular datasets, 794 subjects, 794 samples","","NCI","GRU --- General Research Use","2015-12-02","2015-12-02","Mammographic Density; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000953.v1.p1","Microdissected Pancreatic Cancer Whole Exome Sequencing","109 micro-dissected pancreatic cancer cases and normal control tissue were subjected to whole-exome sequencing. Microdissection enriches tumor cellularity and enhances mutation calling. Inclusion: Diagnosis of pancreatic cancer with sufficient available  tumor tissue and normal control. Principal Investigator: Agnieszka Witkiewicz, University of Texas Southwestern Medical Center, Dallas, TX, USA","Not Applicable","Pancreatic Neoplasms","Prospective Longitudinal Cohort","Not Provided","WXS","3 phenotype datasets, 11 variables, 218 samples sequenced,  SRA, 109 subjects, 218 samples","","NCI","DS-PACA-IRB-NPU-MDS --- Disease-Specific (Pancreatic Cancer, IRB, NPU, MDS)","2015-11-30","2015-11-30","Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic",""
"phs000980.v1.p1","PD-1 Blockade in Non-Small Cell Lung Cancer","Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced. Inclusion: non-small cell lung cancer, treated with pembrolizumab Principal Investigators: Timothy Chan,  MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA Principal Investigators: Matthew Hellmann, MD,","Not Applicable","Carcinoma, Non-Small-Cell Lung","Tumor vs. Matched-Normal","other","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 36 variables, 1 molecular datasets, 68 samples sequenced,  SRA, 34 subjects, 68 samples","","NCI","HMB-PUB-NPU --- Health/Medical/Biomedical (PUB, NPU)","2015-11-19","2022-12-06","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell; NONSMALL CELL LUNG CANCER",""
"phs000813.v1.p1","Sequencing of Targeted Genomic Regions Associated with Smoking","This study includes samples from two projects: Collaborative Genetic Study of Nicotine Dependence (COGEND; PI: Laura Bierut) and Genetic Study of Nicotine Dependence in African Americans (AAND; PI: Laura Bierut  and Eric Johnson). The majority of the COGEND subjects included in the current study overlap with the two datasets already available on dbGaP. GWAS","Not Applicable","Tobacco Use Disorder","Case-Control","target_markerset_grc37, Not Provided, Not Provided, other","SNP Genotypes (Array), SNP Genotypes (NGS), WXS","4 phenotype datasets, 131 variables, 27 documents, 1 molecular datasets, 3098 samples sequenced,  SRA, 2969 subjects, 3098 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2015-10-23","2016-10-23","Compulsive tobacco user syndrome; Dependence, Tobacco; Tobacco Dependence","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000977.v1.p1","Genetic Analysis of Desmoplastic Melanoma","Desmoplastic melanoma is an infrequent variant of melanoma with sarcomatous histology, distinct clinical behavior, and unknown pathogenesis. We performed low-coverage genome and high-coverage exome sequencing of 20 desmoplastic melanomas, followed  by targeted sequencing of 293 genes to validate candidate genes. A high mutation burden (median 62 mutations/Mb) ranked desmoplastic melanoma among","Not Applicable","Melanoma","Tumor vs. Matched-Normal","Not Provided","WGS, WXS","3 phenotype datasets, 12 variables, 140 samples sequenced,  SRA, 62 subjects, 140 samples","","NCI","GRU --- General Research Use, DS-M-MDS --- Disease-Specific (Melanoma, MDS)","2015-10-01","2015-10-01","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000884.v1.p1","Gut Microbiome Profiles and Risk of Colorectal Cancer","Findings from recent studies suggest that the community of microbes residing in the human body is important in disease etiology; however, it remains unclear whether personal factors modulate human microbial  composition. Studies based on animal models indicate that differences in composition might be attributed to sex-mediated effects. We analyzed the","Not Applicable","Microbiota","Case-Control","Not Provided","POOLCLONE","4 phenotype datasets, 35 variables, 1 documents, 240 samples sequenced,  SRA, 240 subjects, 240 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2015-09-21","2015-09-21","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000941.v1.p1","Phylogenetic Analyses Reveal Complex Patterns of Melanoma Metastasis","Subpopulations of cells in a primary melanoma can disseminate and establish metastases. Still, the precise ancestral relationship between primary tumors and their metastases is not well understood. Using whole-exome sequencing  (for discovery) and targeted sequencing (for validation), we analyzed mutation patterns of primary melanomas and two or more metastases in each of 8","Not Applicable","Melanoma","Tumor vs. Matched-Normal","Not Provided","WXS","3 phenotype datasets, 11 variables, 39 samples sequenced,  SRA, 8 subjects, 39 samples","","NCI","GRU --- General Research Use, DS-M-MDS --- Disease-Specific (Melanoma, MDS)","2015-09-18","2015-09-18","Neoplasm Metastasis; Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000885.v1.p1","Strong Activation of Retroviral LTRs in HCC","The ncRNA transcriptome of human hepatocellular carcinoma (HCC) is largely unexplored. We used CAGE to characterize transcription start sites across different etiologies of human HCCs with emphasis on ncRNAs. Here  we report that retroviral LTR promoters, expressed in healthy tissues such as testis and placenta but not liver, are widely activated in HCC. Despite","Not Applicable","Carcinoma, Hepatocellular","Case-Control","CAGE_RNA_seq_markerset","RNA-Seq, Expression ncRNA (NGS)","4 phenotype datasets, 16 variables, 1 molecular datasets, 105 samples sequenced,  SRA, 55 subjects, 105 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2015-09-17","2015-09-17","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000830.v1.p1","XPC and Non-XPC Cutaneous Squamous Cell Carcinoma Mutation Rate Study","Base mutations occur at higher frequencies within heterochromatin and late-replicating DNA. In this study, we show that regional differences in mutation frequency are absent in portions of the genome that  are not transcribed within cutaneous squamous cell carcinomas (cSCCs) with an XPC-\- genetic background. The XPC-\- genetic background predicates a","Not Applicable","Xeroderma Pigmentosum, Complementation Group C","Prospective Longitudinal Cohort","Not Provided","WGS","4 phenotype datasets, 20 variables, 26 samples sequenced,  SRA, 13 subjects, 26 samples","","NCI","DS-SKCA-MDS --- Disease-Specific (Skin Cancer, MDS), DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2015-09-16","2015-09-16","Skin Neoplasms; Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinoma, Squamous Cell; Carcinomas, Epidermoid",""
"phs000913.v1.p1","Genomic Analysis of Mycosis Fungoides and S&#x000e9;zary Syndrome","Mycosis Fungoides (MF) and S&#x000e9;zary Syndrome (Sz) comprise the majority of Cutaneous T-Cell Lymphoma (CTCL) cases and are characterized by clinical heterogeneity. This array of symptoms includes skin patches, plaques  and tumors as well as blood involvement and erythroderma. Because the genetic basis of CTCL is still poorly understood, we performed whole-exome","Not Applicable","Mycosis Fungoides","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), WXS","4 phenotype datasets, 17 variables, 1 molecular datasets, 170 samples sequenced,  SRA, 93 subjects, 170 samples","","NCI","HMB --- Health/Medical/Biomedical","2015-08-10","2015-08-10","Sezary Syndrome; CTCL / Sezary syndrome; Erythroderma, Sezary; Lymphoma, Sezary's; SC)zary syndrome; SEZARY SYNDROME, SOMATIC","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000838.v1.p1","Ghana Prostate Study","Participants were recruited through the Ghana Prostate Study-a population-based component, and a clinical component. The population-based component was a probability sample designed using the 2000 Ghana Population and Housing Census  data in an attempt to recruit approximately 1,000 men aged 50-74 years in the Greater Accra region ( 3 million people), which successfully recruited","Not Applicable","Prostatic Neoplasms","Case-Control","HumanOmni5-4","SNP Genotypes (Array)","4 phenotype datasets, 18 variables, 1 molecular datasets, 932 subjects, 932 samples","","NCI","DS-UC-MDS --- Disease-Specific (Urinary Conditions, MDS)","2015-07-10","2015-07-10","Prostatic Hyperplasia; BEP - Benign enlargement of prostate; BPH; BPH - benign prostatic hyperplasia; Benign Hyperplasia of Prostate; Benign Hyperplasia of the Prostate",""
"phs000634.v1.p1","NCI GWAS of Lung Cancer in Never Smokers","A genomewide study of lung cancer in never smokers Abstract and specific aims In the United States, lung cancer incidence and mortality rates have been steadily declining over the past  decade, following decline in the prevalence of tobacco smoking. However, lung cancer remains the leading cause of cancer death, killing more patients","Not Applicable","Lung Neoplasms","Case-Control","HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 26 variables, 4 analyses, 1 molecular datasets, 2320 subjects, 2320 samples","","NCI","GRU-MDS --- General Research Use (MDS), DS-CA --- Disease-Specific (Cancer)","2015-06-29","2015-06-29","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000863.v1.p1","NCI GWAS of Renal Cell Carcinoma in African Americans","The NCI GWAS of renal cell carcinoma (RCC) in African Americans was undertaken to provide insight into genetic loci affecting susceptibility to this malignancy in a racial group known to  be at elevated risk. We genotyped 1,136,723 single-nucleotide polymorphisms (SNPs) among 255 cases and 375 controls of African ancestry from the NCI","Not Applicable","Carcinoma, Renal Cell","Case-Control","Human1M-Duo","SNP Genotypes (Array)","4 phenotype datasets, 17 variables, 1 molecular datasets, 630 subjects, 650 samples","","NCI","DS-RCC-NPU-MDS --- Disease-Specific (Kidney Cancer, NPU, MDS)","2015-06-24","2015-06-24","ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell; Adenocarcinomas, Renal Cell",""
"phs000648.v1.p1","Pancreatic Cancer Case-Control Association Study","Pancreatic cancer is the 4th leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the  vast majority of patients die within months of diagnosis and the five-year survival rate is less than 5. We have brought together over 8000","Not Applicable","Pancreatic Neoplasms","Case-Control","HumanOmniExpressExome-8","SNP Genotypes (Array)","4 phenotype datasets, 19 variables, 1 molecular datasets, 8021 subjects, 8377 samples","European (7589), African (5), East Asian (91), African American (123), Hispanic1 (31), Hispanic2 (73), Other Asian or Pacific Islander (30), South Asian (39), Other (40)","NCI","DS-PACA --- Disease-Specific (Pancreatic Cancer)","2015-06-22","2015-06-22","Cancer of the pancreas; Neoplasia of the pancreas; Neoplasm of Pancreas; Neoplasm of the Pancreas; Neoplasm, Pancreas; Neoplasm, Pancreatic",""
"phs000869.v1.p1","Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study    (BEAGESS)","BEAGESS is a genome-wide association study (GWAS) which takes advantage of the extensive data collected by investigators in the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON, http://beacon.tlvnet.net), representing many of the  high-quality population-based and other epidemiologic studies of BE and EA in the world. The overall goal of our research is to evaluate the","Not Applicable","Esophageal Neoplasms","Case-Control","HumanOmni1-Quad","SNP Genotypes (Array)","5 phenotype datasets, 34 variables, 1 molecular datasets, 6923 subjects, 6929 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2015-06-19","2015-06-19","Barrett Esophagus; BARRETT METAPLASIA; BE; Barret syndrome; Barrett Metaplasias; Barrett Syndrome","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000346.v2.p2","Cancer Genetic Markers of Susceptibility for Bladder Cancer (CGEMS    Bladder)","This study funded by the National Cancer Institute (NCI) involves conducting a genome-wide association study of common genetic variants to identify markers of susceptibility to bladder cancer. This bladder GWAS  has led to the discovery of three novel regions in the genome associated with bladder cancer risk. Cases were defined as individuals having","Not Applicable","Urinary Bladder Neoplasms","Case-Control","HumanHap240S, HumanHap300, HumanHap550, Human610-Quad, Human1M-Duo, HumanHap240S, HumanHap300, HumanHap550, Human610-Quad, Human1M-Duo, Human660W-Quad, Not Provided, Human660W-Quad","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 documents, 2 molecular datasets, 11424 subjects, 13060 samples","","NCI","CADM --- Cancer in all age groups, adult diseases, and methods","2015-06-12","2015-06-12","Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma",""
"phs000912.v1.p1","San Francisco Bay Area Latina Breast Cancer Study","The genome-wide association study (GWAS) includes participants enrolled into two different studies. The first study, the San Francisco Bay Area Cancer Study (SFBCS) is a population-based case-control study of breast  cancer conducted in the San Francisco Bay Area and included women ages 35-79 years from three racial/ethnic groups: Non-Hispanic whites, African","Not Applicable","Breast Neoplasms","Case-Control","imputation_panel, Affymetrix_WG_Array","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 23 variables, 2 molecular datasets, 1165 subjects, 1165 samples","European (94), African American (8), Hispanic1 (34), Hispanic2 (977), Other Asian or Pacific Islander (2), South Asian (1), Other (49)","NCI","DS-CABNHD-MDS --- Disease-Specific (Cancer, benign neoplasms, or hematopoietic diseases related to cancer, MDS), GRU-COL --- General Research Use (COL)","2015-06-11","2018-10-25","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000812.v1.p1","The Breast and Prostate Cancer Cohort Consortium (BPC3) GWAS of    Aggressive Prostate Cancer and ER- Breast Cancer","The Breast and Prostate Cancer Cohort Consortium (BPC3) was established in 2003 to pool data and biospecimens from nine large prospective cohorts to conduct research on gene-environment interactions in cancer  etiology. The BPC3 initially focused on the association of 70 candidate genes in the Steroid Hormone Metabolism and IGF pathways with risk of breast","Not Applicable","Prostatic Neoplasms","Case-Control","imputation_panel, Human610-Quad, HumanHap550, Human660W-Quad, HumanHap550","SNP Genotypes (Array), SNP Genotypes (imputed)","5 phenotype datasets, 46 variables, 2 analyses, 4 molecular datasets, 12501 subjects, 12501 samples","European (12484), Hispanic1 (4), Hispanic2 (6), South Asian (1), Other (6)","NCI","GRU-MDS --- General Research Use (MDS), HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS), DS-BOED-MDS --- Disease-Specific (Breast, Ovarian, or Endometrial Disease, MDS), CADM --- Cancer in all age groups, other disease in adults only and methods","2015-06-11","2015-06-11","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000799.v1.p1","Shanghai Breast Cancer Genetics Study (SBCGS)","The Shanghai Breast Cancer Genetics Study (SBCGS) includes data from four population-based studies conducted among Chinese women in urban Shanghai: the Shanghai Breast Cancer Study (SBCS), the Shanghai Breast Cancer  Survival Study (SBCSS), the Shanghai Women's Health Study (SWHS), and the Shanghai Endometrial Cancer Study (SECS, contributing controls only).","Not Applicable","Breast Neoplasms","Case-Control","imputation_panel, Affymetrix_WG_Array","SNP Genotypes (imputed), SNP Genotypes (NGS)","4 phenotype datasets, 17 variables, 2 molecular datasets, 5152 subjects, 5152 samples","","NCI","GRU-PUB-NPU --- General Research Use (PUB, NPU)","2015-06-11","2018-08-28","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000517.v3.p1","Multiethnic Cohort (MEC) Breast Cancer Genetics","The Multiethnic Cohort Study is a population-based prospective cohort study (n 215,251) that was initiated between 1993 and 1996 and includes subjects from various ethnic groups - African Americans and  Latinos primarily from Californian (great Los Angeles area) and Native Hawaiians, Japanese-Americans, and European Americans primarily from Hawaii.","Not Applicable","Breast Neoplasms","Case-Control","Human660W-Quad, Human1M-Duo, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 19 variables, 1 documents, 2 molecular datasets, 3708 subjects, 3790 samples","European (34), African (21), East Asian (1650), African American (869), Hispanic1 (45), Hispanic2 (992), Other Asian or Pacific Islander (58), Other (39)","NCI","DS-CA --- Disease-Specific (Cancer), GRU-MDS --- General Research Use (MDS), HMB-MDS --- Health/Medical/Biomedical (MDS)","2015-06-11","2014-01-25","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1); NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000147.v3.p1","CGEMS Breast Cancer GWAS","The initial stage of the Cancer Genetic Markers of Susceptibility (CGEMS) breast cancer genome-wide association study (GWAS) included genotyping 528,173 SNPs (Illumina HumanHap550) in 1,145 postmenopausal women of European ancestry  with invasive breast cancer and 1,142 controls from the Nurses' Health Study (NHS). Subsequently, incident invasive breast cancer cases from the","Not Applicable","Breast Neoplasms","Case-Control","HumanHap550, HumanHap550, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed), WXS","4 phenotype datasets, 16 variables, 1 documents, 1 analyses, 3 molecular datasets, 1558 samples sequenced,  SRA, 2576 subjects, 2723 samples","","NCI","GRU --- General Research Use","2015-06-11","2014-02-13","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000868.v1.p1","Transcriptome Sequencing of Pediatric Neuroblastoma","Neuroblastoma is the most common extra-cranial solid tumor in children. It represents 8% to 10% of all childhood cancers. Stage 4 Neuroblastoma is characterized by its clinical heterogeneous outcome. The  special category, stage 4S tumors (2-5% of all NB) are chemo-sensitive, and the patients show spontaneous regression. On the other hand, MYCN","Not Applicable","Neuroblastoma","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 14 variables, 29 samples sequenced,  SRA, 29 subjects, 29 samples","","NCI","GRU --- General Research Use","2015-06-05","2015-06-05","Not Provided","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000826.v1.p1","Prediction of Trastuzumab Benefit in Adjuvant Breast Cancer: NSABP B31","Background National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive  model for degree of benefit from trastuzumab using archived tumor blocks from B-31. Methods Case subjects with tumor blocks were randomly divided","Not Applicable","Breast Neoplasms","Clinical Trial","nCounter_GeneExpressionAssay","miRNA Expression (Array)","4 phenotype datasets, 25 variables, 1 molecular datasets, 1579 subjects, 1579 samples","","NCI","DS-CA-IRB-MDS --- Disease-Specific (Cancer, IRB, MDS)","2015-05-12","2015-05-12","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000900.v1.p1","Functionally-defined Therapeutic Targets in DIPG","Diffuse Intrinsic Pontine Glioma (DIPG) is a universally fatal childhood cancer. Here, we performed a chemical screen in patient-derived DIPG cell cultures along with RNAseq expression analysis and integrated computational  modeling to identify potentially effective therapeutic strategies. Panobinostat, among the more promising agents identified, demonstrated efficacy in","Not Applicable","Glioma","Prospective Longitudinal Cohort","Not Provided","RNA-Seq, WXS","3 phenotype datasets, 13 variables, 75 samples sequenced,  SRA, 22 subjects, 75 samples","","NCI","GRU --- General Research Use","2015-05-01","2015-05-01","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000794.v1.p1","Longitudinal Genome-Wide Analysis of Patients with Chronic Lymphocytic    Leukemia","Samples from two-center prospective phase 2 clinical trail conducted at Ohio State University (Columbus, OH) and Mayo Clinic (Rochester, MN) were analyzed in 12 cases. All patients had progressive CLL  as defined by National Cancer Institute (NCI) Working Group criteria. Patients provided written informed consent for correlative studies according to","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Prospective Longitudinal Cohort","Not Provided","WXS","4 phenotype datasets, 20 variables, 42 samples sequenced,  SRA, 12 subjects, 42 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2015-04-15","2015-04-15","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000733.v1.p1","ICPCG Genome Wide Association Study of Familial Prostate Cancer","Initially, the ICPCG focused largely on high-risk prostate cancer pedigrees using linkage analysis. However, association studies have also been informative to find prostate cancer susceptibility variants in the genome. We  hypothesize that genome-wide (GW) association studies of familial cases of prostate cancer will have the power to identify rarer and perhaps less","Not Applicable","Prostate cancer, familial","Case-Control","HumanOmni5Exome-4, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 21 variables, 2 molecular datasets, 4036 subjects, 4181 samples","European (3930), African (6), East Asian (2), African American (26), Hispanic1 (10), Hispanic2 (5), Other Asian or Pacific Islander (3), South Asian (4), Other (4)","NCI","DS-PC --- Disease-Specific (Prostate Cancer)","2015-03-10","2015-03-10","Familial malignant neoplasm of prostate; Hereditary prostate cancer",""
"phs000790.v1.p1","Comparative Analysis of Primary and Metastatic Colorectal Cancer","Molecular profiling for somatic mutations that predict response to anti-EGFR therapy in colorectal cancer (CRC) has become standard practice. However, abundant tissue from metastatic lesions is not always available from  patients with metastatic CRC. Concerns involving genetic heterogeneity between primary and metastatic lesions have called into question the","Not Applicable","Colorectal Neoplasms","Prospective Longitudinal Cohort","other","SNV (.MAF), WGS","3 phenotype datasets, 17 variables, 1 molecular datasets, 12 samples sequenced, 4 subjects, 12 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2015-01-29","2015-01-29","CA - Cancer of colon; COLON CANCER; Cancer of Colon; Cancer of the Colon; Cancer, Colon; Cancer, Colonic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000699.v1.p1","Osteosarcoma Genomics","In this study we attempt to elucidate the genomic characteristics of osteosarcoma. Clinical characteristics 58 tumor / normal pairs from 58 patients were included in the study. Median age at  diagnosis was 12 years. 49% of the patients were male and 47% had metastases at diagnosis. 5 year overall survival was 49% for the entire population,","Not Applicable","Osteosarcoma","Case Set","Somatic_Variant","RNA-Seq, SNV (.MAF), WGS, WXS","4 phenotype datasets, 14 variables, 1 analyses, 1 molecular datasets, 116 samples sequenced,  SRA, 58 subjects, 116 samples","","NCI","DS-CA-NPU-MDS --- Disease-Specific (Cancer, NPU, MDS)","2015-01-07","2015-01-07","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma",""
"phs000348.v2.p1","Towards a Genomic Understanding of Myeloma","This project was designed to describe genetic abnormalities in primary samples from patients with multiple myeloma by next generation sequencing. We generated sequence data from multiple myeloma (MM) patients analyzing  DNA both from tumor cells (purified from bone marrow using CD138 selection as a marker of plasma cells) and from normal peripheral blood cells","Not Applicable","Multiple Myeloma","Tumor vs. Matched-Normal","WGS_markerset_grc37, other","SNV Aggregate (.MAF), WGS, WXS","4 phenotype datasets, 32 variables, 2 molecular datasets, 408 samples sequenced,  SRA, 204 subjects, 409 samples","","NCI","GRU-MDS --- General Research Use (MDS), DS-CCRD-MDS --- Disease-Specific (Cancer and Cancer-Related Disorders, MDS)","2014-12-22","2014-12-22","Al amyloidosis; Cell Myeloma, Plasma; Cell Myelomas, Plasma; Disease, Kahler; Familial Myeloma; Kahler Disease","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000628.v1.p1","Characterization of a Metastatic Cervical Cancer Using NGS","In this study, we used shallow whole genome, exome, and RNA sequencing to genomically and transcriptomically characterize a cervical squamous carcinoma lesion metastatic to the lung and to detect and  analyze HPV infection in the same sample. Principal Investigator: Winnie S. Liang, PhD, Translational Genomics Research Institute, Phoenix, AZ, USA","Not Applicable","Uterine Cervical Neoplasms","Case Set","WES_markerset_grc37","RNA-Seq, SNP Genotypes (NGS), WGS, WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 7 samples sequenced,  SRA, 3 subjects, 7 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-12-16","2014-12-16","Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000792.v1.p1","Oncogenomics of Malignant Peripheral Nerve Sheath Tumors","Malignant peripheral nerve sheath tumors (MPNSTs) are a group of highly aggressive soft tissue sarcomas that may occur sporadically, in association with neurofibromatosis type I (NF1-associated), or after radiotherapy (RT-associated).  We utilized comprehensive genomic approaches and identified recurrent loss-of-function somatic alterations in the Polycomb repressive complex 2","Not Applicable","Neurilemmoma","Case Set","Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 46 samples sequenced, 18 subjects, 46 samples","","NCI","GRU-PUB-MDS --- General Research Use (PUB, MDS)","2014-11-24","2014-11-24","Nerve Sheath Neoplasms; Blastoma; CA; CA - Cancer; Cancer; MT",""
"phs000689.v1.p1","Genomic Analysis of Peripheral T-Cell Lymphomas","Peripheral T-cell lymphomas (PTCLs) are a heterogeneous and poorly understood group of non Hodgkin lymphomas. We aim to identify new genetic alterations in PTCL transformation by using a combination of  whole exome sequencing of tumor-normal DNA pairs, RNAseq analysis and targeted deep sequencing of candidate genes. Our data identified highly","Not Applicable","Lymphoma, T-Cell, Peripheral","Case-Control","Not Provided","RNA-Seq, WXS","3 phenotype datasets, 18 variables, 59 samples sequenced,  SRA, 59 subjects, 55 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2014-11-18","2014-11-18","Lymphoma, Non-Hodgkin; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology",""
"phs000543.v1.p1","Exome Sequencing of Pleuropulmonary Blastoma","Pleuropulmonary blastoma (PPB) is a rare, aggressive pediatric cancer arising from the lung or pleural cavity. In this study, we sequenced and analyzed the exomes of 15 PPB matched tumor  and normal pairs. This study is part of a larger effort to characterize pediatric cancers as part of the Slim Initiative for Genomic Medicine (SIGMA)","Not Applicable","Pleuropulmonary blastoma","Case Set","Somatic_Variant","SNV (.MAF), WXS","4 phenotype datasets, 14 variables, 1 analyses, 1 molecular datasets, 30 samples sequenced,  SRA, 15 subjects, 30 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-11-06","2014-11-06","","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000772.v1.p1","Genetic Predictors of Adverse Radiotherapy Effects (Gene-PARE)","The goal of this study was to identify SNPs and CNPs that are associated with development of normal tissue toxicities resulting from radiotherapy for prostate cancer. The study population includes  approximately 1,400 men treated with brachytherapy, external beam radiation therapy, or a combination of the two treatments, and assessed for adverse","Not Applicable","Prostatic Neoplasms","Prospective Longitudinal Cohort","custom_markerset","SNP Genotypes (Array)","4 phenotype datasets, 39 variables, 1 molecular datasets, 787 subjects, 848 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-10-17","2014-10-17","Erectile Dysfunction; Proctitis; Abnormal erection; Dysfunction, Erectile; Erectile abnormalities; Failure of erection","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000717.v1.p1","Genomics of Circulating Tumor Cells","Comprehensive analyses of cancer genomes in clinical settings promise to inform prognoses and guide the deployment of precise cancer treatments. A major barrier, however, is the inaccessibility of adequate metastatic  tissue for accurate genomic analysis in prostate and other cancers. A potential solution is to characterize circulating tumor cells (CTCs), but this","Not Applicable","Prostatic Neoplasms","Case Set","other","SNV (.MAF), WXS","4 phenotype datasets, 10 variables, 1 molecular datasets, 36 samples sequenced,  SRA, 2 subjects, 48 samples","","NCI","DS-PC-MDS --- Disease-Specific (Prostate Cancer, MDS)","2014-10-17","2014-10-17","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000629.v1.p1","GWAS of Familial Lung Cancer","Familial lung cancer cases were collected by the Genetic Epidemiology of Lung Cancer Consortium (GELCC) recruitment sites: University of Cincinnati, Karmanos Cancer Institute at Wayne State University, Louisiana State University  Health Sciences Center-New Orleans, Mayo Clinic, and Medical College of Ohio. Familial cases for this study came from three sources: 1) one case each","Not Applicable","Lung Neoplasms","Case-Control","HumanOmniExpressExome-8, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 22 variables, 2 molecular datasets, 1553 subjects, 1620 samples","European (1531), East Asian (4), African American (9), Hispanic1 (3), Hispanic2 (4), Other Asian or Pacific Islander (1), South Asian (1)","NCI","DS-LC-IRB-COL-MDS --- Disease-Specific (Lung Cancer, IRB, COL, MDS)","2014-10-16","2014-10-16","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs000759.v1.p1","Spectrum of Mutations in Myeloid Neoplasms","Patients with myeloid malignancies bearing high-risk cytogenetic abnormalities lack effective therapies and have a poor overall survival. -7/del(7q) is identified in half of high-risk myeloid neoplasms. We recently identified CUX1  to be a haploinsufficient myeloid tumor suppressor gene located within the commonly deleted segment of 7q22. Here we identify the spectrum of somatic","Not Applicable","Leukemia, Myeloid, Acute","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WXS","4 phenotype datasets, 21 variables, 25 samples sequenced,  SRA, 18 subjects, 25 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-10-08","2014-10-08","Monosomy 7; AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000753.v1.p1","High Density SNP Association Analysis of Lung Cancer","This research builds upon an extensive resource of a case-control study that has been ongoing at the UT MD Anderson Cancer Center since 1991. To identify risk variants for lung  cancer, we conducted a genome-wide association study. Cases are newly diagnosed, histologically-confirmed patients presenting at MD Anderson Cancer","Not Applicable","Lung Neoplasms","Case-Control","HumanHap300","SNP Genotypes (Array)","4 phenotype datasets, 20 variables, 1 molecular datasets, 2290 subjects, 2290 samples","European (2284), African American (1), Hispanic1 (1), Hispanic2 (2), Other (2)","NCI","GRU-MDS --- General Research Use (MDS)","2014-09-30","2014-09-30","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000767.v1.p1","The UC San Diego Chronic Lymphocytic Leukemia (CLL) Study","The UC San Diego Chronic Lymphocytic Leukemia Study is designed to identify genetic, epigenetic, and transcriptional changes important for CLL. This data release consists of samples collected to 1) identify  genomic changes associated with CLL progression using serially collected tumor samples; 2) characterize the transcriptional consequences of SF3B1","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Tumor vs. Matched-Normal","Not Provided","AMPLICON, RNA-Seq","4 phenotype datasets, 27 variables, 139 samples sequenced,  SRA, 49 subjects, 177 samples","","NCI","DS-CLL --- Disease-Specific (Chronic Lymphocytic Leukemia)","2014-07-11","2014-07-11","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs000729.v1.p1","Follicular Lymphoma 2013 - Malek","A cohort of follicular lymphoma cases had tumor cells purified from tissue samples after informed consent using flow cytometry. DNA was extracted from the cells, and samples were subjected to  solution-based exome capture using the Illumina TruSeq Exome Enrichment Kit and the Illumina HiSeq 2000 platform. Patients were enrolled between 2008","Not Applicable","Lymphoma, Follicular","Case Set","WES_markerset_grc36","SNP Genotypes (NGS), WXS","4 phenotype datasets, 16 variables, 1 molecular datasets, 18 samples sequenced, 9 subjects, 18 samples","","NCI","DS-LYM-MDS --- Disease-Specific (Lymphoma, MDS)","2014-06-24","2014-06-24","Lymphoma, Non-Hodgkin; Brill - Symmers' disease; Brill Symmers Disease; Brill-Symmers Disease; Disease, Brill-Symmers; FOLLICULAR LYMPHOMA, SOMATIC",""
"phs000706.v1.p1","RAD50 Hypomorphism as Basis for Response to Chemotherapy","Outlier analyses represent a versatile method to identify predictive biomarkers of response to both targeted agents and chemotherapy. We performed whole genome sequencing (WGS) of tumor and germline blood from  a patient with metastatic small cell carcinoma of the ureter who experienced a durable complete response to a combination of irinotecan plus AZD7762,","Not Applicable","Ureteral Neoplasms","Case Set","Not Provided","OTHER, WGS","4 phenotype datasets, 20 variables, 5 samples sequenced, 1 subjects, 5 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-06-19","2014-06-19","Neoplasia of the ureters; Neoplasm of Ureter; Neoplasm of the Ureter; Neoplasm, Ureteral; Neoplasms of Ureter; Neoplasms of the Ureter","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000734.v1.p1","Osteosarcoma Genome-Wide Association Study","This is a genome-wide association study (GWAS) of osteosarcoma, the most common primary bone malignancy. Osteosarcoma typically occurs in adolescents and young adults. It occurs at increased frequency in several  inherited cancer predisposition syndromes but the genetic contribution to sporadic osteosarcoma is largely unexplored. The objective of this study","Not Applicable","Osteosarcoma","Case Set","HumanOmniExpress-12","SNP Genotypes (Array)","4 phenotype datasets, 14 variables, 1 molecular datasets, 694 subjects, 717 samples","","NCI","GRU --- General Research Use","2014-06-10","2014-06-10","Bone cell cancer; OSRC; OSTEOSARCOMA; Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma","dbGaP Collection: Compilation of Individual-Level Genomic Data for    General Research Use (phs000688.v1.p1); NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000716.v1.p1","GWAS of Lung Cancer Susceptibility in Never-Smoking Women in Asia","To learn about the etiology of lung cancer among never-smoking women in Asia, we formed the Female Lung Cancer Consortium in Asia (FLCCA), which includes studies of lung cancer in  Eastern Asia and conducted a GWAS. We analyzed a total of 5510 lung cancer cases and 4544 controls and identified 3 novel loci (Lan et al., 2012). Of","Not Applicable","Lung Neoplasms","Case-Control","Human610-Quad, Human660W-Quad","SNP Genotypes (Array)","4 phenotype datasets, 16 variables, 3 analyses, 2 molecular datasets, 8881 subjects, 9178 samples","","NCI","DS-LC-MDS --- Disease Specific (LC, MDS)","2014-06-04","2014-06-04","Adenocarcinoma; ADNOS; Adenocarcinomas; Adenoma, Malignant; Adenomas, Malignant; Malignant Adenoma",""
"phs000709.v1.p1","The Genome and Transcriptome of Fibrolamellar Hepatocellular Carcinoma","Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver tumor primarily affecting adolescents and young adults. Little is known of the molecular pathogenesis. To characterize the disease we performed RNA sequencing  and whole genome sequencing on FL-HCC tumors and adjacent normal tissue. The results demonstrate few consistent differences on the chromosomal level","Not Applicable","Fibrolamellar hepatocellular carcinoma","Tumor vs. Matched-Normal","Not Provided","RNA-Seq","3 phenotype datasets, 12 variables, 29 samples sequenced,  SRA, 11 subjects, 29 samples","","NCI","DS-CA-IRB-MDS --- Disease-Specific (Cancer, IRB, MDS)","2014-05-09","2014-05-09","Carcinoma, Hepatocellular; Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells",""
"phs000739.v1.p1","Identification of Recurrent SMO and BRAF Mutations in Ameloblastomas","RNA-seq data from two cases of ameloblastoma was analyzed for candidate gene fusions and point mutations. Recurrent point mutations identified in the RNA-seq data, as well as mutations identified with  limited panel targeted deep sequencing, were validated as somatic. Expanding to a larger cohort of 28, one of two activating mutations was found in","Not Applicable","Ameloblastoma","Case Set","WES_markerset_grc37","AMPLICON, RNA Seq (NGS)","4 phenotype datasets, 20 variables, 1 molecular datasets, 9 samples sequenced,  SRA, 7 subjects, 7 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-05-05","2014-05-05","","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000370.v2.p1","The Mutational Landscape of Head and Neck Squamous Cell Carcinoma","This study was the first-known large-scale effort to uncover the mutational spectrum of head and neck cancers. We analyzed whole-exome sequence from 92 tumor-normal pairs and retained 74 of them  for significance analysis. The majority exhibited a mutational profile consistent with tobacco exposure; human papilloma virus sequence was","Not Applicable","Head and Neck Neoplasms","Case Set","Somatic_Variant","SNV (.MAF), WXS","4 phenotype datasets, 21 variables, 1 molecular datasets, 184 samples sequenced,  SRA, 92 subjects, 184 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2014-04-17","2014-04-17","Head Neoplasm; Head Neoplasms; Neoplasm, Head; Neoplasms, Head",""
"phs000306.v4.p1","A Multiethnic Genome-wide Scan of Prostate Cancer","Multiple GWA studies of prostate cancer conducted in European White populations are ongoing. These studies will continue to have a dramatic impact on our understanding of the contribution of common  genetic variation on inter-individual susceptibility to this common cancer. Important questions that will remain unanswered, however, are whether all","Not Applicable","Prostatic Neoplasms","Case-Control","Human660W-Quad, Human1M-Duo, imputation_panel, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","7 phenotype datasets, 67 variables, 2 documents, 6 molecular datasets,  SRA, 9457 subjects, 11325 samples","European (115), African (185), East Asian (2157), African American (4425), Hispanic1 (112), Hispanic2 (1997), Other Asian or Pacific Islander (56), South Asian (1), Other (81)","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS), GRU-MDS --- General Research Use (MDS), DS-PC --- Disease-Specific (Prostate Cancer), CHDSADM --- Cancer, Heart Disease, Stroke, Alzheimer Disease, and Diabetes Research and Methods, HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2014-04-17","2013-02-01","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000201.v2.p1","Acquired Copy Number Alterations in Adult Acute Myeloid Leukemia Genomes","We performed genome-wide copy number analysis with paired normal and tumor DNA obtained from 86 adult patients with de novo AML using the Affymetrix Genome-Wide Human SNP array 6.0 containing  1.85 million features. Acquired copy number alterations (CNA) were confirmed using an independent, higher resolution, custom array comparative","Not Applicable","Leukemia, Myeloid, Acute","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array)","3 phenotype datasets, 47 variables, 1 molecular datasets, 86 subjects, 172 samples","","NCI","DS-HEM-MDS-GSO --- Disease-Specific (Hematologic Disease, MDS, GSO)","2014-04-17","2010-01-12","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs000602.v2.p1","Identification of Targetable FGFR Gene Fusions in Diverse Cancers","In this study, patients with advanced cancer across all histologies were enrolled in our IRB approved clinical sequencing program, called MI-ONCOSEQ, to go through an integrative sequencing which includes whole  exome sequencing of the tumor and matched normal, and transcriptome sequencing. Four index cases were identified which harbor gene rearrangements of","Not Applicable","Neoplasms","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 16 variables, 7 samples sequenced,  SRA, 7 subjects, 6 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2014-04-16","2013-05-21","Mouth Neoplasms; Urinary Bladder Neoplasms; Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor",""
"phs000418.v2.p1","Temporal Dissection of Tumorigenesis in Primary Cancers","The earliest genetic abnormalities in cancer represent a unique opportunity for timely clinical diagnosis. Classic deep sequencing of tumors identifies many aberrations acquired later in cancer progression. In this study,  data regarding simple mutation and chromosomal aberration were integrated to trace the evolution of cutaneous squamous cell carcinomas and ovarian","Not Applicable","Carcinoma, Squamous Cell","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 27 variables, 16 samples sequenced,  SRA, 8 subjects, 16 samples","","NCI","DS-CA-IRB-MDS --- Disease-Specific (Cancer, IRB, MDS)","2014-04-16","2012-05-15","Carcinoma, Epidermoid; Carcinoma, Planocellular; Carcinoma, Squamous; Carcinomas, Epidermoid; Carcinomas, Planocellular; Carcinomas, Squamous",""
"phs000340.v3.p1","Sequencing of ETP T-ALL","CREST The accurate identification of structural variations using whole-genome DNA sequencing data generated by next-generation sequencing technology is extremely difficult. To address this challenge, we have developed CREST, an algorithm  that uses sequencing reads with partial alignments to the reference human genome (so-called soft-clipped reads) to directly map the breakpoints of","Not Applicable","Leukemia, T-Cell","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WGS, WXS","5 phenotype datasets, 33 variables, 1 molecular datasets, 30 samples sequenced,  SRA, 106 subjects, 196 samples","European (68), African American (11), Hispanic1 (2), Hispanic2 (8), Other Asian or Pacific Islander (2)","NCI","GRU-MDS --- General Research Use (MDS)","2014-04-16","2012-01-12","Leukemia, Lymphocytic, T Cell; Leukemia, Lymphocytic, T-Cell; Leukemia, T Cell; Leukemia, T Lymphocytic; Leukemia, T-Cell Lymphocytic; Leukemia, T-Lymphocytic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000552.v2.p1","Genomic Characterization of Meningiomas","Meningiomas are the most common primary brain tumor in the US. Although the tumor suppressor gene NF2 is disrupted in approximately half of meningiomas, the complete spectrum of genetic changes  in meningiomas remains poorly understood, particularly in the large subset of tumors without NF2 alterations. Therefore we performed whole-genome","Not Applicable","Meningioma","Case Set","WES_markerset_grc37","AMPLICON, SNP/CNV Genotypes (NGS), WGS, WXS","4 phenotype datasets, 15 variables, 1 analyses, 2 molecular datasets, 130 samples sequenced,  SRA, 65 subjects, 130 samples","","NCI","DS-BDBC-NPU-MDS --- Disease-Specific (Brain Disorders and Brain Cancer, NPU, MDS)","2014-04-15","2013-01-17","Diffuse meningiomatosis; Meningioma, Multiple; Meningiomas, Multiple; Meningiomatoses; Meningiomatosis; Multifocal meningiomata",""
"phs000508.v2.p1","Genomic Sequencing of Pediatric Rhabdoid Cancers","In this study, we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood. This study is part of a larger effort to characterize pediatric cancers as  part of the Slim Initiative for Genomic Medicine (SIGMA) project. Principal Investigator: Charles Roberts, MD, PhD, Dana Farber Cancer Institute,","Not Applicable","Rhabdoid Tumor","Case-Control","other","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 14 variables, 1 molecular datasets, 70 samples sequenced,  SRA, 35 subjects, 70 samples","","NCI","PCR --- Pediatric Cancer Research, DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2014-04-15","2014-04-15","",""
"phs000487.v2.p1","Functionally Active Copy Number Variants Associated with Prostate Cancer    Risk","Prostate cancer is a leading cause of cancer death in males throughout the world and has the largest estimated effect of heritability among the most common tumor types. Copy Number  Variants (CNVs) are a recently recognized class of human germline polymorphisms (Iafrate AJ, et al. (2004) Nat Genet 36, 949-951; Sebat J, et al.","Not Applicable","Prostatic Neoplasms","Case-Control","Affymetrix_WG_Array","CNV Genotypes","4 phenotype datasets, 22 variables, 2 analyses, 1 molecular datasets, 1903 subjects, 1903 samples","","NCI","DS-PC-NPU-MDS-GSO --- Disease-Specific (Prostate Cancer, NPU, MDS, GSO)","2014-04-15","2014-01-04","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000350.v1.p1","FHCRC - Whole-Exome Sequencing of Hereditary Prostate Cancer Families","The specific aim of this study is to identify hereditary prostate cancer (HPC) susceptibility genes using a novel study design, whereby whole-exome sequencing will be undertaken on multiple affected relatives  from 19 HPC families, in which &#x02265; 3 affected relatives were diagnosed with clinically aggressive and/or early onset prostate cancer (PC).","Not Applicable","Prostatic Neoplasms","Family/Twin/Trios","Not Provided","WXS","5 phenotype datasets, 26 variables, 1 documents, 95 samples sequenced,  SRA, 94 subjects, 96 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-04-01","2014-04-01","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000600.v1.p1","Genomic Sequencing of Cervical Cancers","Cervical cancer is responsible for 10-15% of cancer related deaths in women worldwide. The etiological role of infection with high-risk human papilloma viruses (HPV) in carcinomas of the cervix is  well established. In general, the development of cervical carcinomas follows a progression from persistent HPV infection through precancerous lesions","Not Applicable","Uterine Cervical Neoplasms","Case-Control","Somatic_Variant","RNA-Seq, SNV (.MAF), WGS, WXS","4 phenotype datasets, 24 variables, 2 analyses, 1 molecular datasets, 230 samples sequenced,  SRA, 115 subjects, 230 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2014-03-19","2014-03-19","Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms",""
"phs000627.v1.p1","UNC Hepatocellular Carcinoma Study by Exome Sequencing (HCCSES)","Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical events in the instigation and progression of hepatocellular carcinoma. As a prerequisite for individualized cancer  treatment, we sought to characterize the landscape of recurrent somatic mutations in hepatocellular carcinoma. We performed whole exome sequencing on","Not Applicable","Carcinoma, Hepatocellular","Case Set","WES_markerset_grc37","SNP Genotypes (NGS), WXS","3 phenotype datasets, 18 variables, 1 molecular datasets, 174 samples sequenced,  SRA, 87 subjects, 174 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2014-03-14","2014-03-14","Adult Liver Cancer; Adult Liver Cancers; Cancer, Adult Liver; Cancers, Adult Liver; Carcinoma of Liver Cells; Carcinoma of the Liver Cells","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000410.v1.p1","Whole Exome Sequencing for Colorectal Cancer","This project was designed to use next generation sequencing technology to screen the protein coding regions of the genome for low frequency variants in a panel of high-risk colorectal adenocarcinoma  cases. Blood and cell-line DNA for colorectal cancer patients and a subset of quality control samples that had existing whole exome sequence data","Not Applicable","Colorectal Neoplasms","Case Set","Not Provided","WXS","4 phenotype datasets, 21 variables, 168 samples sequenced,  SRA, 165 subjects, 174 samples","","NCI","GRU-MDS --- General Research Use (MDS), GRU-NPU-MDS --- General Research Use (NPU, MDS)","2014-03-14","2014-03-14","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000519.v1.p1","Study of Melanoma Risk in Australia and the United Kingdom","The results from a small number of melanoma GWAS have been published. Initial studies identified several pigmentation- and nevus-associated loci that mediate an effect on melanoma risk, however, these studies  were somewhat limited in that sample number (hence power) was low, they used first-generation low density SNP arrays, or used pools of DNA samples.","Not Applicable","Melanoma","Case Set","HumanOmniExpressExome-8","SNP Genotypes (Array)","4 phenotype datasets, 353 variables, 1 molecular datasets, 3912 subjects, 4079 samples","","NCI","GRU-MDS --- General Research Use (MDS), DS-M-MDS --- Disease-Specific (Melanoma, MDS)","2014-03-12","2015-03-12","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000299.v2.p1","Genentech Lung Cancer Sequencing","Version 1 Whole genome sequencing was applied to tumor and adjacent normal lung tissue in an individual non-small-cell lung cancer patient. We present an analysis of somatic changes identified throughout  the tumor genome, including single-nucleotide variants, copy number variants, and large-scale chromosomal rearrangements. Over 50,000 high-confidence","Not Applicable","Lung Neoplasms","Tumor vs. Matched-Normal","Not Provided","RNA-Seq, WGS","5 phenotype datasets, 24 variables, 25 samples sequenced,  SRA, 21 subjects, 25 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2014-02-28","2010-08-18","Carcinoma, Non Small Cell Lung; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Carcinomas, Non-Small-Cell Lung; Lung Carcinoma, Non-Small-Cell; Lung Carcinomas, Non-Small-Cell","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000677.v1.p1","An APOBEC Cytidine Deaminase Mutagenesis in Human Cancers","Reprinted from Roberts et al. ""An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers"", Nature Genetics, 45:970-976, 2013, with permission of Nature Publishing Group: Recent studies indicate that  a subclass of APOBEC cytidine deaminases, which convert cytosine to uracil during RNA editing and retrovirus or retrotransposon restriction, may","Not Applicable","Neoplasms","Cross-Sectional","WES_markerset_grc36","SNV (.MAF)","3 phenotype datasets, 12 variables, 1 molecular datasets,  SRA, 5427 subjects, 5427 samples","","NCI","GRU --- General Research Use","2013-12-20","2013-12-20","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000652.v1.p1","Cohort-Based Genome-Wide Association Study of Glioma (GliomaScan)","We conducted a new independent GWAS of adult glioma using 1,856 cases and 4,955 controls from 14 cohort studies belonging to the Cohort Consortium, 3 case-control studies, and 1 population-based  case only study. Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were cancer-free at the time of glioma","Not Applicable","Glioma","Case-Control","HumanHap550, Human610-Quad, Human660W-Quad","SNP Genotypes (Array)","4 phenotype datasets, 15 variables, 1 analyses, 3 molecular datasets, 6811 subjects, 7072 samples","","NCI","DS-GAO-GSO --- Disease-Specific (Glioma in Adults Only, GSO), CADM --- Cancer in all age groups, other diseases in adults only, and methods","2013-12-17","2014-12-17","Glial Cell Tumor; Glial Cell Tumors; Glial Neoplasm; Glial Tumor; Neoplasm of Neuroglia; Neoplasm of the Neuroglia",""
"phs000597.v1.p1","DNA Methylation Analysis of Prostate Cancer","Aberrant DNA methylation changes are known to occur during prostate cancer progression beginning with precursor lesions. Utilizing fifty nanograms of genomic DNA in Methylplex-Next Generation Sequencing (M-NGS) we mapped the  global DNA methylation patterns in prostate tissues (n 17) and cells (n 2). Peaks were located from mapped reads obtained in each sequencing run","Not Applicable","Prostatic Neoplasms","Case-Control","Not Provided","OTHER","4 phenotype datasets, 23 variables, 19 samples sequenced,  SRA, 17 subjects, 19 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2013-11-26","2013-11-26","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000657.v1.p1","NGS in Advanced Cancers","In this study, we used NGS to identify somatic events in advanced stage cancer patients to demonstrate the feasibility for using this approach to improve patient treatment. Principal Investigator: Glen  Weiss, MD, Translational Genomics Research Institute, Phoenix, AZ, USA Co-Investigator: Winnie Liang, PhD, Translational Genomics Research Institute,","Not Applicable","Carcinoma","Case Set","Not Provided","RNA-Seq, WGS, WXS","4 phenotype datasets, 17 variables, 31 samples sequenced,  SRA, 15 subjects, 31 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2013-11-20","2013-11-20","Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000364.v2.p1","Genome-Wide Analysis of Chronic Lymphocytic Leukemia","Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is still largely unknown  since the full spectrum of genetic lesions that are present in the CLL genome, and therefore the number and identity of dysregulated cellular","Not Applicable","Leukemia, Lymphocytic, Chronic, B-Cell","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), WXS","4 phenotype datasets, 13 variables, 2 molecular datasets, 49 samples sequenced,  SRA, 43 subjects, 61 samples","","NCI","DS-CA-PUB-MDS --- Disease-Specific (Cancer, PUB, MDS)","2013-11-15","2013-11-15","B Cell CLL; B Cell Chronic Lymphocytic Leukemia; B Cell Leukemia, Chronic; B Cell Lymphocytic Leukemia; B Cell Malignancy, Low Grade; B Lymphocytic Leukemia, Chronic",""
"phs000671.v1.p1","Somatic Mutations in Variant and IGHV4-34 Expressing Hairy Cell Leukemia","To understand the genetic mechanisms driving variant and IGHV4-34 expressing hairy-cell leukemia, we performed whole exome sequencing of tumor/normal pairs from ten patients. All patients have either IGHV4-34 expressing classic  hairy cell leukemia, IGHV4-34 expressing variant hairy-cell leukemia, or IGHV4-34 non-expressing variant hairy-cell leukemia. Principal Investigator:","Not Applicable","Leukemia, Hairy Cell","Case Set","WES_markerset_grc37","SNP Genotypes (NGS), WXS","4 phenotype datasets, 15 variables, 1 molecular datasets, 20 samples sequenced,  SRA, 10 subjects, 20 samples","","NCI","HMB-MDS --- Health/Medical/Biomedical (MDS)","2013-11-14","2013-11-14","HCL; HCL - Hairy cell leukemia; HCL-C; Hairy Cell Leukemias; LRE - Leukemic reticuloendotheliosis; Leukemias, Hairy Cell","NCI's Collection of Datasets for Health, Medical, and Biomedical Research    Purposes (phs003044.v1.p1)"
"phs000579.v1.p1","Small Intestine Neuroendocrine Tumors (Carcinoid Tumors)","The diagnosed incidence of small bowel neuroendocrine tumors (NETs) is increasing. While patients with localized disease can be treated surgically, those with metastatic disease currently have few treatment options. The  success of biologically targeted therapies in other malignancies has led to interest in the molecular alterations underlying the pathogenesis of","Not Applicable","Intestinal Neoplasms","Case Set","Somatic_Variant","SNV (.MAF), WGS, WXS","4 phenotype datasets, 20 variables, 1 analyses, 1 molecular datasets, 105 samples sequenced,  SRA, 51 subjects, 105 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS), DS-GI-MDS --- Disease-Specific (Gastrointestinal Illness, MDS), GRU-MDS --- General Research Use (MDS)","2013-11-06","2013-11-22","Intestinal Tumor; Intestinal Tumors; Intestines Neoplasm; Intestines Neoplasms; Neoplasm of Intestines; Neoplasm of intestine","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000601.v1.p1","Identifying the Genetic Explanation for Heritable Breast Cancer","The project developed a suite of new methods (FAVR) designed to assist the shortlisting of genetic variants under a rare variant-phenotype/disease model. The methods were designed to work with commonly  used massively parallel sequencing analysis pipelines, such as the GATK or ANNOVAR, and have been made publically available as a suite of software","Not Applicable","Breast Neoplasms","Family/Twin/Trios","WES_markerset_grc37","SNP Genotypes (NGS), WXS","4 phenotype datasets, 19 variables, 1 molecular datasets, 20 samples sequenced,  SRA, 20 subjects, 20 samples","","NCI","DS-CA-MDS --- Disease-Specific (Cancer, MDS)","2013-10-29","2013-10-29","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000646.v1.p1","Breakpoint Detection Using Long Insert Whole Genome Sequencing","In this study, we hypothesize that shallow long insert whole genome sequencing (LI-WGS) increases our power for detecting breakpoints compared to shallow short insert WGS. We performed a priori analyses  to demonstrate the benefits of LI-WGS, developed a long insert library preparation protocol based off Illumina's protocol, and compared LI-WGS","Not Applicable","Chromosome Breakpoints","Case Set","Not Provided","WGS","4 phenotype datasets, 16 variables, 6 samples sequenced, 3 subjects, 6 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2013-09-10","2013-09-10","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000644.v1.p1","The Effect of the Menstrual Cycle on the Normal Human Breast","The Susan G. Komen for the Cure&#x000ae; Tissue Bank at the IU Simon Cancer Center [www.komentissuebank.iu.edu] (KTB) was established expressly for the prospective collection of normal, healthy breast tissue from  volunteer donors. Blood is also obtained from donors at the time of donation and is processed for serum, plasma and peripheral blood leukocyte DNA.","Not Applicable","Menstrual Cycle","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 44 variables, 20 samples sequenced,  SRA, 20 subjects, 20 samples","","NCI","DS-BRCA-PUB-MDS --- Disease-Specific (Breast Cancer, PUB, MDS)","2013-09-10","2013-09-10","Not Provided",""
"phs000604.v1.p1","Mapping Genes for Mammographic Density","We recruited 1,521 women from the Old Order Amish (OOA) population of Lancaster County, Pennsylvania, with the primary goal of identifying genetic factors that influence mammographic density. All women were  between the ages of 40 and 88 years, with a mean of 54 years. Additional study design details, including eligibility criteria, are described","Not Applicable","Neoplasms","Collection","Not Provided","Not Provided","3 analyses","","NCI","GRU-MDS --- General Research Use (MDS)","2013-08-22","","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000505.v2.p1","Gene Fusion Discovery through RNA Sequencing of Human Glioblastoma Stem    Cell Lines","We used massively parallel, paired-end sequencing of expressed transcripts (RNA-seq) to detect novel gene fusions in short-term cultures of glioma stem-like cells freshly isolated from nine patients carrying primary glioblastoma  multiforme (GBM). The culture of primary GBM tumors under serum-free conditions selects cells that retain phenotypes and genotypes closely mirroring","Not Applicable","Glioblastoma","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 10 variables, 24 samples sequenced,  SRA, 24 subjects, 24 samples","","NCI","GRU-MDS --- General Research Use (MDS)","2013-07-31","2012-10-31","Astrocytoma, Grade IV; Astrocytomas, Grade IV; GBM; GBM (glioblastoma); Giant cell glioblastoma (histologic variant); Glioblastoma multiforme","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000614.v1.p1","Genomic Analysis of Pediatric Low Grade Gliomas","Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from mutations or duplications in the BRAF kinase in specific subclasses, few genetic driver events  are known. Diffuse PLGGs compose a set of uncommon subtypes that exhibit invasive growth and are therefore especially challenging clinically. These","Not Applicable","Astrocytoma","Tumor vs. Matched-Normal","HumanOmni2.5-8, WGS_markerset_grc37","SNP Genotypes (NGS), WGS","5 phenotype datasets, 17 variables, 1 molecular datasets, 2 samples sequenced,  SRA, 1 subjects, 2 samples","","NCI","DS-PBDPBC-NPU-MDS --- Disease-Specific (Pediatric Brain Disorders and Pediatric Brain Cancer, NPU, MDS)","2013-07-22","2013-07-22","ASTROCYTOMA; Astrocytic Glioma; Astrocytic Gliomas; Astrocytic Neoplasm; Astrocytoma (excluding glioblastoma); Astrocytomas",""
"phs000621.v1.p1","Genome Wide Association Studies in ECOG 2997 Trial","The ECOG 2997 trial was a randomized controlled trial for patients with previously untreated CLL comparing fludarabine monotherapy to the combination of fludarabine and cyclophosphamide. The initial clinical findings of  this study were published in the Journal of Clinical Oncology in 2007 (JCO 25:793-8). Additional laboratory studies have also published (JCO","Not Applicable","Leukemia, Lymphoid","Clinical Trial","HumanHap550","SNP Genotypes (Array)","4 phenotype datasets, 33 variables, 1 molecular datasets, 215 subjects, 215 samples","European (177), African (2), East Asian (1), African American (31), Hispanic1 (1), Hispanic2 (1), South Asian (2)","NCI","HMB-PUB-MDS --- Health/Medical/Biomedical (PUB, MDS)","2013-06-26","2013-06-26","Leukemia, Lymphocytic; Leukemias, Lymphocytic; Leukemias, Lymphoid; Lymphatic leukemia; Lymphocytic Leukemia; Lymphocytic Leukemias",""
"phs000341.v2.p1","The Genetic Basis of Hypodiploid ALL","The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases, including whole-genome  and exome sequencing of 40 cases, identified two subtypes that differ in the severity of aneuploidy, transcriptional profiles and submicroscopic","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Tumor vs. Matched-Normal","Affymetrix_WG_Array, Affymetrix_WG_Array, Not Provided, Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WGS, WXS","5 phenotype datasets, 33 variables, 2 molecular datasets, 83 samples sequenced,  SRA, 241 subjects, 379 samples","European (78), African American (15), Hispanic1 (4), Hispanic2 (16), Other Asian or Pacific Islander (4), South Asian (1), Other (7)","NCI","GRU --- General Research Use","2013-06-11","2013-06-11","ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic; Leukemia, Lymphoblastic, Acute, L1","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000573.v1.p1","Genetic Heterogeneity of Diffuse Large B Cell Lymphoma","We sequenced exomes of 94 DLBCL tumors and cell lines. 34 of the tumors had paired normal tissue. Our work elucidates commonly occurring gene-coding mutations in DLBCL. Principal Investigator: Sandeep  Dave, MD, Duke University, Durham, NC, USA Funding Source: R21CA156168, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA","Not Applicable","Lymphoma, Large B-Cell, Diffuse","Case-Control","target_markerset_grc36","SNP Genotypes (NGS), WXS","5 phenotype datasets, 16 variables, 1 molecular datasets, 128 samples sequenced,  SRA, 94 subjects, 128 samples","","NCI","GRU --- General Research Use","2013-04-02","2013-04-02","Lymphoma, Non-Hodgkin; Centroblastic diffuse large B-cell malignant lymphoma; Centroblastic diffuse malignant lymphoma; Centroblastic malignant lymphoma; DLBCL; DLBCL - diffuse large B cell lymphoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000525.v1.p1","Expressed Pseudogenes in the Transcriptional Landscape of Human Cancers","In this study, we describe a systematic analysis of pseudogene 'transcription' from an RNA-Seq resource of 293 samples, from 13 cancer and normal tissue types. We observed a highly prevalent,  genome-wide expression of pseudogenes that could be categorized as universally expressed or lineage- and/or cancer-specific. We also explored disease","Not Applicable","Neoplasms","Cross-Sectional","Not Provided","RNA-Seq","3 phenotype datasets, 15 variables, 293 samples sequenced,  SRA, 293 subjects, 293 samples","","NCI","CRGM --- Cancer Research and General Methods","2013-03-29","2013-03-29","Blastoma; CA; CA - Cancer; Cancer; MT; Malignancies",""
"phs000562.v1.p1","The Genetic Landscape of Mutations in Burkitt Lymphoma","Burkitt lymphoma (BL) is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. We sequenced exomes of 59 BL tumors, 14  of which had paired normal tissue. Our work elucidates commonly occurring gene-coding mutations in Burkitt lymphoma and implicates ID3 as a novel","Not Applicable","Burkitt Lymphoma","Tumor vs. Matched-Normal","Not Provided","WXS","4 phenotype datasets, 14 variables, 72 samples sequenced,  SRA, 59 subjects, 72 samples","","NCI","GRU --- General Research Use","2013-01-29","2013-01-29","Lymphoma, Non-Hodgkin; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000550.v1.p1","Characterization of Pancreatic Adenocarcinoma Patients Using NGS","In this study, we whole genome sequenced tumor/normal pairs from three pancreatic adenocarcinoma patients to separately characterize each patient with respect to somatic alterations. For 2 patients for whom tumor  RNA was available, we also performed RNA sequencing to evaluate gene expression changes. While additional sequencing is needed to improve our","Not Applicable","Pancreatic Neoplasms","Case Set","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 19 variables, 9 samples sequenced,  SRA, 4 subjects, 9 samples","","NCI","GRU --- General Research Use","2013-01-29","2013-01-29","Epithelial Carcinoma; Epithelial Neoplasm, Malignant; Epithelial Neoplasms, Malignant; Epithelial Tumor, Malignant; Epithelial Tumors, Malignant; Epithelioma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000522.v1.p1","Hyperdiploid Acute Lymphoblastic Leukemia RNA-Seq","Few genetic drivers of children with hyperdiploid precursor B-cell acute lymphoblastic leukemia (ALL) have been identified to date. In an effort to detect novel genomic rearrangements that could be promoting  leukemogenesis in this subset of patients, we sequenced ribosomal RNA-depleted transcriptomes isolated from 5 hyperdiploid acute lymphoblastic","Not Applicable","Precursor B-Cell Lymphoblastic Leukemia-Lymphoma","Case Set","Not Provided","RNA-Seq","3 phenotype datasets, 10 variables, 5 samples sequenced,  SRA, 5 subjects, 5 samples","","NCI","PCRGM --- Pediatric Cancer Research and General Methods","2013-01-16","2014-01-16","Leukemia, Pre B Cell; Leukemia, Pre-B-Cell; Leukemias, Pre-B-Cell; Pre B ALL; Pre B Cell Leukemia; Pre B-ALL",""
"phs000567.v1.p1","NAB2-STAT6 Gene Fusions in Solitary Fibrous Tumor by Integrative    Sequencing","Transcriptome sequencing of solitary fibrous tumors / hemangiopericytomas from a variety of anatomic sites revealed recurrent gene fusions between two genes, NAB2 and STAT6. All SFTs examined exhibited an in-frame  fusion transcript encoding a fusion protein containing the EGR1 interaction domain of NAB2 with the transcriptional activation domain of STAT6.","Not Applicable","Solitary Fibrous Tumors","Case Set","Not Provided","RNA-Seq","4 phenotype datasets, 20 variables, 26 samples sequenced,  SRA, 26 subjects, 26 samples","","NCI","CRM --- Cancer Research and Methods","2013-01-11","2014-01-11","Neoplasms, Connective and Soft Tissue",""
"phs000568.v1.p1","Genomic Sequencing of Solitary Fibrous Tumors","Solitary fibrous tumors (SFTs) are rare mesenchymal tumors that can be benign or malignant. In this study, we sequenced and analyzed the exomes of 17 SFT matched tumor and normal  pairs. This study appertains to a large endeavor to characterize cancers as part of the Slim Initiative for Genomic Medicine in the Americas (SIGMA)","Not Applicable","Sarcoma","Case Set","WES_markerset_grc36","SNV Aggregate (.MAF), WXS","4 phenotype datasets, 23 variables, 1 molecular datasets, 34 samples sequenced,  SRA, 17 subjects, 34 samples","","NCI","GRU --- General Research Use","2013-01-10","2013-01-10","Solitary Fibrous Tumors; Sarcoma, Spindle Cell; Sarcomas, Spindle Cell; Spindle Cell Sarcomas; spindle cell sarcoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000383.v1.p1","GWAS of Breast Cancer in the African Diaspora","The paucity of data on the genetic epidemiology of breast cancer for racial/ethnic groups other than those of European ancestry hinders the development of innovative interventions to reduce health disparities.  Women in the African Diaspora experience a disproportionate burden of pre-menopausal breast cancer in comparison to all other races for reasons that","Not Applicable","Breast Neoplasms","Case-Control","HumanOmni2.5-8, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 34 variables, 2 molecular datasets, 3766 subjects, 4001 samples","European (20), African (1481), African American (2234), Hispanic1 (21), Other Asian or Pacific Islander (1), South Asian (2), Other (7)","NCI","HRGM --- Health Research and General Methods","2012-12-14","2013-12-14","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000413.v2.p1","Transcriptome Sequencing of Pediatric AML FAB-M7","High resolution analysis of DNA copy number abnormalities and loss-of-heterozygosity on acute myeloblastic leukemia samples utilizing SNP arrays has demonstrated that in contrast to pediatric ALL, de novo AML is  characterized by a very low burden of genomic alterations (Radtke, et al., PNAS, 2009). Samples for this study represented a cross-section of the","Not Applicable","Leukemia, Megakaryoblastic, Acute","Case Set","Not Provided","SNP Genotypes (Array), RNA-Seq, WGS, WXS","5 phenotype datasets, 32 variables, 1 molecular datasets, 47 samples sequenced,  SRA, 15 subjects, 85 samples","","NCI","GRU --- General Research Use","2012-11-20","2013-08-20","AMKL; AML M7; AMegL; Acute M7 Myeloid Leukemia; Acute Megakaryoblastic Leukemia (FAB Type M7); Acute Megakaryoblastic Leukemias","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000535.v1.p1","Genome and Targeted Sequencing of Bladder Cancer","One primary bladder cancer and paired peripheral blood sample were subjected to whole genome sequencing on an Illumina HiSeq 2000 platform. This technology was utilized to investigate the genetic basis  of a durable remission of metastatic bladder cancer in a patient treated with everolimus, a drug that inhibits the mTOR (mammalian target of","Not Applicable","Urinary Bladder Neoplasms","Clinical Trial","Not Provided","OTHER, WGS","4 phenotype datasets, 18 variables, 16 samples sequenced,  SRA, 14 subjects, 16 samples","","NCI","GRU --- General Research Use","2012-11-02","2012-11-02","Bladder Cancer; Bladder Cancers; Cancer of Bladder; Cancer of the Bladder; Cancer, Bladder; Cancer, Urinary Bladder","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000445.v1.p1","HIV-Resistant People with Hemophilia","Rare individuals are highly resistant to infection with human immunodeficiency virus (HIV). Studies of candidate genes resulted in the discovery of a 32bp deletion in the CC-chemokine receptor 5 gene  (CCR5&#x00394;32), which rendered this critical co-receptor for primary HIV infection to be non-functional. Pharmacologic and vaccine-induced","Not Applicable","HIV","Case-Control","Not Provided","OTHER, WGS","4 phenotype datasets, 14 variables, 11 samples sequenced,  SRA, 20 subjects, 21 samples","","NCI","HVI --- Hemophilia and Viral Infections","2012-10-16","2012-10-16","Hemophilia A; AHG deficiency disease; AUTOSOMAL HEMOPHILIA A; Classic Hemophilia; Classic Hemophilias; Classical hemophilia",""
"phs000491.v1.p1","Whole-Genome and Exome Sequencing in Clear-Cell Renal Cell Carcinoma","Study to evaluate the molecular genetics of ccRCC through integrative analyses of tumors and tumorgrafts using multiple platforms in clinically annotated samples. Genome and exome data for patients giving consent  to have the information available on a public, secure, database is being submitted. Principal Investigator: James Brugarolas, MD, PhD, UT","Not Applicable","Carcinoma, Renal Cell","Case-Control","Not Provided","WXS","5 phenotype datasets, 30 variables, 5 samples sequenced,  SRA, 3 subjects, 7 samples","","NCI","GRU --- General Research Use","2012-10-05","2013-01-05","Urogenital Neoplasms; Urologic Diseases; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000513.v1.p1","MAST Kinase and Notch Gene Families in Breast Cancer","Paired-end transcriptome sequencing was performed on a panel of breast cancer cell lines and tissues and a set of benign cell line and tissue controls. Analyses of the paired end  sequences were performed and chimeric transcripts derived from gene rearrangement events were identified. Sequencing was performed on Illumina GAII","Not Applicable","Breast Neoplasms","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 19 variables, 89 samples sequenced,  SRA, 89 subjects, 89 samples","","NCI","CRGM --- Cancer Research and General Methods","2012-09-14","2012-09-14","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer",""
"phs000502.v1.p1","Genome-Wide Analysis of Splenic Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma (SMZL) is a B-cell malignancy of unknown pathogenesis and thus orphan of targeted therapies. By integrating whole-exome sequencing and copy-number analysis of 8 paired tumor-normal DNAs  from patients with SMZL, we show that the typical SMZL exome carries 30 genetic alterations. Targeted resequencing of selected candidates in an","Not Applicable","Lymphoma, Non-Hodgkin","Case-Control","Affymetrix_WG_Array","SNP Genotypes (Array), WXS","3 phenotype datasets, 10 variables, 1 molecular datasets, 16 samples sequenced,  SRA, 8 subjects, 16 samples","","NCI","CRGM_PUB --- Cancer Research and General Methods with Publication Statement","2012-08-02","2013-08-02","Lymphoma, B-Cell; Interdigitating cell sarcoma; Reticulosarcomas; Reticulum Cell Sarcoma; Reticulum Cell Sarcomas; Reticulum cell sarcoma morphology",""
"phs000384.v1.p1","Genentech Whole Genome Sequencing of Four Hepatocellular Carcinoma    Patients","Hepatitis B virus (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). In this study we sequenced the whole genome ( 80X) and transcriptome of tumor and non-tumor  samples from four HCC patients and identified over two hundred HBV integration sites. We found significant clonal expansion of HBV-integrated","Not Applicable","Carcinoma, Hepatocellular","Case-Control","Not Provided","RNA-Seq, WGS","4 phenotype datasets, 20 variables, 16 samples sequenced,  SRA, 4 subjects, 18 samples","","NCI","GRU --- General Research Use","2012-07-30","2012-07-30","Hepatitis B; Hepatocellular Carcinomas; HBV infection; Hepatitis B Virus Infection; Hepatitis B infection; Hepatitis B virus caused hepatitis","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000395.v1.p1","CPMCRI Breast Health Cohort","Description of Cohort: The California Pacific Medical Center (CPMC) Breast Health Cohort is a cohort study based at CPMC and is linked to the San Francisco Mammography Registry, one of  the sites of the NCI-funded Breast Cancer Screening Consortium (U01CA063740). CPMC is a community hospital in San Francisco, which has one of the","Not Applicable","Breast Neoplasms","Case-Control","HumanOmni1-Quad","SNP Genotypes (Array)","4 phenotype datasets, 30 variables, 1 documents, 1 molecular datasets, 982 subjects, 1014 samples","","NCI","GRU --- General Research Use","2012-07-20","2012-07-20","Breast Cancer; Breast Malignant Neoplasm; Breast Malignant Neoplasms; Breast Malignant Tumor; Breast Malignant Tumors; CA - Breast cancer","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000414.v1.p1","Whole Genome Sequencing of CBF-Leukemia","Pediatric de novo acute myeloid leukemia (AML) is a heterogeneous disease that can be divided into clinically distinct subtypes based on the presence of specific chromosomal abnormalities or gene alterations.  One of the best characterized subtypes of AML involves leukemias with alterations of the core-binding factor (CBF)-complex, which comprises the FAB","Not Applicable","Leukemia, Myeloid, Acute","Tumor vs. Matched-Normal","Not Provided","WGS","3 phenotype datasets, 16 variables, 34 samples sequenced,  SRA, 17 subjects, 34 samples","","NCI","GRU --- General Research Use","2012-05-30","2013-03-02","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000409.v1.p1","Sequencing of Medulloblastoma","Medulloblastoma is a heterogenous disease made up of at least four distinct subtypes of disease which appear to exploit and disrupt naturally occurring developmental pathways of cellular growth and hindbrain  development. To better understand the driver mutations of this disease, we performed whole genome sequencing of 37 medulloblastomas and the","Not Applicable","Medulloblastoma","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WGS","5 phenotype datasets, 33 variables, 1 molecular datasets, 78 samples sequenced,  SRA, 93 subjects, 306 samples","European (45), East Asian (2), African American (6), Hispanic1 (3), Hispanic2 (8), Other Asian or Pacific Islander (4), South Asian (3), Other (5)","NCI","GRU --- General Research Use","2012-05-30","2012-05-30","Arachnoidal Cerebellar Sarcoma, Circumscribed; Circumscribed arachnoidal cerebellar sarcoma; Desmoplastic Medulloblastomas; Desmoplastic Nodular Medulloblastoma; Desmoplastic medulloblastoma; Medulloblastoma, Desmoplastic","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000443.v1.p1","Molecular Profiling of Cancer","Noncoding RNAs (ncRNAs) are emerging as key molecules in human cancer, with the potential to serve as novel markers of disease and to reveal uncharacterized aspects of tumor biology. Here  we discover 121 unannotated prostate cancer-associated ncRNA transcripts (PCATs) by ab initio assembly of high-throughput sequencing of polyA+ RNA","Not Applicable","Prostatic Neoplasms","Case-Control","Not Provided","RNA-Seq","4 phenotype datasets, 22 variables, 144 samples sequenced,  SRA, 72 subjects, 144 samples","","NCI","CRGM --- Cancer Research and General Methods","2012-05-08","2012-05-08","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000369.v1.p1","Sequence Analysis of Mutations and Translocations Across Breast Cancer    Subtypes","This study combined whole exome (103 samples) and whole genome (22 samples) sequencing over a total of 108 breast tumors and matched normal DNA to identify novel mutations and translocations.  Samples were subjected to paired-end Illumina sequencing with goal of 30x coverage of tumor/normal for whole genomes and 100x tumor/normal coverage","Not Applicable","Carcinoma, Ductal, Breast","Case Set","Affymetrix_expression_array, Affymetrix_WG_Array","SNP Genotypes (Array), mRNA Expression (Array), WGS, WXS","4 phenotype datasets, 23 variables, 2 molecular datasets, 216 samples sequenced,  SRA, 108 subjects, 216 samples","","NCI","GRU --- General Research Use, CRGM --- Cancer Research and General Methods","2012-04-19","2012-04-19","BREAST CANCER, INVASIVE DUCTAL; Carcinoma, Infiltrating Duct; Carcinoma, Invasive Ductal, Breast; Carcinomas, Infiltrating Duct; Infiltrating Ductal Adenocarcinoma; Infiltrating Ductal Breast Carcinoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000419.v1.p1","A Novel Recurrent Mutation in MITF Predisposes to Familial and Sporadic    Melanoma","We conducted whole-genome sequencing of probands from several melanoma families, identifying one individual carrying a novel germline variant (c.G1075A, NM_000248.3; p.E318K, NP_000239.1; rs149617956) in the melanoma lineage-specific oncogene MITF. While  the variant cosegregated with melanoma in some, but not all cases in the family, linkage analysis of 31 families subsequently identified to carry the","Not Applicable","Melanoma","Case-Control","Not Provided","WGS","4 phenotype datasets, 15 variables, 1 samples sequenced,  SRA, 1 subjects, 1 samples","","NCI","CRO --- Cancer Research Only","2012-02-03","2012-02-03","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs000352.v1.p1","Sequencing of Retinoblastoma","Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we  performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1","Not Applicable","Retinoblastoma","Tumor vs. Matched-Normal","Affymetrix_WG_Array","SNP Genotypes (Array), RNA-Seq, WGS","5 phenotype datasets, 34 variables, 1 molecular datasets, 9 samples sequenced,  SRA, 46 subjects, 93 samples","European (22), African American (13), Hispanic1 (1), Hispanic2 (7), South Asian (1), Other (1)","NCI","GRU --- General Research Use","2012-01-19","2012-01-19","Cancer, Retinoblastoma Eye; Cancers, Retinoblastoma Eye; Eye Cancer, Retinoblastoma; Eye Cancers, Retinoblastoma; RB; RB - retinoblastoma","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000385.v1.p1","Epigenetic Profiling of Human Colorectal Cancer","DNA methylation, together with chromatin modifications, constitute the epigenome that functions to regulate gene expression and genome integrity. DNA methylation alterations are ubiquitous in human cancers, as many genes acquire  DNA methylation in a cancer-specific manner. DNA methylation at these sites in the genome of cancer cells not only serves as a marker for tumor","Not Applicable","Colorectal Neoplasms","Case-Control","Affymetrix_WG_Array","SNP Genotypes (Array), Bisulfite-Seq","5 phenotype datasets, 42 variables, 1 documents, 1 molecular datasets, 2 samples sequenced,  SRA, 100 subjects, 104 samples","","NCI","GRU --- General Research Use","2011-11-29","2011-11-29","CRC; Cancer of Large Bowel; Cancer of Large Intestine; Cancer of the Large Bowel; Cancer of the Large Intestine; Cancer, Colorectal","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000361.v1.p1","Genome-Wide Association Studies in Upper Gastrointestinal Cancers (Asian)","This project aims to conduct genome-wide association studies (GWAS) in two anatomically different upper gastrointestinal (UGI) cancer sites in two populations with distinctly different disease rates and genetic profiles. One  population has very high rates for both esophageal squamous cell carcinomas (ESCCs) and gastric cancers (GCs) and is comprised of Asians (the ""Asian","Not Applicable","Intestinal Neoplasms","Case-Control","Human660W-Quad","SNP Genotypes (Array)","3 phenotype datasets, 10 variables, 1 documents, 2 analyses, 1 molecular datasets, 5623 subjects, 5754 samples","","NCI","CODA --- Cancer and other important diseases in adults, EGA --- Esophageal and gastric cancer in adults","2011-06-21","2011-06-21","Esophageal Cancer; Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour",""
"phs000336.v1.p1","DCEG Lung Cancer Study","Three genetic loci for lung cancer risk have been identified by genome-wide association studies (GWAS), but inherited susceptibility to specific histologic types of lung cancer is not well established. We  conducted a GWAS of lung cancer and its major histologic types genotyping 515,922 single nucleotide polymorphisms (SNPs) in 5,739 incident lung","Not Applicable","Lung Neoplasms","Prospective Longitudinal Cohort","Human1M-Duo, Human610-Quad, HumanHap240S, HumanHap300, HumanHap550, Human1M-Duo, Human610-Quad, HumanHap240S, HumanHap300, HumanHap550","SNP Genotypes (Array)","3 phenotype datasets, 14 variables, 1 documents, 1 molecular datasets, 11517 subjects, 13073 samples","","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods, SLD --- Research related to lung disease or smoking","2011-05-27","2011-05-27","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs000351.v1.p1","NCI Genome-Wide Association Study of Renal Cell Carcinoma","The National Cancer Institute (NCI) genome-wide association study (GWAS) of renal cell carcinoma (RCC) was conducted to investigate common genetic variants associated with RCC risk. The GWAS includes 1,453 RCC  cases and 3,531 controls of European background from 4 studies (3 cohort, 1 case-control), scanned using the Illumina InfiniumHumanHap 550, 610 and","Not Applicable","Carcinoma, Renal Cell","Case-Control","HumanHap550, Human610-Quad, Human660W-Quad","SNP Genotypes (Array)","3 phenotype datasets, 9 variables, 1 documents, 1 molecular datasets, 4735 subjects, 4909 samples","","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods","2011-05-17","2011-05-17","Kidney Neoplasms; ADENOCARCINOMA OF KIDNEY; Adenocarcinoma Of Kidneys; Adenocarcinoma of the Kidney; Adenocarcinoma, Renal; Adenocarcinoma, Renal Cell",""
"phs000396.v1.p1","DCEG Imputation Reference Dataset","We have built a new resource for imputation of SNPs for existing and future genome-wide association studies (GWAS), known as the Division of Cancer Epidemiology and Genetics (DCEG) Reference Set.  The first build of the data set includes 728 cancer-free individuals of European descent from three large prospectively sampled studies, 98","Not Applicable","National Program of Cancer Registries","Clinical Trial","imputation_panel, imputation_panel","SNP Genotypes (imputed)","2 phenotype datasets, 4 variables, 1 molecular datasets, 1249 subjects, 1249 samples","","NCI","CADM --- Cancer in all age groups, other diseases in adults only, and methods, EGC --- Esophageal and stomach cancer","2011-05-07","2011-05-07","Not Provided",""
"phs000187.v1.p1","High Density SNP Association Analysis of Melanoma","This research builds upon an extensive resource of melanoma cases and hospital based controls collected over several years at the U.T. M.D. Anderson Cancer Center. The goal of this research  is to identify novel susceptibility and outcome-related genes for melanoma using a systematic genome-wide association-based approach. Our goal is to","Not Applicable","Melanoma","Case-Control","HumanOmni1-Quad","SNP Genotypes (Array), SNP Genotypes (imputed)","4 phenotype datasets, 38 variables, 7 documents, 3 molecular datasets, 3115 subjects, 3311 samples","","NCI","GRU --- General Research Use","2010-05-18","2011-05-18","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas","NCI's Collection of Datasets for General Research Use (phs003014.v1.p1)"
"phs000207.v1.p1","CGEMS Prostate Cancer GWAS - Stage 1 - PLCO","The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San  Diego, CA) in 1,172 prostate cancer patients and 1,157 controls of European ancestry from the Prostate, Lung, Colon and Ovarian (PLCO,","Not Applicable","Prostatic Neoplasms","Case-Control","HumanHap240S, HumanHap300, HumanHap240S, HumanHap300","SNP Genotypes (Array)","3 phenotype datasets, 10 variables, 2 analyses, 1 molecular datasets, 2252 subjects, 2300 samples","","NCI","CADM --- Research related to adult diseases and methods","2009-12-22","2009-12-22","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs000093.v2.p2","A Genome Wide Scan of Lung Cancer and Smoking","The majority of cases of lung cancer are the culmination of a dynamic process that begins with smoking initiation, proceeds through dependency and smoking persistence, continues with lung cancer development  and ends with progression to disseminated disease or response to therapy and survival. We are conducting a whole genome study of lung cancer and","Not Applicable","Lung Neoplasms","Case-Control","HumanHap550, imputation_panel","SNP Genotypes (Array), SNP Genotypes (imputed)","5 phenotype datasets, 34 variables, 33 documents, 3 molecular datasets, 5566 subjects, 11337 samples","","NCI","CADM --- Research related to adult diseases and methods, SLD --- Research related to smoking or lung disease","2009-10-22","2010-01-08","Lung Tumor; Lung cancer; Lung neoplasm; Lung tumour; Neoplasm of Lung; Neoplasm of the Lung",""
"phs003706.v1.p1","Clinical Outcomes and ctDNA Correlates for CAPOX BETR: A phase II trial    of Capecitabine, Oxaliplatin, Bevacizumab, Trastuzumab in Previously    Untreated Advanced HER2+ Gastroesophageal Adenocarcinoma","We performed circulating tumor DNA (ctDNA) analysis on plasma of patients with advanced HER2 positive gastroesophageal adenocarcinomas who were treated on a phase 2 clinical trial testing the addition of  bevacizumab to capecitabine, oxaliplatin, and trastuzumab. ctDNA was analyzed using panel based next generation sequencing assay (Predicine CARE),","Not Applicable","Esophageal Neoplasms","Clinical Trial","Not Provided","WGS","57 samples sequenced, 30 subjects, 58 samples","","NCI","","","","Esophageal Neoplasms, Benign and Malignant; Esophageal Tumor; Esophageal Tumors; Esophageal neoplasm; Esophageal tumour; Esophagus Neoplasm",""
"phs003691.v1.p1","Somatic Mutations in 3,929 HPV-Positive Exfoliated Cervical Cell Samples","We investigated the detection, timing, and HPV type specificity of cervical somatic hotspot mutations (i.e., previously reported cancer driver mutations) in 3,929 HPV-positive exfoliated cervical cell samples from individuals undergoing  routine cervical screening in the U.S. using deep-targeted sequencing of 20 candidate genes. Our study included samples from 3,351 women with the","Not Applicable","Uterine Cervical Neoplasms","Case-Control","Not Provided","AMPLICON","3928 samples sequenced, 3351 subjects, 3929 samples","","NCI","","","","Cervical Neoplasm, Uterine; Cervical Neoplasms; Cervical Tumor; Cervical neoplasm; Cervix Neoplasm; Cervix Neoplasms",""
"phs003615.v1.p1","Phase 2 Study of Nivolumab and Entinostat in Unresectable or Metastatic    Cholangiocarcinoma and Pancreatic Adenocarcinoma","The study was a single-center, open-label, phase II trial (registration no. NCT03250273) designed to evaluate the efficacy of entinostat in combination with nivolumab in patients with advanced pancreatic ductal adenocarcinoma  (PDAC). The aim was to assess the objective response rate using RECIST v1.1 criteria as the primary endpoint. A total of 27 patients with advanced","Not Applicable","Carcinoma, Pancreatic Ductal","Clinical Trial","Not Provided","RNA-Seq","4 phenotype datasets, 55 variables, 46 samples sequenced, 30 subjects, 53 samples","","NCI","HMB-IRB-NPU --- Health/Medical/Biomedical (IRB, NPU)","","","Carcinoma, Ductal, Pancreatic; Carcinoma, Pancreas Duct-Cell; Carcinomas, Pancreas Duct-Cell; Carcinomas, Pancreatic Ductal; Duct Cell Carcinoma of the Pancreas; Duct Cell Carcinoma, Pancreas",""
"phs003588.v1.p1","The CHK1 Inhibitor Prexasertib in BRCA Wild-Type Platinum-Resistant    Recurrent High-Grade Serous Ovarian Carcinoma: a Phase 2 Trial","Ovarian carcinoma, especially high-grade serous ovarian carcinoma (HGSOC), is the deadliest gynecologic malignancy in the USA. Despite initial treatment with surgery and platinum-based chemotherapy, around 80% of HGSOC patients experience  relapse. This is particularly challenging in platinum-resistant recurrent HGSOC, especially in cases where BRCA1/BRCA2 genes are wild-type (BRCAwt),","Not Applicable","Ovarian Neoplasms","Clinical Trial","Not Provided","WXS","18 samples sequenced, 18 subjects, 18 samples","","NCI","","","","Neoplasm of Ovary; Neoplasm of the Ovary; Neoplasm of the ovaries; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovarian",""
"phs003505.v1.p1","National Cancer Institute Multi-Ancestry Genome-Wide Association Study of    Kidney Cancer (NCI-3)","The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (""NCI-3"") was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer  and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315","Not Applicable","Kidney Neoplasms","Case-Control","Not Provided","SNP/CNV (Array), SNP/CNV Genotypes (NGS)","89808 subjects, 89808 samples","European (82769), African (121), East Asian (550), African American (3439), Hispanic1 (1173), Hispanic2 (1019), Other Asian or Pacific Islander (122), South Asian (1), Other (614)","NCI","","","","Kidney Tumor; Kidney cancer; Kidney neoplasm; Neoplasia of the kidneys; Neoplasm of Kidney; Neoplasm of the Kidney",""
"phs003500.v1.p1","Circulating Tumor DNA Analyses of Breast Cancer Patients Paired and Over    Time","Blood-based 'liquid biopsy' is increasingly utilized in clinical care of cancer patients and the fraction of tumor-derived DNA in circulation ('tumor fraction', TFx) has demonstrated clinical utility across multiple cancer  types. To determine TFx, shallow whole genome sequencing of cell-free DNA can be performed from a single blood sample, using an established","Not Applicable","Neoplasms","Case Set","Not Provided","Not Provided","33 subjects, 109 samples","","NCI","","","","Neoplasm Metastasis; Metastase; Metastases, Neoplasm; Metastasis; Metastasis, Neoplasm; Metastasize",""
"phs003456.v1.p1","Assessing Individual Head and Neck Squamous Cell Carcinoma Patient    Response to Therapy Through Integration of Functional and Genomic Data","This study uses whole exome sequencing (WES) data, copy number variation (CNV) data, and a head and neck squamous cell carcinoma-specific inhibitor panel to characterize tumor cells from patients with  head and neck squamous cell carcinoma, in order to identify potential therapy targets on an individual patient basis. The data that will be available","Not Applicable","Squamous Cell Carcinoma of Head and Neck","Case Set","Not Provided","RNA-Seq, WXS","75 samples sequenced, 20 subjects, 96 samples","","NCI","","","","Epidermoid Carcinoma of Hypopharynx; Epidermoid Carcinoma of the Hypopharynx; Hypopharyngeal Conventional Squamous Cell Carcinoma; Hypopharyngeal Epidermoid Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Hypopharynx",""
"phs003451.v2.p1","The Genetic Evolution of Acral Melanoma","Acral melanoma is a rare melanoma subtype arising on the sole, palm, or nail apparatus. We performed whole-exome sequencing (WES) for a cohort of 35 acral melanoma patients. For each  patient, we sequenced multiple tumor areas representing different tumor stages, including the in situ and invasive portions of the primary tumor and","Not Applicable","Melanoma","Tumor vs. Matched-Normal","Not Provided","Targeted-Capture, WGS, WXS","154 samples sequenced, 35 subjects, 208 samples","","NCI","","","","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs003420.v1.p1","Patient-Derived Models of Prostate Cancer for Personalized Medicine","The aim of this study was to develop a molecular dataset that reflects the heterogeneity of prostate cancer using patient-derived xenografts (PDX) grown in the subcutaneous flank of SCID (CB17/Icr-Prkdcscid/IcrIcoCrl)  mice. Whole-genome, targeted sequencing, and RNA sequencing were performed on tumors from 44 PDXs derived from 38 patients. The cohort included","Not Applicable","Prostatic Neoplasms","Xenograft","Not Provided","Not Provided","38 subjects, 44 samples","","NCI","","","","NGP - New growth of prostate; Neoplasm of Prostate; Neoplasm of the Prostate; Neoplasm, Prostate; Neoplasm, Prostatic; Neoplasms, Prostate",""
"phs003121.v2.p1","Targeted Genomic Sequencing in Large Human Genes to Detect Induced    Structural Variants","Partial inhibition of DNA replication leads to de novo copy number variant (CNV) formation throughout the genome, especially at common fragile sites (CFSs). We previously showed that these hotspots for  genome instability reside in late-replicating domains associated with large, transcribed genes. In this study, we performed targeted, error-corrected","Not Applicable","Chromosome Fragile Sites","Methods","Not Provided","CNV (NGS), Targeted-Capture, WGS","32 samples sequenced, 1 subjects, 32 samples","","NCI","","","","Genomic Instability; Genome Instabilities; Genome Instability; Genomic Instabilities; Instabilities, Genome; Instabilities, Genomic",""
"phs003015.v2.p1","Ipilimumab and Decitabine in Treating Patients With Relapsed or    Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","The NCI Experimental Therapeutics Clinical Trials Network (ETCTN)/Cancer Therapy Evaluation Program (CTEP) 10026 study (NCT02890329) tested combined ipilimumab and decitabine treatment in two cohorts: Arm A consisted of patients with  relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation. Arm B consisted of patients with advanced","Not Applicable","Leukemia, Myeloid, Acute","Clinical Trial","Not Provided","ATAC-seq, RNA-Seq, Targeted-Capture, WXS","5 phenotype datasets, 19 variables, 220 samples sequenced, 38 subjects, 220 samples","","NCI","HMB-COL --- Health/Medical/Biomedical (COL)","","","AML; AML - Acute Myeloid Leukemia; AML - Acute myeloblastic leukemia; AML - acute myeloid leukaemia; AML adult; ANLL",""
"phs002951.v1.p1","Whole Transcriptome Analysis of Melanoma PDX Models","This study reports bulk total RNA sequencing from melanoma patient-derived xenograft (PDX) tumors. The goal is to determine transcriptomic differences across melanomas of distinct subtypes including cutaneous, acral, mucosal, and  unknown primary. Fresh surgical specimens used for deriving PDX models were obtained from the University of Colorado Skin Cancer Biorepository under","Not Applicable","Melanoma","Xenograft","Not Provided","Not Provided","65 subjects, 65 samples","","NCI","","","","Cancer of skin pigment cells; MM - malignant melanoma; Malignant Melanoma; Malignant Melanomas; Melanoma, Malignant; Melanomas",""
"phs002359.v1.p1","Genomic Architecture of LGL Leukemia","LGL leukemia results from a clonal expansion of cytotoxic T lymphocytes with a terminal effector memory (TEMRA) phenotype. LGL leukemia patients have multiple clinical phenotypes including chronic neutropenia, pure red  cell aplasia, and rheumatoid arthritis. The major focus of this project is to identify and understand how genomic changes contribute to the","Not Applicable","Leukemia, Large Granular Lymphocytic","Case Set","Not Provided","Not Provided","7 subjects, 20 samples","","NCI","","","","Anemia; Neutropenia; Aggressive NK Cell Leukemia; Aggressive Natural Killer Cell Leukemia; LGL Leukemia; LGL Leukemias",""
"phs002223.v1.p1","National Cancer Institute Familial Burkitt Lymphoma in Shirati (FBiS)","In 1980, Dr. Glen Brubaker and colleagues reported 5 familial cases of Burkitt Lymphoma (BL) in Shirati in Tanzania and began collecting cryopreserved lymphocytes from affected and non-affected family members  to study the potential genetic basis of familial BL occurring in the malaria belt in Africa. This area is settled by the Luo tribe (85% of the","Not Applicable","Burkitt Lymphoma","Case-Control","Not Provided","Not Provided","Not Provided","","NCI","","","","Epstein-Barr Virus Infections; BL; BL - Burkitt's lymphoma; Burkitt Tumor; Burkitt lymphoma/leukemia; Burkitt's Lymphoma",""
"phs001204.v1.p1","Mayo Clinic - Fecal Microbiota and Colorectal Cancer Development","Background: Adenomatous polyps are the most common precursor to colorectal cancer (CRC), the second leading cause of cancer death in the United States. We sought to learn more about early  events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas. Methods: We analyzed 16S rRNA gene sequences from","Not Applicable","Adenoma","Case-Control","Not Provided","AMPLICON","752 samples sequenced, 819 subjects, 819 samples","","NCI","","","","Adenoma, Microcystic; Adenomas, Microcystic; Microcystic Adenomas; microcystic adenoma; microcystic adenoma (morphologic abnormality); CRC",""
"phs000696.v1.p1","Exome Sequencing of Craniopharyngiomas","Craniopharyngiomas are epithelial tumors of the brain that form in the suprasellar region. Patients experience a broad range of sequelae from growth of the tumors and from therapeutic interventions. We  used whole exome sequencing to investigate the genetic aberrations in both adamantinomatous and papillary craniopharyngiomas. We found mutations in","Not Applicable","Craniopharyngioma","Case Set","Not Provided","Not Provided","Not Provided","","NCI","","","","Adamantinomatous tumor; Adamantinomatous tumour; Craniopharyngeal duct tumor; Craniopharyngioma (WHO Grade 1); Craniopharyngioma (WHO Grade I); Craniopharyngiomas",""
"phs000329.v1.p1","Evolution of Human BCR-ABL1 Lymphoblastic Leukemia-Initiating Cells","Many tumour types are composed of genetically diverse cells, however little is known of how diversity evolves or the impact diversity has on functional properties. Here, using xenografting and DNA  copy number alteration (CNA) profiling of human BCR-ABL1 lymphoblastic leukaemia, we demonstrate that genetic diversity occurs in functionally","Not Applicable","Precursor Cell Lymphoblastic Leukemia-Lymphoma","Xenograft","Not Provided","Not Provided","Not Provided","","NCI","","","","Acute Lymphoblastic Leukemia; ALL, Childhood; Childhood ALL; Childhood Precursor Lymphoblastic Leukemia; L1 Lymphocytic Leukemia; Leukemia, L1 Lymphocytic",""
"phs000124.v3.p1","Neuroblastoma Genome-Wide Association Study (NBL-GWAS)","Neuroblastoma is a malignancy of the developing sympathetic nervous system that most commonly affects young children and is often lethal. The etiology of this embryonal cancer is not fully understood.  We therefore initiated a genome-wide association study (GWAS) in 2007 focused on neuroblastoma patients identified through the Children's Oncology","Not Applicable","Neuroblastoma","Case-Control","Not Provided","Not Provided","2 analyses","","NCI","","","","Not Provided",""
